drug1_db
stringlengths
7
7
drug2_db
stringlengths
7
7
drug1_id
int64
0
1.69k
drug2_id
int64
0
1.69k
drug_pair
sequencelengths
2
2
drug1_name
stringlengths
4
85
drug2_name
stringlengths
4
85
drug1_desc
stringlengths
27
1.09k
drug2_desc
stringlengths
27
6.14k
label
stringclasses
3 values
label_idx
int64
0
2
all_paths
sequencelengths
1
10
all_paths_str
sequencelengths
1
10
path_str
stringlengths
0
3.57k
DB00501
DB01254
752
1,213
[ "DDInter380", "DDInter484" ]
Cimetidine
Dasatinib
A histamine congener, it competitively inhibits histamine binding to histamine H2 receptors. Cimetidine has a range of pharmacological actions. It inhibits gastric acid secretion, as well as pepsin and gastrins output. It also blocks the activity of cytochrome P-450 which might explain proposals for use in neoadjuvant therapy.
Dasatinib is an orally available multikinase inhibitor indicated for the treatment of Philadelphia chromosome (Ph)-positive leukemias.[A2224,L45171] Ph is a chromosomal abnormality found in patients with chronic myelogenous leukemia (CML) and acute lymphocytic leukemia (ALL), where the ABL tyrosine kinase and the breakpoint cluster region (BCR) gene transcribe the chimeric protein BCR-ABL. BCR-ABL is associated with the uncontrolled activity of the ABL tyrosine kinase and is involved in the pathogenesis of CML and 15-30% of ALL cases.[A11377,A33432] Dasatinib also inhibits a spectrum of kinases involved in cancer, including several SRC-family kinases. Unlike [imatinib], another tyrosine kinase used for the treatment of CML and Ph-positive ALL, dasatinib inhibits the active and inactive conformations of the ABL kinase domain.[A2226,A11377] Also, mutations in the kinase domain of BCR-ABL may lead to relapse during imatinib treatment. Since dasatinib does not interact with some of the residues involved in those mutations, the use of this drug represents a therapeutic alternative for patients with cancers that have developed imatinib-resistance. The use of dasatinib was first approved by the FDA in 2006.[L45171,L45186]
Major
2
[ [ [ 752, 25, 1213 ] ], [ [ 752, 6, 4973 ], [ 4973, 45, 1213 ] ], [ [ 752, 18, 6351 ], [ 6351, 57, 1213 ] ], [ [ 752, 21, 28882 ], [ 28882, 60, 1213 ] ], [ [ 752, 23, 907 ], [ 907, 62, 1213 ] ], [ [ 752, 24, 479 ], [ 479, 23, 1213 ] ], [ [ 752, 23, 112 ], [ 112, 23, 1213 ] ], [ [ 752, 25, 543 ], [ 543, 24, 1213 ] ], [ [ 752, 24, 1313 ], [ 1313, 63, 1213 ] ], [ [ 752, 63, 1251 ], [ 1251, 24, 1213 ] ] ]
[ [ [ "Cimetidine", "{u} may lead to a major life threatening interaction when taken with {v}", "Dasatinib" ] ], [ [ "Cimetidine", "{u} (Compound) binds {v} (Gene)", "ABCB1" ], [ "ABCB1", "{u} (Gene) is bound by {v} (Compound)", "Dasatinib" ] ], [ [ "Cimetidine", "{u} (Compound) downregulates {v} (Gene)", "COTL1" ], [ "COTL1", "{u} (Gene) is downregulated by {v} (Compound)", "Dasatinib" ] ], [ [ "Cimetidine", "{u} (Compound) causes {v} (Side Effect)", "Body temperature increased" ], [ "Body temperature increased", "{u} (Side Effect) is caused by {v} (Compound)", "Dasatinib" ] ], [ [ "Cimetidine", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Doravirine" ], [ "Doravirine", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Dasatinib" ] ], [ [ "Cimetidine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Donepezil" ], [ "Donepezil", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Dasatinib" ] ], [ [ "Cimetidine", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Metronidazole" ], [ "Metronidazole", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Dasatinib" ] ], [ [ "Cimetidine", "{u} may lead to a major life threatening interaction when taken with {v}", "Loperamide" ], [ "Loperamide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Dasatinib" ] ], [ [ "Cimetidine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Suvorexant" ], [ "Suvorexant", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Dasatinib" ] ], [ [ "Cimetidine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Mirtazapine" ], [ "Mirtazapine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Dasatinib" ] ] ]
Cimetidine (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Dasatinib (Compound) Cimetidine (Compound) downregulates COTL1 (Gene) and COTL1 (Gene) is downregulated by Dasatinib (Compound) Cimetidine (Compound) causes Body temperature increased (Side Effect) and Body temperature increased (Side Effect) is caused by Dasatinib (Compound) Cimetidine may cause a minor interaction that can limit clinical effects when taken with Doravirine and Doravirine may cause a minor interaction that can limit clinical effects when taken with Dasatinib Cimetidine may cause a moderate interaction that could exacerbate diseases when taken with Donepezil and Donepezil may cause a minor interaction that can limit clinical effects when taken with Dasatinib Cimetidine may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Dasatinib Cimetidine may lead to a major life threatening interaction when taken with Loperamide and Loperamide may cause a moderate interaction that could exacerbate diseases when taken with Dasatinib Cimetidine may cause a moderate interaction that could exacerbate diseases when taken with Suvorexant and Suvorexant may cause a moderate interaction that could exacerbate diseases when taken with Dasatinib Cimetidine may cause a moderate interaction that could exacerbate diseases when taken with Mirtazapine and Mirtazapine may cause a moderate interaction that could exacerbate diseases when taken with Dasatinib
DB00533
DB01362
1,416
497
[ "DDInter1613", "DDInter960" ]
Rofecoxib
Iohexol
Rofecoxib is used for the treatment of osteoarthritis, rheumatoid arthritis, acute pain in adults, and primary dysmenorrhea, as well as acute treatment of migraine attacks with or without auras. Rofecoxib is a solid. This compound belongs to the stilbenes. These are organic compounds containing a 1,2-diphenylethylene moiety. Stilbenes (C6-C2-C6 ) are derived from the common phenylpropene (C6-C3) skeleton building block. The introduction of one or more hydroxyl groups to a phenyl ring lead to stilbenoids. Rofecoxib has a half-life of 17 hours and its mean oral bioavailability at therapeutically recommended doses of 125, 25, and 50 mg is approximately 93%. The proteins that rofecoxib target include elastin and prostaglandin G/H synthase 2
Iohexol is an effective non-ionic, water-soluble contrast agent which is used in myelography, arthrography, nephroangiography, arteriography, and other radiographic procedures. Its low systemic toxicity is the combined result of low chemotoxicity and low osmolality.
Major
2
[ [ [ 1416, 25, 497 ] ], [ [ 1416, 24, 891 ], [ 891, 25, 497 ] ], [ [ 1416, 63, 91 ], [ 91, 25, 497 ] ], [ [ 1416, 24, 1613 ], [ 1613, 64, 497 ] ], [ [ 1416, 25, 629 ], [ 629, 25, 497 ] ], [ [ 1416, 24, 891 ], [ 891, 21, 28681 ], [ 28681, 60, 497 ] ], [ [ 1416, 24, 50 ], [ 50, 25, 258 ], [ 258, 40, 497 ] ], [ [ 1416, 63, 91 ], [ 91, 25, 258 ], [ 258, 40, 497 ] ], [ [ 1416, 24, 1613 ], [ 1613, 63, 1523 ], [ 1523, 24, 497 ] ], [ [ 1416, 24, 1220 ], [ 1220, 7, 5774 ], [ 5774, 46, 497 ] ] ]
[ [ [ "Rofecoxib", "{u} may lead to a major life threatening interaction when taken with {v}", "Iohexol" ] ], [ [ "Rofecoxib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Prednisolone" ], [ "Prednisolone", "{u} may lead to a major life threatening interaction when taken with {v}", "Iohexol" ] ], [ [ "Rofecoxib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Vancomycin" ], [ "Vancomycin", "{u} may lead to a major life threatening interaction when taken with {v}", "Iohexol" ] ], [ [ "Rofecoxib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Peginterferon beta-1a" ], [ "Peginterferon beta-1a", "{u} may lead to a major life threatening interaction when taken with {v}", "Iohexol" ] ], [ [ "Rofecoxib", "{u} may lead to a major life threatening interaction when taken with {v}", "Sirolimus" ], [ "Sirolimus", "{u} may lead to a major life threatening interaction when taken with {v}", "Iohexol" ] ], [ [ "Rofecoxib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Prednisolone" ], [ "Prednisolone", "{u} (Compound) causes {v} (Side Effect)", "Hypersensitivity" ], [ "Hypersensitivity", "{u} (Side Effect) is caused by {v} (Compound)", "Iohexol" ] ], [ [ "Rofecoxib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Sulfasalazine" ], [ "Sulfasalazine", "{u} may lead to a major life threatening interaction when taken with {v}", "Iodixanol" ], [ "Iodixanol", "{u} (Compound) resembles {v} (Compound)", "Iohexol" ] ], [ [ "Rofecoxib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Vancomycin" ], [ "Vancomycin", "{u} may lead to a major life threatening interaction when taken with {v}", "Iodixanol" ], [ "Iodixanol", "{u} (Compound) resembles {v} (Compound)", "Iohexol" ] ], [ [ "Rofecoxib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Peginterferon beta-1a" ], [ "Peginterferon beta-1a", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Labetalol" ], [ "Labetalol", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Iohexol" ] ], [ [ "Rofecoxib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Dexamethasone" ], [ "Dexamethasone", "{u} (Compound) upregulates {v} (Gene)", "SELL" ], [ "SELL", "{u} (Gene) is upregulated by {v} (Compound)", "Iohexol" ] ] ]
Rofecoxib may cause a moderate interaction that could exacerbate diseases when taken with Prednisolone and Prednisolone may lead to a major life threatening interaction when taken with Iohexol Rofecoxib may cause a moderate interaction that could exacerbate diseases when taken with Vancomycin and Vancomycin may lead to a major life threatening interaction when taken with Iohexol Rofecoxib may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon beta-1a and Peginterferon beta-1a may lead to a major life threatening interaction when taken with Iohexol Rofecoxib may lead to a major life threatening interaction when taken with Sirolimus and Sirolimus may lead to a major life threatening interaction when taken with Iohexol Rofecoxib may cause a moderate interaction that could exacerbate diseases when taken with Prednisolone and Prednisolone (Compound) causes Hypersensitivity (Side Effect) and Hypersensitivity (Side Effect) is caused by Iohexol (Compound) Rofecoxib may cause a moderate interaction that could exacerbate diseases when taken with Sulfasalazine and Sulfasalazine may lead to a major life threatening interaction when taken with Iodixanol and Iodixanol (Compound) resembles Iohexol (Compound) Rofecoxib may cause a moderate interaction that could exacerbate diseases when taken with Vancomycin and Vancomycin may lead to a major life threatening interaction when taken with Iodixanol and Iodixanol (Compound) resembles Iohexol (Compound) Rofecoxib may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon beta-1a and Peginterferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Labetalol and Labetalol may cause a moderate interaction that could exacerbate diseases when taken with Iohexol Rofecoxib may cause a moderate interaction that could exacerbate diseases when taken with Dexamethasone and Dexamethasone (Compound) upregulates SELL (Gene) and SELL (Gene) is upregulated by Iohexol (Compound)
DB04865
DB11730
4
351
[ "DDInter1335", "DDInter1588" ]
Omacetaxine mepesuccinate
Ribociclib
Omacetaxine mepesuccinate (formerly known as HHT or Homoharringtonine), is a cephalotaxine ester and protein synthesis inhibitor with established clinical activity as a single agent in hematological malignancies. Omacetaxine mepesuccinate is synthesized from cephalotaxine, which is an extract from the leaves of the plant, Cephalotaxus species. In October 2005, omacetaxine mepesuccinate received Orphan Drug designation from the EMEA for the treatment of chronic myeloid leukemia (CML). Then in March 2006, it received Orphan Drug status from the FDA for the treatment of CML. In November 2006, omacetaxine mepesuccinate, for the treatment of CML, was granted Fast Track designation by the FDA. Most recently, in October 2012, omacetaxine mepesuccinate was
Ribociclib is a selective cyclin-dependent kinase inhibitor, a class of drugs that help slow the progression of cancer by inhibiting two proteins called cyclin-dependent kinase 4 and 6 (CDK4/6). These proteins, when over-activated, can enable cancer cells to grow and divide too quickly. Targeting CDK4/6 with enhanced precision may play a role in ensuring that cancer cells do not continue to replicate uncontrollably. Ribociclib was approved by the U.S. FDA in March, 2017 as Kisqali.
Moderate
1
[ [ [ 4, 24, 351 ] ], [ [ 4, 25, 283 ], [ 283, 62, 351 ] ], [ [ 4, 24, 310 ], [ 310, 24, 351 ] ], [ [ 4, 63, 597 ], [ 597, 24, 351 ] ], [ [ 4, 24, 987 ], [ 987, 63, 351 ] ], [ [ 4, 25, 1409 ], [ 1409, 24, 351 ] ], [ [ 4, 25, 710 ], [ 710, 63, 351 ] ], [ [ 4, 64, 804 ], [ 804, 24, 351 ] ], [ [ 4, 24, 975 ], [ 975, 64, 351 ] ], [ [ 4, 25, 1259 ], [ 1259, 64, 351 ] ] ]
[ [ [ "Omacetaxine mepesuccinate", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Ribociclib" ] ], [ [ "Omacetaxine mepesuccinate", "{u} may lead to a major life threatening interaction when taken with {v}", "Fedratinib" ], [ "Fedratinib", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Ribociclib" ] ], [ [ "Omacetaxine mepesuccinate", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Cabazitaxel" ], [ "Cabazitaxel", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Ribociclib" ] ], [ [ "Omacetaxine mepesuccinate", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Chloramphenicol" ], [ "Chloramphenicol", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Ribociclib" ] ], [ [ "Omacetaxine mepesuccinate", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Vibrio cholerae CVD 103-HgR strain live antigen" ], [ "Vibrio cholerae CVD 103-HgR strain live antigen", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Ribociclib" ] ], [ [ "Omacetaxine mepesuccinate", "{u} may lead to a major life threatening interaction when taken with {v}", "Apixaban" ], [ "Apixaban", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Ribociclib" ] ], [ [ "Omacetaxine mepesuccinate", "{u} may lead to a major life threatening interaction when taken with {v}", "Binimetinib" ], [ "Binimetinib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Ribociclib" ] ], [ [ "Omacetaxine mepesuccinate", "{u} may lead to a major life threatening interaction when taken with {v}", "Sulfinpyrazone" ], [ "Sulfinpyrazone", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Ribociclib" ] ], [ [ "Omacetaxine mepesuccinate", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Lurbinectedin" ], [ "Lurbinectedin", "{u} may lead to a major life threatening interaction when taken with {v}", "Ribociclib" ] ], [ [ "Omacetaxine mepesuccinate", "{u} may lead to a major life threatening interaction when taken with {v}", "Baricitinib" ], [ "Baricitinib", "{u} may lead to a major life threatening interaction when taken with {v}", "Ribociclib" ] ] ]
Omacetaxine mepesuccinate may lead to a major life threatening interaction when taken with Fedratinib and Fedratinib may cause a minor interaction that can limit clinical effects when taken with Ribociclib Omacetaxine mepesuccinate may cause a moderate interaction that could exacerbate diseases when taken with Cabazitaxel and Cabazitaxel may cause a moderate interaction that could exacerbate diseases when taken with Ribociclib Omacetaxine mepesuccinate may cause a moderate interaction that could exacerbate diseases when taken with Chloramphenicol and Chloramphenicol may cause a moderate interaction that could exacerbate diseases when taken with Ribociclib Omacetaxine mepesuccinate may cause a moderate interaction that could exacerbate diseases when taken with Vibrio cholerae CVD 103-HgR strain live antigen and Vibrio cholerae CVD 103-HgR strain live antigen may cause a moderate interaction that could exacerbate diseases when taken with Ribociclib Omacetaxine mepesuccinate may lead to a major life threatening interaction when taken with Apixaban and Apixaban may cause a moderate interaction that could exacerbate diseases when taken with Ribociclib Omacetaxine mepesuccinate may lead to a major life threatening interaction when taken with Binimetinib and Binimetinib may cause a moderate interaction that could exacerbate diseases when taken with Ribociclib Omacetaxine mepesuccinate may lead to a major life threatening interaction when taken with Sulfinpyrazone and Sulfinpyrazone may cause a moderate interaction that could exacerbate diseases when taken with Ribociclib Omacetaxine mepesuccinate may cause a moderate interaction that could exacerbate diseases when taken with Lurbinectedin and Lurbinectedin may lead to a major life threatening interaction when taken with Ribociclib Omacetaxine mepesuccinate may lead to a major life threatening interaction when taken with Baricitinib and Baricitinib may lead to a major life threatening interaction when taken with Ribociclib
DB00365
DB00816
839
1,674
[ "DDInter842", "DDInter1346" ]
Grepafloxacin
Orciprenaline
Grepafloxacin is an oral broad-spectrum quinoline antibacterial agent used to treat bacterial infections. Due to the QTc-prolonging potential, as indicated by the changes in the QT interval on the electrocardiogram, and the risk for cardiovascular adverse events, grepafloxacin was withdrawn in the United States.
A beta-adrenergic agonist used in the treatment of asthma and bronchospasms. [PubChem]
Major
2
[ [ [ 839, 25, 1674 ] ], [ [ 839, 25, 251 ], [ 251, 23, 1674 ] ], [ [ 839, 25, 891 ], [ 891, 62, 1674 ] ], [ [ 839, 24, 617 ], [ 617, 62, 1674 ] ], [ [ 839, 25, 959 ], [ 959, 63, 1674 ] ], [ [ 839, 63, 1647 ], [ 1647, 24, 1674 ] ], [ [ 839, 24, 1002 ], [ 1002, 63, 1674 ] ], [ [ 839, 64, 600 ], [ 600, 24, 1674 ] ], [ [ 839, 25, 888 ], [ 888, 24, 1674 ] ], [ [ 839, 24, 127 ], [ 127, 24, 1674 ] ] ]
[ [ [ "Grepafloxacin", "{u} may lead to a major life threatening interaction when taken with {v}", "Orciprenaline" ] ], [ [ "Grepafloxacin", "{u} may lead to a major life threatening interaction when taken with {v}", "Betamethasone" ], [ "Betamethasone", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Orciprenaline" ] ], [ [ "Grepafloxacin", "{u} may lead to a major life threatening interaction when taken with {v}", "Prednisolone" ], [ "Prednisolone", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Orciprenaline" ] ], [ [ "Grepafloxacin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Budesonide" ], [ "Budesonide", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Orciprenaline" ] ], [ [ "Grepafloxacin", "{u} may lead to a major life threatening interaction when taken with {v}", "Glipizide" ], [ "Glipizide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Orciprenaline" ] ], [ [ "Grepafloxacin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Acarbose" ], [ "Acarbose", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Orciprenaline" ] ], [ [ "Grepafloxacin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Alogliptin" ], [ "Alogliptin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Orciprenaline" ] ], [ [ "Grepafloxacin", "{u} may lead to a major life threatening interaction when taken with {v}", "Fluconazole" ], [ "Fluconazole", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Orciprenaline" ] ], [ [ "Grepafloxacin", "{u} may lead to a major life threatening interaction when taken with {v}", "Tamoxifen" ], [ "Tamoxifen", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Orciprenaline" ] ], [ [ "Grepafloxacin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Miglitol" ], [ "Miglitol", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Orciprenaline" ] ] ]
Grepafloxacin may lead to a major life threatening interaction when taken with Betamethasone and Betamethasone may cause a minor interaction that can limit clinical effects when taken with Orciprenaline Grepafloxacin may lead to a major life threatening interaction when taken with Prednisolone and Prednisolone may cause a minor interaction that can limit clinical effects when taken with Orciprenaline Grepafloxacin may cause a moderate interaction that could exacerbate diseases when taken with Budesonide and Budesonide may cause a minor interaction that can limit clinical effects when taken with Orciprenaline Grepafloxacin may lead to a major life threatening interaction when taken with Glipizide and Glipizide may cause a moderate interaction that could exacerbate diseases when taken with Orciprenaline Grepafloxacin may cause a moderate interaction that could exacerbate diseases when taken with Acarbose and Acarbose may cause a moderate interaction that could exacerbate diseases when taken with Orciprenaline Grepafloxacin may cause a moderate interaction that could exacerbate diseases when taken with Alogliptin and Alogliptin may cause a moderate interaction that could exacerbate diseases when taken with Orciprenaline Grepafloxacin may lead to a major life threatening interaction when taken with Fluconazole and Fluconazole may cause a moderate interaction that could exacerbate diseases when taken with Orciprenaline Grepafloxacin may lead to a major life threatening interaction when taken with Tamoxifen and Tamoxifen may cause a moderate interaction that could exacerbate diseases when taken with Orciprenaline Grepafloxacin may cause a moderate interaction that could exacerbate diseases when taken with Miglitol and Miglitol may cause a moderate interaction that could exacerbate diseases when taken with Orciprenaline
DB00526
DB01224
1,555
623
[ "DDInter1355", "DDInter1553" ]
Oxaliplatin
Quetiapine
Oxaliplatin is a platinum-based chemotherapy drug in the same family as cisplatin and carboplatin. Compared to cisplatin the two amine groups are replaced by diamino cyclohexane (DACH) group to provide a greater antitumor effect. However, this leads to poorer water solubility, which was compensated by the addition of the chloride moieties. Due to this chemical moiety, oxaliplatin readily undergoes non-enzymatic biotransformation, thus complicating oxaliplatin's pharmacokinetics. Like most platinum-based compounds, oxaliplatin's mechanism of action is primarily through DNA damage through DNA crosslinking, particularly intrastrand and interstrand crosslinking. However, due to the structure of oxaliplatin, its adducts make the binding of mismatch repair protein to DNA harder compared to cisplatin or carboplatin's adducts, resulting in greater cytotoxic effects. The
Initially approved by the FDA in 1997, quetiapine is a second-generation atypical antipsychotic used in schizophrenia, major depression, and bipolar disorder. Quetiapine demonstrates a high level of therapeutic efficacy and low risk of adverse effects during long-term treatment. It is well-tolerated and a suitable option for some patients with high sensitivity to other drugs, such as [clozapine] and [olanzapine].
Moderate
1
[ [ [ 1555, 24, 623 ] ], [ [ 1555, 24, 827 ], [ 827, 1, 623 ] ], [ [ 1555, 64, 695 ], [ 695, 1, 623 ] ], [ [ 1555, 63, 508 ], [ 508, 1, 623 ] ], [ [ 1555, 24, 112 ], [ 112, 23, 623 ] ], [ [ 1555, 24, 1297 ], [ 1297, 63, 623 ] ], [ [ 1555, 24, 888 ], [ 888, 24, 623 ] ], [ [ 1555, 63, 1181 ], [ 1181, 24, 623 ] ], [ [ 1555, 25, 770 ], [ 770, 24, 623 ] ], [ [ 1555, 24, 609 ], [ 609, 25, 623 ] ] ]
[ [ [ "Oxaliplatin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Quetiapine" ] ], [ [ "Oxaliplatin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Trazodone" ], [ "Trazodone", "{u} (Compound) resembles {v} (Compound)", "Quetiapine" ] ], [ [ "Oxaliplatin", "{u} may lead to a major life threatening interaction when taken with {v}", "Clozapine" ], [ "Clozapine", "{u} (Compound) resembles {v} (Compound)", "Quetiapine" ] ], [ [ "Oxaliplatin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Promazine" ], [ "Promazine", "{u} (Compound) resembles {v} (Compound)", "Quetiapine" ] ], [ [ "Oxaliplatin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Metronidazole" ], [ "Metronidazole", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Quetiapine" ] ], [ [ "Oxaliplatin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Osilodrostat" ], [ "Osilodrostat", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Quetiapine" ] ], [ [ "Oxaliplatin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Tamoxifen" ], [ "Tamoxifen", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Quetiapine" ] ], [ [ "Oxaliplatin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Terfenadine" ], [ "Terfenadine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Quetiapine" ] ], [ [ "Oxaliplatin", "{u} may lead to a major life threatening interaction when taken with {v}", "Thalidomide" ], [ "Thalidomide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Quetiapine" ] ], [ [ "Oxaliplatin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Clarithromycin" ], [ "Clarithromycin", "{u} may lead to a major life threatening interaction when taken with {v}", "Quetiapine" ] ] ]
Oxaliplatin may cause a moderate interaction that could exacerbate diseases when taken with Trazodone and Trazodone (Compound) resembles Quetiapine (Compound) Oxaliplatin may lead to a major life threatening interaction when taken with Clozapine and Clozapine (Compound) resembles Quetiapine (Compound) Oxaliplatin may cause a moderate interaction that could exacerbate diseases when taken with Promazine and Promazine (Compound) resembles Quetiapine (Compound) Oxaliplatin may cause a moderate interaction that could exacerbate diseases when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Quetiapine Oxaliplatin may cause a moderate interaction that could exacerbate diseases when taken with Osilodrostat and Osilodrostat may cause a moderate interaction that could exacerbate diseases when taken with Quetiapine Oxaliplatin may cause a moderate interaction that could exacerbate diseases when taken with Tamoxifen and Tamoxifen may cause a moderate interaction that could exacerbate diseases when taken with Quetiapine Oxaliplatin may cause a moderate interaction that could exacerbate diseases when taken with Terfenadine and Terfenadine may cause a moderate interaction that could exacerbate diseases when taken with Quetiapine Oxaliplatin may lead to a major life threatening interaction when taken with Thalidomide and Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Quetiapine Oxaliplatin may cause a moderate interaction that could exacerbate diseases when taken with Clarithromycin and Clarithromycin may lead to a major life threatening interaction when taken with Quetiapine
DB01263
DB06603
859
39
[ "DDInter1494", "DDInter1387" ]
Posaconazole
Panobinostat
Posaconazole is a triazole antifungal drug that is used to treat invasive infections by Candida species and Aspergillus species in severely immunocompromised patients.
Panobinostat is an oral deacetylace (DAC) inhibitor approved on February 23, 2015 by the FDA for the treatment of multiple myeloma. The approval was accelerated based on progression-free survival, therefore confirmatory trials by the sponsor to demonstrate clinical efficacy in multiple myeloma treatment are in progress of being conducted. Panobinostat is marketed by Novartis under the brand name Farydak. Panobinostat acts as a non-selective histone deacetylase inhibitor (pan-HDAC inhibitor) and it is the most potent DAC inhibiting agent available on the market.
Major
2
[ [ [ 859, 25, 39 ] ], [ [ 859, 62, 112 ], [ 112, 23, 39 ] ], [ [ 859, 63, 912 ], [ 912, 24, 39 ] ], [ [ 859, 25, 578 ], [ 578, 63, 39 ] ], [ [ 859, 24, 850 ], [ 850, 63, 39 ] ], [ [ 859, 62, 1101 ], [ 1101, 24, 39 ] ], [ [ 859, 64, 543 ], [ 543, 24, 39 ] ], [ [ 859, 25, 594 ], [ 594, 64, 39 ] ], [ [ 859, 63, 485 ], [ 485, 25, 39 ] ], [ [ 859, 64, 1181 ], [ 1181, 25, 39 ] ] ]
[ [ [ "Posaconazole", "{u} may lead to a major life threatening interaction when taken with {v}", "Panobinostat" ] ], [ [ "Posaconazole", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Metronidazole" ], [ "Metronidazole", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Panobinostat" ] ], [ [ "Posaconazole", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Interferon beta-1a" ], [ "Interferon beta-1a", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Panobinostat" ] ], [ [ "Posaconazole", "{u} may lead to a major life threatening interaction when taken with {v}", "Ticagrelor" ], [ "Ticagrelor", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Panobinostat" ] ], [ [ "Posaconazole", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Brentuximab vedotin" ], [ "Brentuximab vedotin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Panobinostat" ] ], [ [ "Posaconazole", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Bexarotene" ], [ "Bexarotene", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Panobinostat" ] ], [ [ "Posaconazole", "{u} may lead to a major life threatening interaction when taken with {v}", "Loperamide" ], [ "Loperamide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Panobinostat" ] ], [ [ "Posaconazole", "{u} may lead to a major life threatening interaction when taken with {v}", "Bosutinib" ], [ "Bosutinib", "{u} may lead to a major life threatening interaction when taken with {v}", "Panobinostat" ] ], [ [ "Posaconazole", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Pentamidine" ], [ "Pentamidine", "{u} may lead to a major life threatening interaction when taken with {v}", "Panobinostat" ] ], [ [ "Posaconazole", "{u} may lead to a major life threatening interaction when taken with {v}", "Terfenadine" ], [ "Terfenadine", "{u} may lead to a major life threatening interaction when taken with {v}", "Panobinostat" ] ] ]
Posaconazole may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Panobinostat Posaconazole may cause a moderate interaction that could exacerbate diseases when taken with Interferon beta-1a and Interferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Panobinostat Posaconazole may lead to a major life threatening interaction when taken with Ticagrelor and Ticagrelor may cause a moderate interaction that could exacerbate diseases when taken with Panobinostat Posaconazole may cause a moderate interaction that could exacerbate diseases when taken with Brentuximab vedotin and Brentuximab vedotin may cause a moderate interaction that could exacerbate diseases when taken with Panobinostat Posaconazole may cause a minor interaction that can limit clinical effects when taken with Bexarotene and Bexarotene may cause a moderate interaction that could exacerbate diseases when taken with Panobinostat Posaconazole may lead to a major life threatening interaction when taken with Loperamide and Loperamide may cause a moderate interaction that could exacerbate diseases when taken with Panobinostat Posaconazole may lead to a major life threatening interaction when taken with Bosutinib and Bosutinib may lead to a major life threatening interaction when taken with Panobinostat Posaconazole may cause a moderate interaction that could exacerbate diseases when taken with Pentamidine and Pentamidine may lead to a major life threatening interaction when taken with Panobinostat Posaconazole may lead to a major life threatening interaction when taken with Terfenadine and Terfenadine may lead to a major life threatening interaction when taken with Panobinostat
DB01764
DB06626
805
263
[ "DDInter469", "DDInter147" ]
Dalfopristin
Axitinib
Dalfopristin is a combination of two antibiotics (Dalfopristin and quinupristin) used to treat infections by staphylococci and by vancomycin-resistant Enterococcus faecium. It is not effective against Enterococcus faecalis infections. Dalfopristin inhibits the early phase of protein synthesis in the bacterial ribosome and quinupristin inhibits the late phase of protein synthesis.
Axitinib is a second generation tyrosine kinase inhibitor that works by selectively inhibiting vascular endothelial growth factor receptors (VEGFR-1, VEGFR-2, VEGFR-3). Through this mechanism of action, axitinib blocks angiogenesis, tumour growth and metastases. It is reported to exhibit potency that is 50-450 times higher than that of the first generation VEGFR inhibitors. Axitinib is an indazole derivative. It is most commonly marketed under the name Inlyta® and is available in oral formulations.
Moderate
1
[ [ [ 805, 24, 263 ] ], [ [ 805, 63, 1215 ], [ 1215, 23, 263 ] ], [ [ 805, 63, 392 ], [ 392, 24, 263 ] ], [ [ 805, 24, 1593 ], [ 1593, 63, 263 ] ], [ [ 805, 62, 1101 ], [ 1101, 24, 263 ] ], [ [ 805, 24, 1250 ], [ 1250, 24, 263 ] ], [ [ 805, 25, 484 ], [ 484, 63, 263 ] ], [ [ 805, 23, 283 ], [ 283, 63, 263 ] ], [ [ 805, 63, 1220 ], [ 1220, 25, 263 ] ], [ [ 805, 24, 384 ], [ 384, 64, 263 ] ] ]
[ [ [ "Dalfopristin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Axitinib" ] ], [ [ "Dalfopristin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Lansoprazole" ], [ "Lansoprazole", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Axitinib" ] ], [ [ "Dalfopristin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Lapatinib" ], [ "Lapatinib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Axitinib" ] ], [ [ "Dalfopristin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Crizotinib" ], [ "Crizotinib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Axitinib" ] ], [ [ "Dalfopristin", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Bexarotene" ], [ "Bexarotene", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Axitinib" ] ], [ [ "Dalfopristin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Pazopanib" ], [ "Pazopanib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Axitinib" ] ], [ [ "Dalfopristin", "{u} may lead to a major life threatening interaction when taken with {v}", "Entrectinib" ], [ "Entrectinib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Axitinib" ] ], [ [ "Dalfopristin", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Fedratinib" ], [ "Fedratinib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Axitinib" ] ], [ [ "Dalfopristin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Dexamethasone" ], [ "Dexamethasone", "{u} may lead to a major life threatening interaction when taken with {v}", "Axitinib" ] ], [ [ "Dalfopristin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Idelalisib" ], [ "Idelalisib", "{u} may lead to a major life threatening interaction when taken with {v}", "Axitinib" ] ] ]
Dalfopristin may cause a moderate interaction that could exacerbate diseases when taken with Lansoprazole and Lansoprazole may cause a minor interaction that can limit clinical effects when taken with Axitinib Dalfopristin may cause a moderate interaction that could exacerbate diseases when taken with Lapatinib and Lapatinib may cause a moderate interaction that could exacerbate diseases when taken with Axitinib Dalfopristin may cause a moderate interaction that could exacerbate diseases when taken with Crizotinib and Crizotinib may cause a moderate interaction that could exacerbate diseases when taken with Axitinib Dalfopristin may cause a minor interaction that can limit clinical effects when taken with Bexarotene and Bexarotene may cause a moderate interaction that could exacerbate diseases when taken with Axitinib Dalfopristin may cause a moderate interaction that could exacerbate diseases when taken with Pazopanib and Pazopanib may cause a moderate interaction that could exacerbate diseases when taken with Axitinib Dalfopristin may lead to a major life threatening interaction when taken with Entrectinib and Entrectinib may cause a moderate interaction that could exacerbate diseases when taken with Axitinib Dalfopristin may cause a minor interaction that can limit clinical effects when taken with Fedratinib and Fedratinib may cause a moderate interaction that could exacerbate diseases when taken with Axitinib Dalfopristin may cause a moderate interaction that could exacerbate diseases when taken with Dexamethasone and Dexamethasone may lead to a major life threatening interaction when taken with Axitinib Dalfopristin may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib and Idelalisib may lead to a major life threatening interaction when taken with Axitinib
DB00059
DB13873
1,560
1,534
[ "DDInter1404", "DDInter719" ]
Pegaspargase
Fenofibric acid
Pegaspargase is a conjugate of monomethoxypolyethylene glycol (mPEG) and L-asparaginase (L-asparagine amidohydrolase), an asparagine-specific enzyme that converts L-asparagine into aspartic acid and ammonia. Asparagine is an amino acid that is vital for cell survival. In humans, most normal tissues can produce asparagine through the action of asparagine synthetase. However, leukemia cells have low levels of this enzyme and depend on exogenous sources. Therefore, the use of pegaspargase results in leukemic cell death.[A103,A255912,L44667] Pegaspargase has the same mechanism of action as [L-asparaginase] derived from _Escherichia coli_, a previously developed enzyme used for the treatment of acute lymphoblastic leukemia (ALL). However, using L-asparaginase derived from _Escherich
Fenofibric acid is a lipid-lowering agent that is used in severe hypertriglyceridemia, primary hyperlipidemia, and mixed dyslipidemia. It works to decrease elevated low-density lipoprotein cholesterol, total cholesterol, triglycerides, apolipoprotein B, while increasing high-density lipoprotein cholesterol.[A32038,L12855] Due to its high hydrophilicity and poor absorption profile, prodrug ,[fenofibrate], and other conjugated compounds of fenofibric acid, such as choline fenofibrate, have been developed for improved solubility, gastrointestinal absorption, and bioavailability, and more convenient administration.[A32038,A193362]
Moderate
1
[ [ [ 1560, 24, 1534 ] ], [ [ 1560, 24, 267 ], [ 267, 24, 1534 ] ], [ [ 1560, 63, 1685 ], [ 1685, 24, 1534 ] ], [ [ 1560, 24, 126 ], [ 126, 25, 1534 ] ], [ [ 1560, 25, 1377 ], [ 1377, 25, 1534 ] ], [ [ 1560, 24, 267 ], [ 267, 63, 372 ], [ 372, 24, 1534 ] ], [ [ 1560, 24, 372 ], [ 372, 24, 267 ], [ 267, 24, 1534 ] ], [ [ 1560, 63, 1685 ], [ 1685, 24, 959 ], [ 959, 24, 1534 ] ], [ [ 1560, 25, 1377 ], [ 1377, 64, 267 ], [ 267, 24, 1534 ] ], [ [ 1560, 63, 1685 ], [ 1685, 63, 305 ], [ 305, 24, 1534 ] ] ]
[ [ [ "Pegaspargase", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Fenofibric acid" ] ], [ [ "Pegaspargase", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Naltrexone" ], [ "Naltrexone", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Fenofibric acid" ] ], [ [ "Pegaspargase", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Insulin human" ], [ "Insulin human", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Fenofibric acid" ] ], [ [ "Pegaspargase", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Warfarin" ], [ "Warfarin", "{u} may lead to a major life threatening interaction when taken with {v}", "Fenofibric acid" ] ], [ [ "Pegaspargase", "{u} may lead to a major life threatening interaction when taken with {v}", "Leflunomide" ], [ "Leflunomide", "{u} may lead to a major life threatening interaction when taken with {v}", "Fenofibric acid" ] ], [ [ "Pegaspargase", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Naltrexone" ], [ "Naltrexone", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Clofarabine" ], [ "Clofarabine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Fenofibric acid" ] ], [ [ "Pegaspargase", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Clofarabine" ], [ "Clofarabine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Naltrexone" ], [ "Naltrexone", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Fenofibric acid" ] ], [ [ "Pegaspargase", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Insulin human" ], [ "Insulin human", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Glipizide" ], [ "Glipizide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Fenofibric acid" ] ], [ [ "Pegaspargase", "{u} may lead to a major life threatening interaction when taken with {v}", "Leflunomide" ], [ "Leflunomide", "{u} may lead to a major life threatening interaction when taken with {v}", "Naltrexone" ], [ "Naltrexone", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Fenofibric acid" ] ], [ [ "Pegaspargase", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Insulin human" ], [ "Insulin human", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Asparaginase Escherichia coli" ], [ "Asparaginase Escherichia coli", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Fenofibric acid" ] ] ]
Pegaspargase may cause a moderate interaction that could exacerbate diseases when taken with Naltrexone and Naltrexone may cause a moderate interaction that could exacerbate diseases when taken with Fenofibric acid Pegaspargase may cause a moderate interaction that could exacerbate diseases when taken with Insulin human and Insulin human may cause a moderate interaction that could exacerbate diseases when taken with Fenofibric acid Pegaspargase may cause a moderate interaction that could exacerbate diseases when taken with Warfarin and Warfarin may lead to a major life threatening interaction when taken with Fenofibric acid Pegaspargase may lead to a major life threatening interaction when taken with Leflunomide and Leflunomide may lead to a major life threatening interaction when taken with Fenofibric acid Pegaspargase may cause a moderate interaction that could exacerbate diseases when taken with Naltrexone and Naltrexone may cause a moderate interaction that could exacerbate diseases when taken with Clofarabine and Clofarabine may cause a moderate interaction that could exacerbate diseases when taken with Fenofibric acid Pegaspargase may cause a moderate interaction that could exacerbate diseases when taken with Clofarabine and Clofarabine may cause a moderate interaction that could exacerbate diseases when taken with Naltrexone and Naltrexone may cause a moderate interaction that could exacerbate diseases when taken with Fenofibric acid Pegaspargase may cause a moderate interaction that could exacerbate diseases when taken with Insulin human and Insulin human may cause a moderate interaction that could exacerbate diseases when taken with Glipizide and Glipizide may cause a moderate interaction that could exacerbate diseases when taken with Fenofibric acid Pegaspargase may lead to a major life threatening interaction when taken with Leflunomide and Leflunomide may lead to a major life threatening interaction when taken with Naltrexone and Naltrexone may cause a moderate interaction that could exacerbate diseases when taken with Fenofibric acid Pegaspargase may cause a moderate interaction that could exacerbate diseases when taken with Insulin human and Insulin human may cause a moderate interaction that could exacerbate diseases when taken with Asparaginase Escherichia coli and Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate diseases when taken with Fenofibric acid
DB00512
DB01172
91
416
[ "DDInter1916", "DDInter1004" ]
Vancomycin
Kanamycin
Antibacterial obtained from Streptomyces orientalis. It is a glycopeptide related to ristocetin that inhibits bacterial cell wall assembly and is toxic to kidneys and the inner ear. As of January 29 2018, CutisPharma's Firvanq is the only FDA approved vancomycin oral liquid treatment option available for the the treatment of _Clostridium difficile_ associated diarrhea and enterocolitis caused by _Staphylococcus aureus_, including methicillin-resistant strains. Such an oral liquid formulation is expected to make _Clostridium difficile_ associated diarrhea therapy more accessible in comparison to previously available specialty compounding products.
Kanamycin (also known as kanamycin A) is an aminoglycoside bacteriocidal antibiotic, available in oral, intravenous, and intramuscular forms, and used to treat a wide variety of infections. Kanamycin is isolated from the bacterium Streptomyces kanamyceticus and its most commonly used form is kanamycin sulfate.
Moderate
1
[ [ [ 91, 24, 416 ] ], [ [ 91, 21, 31264 ], [ 31264, 60, 416 ] ], [ [ 91, 63, 831 ], [ 831, 24, 416 ] ], [ [ 91, 24, 712 ], [ 712, 63, 416 ] ], [ [ 91, 24, 59 ], [ 59, 24, 416 ] ], [ [ 91, 64, 790 ], [ 790, 24, 416 ] ], [ [ 91, 24, 1680 ], [ 1680, 25, 416 ] ], [ [ 91, 25, 1312 ], [ 1312, 64, 416 ] ], [ [ 91, 25, 629 ], [ 629, 25, 416 ] ], [ [ 91, 24, 728 ], [ 728, 64, 416 ] ] ]
[ [ [ "Vancomycin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Kanamycin" ] ], [ [ "Vancomycin", "{u} (Compound) causes {v} (Side Effect)", "Nephrotoxicity" ], [ "Nephrotoxicity", "{u} (Side Effect) is caused by {v} (Compound)", "Kanamycin" ] ], [ [ "Vancomycin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Indomethacin" ], [ "Indomethacin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Kanamycin" ] ], [ [ "Vancomycin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Olsalazine" ], [ "Olsalazine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Kanamycin" ] ], [ [ "Vancomycin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Etodolac" ], [ "Etodolac", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Kanamycin" ] ], [ [ "Vancomycin", "{u} may lead to a major life threatening interaction when taken with {v}", "Piperacillin" ], [ "Piperacillin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Kanamycin" ] ], [ [ "Vancomycin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Etacrynic acid" ], [ "Etacrynic acid", "{u} may lead to a major life threatening interaction when taken with {v}", "Kanamycin" ] ], [ [ "Vancomycin", "{u} may lead to a major life threatening interaction when taken with {v}", "Human botulinum neurotoxin A/B immune globulin" ], [ "Human botulinum neurotoxin A/B immune globulin", "{u} may lead to a major life threatening interaction when taken with {v}", "Kanamycin" ] ], [ [ "Vancomycin", "{u} may lead to a major life threatening interaction when taken with {v}", "Sirolimus" ], [ "Sirolimus", "{u} may lead to a major life threatening interaction when taken with {v}", "Kanamycin" ] ], [ [ "Vancomycin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Vecuronium" ], [ "Vecuronium", "{u} may lead to a major life threatening interaction when taken with {v}", "Kanamycin" ] ] ]
Vancomycin (Compound) causes Nephrotoxicity (Side Effect) and Nephrotoxicity (Side Effect) is caused by Kanamycin (Compound) Vancomycin may cause a moderate interaction that could exacerbate diseases when taken with Indomethacin and Indomethacin may cause a moderate interaction that could exacerbate diseases when taken with Kanamycin Vancomycin may cause a moderate interaction that could exacerbate diseases when taken with Olsalazine and Olsalazine may cause a moderate interaction that could exacerbate diseases when taken with Kanamycin Vancomycin may cause a moderate interaction that could exacerbate diseases when taken with Etodolac and Etodolac may cause a moderate interaction that could exacerbate diseases when taken with Kanamycin Vancomycin may lead to a major life threatening interaction when taken with Piperacillin and Piperacillin may cause a moderate interaction that could exacerbate diseases when taken with Kanamycin Vancomycin may cause a moderate interaction that could exacerbate diseases when taken with Etacrynic acid and Etacrynic acid may lead to a major life threatening interaction when taken with Kanamycin Vancomycin may lead to a major life threatening interaction when taken with Human botulinum neurotoxin A/B immune globulin and Human botulinum neurotoxin A/B immune globulin may lead to a major life threatening interaction when taken with Kanamycin Vancomycin may lead to a major life threatening interaction when taken with Sirolimus and Sirolimus may lead to a major life threatening interaction when taken with Kanamycin Vancomycin may cause a moderate interaction that could exacerbate diseases when taken with Vecuronium and Vecuronium may lead to a major life threatening interaction when taken with Kanamycin
DB00031
DB00461
20
598
[ "DDInter1764", "DDInter1254" ]
Tenecteplase
Nabumetone
Tenecteplase is a tissue plasminogen activator (tPA) developed from modifications of natural human tPA complementary DNA (cDNA). It is a 527 amino acid with a substitution of threonine 103 with asparagine and substitution of asparagine 117 with glutamine within the kringle 1 domain, and a tetra-alanine substitution at amino acids 296-299 in the protease domain.
Nabumetone was originally developed as a non-acidic non-steroidal anti-inflammatory drug (NSAID).[label] It was thought to avoid trapping of the drug in the stomach by making it unable to dissociate into ions which was believed to reduce GI toxicity by limiting local action. While slightly reduced, possibly due to a degree of cyclooxygenase-2 selectivity (COX-2), nabumetone still produces significant adverse effects in the GI tract.[label,A178903] The molecule itself is a pro-drug with its 6-methoxy-2-naphthylacetic acid (6-MNA) metabolite acting as a potent COX inhibitor similar in structure to [naproxen]. Nabumetone was developed by Smithkline Beecham under the trade name Relafen and first received FDA approval in December, 1991.
Moderate
1
[ [ [ 20, 24, 598 ] ], [ [ 20, 25, 366 ], [ 366, 24, 598 ] ], [ [ 20, 24, 1512 ], [ 1512, 63, 598 ] ], [ [ 20, 25, 936 ], [ 936, 63, 598 ] ], [ [ 20, 24, 1061 ], [ 1061, 24, 598 ] ], [ [ 20, 64, 942 ], [ 942, 24, 598 ] ], [ [ 20, 25, 500 ], [ 500, 64, 598 ] ], [ [ 20, 25, 273 ], [ 273, 25, 598 ] ], [ [ 20, 25, 366 ], [ 366, 64, 1271 ], [ 1271, 24, 598 ] ], [ [ 20, 24, 1512 ], [ 1512, 6, 7950 ], [ 7950, 45, 598 ] ] ]
[ [ [ "Tenecteplase", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Nabumetone" ] ], [ [ "Tenecteplase", "{u} may lead to a major life threatening interaction when taken with {v}", "Eptifibatide" ], [ "Eptifibatide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Nabumetone" ] ], [ [ "Tenecteplase", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Diclofenac" ], [ "Diclofenac", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Nabumetone" ] ], [ [ "Tenecteplase", "{u} may lead to a major life threatening interaction when taken with {v}", "Cangrelor" ], [ "Cangrelor", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Nabumetone" ] ], [ [ "Tenecteplase", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Treprostinil" ], [ "Treprostinil", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Nabumetone" ] ], [ [ "Tenecteplase", "{u} may lead to a major life threatening interaction when taken with {v}", "Bivalirudin" ], [ "Bivalirudin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Nabumetone" ] ], [ [ "Tenecteplase", "{u} may lead to a major life threatening interaction when taken with {v}", "Enoxaparin" ], [ "Enoxaparin", "{u} may lead to a major life threatening interaction when taken with {v}", "Nabumetone" ] ], [ [ "Tenecteplase", "{u} may lead to a major life threatening interaction when taken with {v}", "Tositumomab" ], [ "Tositumomab", "{u} may lead to a major life threatening interaction when taken with {v}", "Nabumetone" ] ], [ [ "Tenecteplase", "{u} may lead to a major life threatening interaction when taken with {v}", "Eptifibatide" ], [ "Eptifibatide", "{u} may lead to a major life threatening interaction when taken with {v}", "Alteplase" ], [ "Alteplase", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Nabumetone" ] ], [ [ "Tenecteplase", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Diclofenac" ], [ "Diclofenac", "{u} (Compound) binds {v} (Gene)", "CYP1A2" ], [ "CYP1A2", "{u} (Gene) is bound by {v} (Compound)", "Nabumetone" ] ] ]
Tenecteplase may lead to a major life threatening interaction when taken with Eptifibatide and Eptifibatide may cause a moderate interaction that could exacerbate diseases when taken with Nabumetone Tenecteplase may cause a moderate interaction that could exacerbate diseases when taken with Diclofenac and Diclofenac may cause a moderate interaction that could exacerbate diseases when taken with Nabumetone Tenecteplase may lead to a major life threatening interaction when taken with Cangrelor and Cangrelor may cause a moderate interaction that could exacerbate diseases when taken with Nabumetone Tenecteplase may cause a moderate interaction that could exacerbate diseases when taken with Treprostinil and Treprostinil may cause a moderate interaction that could exacerbate diseases when taken with Nabumetone Tenecteplase may lead to a major life threatening interaction when taken with Bivalirudin and Bivalirudin may cause a moderate interaction that could exacerbate diseases when taken with Nabumetone Tenecteplase may lead to a major life threatening interaction when taken with Enoxaparin and Enoxaparin may lead to a major life threatening interaction when taken with Nabumetone Tenecteplase may lead to a major life threatening interaction when taken with Tositumomab and Tositumomab may lead to a major life threatening interaction when taken with Nabumetone Tenecteplase may lead to a major life threatening interaction when taken with Eptifibatide and Eptifibatide may lead to a major life threatening interaction when taken with Alteplase and Alteplase may cause a moderate interaction that could exacerbate diseases when taken with Nabumetone Tenecteplase may cause a moderate interaction that could exacerbate diseases when taken with Diclofenac and Diclofenac (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Nabumetone (Compound)
DB00231
DB08900
1,174
1,162
[ "DDInter1761", "DDInter1753" ]
Temazepam
Teduglutide
Temazepam, like many other similar and related benzodiazepines, acts as a gamma-aminobutyric acid (GABA) modulator and is capable of eliciting a variety of actions including sedation, hypnosis, skeletal muscle relaxation, anticonvulsant activity, and anxiolytic action [A175207, A175210, F3718, F3721]. Although the chemical synthesis of temazepam was established by 1965, mainstream contemporary use of the medication did not occur until it's legitimate use as treatment for insomnia was accepted and approved later on. In particular, before temazepam saw regular prescription use in civilians it was - and still is - employed by the US military as a sedative-hypnotic medication to be taken by soldiers, pilots, etc. to obtain the necessary rest required for medical recovery or scheduled maneuvers and operations. Regardless, temazepam has become one of the most frequently prescribed medications internationally and sees
Teduglutide is a glucagon-like peptide-2 (GLP-2) analogue. It is made up of 33 amino acids and is manufactured using a strain of Escherichia coli modified by recombinant DNA technology. Teduglutide differs from GLP-2 by one amino acid (alanine is substituted by glycine). The significance of this substitution is that teduglutide is longer acting than endogenous GLP-2 as it is more resistant to proteolysis from dipeptidyl peptidase-4. FDA approved on December 21, 2012.
Moderate
1
[ [ [ 1174, 24, 1162 ] ], [ [ 1174, 1, 1119 ], [ 1119, 24, 1162 ] ], [ [ 1174, 40, 1382 ], [ 1382, 24, 1162 ] ], [ [ 1174, 1, 1119 ], [ 1119, 40, 1382 ], [ 1382, 24, 1162 ] ], [ [ 1174, 40, 1382 ], [ 1382, 1, 1119 ], [ 1119, 24, 1162 ] ], [ [ 1174, 1, 1216 ], [ 1216, 1, 481 ], [ 481, 24, 1162 ] ], [ [ 1174, 40, 11283 ], [ 11283, 40, 1382 ], [ 1382, 24, 1162 ] ], [ [ 1174, 40, 1382 ], [ 1382, 63, 1101 ], [ 1101, 25, 1162 ] ], [ [ 1174, 1, 1418 ], [ 1418, 63, 1101 ], [ 1101, 25, 1162 ] ], [ [ 1174, 6, 3721 ], [ 3721, 45, 1119 ], [ 1119, 24, 1162 ] ] ]
[ [ [ "Temazepam", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Teduglutide" ] ], [ [ "Temazepam", "{u} (Compound) resembles {v} (Compound)", "Chlordiazepoxide" ], [ "Chlordiazepoxide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Teduglutide" ] ], [ [ "Temazepam", "{u} (Compound) resembles {v} (Compound)", "Midazolam" ], [ "Midazolam", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Teduglutide" ] ], [ [ "Temazepam", "{u} (Compound) resembles {v} (Compound)", "Chlordiazepoxide" ], [ "Chlordiazepoxide", "{u} (Compound) resembles {v} (Compound)", "Midazolam" ], [ "Midazolam", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Teduglutide" ] ], [ [ "Temazepam", "{u} (Compound) resembles {v} (Compound)", "Midazolam" ], [ "Midazolam", "{u} (Compound) resembles {v} (Compound)", "Chlordiazepoxide" ], [ "Chlordiazepoxide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Teduglutide" ] ], [ [ "Temazepam", "{u} (Compound) resembles {v} (Compound)", "Flurazepam" ], [ "Flurazepam", "{u} (Compound) resembles {v} (Compound)", "Quazepam" ], [ "Quazepam", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Teduglutide" ] ], [ [ "Temazepam", "{u} (Compound) resembles {v} (Compound)", "Fludiazepam" ], [ "Fludiazepam", "{u} (Compound) resembles {v} (Compound)", "Midazolam" ], [ "Midazolam", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Teduglutide" ] ], [ [ "Temazepam", "{u} (Compound) resembles {v} (Compound)", "Midazolam" ], [ "Midazolam", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Bexarotene" ], [ "Bexarotene", "{u} may lead to a major life threatening interaction when taken with {v}", "Teduglutide" ] ], [ [ "Temazepam", "{u} (Compound) resembles {v} (Compound)", "Estazolam" ], [ "Estazolam", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Bexarotene" ], [ "Bexarotene", "{u} may lead to a major life threatening interaction when taken with {v}", "Teduglutide" ] ], [ [ "Temazepam", "{u} (Compound) binds {v} (Gene)", "GABRB2" ], [ "GABRB2", "{u} (Gene) is bound by {v} (Compound)", "Chlordiazepoxide" ], [ "Chlordiazepoxide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Teduglutide" ] ] ]
Temazepam (Compound) resembles Chlordiazepoxide (Compound) and Chlordiazepoxide may cause a moderate interaction that could exacerbate diseases when taken with Teduglutide Temazepam (Compound) resembles Midazolam (Compound) and Midazolam may cause a moderate interaction that could exacerbate diseases when taken with Teduglutide Temazepam (Compound) resembles Chlordiazepoxide (Compound) and Chlordiazepoxide (Compound) resembles Midazolam (Compound) and Midazolam may cause a moderate interaction that could exacerbate diseases when taken with Teduglutide Temazepam (Compound) resembles Midazolam (Compound) and Midazolam (Compound) resembles Chlordiazepoxide (Compound) and Chlordiazepoxide may cause a moderate interaction that could exacerbate diseases when taken with Teduglutide Temazepam (Compound) resembles Flurazepam (Compound) and Flurazepam (Compound) resembles Quazepam (Compound) and Quazepam may cause a moderate interaction that could exacerbate diseases when taken with Teduglutide Temazepam (Compound) resembles Fludiazepam (Compound) and Fludiazepam (Compound) resembles Midazolam (Compound) and Midazolam may cause a moderate interaction that could exacerbate diseases when taken with Teduglutide Temazepam (Compound) resembles Midazolam (Compound) and Midazolam may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may lead to a major life threatening interaction when taken with Teduglutide Temazepam (Compound) resembles Estazolam (Compound) and Estazolam may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may lead to a major life threatening interaction when taken with Teduglutide Temazepam (Compound) binds GABRB2 (Gene) and GABRB2 (Gene) is bound by Chlordiazepoxide (Compound) and Chlordiazepoxide may cause a moderate interaction that could exacerbate diseases when taken with Teduglutide
DB01050
DB09237
848
1,586
[ "DDInter900", "DDInter1045" ]
Ibuprofen
Levamlodipine
Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics. The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin. Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID. On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than
Levamlodipine, also known as S-amlodipine, is a pharmacologically active enantiomer of [amlodipine], an antihypertensive medication. Levamlodipine belongs to the dihydropyridine group of calcium channel blockers. This medication was first marketed in Russia and India before being granted FDA approval. The names S-amlodipine and levamlodipine may be used interchangeably as both substances are the same, however. As a racemic mixture, amlodipine contains (R) and (S)-amlodipine isomers, but only (S)-amlodipine as the active moiety possesses therapeutic activity. Levamlodipine was granted FDA approval on 19 December 2019.
Moderate
1
[ [ [ 848, 24, 1586 ] ], [ [ 848, 24, 578 ], [ 578, 23, 1586 ] ], [ [ 848, 63, 870 ], [ 870, 24, 1586 ] ], [ [ 848, 24, 1478 ], [ 1478, 24, 1586 ] ], [ [ 848, 74, 1274 ], [ 1274, 24, 1586 ] ], [ [ 848, 25, 405 ], [ 405, 63, 1586 ] ], [ [ 848, 64, 1479 ], [ 1479, 24, 1586 ] ], [ [ 848, 24, 1017 ], [ 1017, 63, 1586 ] ], [ [ 848, 25, 1409 ], [ 1409, 24, 1586 ] ], [ [ 848, 40, 1053 ], [ 1053, 24, 1586 ] ] ]
[ [ [ "Ibuprofen", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Levamlodipine" ] ], [ [ "Ibuprofen", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Ticagrelor" ], [ "Ticagrelor", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Levamlodipine" ] ], [ [ "Ibuprofen", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Fludrocortisone" ], [ "Fludrocortisone", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Levamlodipine" ] ], [ [ "Ibuprofen", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Ivacaftor" ], [ "Ivacaftor", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Levamlodipine" ] ], [ [ "Ibuprofen", "{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Flurbiprofen" ], [ "Flurbiprofen", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Levamlodipine" ] ], [ [ "Ibuprofen", "{u} may lead to a major life threatening interaction when taken with {v}", "Acalabrutinib" ], [ "Acalabrutinib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Levamlodipine" ] ], [ [ "Ibuprofen", "{u} may lead to a major life threatening interaction when taken with {v}", "Acetylsalicylic acid" ], [ "Acetylsalicylic acid", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Levamlodipine" ] ], [ [ "Ibuprofen", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Lorlatinib" ], [ "Lorlatinib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Levamlodipine" ] ], [ [ "Ibuprofen", "{u} may lead to a major life threatening interaction when taken with {v}", "Apixaban" ], [ "Apixaban", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Levamlodipine" ] ], [ [ "Ibuprofen", "{u} (Compound) resembles {v} (Compound)", "Procarbazine" ], [ "Procarbazine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Levamlodipine" ] ] ]
Ibuprofen may cause a moderate interaction that could exacerbate diseases when taken with Ticagrelor and Ticagrelor may cause a minor interaction that can limit clinical effects when taken with Levamlodipine Ibuprofen may cause a moderate interaction that could exacerbate diseases when taken with Fludrocortisone and Fludrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Levamlodipine Ibuprofen may cause a moderate interaction that could exacerbate diseases when taken with Ivacaftor and Ivacaftor may cause a moderate interaction that could exacerbate diseases when taken with Levamlodipine Ibuprofen (Compound) resembles Flurbiprofen (Compound) and Ibuprofen may cause a moderate interaction that could exacerbate diseases when taken with Flurbiprofen and Flurbiprofen may cause a moderate interaction that could exacerbate diseases when taken with Levamlodipine Ibuprofen may lead to a major life threatening interaction when taken with Acalabrutinib and Acalabrutinib may cause a moderate interaction that could exacerbate diseases when taken with Levamlodipine Ibuprofen may lead to a major life threatening interaction when taken with Acetylsalicylic acid and Acetylsalicylic acid may cause a moderate interaction that could exacerbate diseases when taken with Levamlodipine Ibuprofen may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib and Lorlatinib may cause a moderate interaction that could exacerbate diseases when taken with Levamlodipine Ibuprofen may lead to a major life threatening interaction when taken with Apixaban and Apixaban may cause a moderate interaction that could exacerbate diseases when taken with Levamlodipine Ibuprofen (Compound) resembles Procarbazine (Compound) and Procarbazine may cause a moderate interaction that could exacerbate diseases when taken with Levamlodipine
DB00035
DB00988
1,314
817
[ "DDInter507", "DDInter584" ]
Desmopressin
Dopamine
Desmopressin (dDAVP), a synthetic analogue of 8-arginine vasopressin (ADH), is an antidiuretic peptide drug modified by deamination of 1-cysteine and substitution of 8-L-arginine by 8-D-arginine. ADH is an endogenous pituitary hormone that has a crucial role in the control of the water content in the body. Upon release from the stimulation of increased plasma osmolarity or decreased circulating blood volume, ADH mainly acts on the cells of the distal part of the nephron and the collecting tubules in the kidney. The hormone interacts with V1, V2 or V3 receptors with differing signal cascade systems. Desmopressin displays enhanced antidiuretic potency, fewer pressor effects due to V2-selective actions, and a prolonged half-life and duration of action compared to endogenous ADH. It has been employed clinically since 1972
One of the catecholamine neurotransmitters in the brain. It is derived from tyrosine and is the precursor to norepinephrine and epinephrine. Dopamine is a major transmitter in the extrapyramidal system of the brain, and important in regulating movement. A family of receptors (receptors, dopamine) mediate its action.
Moderate
1
[ [ [ 1314, 24, 817 ] ], [ [ 1314, 24, 532 ], [ 532, 1, 817 ] ], [ [ 1314, 24, 1148 ], [ 1148, 63, 817 ] ], [ [ 1314, 24, 874 ], [ 874, 40, 817 ] ], [ [ 1314, 21, 28722 ], [ 28722, 60, 817 ] ], [ [ 1314, 24, 1264 ], [ 1264, 64, 817 ] ], [ [ 1314, 24, 532 ], [ 532, 40, 11484 ], [ 11484, 1, 817 ] ], [ [ 1314, 24, 1551 ], [ 1551, 1, 584 ], [ 584, 1, 817 ] ], [ [ 1314, 24, 1148 ], [ 1148, 63, 532 ], [ 532, 1, 817 ] ], [ [ 1314, 21, 28722 ], [ 28722, 60, 532 ], [ 532, 1, 817 ] ] ]
[ [ [ "Desmopressin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Dopamine" ] ], [ [ "Desmopressin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Dobutamine" ], [ "Dobutamine", "{u} (Compound) resembles {v} (Compound)", "Dopamine" ] ], [ [ "Desmopressin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Isoprenaline" ], [ "Isoprenaline", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Dopamine" ] ], [ [ "Desmopressin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Epinephrine" ], [ "Epinephrine", "{u} (Compound) resembles {v} (Compound)", "Dopamine" ] ], [ [ "Desmopressin", "{u} (Compound) causes {v} (Side Effect)", "Nausea" ], [ "Nausea", "{u} (Side Effect) is caused by {v} (Compound)", "Dopamine" ] ], [ [ "Desmopressin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Doxepin" ], [ "Doxepin", "{u} may lead to a major life threatening interaction when taken with {v}", "Dopamine" ] ], [ [ "Desmopressin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Dobutamine" ], [ "Dobutamine", "{u} (Compound) resembles {v} (Compound)", "Masoprocol" ], [ "Masoprocol", "{u} (Compound) resembles {v} (Compound)", "Dopamine" ] ], [ [ "Desmopressin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Methyldopa" ], [ "Methyldopa", "{u} (Compound) resembles {v} (Compound)", "Levonordefrin" ], [ "Levonordefrin", "{u} (Compound) resembles {v} (Compound)", "Dopamine" ] ], [ [ "Desmopressin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Isoprenaline" ], [ "Isoprenaline", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Dobutamine" ], [ "Dobutamine", "{u} (Compound) resembles {v} (Compound)", "Dopamine" ] ], [ [ "Desmopressin", "{u} (Compound) causes {v} (Side Effect)", "Nausea" ], [ "Nausea", "{u} (Side Effect) is caused by {v} (Compound)", "Dobutamine" ], [ "Dobutamine", "{u} (Compound) resembles {v} (Compound)", "Dopamine" ] ] ]
Desmopressin may cause a moderate interaction that could exacerbate diseases when taken with Dobutamine and Dobutamine (Compound) resembles Dopamine (Compound) Desmopressin may cause a moderate interaction that could exacerbate diseases when taken with Isoprenaline and Isoprenaline may cause a moderate interaction that could exacerbate diseases when taken with Dopamine Desmopressin may cause a moderate interaction that could exacerbate diseases when taken with Epinephrine and Epinephrine (Compound) resembles Dopamine (Compound) Desmopressin (Compound) causes Nausea (Side Effect) and Nausea (Side Effect) is caused by Dopamine (Compound) Desmopressin may cause a moderate interaction that could exacerbate diseases when taken with Doxepin and Doxepin may lead to a major life threatening interaction when taken with Dopamine Desmopressin may cause a moderate interaction that could exacerbate diseases when taken with Dobutamine and Dobutamine (Compound) resembles Masoprocol (Compound) and Masoprocol (Compound) resembles Dopamine (Compound) Desmopressin may cause a moderate interaction that could exacerbate diseases when taken with Methyldopa and Methyldopa (Compound) resembles Levonordefrin (Compound) and Levonordefrin (Compound) resembles Dopamine (Compound) Desmopressin may cause a moderate interaction that could exacerbate diseases when taken with Isoprenaline and Isoprenaline may cause a moderate interaction that could exacerbate diseases when taken with Dobutamine and Dobutamine (Compound) resembles Dopamine (Compound) Desmopressin (Compound) causes Nausea (Side Effect) and Nausea (Side Effect) is caused by Dobutamine (Compound) and Dobutamine (Compound) resembles Dopamine (Compound)
DB00712
DB01133
1,274
1,104
[ "DDInter763", "DDInter1808" ]
Flurbiprofen
Tiludronic acid
Flurbiprofen, a propionic acid derivative, is a nonsteroidal anti-inflammatory agent (NSAIA) with antipyretic and analgesic activity. Oral formulations of flurbiprofen may be used for the symptomatic treatment of rheumatoid arthritis, osteoarthritis and anklylosing spondylitis. Flurbiprofen may also be used topically prior to ocular surgery to prevent or reduce intraoperative miosis. Flurbiprofen is structurally and pharmacologically related to fenoprofen, ibuprofen, and ketoprofen.
Tiludronate, or (4-chlorophenyl)thio-methylene-1,1-bisphosphonate, is a first generation bisphosphonate similar to [etidronic acid] and [clodronic acid].[A1923,A203111] These drugs were developed to mimic the action of pyrophosphate, a regulator of calcification and decalcification. Tiludronic acid was first described in the literature in 1988 as a potential treatment for Paget's disease of bone. Tiludronic acid was granted FDA approval on 7 March 1997.
Moderate
1
[ [ [ 1274, 24, 1104 ] ], [ [ 1274, 21, 28809 ], [ 28809, 60, 1104 ] ], [ [ 1274, 24, 1448 ], [ 1448, 24, 1104 ] ], [ [ 1274, 63, 1512 ], [ 1512, 24, 1104 ] ], [ [ 1274, 24, 1033 ], [ 1033, 63, 1104 ] ], [ [ 1274, 35, 848 ], [ 848, 24, 1104 ] ], [ [ 1274, 21, 28809 ], [ 28809, 60, 361 ], [ 361, 24, 1104 ] ], [ [ 1274, 24, 1448 ], [ 1448, 21, 28748 ], [ 28748, 60, 1104 ] ], [ [ 1274, 63, 1512 ], [ 1512, 21, 28809 ], [ 28809, 60, 1104 ] ], [ [ 1274, 24, 1033 ], [ 1033, 63, 1512 ], [ 1512, 24, 1104 ] ] ]
[ [ [ "Flurbiprofen", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Tiludronic acid" ] ], [ [ "Flurbiprofen", "{u} (Compound) causes {v} (Side Effect)", "Diarrhoea" ], [ "Diarrhoea", "{u} (Side Effect) is caused by {v} (Compound)", "Tiludronic acid" ] ], [ [ "Flurbiprofen", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Streptomycin" ], [ "Streptomycin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Tiludronic acid" ] ], [ [ "Flurbiprofen", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Diclofenac" ], [ "Diclofenac", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Tiludronic acid" ] ], [ [ "Flurbiprofen", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Alpelisib" ], [ "Alpelisib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Tiludronic acid" ] ], [ [ "Flurbiprofen", "{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Ibuprofen" ], [ "Ibuprofen", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Tiludronic acid" ] ], [ [ "Flurbiprofen", "{u} (Compound) causes {v} (Side Effect)", "Diarrhoea" ], [ "Diarrhoea", "{u} (Side Effect) is caused by {v} (Compound)", "Neomycin" ], [ "Neomycin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Tiludronic acid" ] ], [ [ "Flurbiprofen", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Streptomycin" ], [ "Streptomycin", "{u} (Compound) causes {v} (Side Effect)", "Vertigo" ], [ "Vertigo", "{u} (Side Effect) is caused by {v} (Compound)", "Tiludronic acid" ] ], [ [ "Flurbiprofen", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Diclofenac" ], [ "Diclofenac", "{u} (Compound) causes {v} (Side Effect)", "Diarrhoea" ], [ "Diarrhoea", "{u} (Side Effect) is caused by {v} (Compound)", "Tiludronic acid" ] ], [ [ "Flurbiprofen", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Alpelisib" ], [ "Alpelisib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Diclofenac" ], [ "Diclofenac", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Tiludronic acid" ] ] ]
Flurbiprofen (Compound) causes Diarrhoea (Side Effect) and Diarrhoea (Side Effect) is caused by Tiludronic acid (Compound) Flurbiprofen may cause a moderate interaction that could exacerbate diseases when taken with Streptomycin and Streptomycin may cause a moderate interaction that could exacerbate diseases when taken with Tiludronic acid Flurbiprofen may cause a moderate interaction that could exacerbate diseases when taken with Diclofenac and Diclofenac may cause a moderate interaction that could exacerbate diseases when taken with Tiludronic acid Flurbiprofen may cause a moderate interaction that could exacerbate diseases when taken with Alpelisib and Alpelisib may cause a moderate interaction that could exacerbate diseases when taken with Tiludronic acid Flurbiprofen (Compound) resembles Ibuprofen (Compound) and Flurbiprofen may cause a moderate interaction that could exacerbate diseases when taken with Ibuprofen and Ibuprofen may cause a moderate interaction that could exacerbate diseases when taken with Tiludronic acid Flurbiprofen (Compound) causes Diarrhoea (Side Effect) and Diarrhoea (Side Effect) is caused by Neomycin (Compound) and Neomycin may cause a moderate interaction that could exacerbate diseases when taken with Tiludronic acid Flurbiprofen may cause a moderate interaction that could exacerbate diseases when taken with Streptomycin and Streptomycin (Compound) causes Vertigo (Side Effect) and Vertigo (Side Effect) is caused by Tiludronic acid (Compound) Flurbiprofen may cause a moderate interaction that could exacerbate diseases when taken with Diclofenac and Diclofenac (Compound) causes Diarrhoea (Side Effect) and Diarrhoea (Side Effect) is caused by Tiludronic acid (Compound) Flurbiprofen may cause a moderate interaction that could exacerbate diseases when taken with Alpelisib and Alpelisib may cause a moderate interaction that could exacerbate diseases when taken with Diclofenac and Diclofenac may cause a moderate interaction that could exacerbate diseases when taken with Tiludronic acid
DB06697
DB14975
436
988
[ "DDInter121", "DDInter1949" ]
Artemether
Voxelotor
Artemether is an antimalarial agent used to treat acute uncomplicated malaria. It is administered in combination with lumefantrine for improved efficacy. This combination therapy exerts its effects against the erythrocytic stages of <i>Plasmodium spp.</i> and may be used to treat infections caused by <i>P. falciparum</i> and unidentified <i>Plasmodium</i> species, including infections acquired in chloroquine-resistant areas.
Voxelotor is a novel hemoglobin S polymerization inhibitor for the treatment of sickle cell disease. This is a genetically inherited condition most prevalent in the Middle East, Africa, and certain parts of India. Sickle cell disease can lead to excruciating pain, stroke, infection, and various other complications arising from the blockage of blood vessels. Voxelotor was granted accelerated FDA approval on November 25 2019, as it is likely to be a promising treatment for the 100,000 individuals in the U.S. suffering from the disease, in addition to 20 million others worldwide. It was developed by Global Blood Therapeutics, Inc. and is unique from other drugs used to treat sickle cell anemia, such as [hydroxyurea], [L-glutamine], and [crizanlizumab][A188135,A188138] due to its novel mechanism of action. The EMA approved the use of voxelotor for the treatment of hemolytic anemia associated with sickle cell disease in February 2022.[L41419,L41424]
Moderate
1
[ [ [ 436, 24, 988 ] ], [ [ 436, 24, 214 ], [ 214, 24, 988 ] ], [ [ 436, 25, 913 ], [ 913, 25, 988 ] ], [ [ 436, 64, 609 ], [ 609, 25, 988 ] ], [ [ 436, 24, 1478 ], [ 1478, 25, 988 ] ], [ [ 436, 63, 1220 ], [ 1220, 25, 988 ] ], [ [ 436, 24, 214 ], [ 214, 63, 222 ], [ 222, 23, 988 ] ], [ [ 436, 24, 159 ], [ 159, 62, 222 ], [ 222, 23, 988 ] ], [ [ 436, 25, 913 ], [ 913, 25, 466 ], [ 466, 23, 988 ] ], [ [ 436, 25, 760 ], [ 760, 24, 466 ], [ 466, 23, 988 ] ] ]
[ [ [ "Artemether", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Voxelotor" ] ], [ [ "Artemether", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Fostamatinib" ], [ "Fostamatinib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Voxelotor" ] ], [ [ "Artemether", "{u} may lead to a major life threatening interaction when taken with {v}", "Apalutamide" ], [ "Apalutamide", "{u} may lead to a major life threatening interaction when taken with {v}", "Voxelotor" ] ], [ [ "Artemether", "{u} may lead to a major life threatening interaction when taken with {v}", "Clarithromycin" ], [ "Clarithromycin", "{u} may lead to a major life threatening interaction when taken with {v}", "Voxelotor" ] ], [ [ "Artemether", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Ivacaftor" ], [ "Ivacaftor", "{u} may lead to a major life threatening interaction when taken with {v}", "Voxelotor" ] ], [ [ "Artemether", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Dexamethasone" ], [ "Dexamethasone", "{u} may lead to a major life threatening interaction when taken with {v}", "Voxelotor" ] ], [ [ "Artemether", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Fostamatinib" ], [ "Fostamatinib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Sibutramine" ], [ "Sibutramine", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Voxelotor" ] ], [ [ "Artemether", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Larotrectinib" ], [ "Larotrectinib", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Sibutramine" ], [ "Sibutramine", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Voxelotor" ] ], [ [ "Artemether", "{u} may lead to a major life threatening interaction when taken with {v}", "Apalutamide" ], [ "Apalutamide", "{u} may lead to a major life threatening interaction when taken with {v}", "Darolutamide" ], [ "Darolutamide", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Voxelotor" ] ], [ [ "Artemether", "{u} may lead to a major life threatening interaction when taken with {v}", "Cobicistat" ], [ "Cobicistat", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Darolutamide" ], [ "Darolutamide", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Voxelotor" ] ] ]
Artemether may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib and Fostamatinib may cause a moderate interaction that could exacerbate diseases when taken with Voxelotor Artemether may lead to a major life threatening interaction when taken with Apalutamide and Apalutamide may lead to a major life threatening interaction when taken with Voxelotor Artemether may lead to a major life threatening interaction when taken with Clarithromycin and Clarithromycin may lead to a major life threatening interaction when taken with Voxelotor Artemether may cause a moderate interaction that could exacerbate diseases when taken with Ivacaftor and Ivacaftor may lead to a major life threatening interaction when taken with Voxelotor Artemether may cause a moderate interaction that could exacerbate diseases when taken with Dexamethasone and Dexamethasone may lead to a major life threatening interaction when taken with Voxelotor Artemether may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib and Fostamatinib may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine and Sibutramine may cause a minor interaction that can limit clinical effects when taken with Voxelotor Artemether may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib and Larotrectinib may cause a minor interaction that can limit clinical effects when taken with Sibutramine and Sibutramine may cause a minor interaction that can limit clinical effects when taken with Voxelotor Artemether may lead to a major life threatening interaction when taken with Apalutamide and Apalutamide may lead to a major life threatening interaction when taken with Darolutamide and Darolutamide may cause a minor interaction that can limit clinical effects when taken with Voxelotor Artemether may lead to a major life threatening interaction when taken with Cobicistat and Cobicistat may cause a moderate interaction that could exacerbate diseases when taken with Darolutamide and Darolutamide may cause a minor interaction that can limit clinical effects when taken with Voxelotor
DB01232
DB14723
1,327
159
[ "DDInter1640", "DDInter1026" ]
Saquinavir
Larotrectinib
Saquinavir is an HIV-1 protease inhibitor used in combination with [ritonavir] and other antiretrovirals for the treatment of human immunodeficiency virus-1 (HIV-1) infection. In 1995 it became the first protease inhibitor approved by the FDA, followed shortly by ritonavir in 1996, and remains in clinical use today due to a relatively benign adverse effect profile as compared to other antiretroviral therapies. While its efficacy was initially limited by exceptionally poor oral bioavailability (approximately 4%), its current indications require the co-administration of ritonavir - a potent enzyme inhibitor - that increases the bioavailability and subsequent serum concentrations of saquinavir, thus dramatically improving antiviral activity.[A214382,L3450,L14351]
Larotrectinib is an orally administered inhibitor of tropomyosin receptor kinase (Trk), a receptor tyrosine kinase activated by neurotrophins which is mutated in a variety of cancer cell types and plays an important role in tumor cell growth and survival. Upon administration, larotrectinib binds to Trk, thereby preventing neurotrophin-Trk interaction and Trk activation, which results in both the induction of cellular apoptosis and the inhibition of cell growth in tumors that overexpress Trk. Larotrectinib was granted accelerated approval by the FDA in November 2018 for the treatment of Trk-positive solid tumors. It was notable for being the second tissue-agnostic chemotherapy ever approved by the FDA.
Major
2
[ [ [ 1327, 25, 159 ] ], [ [ 1327, 62, 222 ], [ 222, 23, 159 ] ], [ [ 1327, 24, 466 ], [ 466, 23, 159 ] ], [ [ 1327, 25, 1135 ], [ 1135, 23, 159 ] ], [ [ 1327, 24, 98 ], [ 98, 24, 159 ] ], [ [ 1327, 25, 951 ], [ 951, 24, 159 ] ], [ [ 1327, 64, 1181 ], [ 1181, 24, 159 ] ], [ [ 1327, 63, 896 ], [ 896, 24, 159 ] ], [ [ 1327, 25, 676 ], [ 676, 63, 159 ] ], [ [ 1327, 1, 915 ], [ 915, 25, 159 ] ] ]
[ [ [ "Saquinavir", "{u} may lead to a major life threatening interaction when taken with {v}", "Larotrectinib" ] ], [ [ "Saquinavir", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Sibutramine" ], [ "Sibutramine", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Larotrectinib" ] ], [ [ "Saquinavir", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Darolutamide" ], [ "Darolutamide", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Larotrectinib" ] ], [ [ "Saquinavir", "{u} may lead to a major life threatening interaction when taken with {v}", "Naloxegol" ], [ "Naloxegol", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Larotrectinib" ] ], [ [ "Saquinavir", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Somatrem" ], [ "Somatrem", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Larotrectinib" ] ], [ [ "Saquinavir", "{u} may lead to a major life threatening interaction when taken with {v}", "Palbociclib" ], [ "Palbociclib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Larotrectinib" ] ], [ [ "Saquinavir", "{u} may lead to a major life threatening interaction when taken with {v}", "Terfenadine" ], [ "Terfenadine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Larotrectinib" ] ], [ [ "Saquinavir", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Etoposide" ], [ "Etoposide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Larotrectinib" ] ], [ [ "Saquinavir", "{u} may lead to a major life threatening interaction when taken with {v}", "Upadacitinib" ], [ "Upadacitinib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Larotrectinib" ] ], [ [ "Saquinavir", "{u} (Compound) resembles {v} (Compound)", "Atazanavir" ], [ "Atazanavir", "{u} may lead to a major life threatening interaction when taken with {v}", "Larotrectinib" ] ] ]
Saquinavir may cause a minor interaction that can limit clinical effects when taken with Sibutramine and Sibutramine may cause a minor interaction that can limit clinical effects when taken with Larotrectinib Saquinavir may cause a moderate interaction that could exacerbate diseases when taken with Darolutamide and Darolutamide may cause a minor interaction that can limit clinical effects when taken with Larotrectinib Saquinavir may lead to a major life threatening interaction when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Larotrectinib Saquinavir may cause a moderate interaction that could exacerbate diseases when taken with Somatrem and Somatrem may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib Saquinavir may lead to a major life threatening interaction when taken with Palbociclib and Palbociclib may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib Saquinavir may lead to a major life threatening interaction when taken with Terfenadine and Terfenadine may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib Saquinavir may cause a moderate interaction that could exacerbate diseases when taken with Etoposide and Etoposide may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib Saquinavir may lead to a major life threatening interaction when taken with Upadacitinib and Upadacitinib may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib Saquinavir (Compound) resembles Atazanavir (Compound) and Atazanavir may lead to a major life threatening interaction when taken with Larotrectinib
DB00543
DB01409
87
1,415
[ "DDInter82", "DDInter1815" ]
Amoxapine
Tiotropium
Amoxapine, the <i>N</i>-demethylated derivative of the antipsychotic agent loxapine, is a dibenzoxazepine-derivative tricyclic antidepressant (TCA). TCAs are structurally similar to phenothiazines. They contain a tricyclic ring system with an alkyl amine substituent on the central ring. In non-depressed individuals, amoxapine does not affect mood or arousal, but may cause sedation. In depressed individuals, amoxapine exerts a positive effect on mood. TCAs are potent inhibitors of serotonin and norepinephrine reuptake. In addition, TCAs down-regulate cerebral cortical &beta;-adrenergic receptors and sensitize post-synaptic serotonergic receptors with chronic use. The antidepressant effects of TCAs are thought to be due to an overall increase in serotonergic neurotransmission. TCAs also block
Tiotropium is a long-acting, antimuscarinic bronchodilator used in the management of chronic obstructive pulmonary disease (COPD) and asthma.[A180163,L7084,L7087,L7090,L7093] Tiotropium acts mainly on M3 muscarinic receptors located in the airways to produce smooth muscle relaxation and bronchodilation.[A180163,L7084,L7087,L7090,L7093] Tiotropium is more specific for the subset of muscarinic receptors commonly found in the lungs than [ipratropium]. Tiotropium was granted FDA approval on 30 January 2004.
Moderate
1
[ [ [ 87, 24, 1415 ] ], [ [ 87, 6, 7992 ], [ 7992, 45, 1415 ] ], [ [ 87, 21, 28680 ], [ 28680, 60, 1415 ] ], [ [ 87, 63, 752 ], [ 752, 23, 1415 ] ], [ [ 87, 63, 1594 ], [ 1594, 24, 1415 ] ], [ [ 87, 24, 1219 ], [ 1219, 24, 1415 ] ], [ [ 87, 24, 830 ], [ 830, 63, 1415 ] ], [ [ 87, 1, 623 ], [ 623, 24, 1415 ] ], [ [ 87, 40, 1408 ], [ 1408, 24, 1415 ] ], [ [ 87, 24, 1429 ], [ 1429, 74, 1415 ] ] ]
[ [ [ "Amoxapine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Tiotropium" ] ], [ [ "Amoxapine", "{u} (Compound) binds {v} (Gene)", "CHRM1" ], [ "CHRM1", "{u} (Gene) is bound by {v} (Compound)", "Tiotropium" ] ], [ [ "Amoxapine", "{u} (Compound) causes {v} (Side Effect)", "Rash" ], [ "Rash", "{u} (Side Effect) is caused by {v} (Compound)", "Tiotropium" ] ], [ [ "Amoxapine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Cimetidine" ], [ "Cimetidine", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Tiotropium" ] ], [ [ "Amoxapine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Doxylamine" ], [ "Doxylamine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Tiotropium" ] ], [ [ "Amoxapine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Azatadine" ], [ "Azatadine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Tiotropium" ] ], [ [ "Amoxapine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Phenindamine" ], [ "Phenindamine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Tiotropium" ] ], [ [ "Amoxapine", "{u} (Compound) resembles {v} (Compound)", "Quetiapine" ], [ "Quetiapine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Tiotropium" ] ], [ [ "Amoxapine", "{u} (Compound) resembles {v} (Compound)", "Loxapine" ], [ "Loxapine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Tiotropium" ] ], [ [ "Amoxapine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Aclidinium" ], [ "Aclidinium", "{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Tiotropium" ] ] ]
Amoxapine (Compound) binds CHRM1 (Gene) and CHRM1 (Gene) is bound by Tiotropium (Compound) Amoxapine (Compound) causes Rash (Side Effect) and Rash (Side Effect) is caused by Tiotropium (Compound) Amoxapine may cause a moderate interaction that could exacerbate diseases when taken with Cimetidine and Cimetidine may cause a minor interaction that can limit clinical effects when taken with Tiotropium Amoxapine may cause a moderate interaction that could exacerbate diseases when taken with Doxylamine and Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Tiotropium Amoxapine may cause a moderate interaction that could exacerbate diseases when taken with Azatadine and Azatadine may cause a moderate interaction that could exacerbate diseases when taken with Tiotropium Amoxapine may cause a moderate interaction that could exacerbate diseases when taken with Phenindamine and Phenindamine may cause a moderate interaction that could exacerbate diseases when taken with Tiotropium Amoxapine (Compound) resembles Quetiapine (Compound) and Quetiapine may cause a moderate interaction that could exacerbate diseases when taken with Tiotropium Amoxapine (Compound) resembles Loxapine (Compound) and Loxapine may cause a moderate interaction that could exacerbate diseases when taken with Tiotropium Amoxapine may cause a moderate interaction that could exacerbate diseases when taken with Aclidinium and Aclidinium (Compound) resembles Tiotropium (Compound) and Aclidinium may cause a moderate interaction that could exacerbate diseases when taken with Tiotropium
DB00465
DB01276
886
123
[ "DDInter1010", "DDInter706" ]
Ketorolac
Exenatide
Ketorolac is a Non-steroidal anti-inflammatory drug (NSAID) and is commercially available as an oral tablet, injectable, nasal spray and as an ophthalmic solution. It's analgesic properties make it a useful pain management tool across many settings including postoperative pain, rheumatoid arthritis, osteoarthritis, menstrual disorders, headaches, spinal and soft tissue pain, and ankylosing spondylitis. Impressively, ketorolac has a similar efficacy to standard doses of morphine and meperidine making it a useful opioid sparing agent.
Exenatide is a glucagon-like peptide-1 (GLP-1) analog. It activates the GLP-1 receptor and increases insulin secretion, decreases glucagon secretion, and slows gastric emptying to improve glycemic control. Exenatide was given FDA approval on April 28, 2005. It is available as immediate- and extended-release formulations.[L42685,L42690] Bydureon, the brand name product of extended-release exenatide in an injectable suspension, was discontinued in 2021. Bydureon BCise, an auto-injector extended-release formulation, remains available.
Moderate
1
[ [ [ 886, 24, 123 ] ], [ [ 886, 24, 1573 ], [ 1573, 24, 123 ] ], [ [ 886, 63, 1560 ], [ 1560, 24, 123 ] ], [ [ 886, 24, 850 ], [ 850, 63, 123 ] ], [ [ 886, 25, 126 ], [ 126, 24, 123 ] ], [ [ 886, 25, 4 ], [ 4, 63, 123 ] ], [ [ 886, 1, 935 ], [ 935, 24, 123 ] ], [ [ 886, 24, 1573 ], [ 1573, 63, 1252 ], [ 1252, 23, 123 ] ], [ [ 886, 24, 1039 ], [ 1039, 63, 1338 ], [ 1338, 24, 123 ] ], [ [ 886, 63, 1560 ], [ 1560, 24, 1463 ], [ 1463, 23, 123 ] ] ]
[ [ [ "Ketorolac", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Exenatide" ] ], [ [ "Ketorolac", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Prednisone" ], [ "Prednisone", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Exenatide" ] ], [ [ "Ketorolac", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Pegaspargase" ], [ "Pegaspargase", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Exenatide" ] ], [ [ "Ketorolac", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Brentuximab vedotin" ], [ "Brentuximab vedotin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Exenatide" ] ], [ [ "Ketorolac", "{u} may lead to a major life threatening interaction when taken with {v}", "Warfarin" ], [ "Warfarin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Exenatide" ] ], [ [ "Ketorolac", "{u} may lead to a major life threatening interaction when taken with {v}", "Omacetaxine mepesuccinate" ], [ "Omacetaxine mepesuccinate", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Exenatide" ] ], [ [ "Ketorolac", "{u} (Compound) resembles {v} (Compound)", "Ketoprofen" ], [ "Ketoprofen", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Exenatide" ] ], [ [ "Ketorolac", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Prednisone" ], [ "Prednisone", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Digoxin" ], [ "Digoxin", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Exenatide" ] ], [ [ "Ketorolac", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Dexfenfluramine" ], [ "Dexfenfluramine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Meclofenamic acid" ], [ "Meclofenamic acid", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Exenatide" ] ], [ [ "Ketorolac", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Pegaspargase" ], [ "Pegaspargase", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Lovastatin" ], [ "Lovastatin", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Exenatide" ] ] ]
Ketorolac may cause a moderate interaction that could exacerbate diseases when taken with Prednisone and Prednisone may cause a moderate interaction that could exacerbate diseases when taken with Exenatide Ketorolac may cause a moderate interaction that could exacerbate diseases when taken with Pegaspargase and Pegaspargase may cause a moderate interaction that could exacerbate diseases when taken with Exenatide Ketorolac may cause a moderate interaction that could exacerbate diseases when taken with Brentuximab vedotin and Brentuximab vedotin may cause a moderate interaction that could exacerbate diseases when taken with Exenatide Ketorolac may lead to a major life threatening interaction when taken with Warfarin and Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Exenatide Ketorolac may lead to a major life threatening interaction when taken with Omacetaxine mepesuccinate and Omacetaxine mepesuccinate may cause a moderate interaction that could exacerbate diseases when taken with Exenatide Ketorolac (Compound) resembles Ketoprofen (Compound) and Ketoprofen may cause a moderate interaction that could exacerbate diseases when taken with Exenatide Ketorolac may cause a moderate interaction that could exacerbate diseases when taken with Prednisone and Prednisone may cause a moderate interaction that could exacerbate diseases when taken with Digoxin and Digoxin may cause a minor interaction that can limit clinical effects when taken with Exenatide Ketorolac may cause a moderate interaction that could exacerbate diseases when taken with Dexfenfluramine and Dexfenfluramine may cause a moderate interaction that could exacerbate diseases when taken with Meclofenamic acid and Meclofenamic acid may cause a moderate interaction that could exacerbate diseases when taken with Exenatide Ketorolac may cause a moderate interaction that could exacerbate diseases when taken with Pegaspargase and Pegaspargase may cause a moderate interaction that could exacerbate diseases when taken with Lovastatin and Lovastatin may cause a minor interaction that can limit clinical effects when taken with Exenatide
DB00373
DB00771
461
262
[ "DDInter1809", "DDInter397" ]
Timolol
Clidinium
Timolol is a nonselective beta-adrenergic antagonist given in an eye drop solution to reduce intraocular pressure, or pressure in the eyes. It is also used in tablet form as a drug to treat hypertension. Timolol was first approved by the FDA in 1978. This drug is marketed by several manufacturers and is an effective agent for the management of conditions such as open-angle glaucoma and hypertension.
Clidinium is a synthetic anticholinergic agent which has been shown in experimental and clinical studies to have a pronounced antispasmodic and antisecretory effect on the gastrointestinal tract. It inhibits muscarinic actions of acetylcholine at postganglionic parasympathetic neuroeffector sites. It is used for the treatment of peptic ulcer disease and also to help relieve abdominal or stomach spasms or cramps due to colicky abdominal pain, diverticulitis, and irritable bowel syndrome.
Moderate
1
[ [ [ 461, 24, 262 ] ], [ [ 461, 24, 1511 ], [ 1511, 63, 262 ] ], [ [ 461, 24, 19 ], [ 19, 24, 262 ] ], [ [ 461, 63, 999 ], [ 999, 24, 262 ] ], [ [ 461, 1, 729 ], [ 729, 63, 262 ] ], [ [ 461, 63, 352 ], [ 352, 35, 262 ] ], [ [ 461, 24, 1511 ], [ 1511, 40, 11286 ], [ 11286, 1, 262 ] ], [ [ 461, 24, 1192 ], [ 1192, 24, 1511 ], [ 1511, 63, 262 ] ], [ [ 461, 24, 849 ], [ 849, 63, 1511 ], [ 1511, 63, 262 ] ], [ [ 461, 63, 999 ], [ 999, 24, 1511 ], [ 1511, 63, 262 ] ] ]
[ [ [ "Timolol", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Clidinium" ] ], [ [ "Timolol", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Mepenzolate" ], [ "Mepenzolate", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Clidinium" ] ], [ [ "Timolol", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Hyoscyamine" ], [ "Hyoscyamine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Clidinium" ] ], [ [ "Timolol", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Thiethylperazine" ], [ "Thiethylperazine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Clidinium" ] ], [ [ "Timolol", "{u} (Compound) resembles {v} (Compound)", "Penbutolol" ], [ "Penbutolol", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Clidinium" ] ], [ [ "Timolol", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Trospium" ], [ "Trospium", "{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Clidinium" ] ], [ [ "Timolol", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Mepenzolate" ], [ "Mepenzolate", "{u} (Compound) resembles {v} (Compound)", "Diphenylpyraline" ], [ "Diphenylpyraline", "{u} (Compound) resembles {v} (Compound)", "Clidinium" ] ], [ [ "Timolol", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Glycopyrronium" ], [ "Glycopyrronium", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Mepenzolate" ], [ "Mepenzolate", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Clidinium" ] ], [ [ "Timolol", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Mepyramine" ], [ "Mepyramine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Mepenzolate" ], [ "Mepenzolate", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Clidinium" ] ], [ [ "Timolol", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Thiethylperazine" ], [ "Thiethylperazine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Mepenzolate" ], [ "Mepenzolate", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Clidinium" ] ] ]
Timolol may cause a moderate interaction that could exacerbate diseases when taken with Mepenzolate and Mepenzolate may cause a moderate interaction that could exacerbate diseases when taken with Clidinium Timolol may cause a moderate interaction that could exacerbate diseases when taken with Hyoscyamine and Hyoscyamine may cause a moderate interaction that could exacerbate diseases when taken with Clidinium Timolol may cause a moderate interaction that could exacerbate diseases when taken with Thiethylperazine and Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken with Clidinium Timolol (Compound) resembles Penbutolol (Compound) and Penbutolol may cause a moderate interaction that could exacerbate diseases when taken with Clidinium Timolol may cause a moderate interaction that could exacerbate diseases when taken with Trospium and Trospium (Compound) resembles Clidinium (Compound) and Trospium may cause a moderate interaction that could exacerbate diseases when taken with Clidinium Timolol may cause a moderate interaction that could exacerbate diseases when taken with Mepenzolate and Mepenzolate (Compound) resembles Diphenylpyraline (Compound) and Diphenylpyraline (Compound) resembles Clidinium (Compound) Timolol may cause a moderate interaction that could exacerbate diseases when taken with Glycopyrronium and Glycopyrronium may cause a moderate interaction that could exacerbate diseases when taken with Mepenzolate and Mepenzolate may cause a moderate interaction that could exacerbate diseases when taken with Clidinium Timolol may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine and Mepyramine may cause a moderate interaction that could exacerbate diseases when taken with Mepenzolate and Mepenzolate may cause a moderate interaction that could exacerbate diseases when taken with Clidinium Timolol may cause a moderate interaction that could exacerbate diseases when taken with Thiethylperazine and Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken with Mepenzolate and Mepenzolate may cause a moderate interaction that could exacerbate diseases when taken with Clidinium
DB00762
DB01155
613
872
[ "DDInter973", "DDInter813" ]
Irinotecan
Gemifloxacin
Irinotecan is an antineoplastic enzyme inhibitor primarily used in the treatment of colorectal cancer. It is a derivative of camptothecin that inhibits the action of topoisomerase I. Irinotecan prevents religation of the DNA strand by binding to topoisomerase I-DNA complex, and causes double-strand DNA breakage and cell death. It is a derivative of camptothecin. Irinotecan was approved for the treatment of advanced pancreatic cancer in October, 2015 (irinotecan liposome injection, trade name Onivyde).
Gemifloxacin is a quinolone antibacterial agent with a broad-spectrum activity that is used in the treatment of acute bacterial exacerbation of chronic bronchitis and mild-to-moderate pneumonia. It is available in oral formulations. Gemifloxacin acts by inhibiting DNA synthesis through the inhibition of both DNA gyrase and topoisomerase IV, which are essential for bacterial growth.
Minor
0
[ [ [ 613, 23, 872 ] ], [ [ 613, 23, 739 ], [ 739, 1, 872 ] ], [ [ 613, 62, 1299 ], [ 1299, 1, 872 ] ], [ [ 613, 23, 945 ], [ 945, 40, 872 ] ], [ [ 613, 21, 29134 ], [ 29134, 60, 872 ] ], [ [ 613, 24, 869 ], [ 869, 23, 872 ] ], [ [ 613, 63, 752 ], [ 752, 23, 872 ] ], [ [ 613, 24, 1250 ], [ 1250, 63, 872 ] ], [ [ 613, 63, 355 ], [ 355, 24, 872 ] ], [ [ 613, 25, 609 ], [ 609, 63, 872 ] ] ]
[ [ [ "Irinotecan", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Gemifloxacin" ] ], [ [ "Irinotecan", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Lomefloxacin" ], [ "Lomefloxacin", "{u} (Compound) resembles {v} (Compound)", "Gemifloxacin" ] ], [ [ "Irinotecan", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Trovafloxacin" ], [ "Trovafloxacin", "{u} (Compound) resembles {v} (Compound)", "Gemifloxacin" ] ], [ [ "Irinotecan", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Sparfloxacin" ], [ "Sparfloxacin", "{u} (Compound) resembles {v} (Compound)", "Gemifloxacin" ] ], [ [ "Irinotecan", "{u} (Compound) causes {v} (Side Effect)", "Flatulence" ], [ "Flatulence", "{u} (Side Effect) is caused by {v} (Compound)", "Gemifloxacin" ] ], [ [ "Irinotecan", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Topotecan" ], [ "Topotecan", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Gemifloxacin" ] ], [ [ "Irinotecan", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Cimetidine" ], [ "Cimetidine", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Gemifloxacin" ] ], [ [ "Irinotecan", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Pazopanib" ], [ "Pazopanib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Gemifloxacin" ] ], [ [ "Irinotecan", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Lactulose" ], [ "Lactulose", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Gemifloxacin" ] ], [ [ "Irinotecan", "{u} may lead to a major life threatening interaction when taken with {v}", "Clarithromycin" ], [ "Clarithromycin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Gemifloxacin" ] ] ]
Irinotecan may cause a minor interaction that can limit clinical effects when taken with Lomefloxacin and Lomefloxacin (Compound) resembles Gemifloxacin (Compound) Irinotecan may cause a minor interaction that can limit clinical effects when taken with Trovafloxacin and Trovafloxacin (Compound) resembles Gemifloxacin (Compound) Irinotecan may cause a minor interaction that can limit clinical effects when taken with Sparfloxacin and Sparfloxacin (Compound) resembles Gemifloxacin (Compound) Irinotecan (Compound) causes Flatulence (Side Effect) and Flatulence (Side Effect) is caused by Gemifloxacin (Compound) Irinotecan may cause a moderate interaction that could exacerbate diseases when taken with Topotecan and Topotecan may cause a minor interaction that can limit clinical effects when taken with Gemifloxacin Irinotecan may cause a moderate interaction that could exacerbate diseases when taken with Cimetidine and Cimetidine may cause a minor interaction that can limit clinical effects when taken with Gemifloxacin Irinotecan may cause a moderate interaction that could exacerbate diseases when taken with Pazopanib and Pazopanib may cause a moderate interaction that could exacerbate diseases when taken with Gemifloxacin Irinotecan may cause a moderate interaction that could exacerbate diseases when taken with Lactulose and Lactulose may cause a moderate interaction that could exacerbate diseases when taken with Gemifloxacin Irinotecan may lead to a major life threatening interaction when taken with Clarithromycin and Clarithromycin may cause a moderate interaction that could exacerbate diseases when taken with Gemifloxacin
DB06372
DB09074
259
1,362
[ "DDInter1594", "DDInter1327" ]
Rilonacept
Olaparib
Rilonacept is a dimeric fusion protein consisting of portions of IL-1R and the IL-1R accessory protein linked to the Fc portion of immunoglobulin G1. Rilonacept functions as an interleukin 1 inhibitor and is used in the treatment of CAPS, also known as cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome (FCAS) and Muckle-Wells Syndrome (MWS), in adults and children greater than 12 years old.
Olaparib is a selective and potent inhibitor of poly (ADP-ribose) polymerase (PARP) enzymes, PARP1 and PARP2.[L41100, L40908, L43792] PARP inhibitors represent a novel class of anti-cancer therapy and they work by taking advantage of a defect in DNA repair in cancer cells with BRCA mutations and inducing cell death. Olaparib is used to treat a number of BRCA-associated tumours, including ovarian cancer, breast cancer, pancreatic cancer, and prostate cancer.[L41100, L40908, L43792] It was first approved by the FDA and EU in December 2014, and by Health Canada in April 2016.
Moderate
1
[ [ [ 259, 24, 1362 ] ], [ [ 259, 25, 725 ], [ 725, 63, 1362 ] ], [ [ 259, 63, 896 ], [ 896, 24, 1362 ] ], [ [ 259, 24, 250 ], [ 250, 24, 1362 ] ], [ [ 259, 24, 385 ], [ 385, 63, 1362 ] ], [ [ 259, 64, 980 ], [ 980, 24, 1362 ] ], [ [ 259, 25, 962 ], [ 962, 64, 1362 ] ], [ [ 259, 64, 1066 ], [ 1066, 25, 1362 ] ], [ [ 259, 63, 362 ], [ 362, 25, 1362 ] ], [ [ 259, 25, 1011 ], [ 1011, 25, 1362 ] ] ]
[ [ [ "Rilonacept", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Olaparib" ] ], [ [ "Rilonacept", "{u} may lead to a major life threatening interaction when taken with {v}", "Satralizumab" ], [ "Satralizumab", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Olaparib" ] ], [ [ "Rilonacept", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Etoposide" ], [ "Etoposide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Olaparib" ] ], [ [ "Rilonacept", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Blinatumomab" ], [ "Blinatumomab", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Olaparib" ] ], [ [ "Rilonacept", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Isatuximab" ], [ "Isatuximab", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Olaparib" ] ], [ [ "Rilonacept", "{u} may lead to a major life threatening interaction when taken with {v}", "Tocilizumab" ], [ "Tocilizumab", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Olaparib" ] ], [ [ "Rilonacept", "{u} may lead to a major life threatening interaction when taken with {v}", "Bacillus calmette-guerin substrain tice live antigen" ], [ "Bacillus calmette-guerin substrain tice live antigen", "{u} may lead to a major life threatening interaction when taken with {v}", "Olaparib" ] ], [ [ "Rilonacept", "{u} may lead to a major life threatening interaction when taken with {v}", "Natalizumab" ], [ "Natalizumab", "{u} may lead to a major life threatening interaction when taken with {v}", "Olaparib" ] ], [ [ "Rilonacept", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Phenytoin" ], [ "Phenytoin", "{u} may lead to a major life threatening interaction when taken with {v}", "Olaparib" ] ], [ [ "Rilonacept", "{u} may lead to a major life threatening interaction when taken with {v}", "Fingolimod" ], [ "Fingolimod", "{u} may lead to a major life threatening interaction when taken with {v}", "Olaparib" ] ] ]
Rilonacept may lead to a major life threatening interaction when taken with Satralizumab and Satralizumab may cause a moderate interaction that could exacerbate diseases when taken with Olaparib Rilonacept may cause a moderate interaction that could exacerbate diseases when taken with Etoposide and Etoposide may cause a moderate interaction that could exacerbate diseases when taken with Olaparib Rilonacept may cause a moderate interaction that could exacerbate diseases when taken with Blinatumomab and Blinatumomab may cause a moderate interaction that could exacerbate diseases when taken with Olaparib Rilonacept may cause a moderate interaction that could exacerbate diseases when taken with Isatuximab and Isatuximab may cause a moderate interaction that could exacerbate diseases when taken with Olaparib Rilonacept may lead to a major life threatening interaction when taken with Tocilizumab and Tocilizumab may cause a moderate interaction that could exacerbate diseases when taken with Olaparib Rilonacept may lead to a major life threatening interaction when taken with Bacillus calmette-guerin substrain tice live antigen and Bacillus calmette-guerin substrain tice live antigen may lead to a major life threatening interaction when taken with Olaparib Rilonacept may lead to a major life threatening interaction when taken with Natalizumab and Natalizumab may lead to a major life threatening interaction when taken with Olaparib Rilonacept may cause a moderate interaction that could exacerbate diseases when taken with Phenytoin and Phenytoin may lead to a major life threatening interaction when taken with Olaparib Rilonacept may lead to a major life threatening interaction when taken with Fingolimod and Fingolimod may lead to a major life threatening interaction when taken with Olaparib
DB00393
DB06691
854
849
[ "DDInter1295", "DDInter1155" ]
Nimodipine
Mepyramine
Nimodipine is a 1,4-dihydropyridine calcium channel blocker. It acts primarily on vascular smooth muscle cells by stabilizing voltage-gated L-type calcium channels in their inactive conformation. By inhibiting the influx of calcium in smooth muscle cells, nimodipine prevents calcium-dependent smooth muscle contraction and subsequent vasoconstriction. Compared to other calcium channel blocking agents, nimodipine exhibits greater effects on cerebral circulation than on peripheral circulation. Nimodipine is used to as an adjunct to improve the neurologic outcome following subarachnoid hemorrhage from ruptured intracranial aneurysm.
Mepyramine, or pyrilamine, targets the H1 receptor. It is a first generation antihistamine. However, it rapidly permeates the brain and so often causes drowsiness as a side effect. It has been found in over-the-counter combination products for colds and menstrual symptoms, but is considered to be an unapproved prescription medication used for cough, cold, or allergic conditions.
Moderate
1
[ [ [ 854, 24, 849 ] ], [ [ 854, 24, 770 ], [ 770, 24, 849 ] ], [ [ 854, 1, 1428 ], [ 1428, 24, 849 ] ], [ [ 854, 24, 407 ], [ 407, 63, 849 ] ], [ [ 854, 63, 999 ], [ 999, 24, 849 ] ], [ [ 854, 24, 770 ], [ 770, 63, 1594 ], [ 1594, 24, 849 ] ], [ [ 854, 1, 1428 ], [ 1428, 24, 770 ], [ 770, 24, 849 ] ], [ [ 854, 1, 336 ], [ 336, 6, 12523 ], [ 12523, 45, 849 ] ], [ [ 854, 24, 1376 ], [ 1376, 40, 11244 ], [ 11244, 1, 849 ] ], [ [ 854, 63, 999 ], [ 999, 63, 1594 ], [ 1594, 24, 849 ] ] ]
[ [ [ "Nimodipine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Mepyramine" ] ], [ [ "Nimodipine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Thalidomide" ], [ "Thalidomide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Mepyramine" ] ], [ [ "Nimodipine", "{u} (Compound) resembles {v} (Compound)", "Isradipine" ], [ "Isradipine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Mepyramine" ] ], [ [ "Nimodipine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Opium" ], [ "Opium", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Mepyramine" ] ], [ [ "Nimodipine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Thiethylperazine" ], [ "Thiethylperazine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Mepyramine" ] ], [ [ "Nimodipine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Thalidomide" ], [ "Thalidomide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Doxylamine" ], [ "Doxylamine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Mepyramine" ] ], [ [ "Nimodipine", "{u} (Compound) resembles {v} (Compound)", "Isradipine" ], [ "Isradipine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Thalidomide" ], [ "Thalidomide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Mepyramine" ] ], [ [ "Nimodipine", "{u} (Compound) resembles {v} (Compound)", "Nifedipine" ], [ "Nifedipine", "{u} (Compound) binds {v} (Gene)", "CYP2D6" ], [ "CYP2D6", "{u} (Gene) is bound by {v} (Compound)", "Mepyramine" ] ], [ [ "Nimodipine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Diphenhydramine" ], [ "Diphenhydramine", "{u} (Compound) resembles {v} (Compound)", "Pheniramine" ], [ "Pheniramine", "{u} (Compound) resembles {v} (Compound)", "Mepyramine" ] ], [ [ "Nimodipine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Thiethylperazine" ], [ "Thiethylperazine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Doxylamine" ], [ "Doxylamine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Mepyramine" ] ] ]
Nimodipine may cause a moderate interaction that could exacerbate diseases when taken with Thalidomide and Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine Nimodipine (Compound) resembles Isradipine (Compound) and Isradipine may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine Nimodipine may cause a moderate interaction that could exacerbate diseases when taken with Opium and Opium may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine Nimodipine may cause a moderate interaction that could exacerbate diseases when taken with Thiethylperazine and Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine Nimodipine may cause a moderate interaction that could exacerbate diseases when taken with Thalidomide and Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Doxylamine and Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine Nimodipine (Compound) resembles Isradipine (Compound) and Isradipine may cause a moderate interaction that could exacerbate diseases when taken with Thalidomide and Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine Nimodipine (Compound) resembles Nifedipine (Compound) and Nifedipine (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Mepyramine (Compound) Nimodipine may cause a moderate interaction that could exacerbate diseases when taken with Diphenhydramine and Diphenhydramine (Compound) resembles Pheniramine (Compound) and Pheniramine (Compound) resembles Mepyramine (Compound) Nimodipine may cause a moderate interaction that could exacerbate diseases when taken with Thiethylperazine and Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken with Doxylamine and Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine
DB00059
DB10429
1,560
200
[ "DDInter1404", "DDInter282" ]
Pegaspargase
Candida albicans
Pegaspargase is a conjugate of monomethoxypolyethylene glycol (mPEG) and L-asparaginase (L-asparagine amidohydrolase), an asparagine-specific enzyme that converts L-asparagine into aspartic acid and ammonia. Asparagine is an amino acid that is vital for cell survival. In humans, most normal tissues can produce asparagine through the action of asparagine synthetase. However, leukemia cells have low levels of this enzyme and depend on exogenous sources. Therefore, the use of pegaspargase results in leukemic cell death.[A103,A255912,L44667] Pegaspargase has the same mechanism of action as [L-asparaginase] derived from _Escherichia coli_, a previously developed enzyme used for the treatment of acute lymphoblastic leukemia (ALL). However, using L-asparaginase derived from _Escherich
Candida albicans is a fungus which can provoke allergic reactions. Candida albicans is used in allergenic testing.
Moderate
1
[ [ [ 1560, 24, 200 ] ], [ [ 1560, 25, 976 ], [ 976, 24, 200 ] ], [ [ 1560, 24, 168 ], [ 168, 24, 200 ] ], [ [ 1560, 24, 1019 ], [ 1019, 63, 200 ] ], [ [ 1560, 63, 816 ], [ 816, 24, 200 ] ], [ [ 1560, 64, 1057 ], [ 1057, 24, 200 ] ], [ [ 1560, 25, 676 ], [ 676, 63, 200 ] ], [ [ 1560, 25, 976 ], [ 976, 64, 1096 ], [ 1096, 24, 200 ] ], [ [ 1560, 24, 168 ], [ 168, 24, 1683 ], [ 1683, 24, 200 ] ], [ [ 1560, 24, 1019 ], [ 1019, 63, 1683 ], [ 1683, 24, 200 ] ] ]
[ [ [ "Pegaspargase", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Candida albicans" ] ], [ [ "Pegaspargase", "{u} may lead to a major life threatening interaction when taken with {v}", "Tofacitinib" ], [ "Tofacitinib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Candida albicans" ] ], [ [ "Pegaspargase", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Bortezomib" ], [ "Bortezomib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Candida albicans" ] ], [ [ "Pegaspargase", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Deflazacort" ], [ "Deflazacort", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Candida albicans" ] ], [ [ "Pegaspargase", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Gemtuzumab ozogamicin" ], [ "Gemtuzumab ozogamicin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Candida albicans" ] ], [ [ "Pegaspargase", "{u} may lead to a major life threatening interaction when taken with {v}", "Etanercept" ], [ "Etanercept", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Candida albicans" ] ], [ [ "Pegaspargase", "{u} may lead to a major life threatening interaction when taken with {v}", "Upadacitinib" ], [ "Upadacitinib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Candida albicans" ] ], [ [ "Pegaspargase", "{u} may lead to a major life threatening interaction when taken with {v}", "Tofacitinib" ], [ "Tofacitinib", "{u} may lead to a major life threatening interaction when taken with {v}", "Mycophenolic acid" ], [ "Mycophenolic acid", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Candida albicans" ] ], [ [ "Pegaspargase", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Bortezomib" ], [ "Bortezomib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Ustekinumab" ], [ "Ustekinumab", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Candida albicans" ] ], [ [ "Pegaspargase", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Deflazacort" ], [ "Deflazacort", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Ustekinumab" ], [ "Ustekinumab", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Candida albicans" ] ] ]
Pegaspargase may lead to a major life threatening interaction when taken with Tofacitinib and Tofacitinib may cause a moderate interaction that could exacerbate diseases when taken with Candida albicans Pegaspargase may cause a moderate interaction that could exacerbate diseases when taken with Bortezomib and Bortezomib may cause a moderate interaction that could exacerbate diseases when taken with Candida albicans Pegaspargase may cause a moderate interaction that could exacerbate diseases when taken with Deflazacort and Deflazacort may cause a moderate interaction that could exacerbate diseases when taken with Candida albicans Pegaspargase may cause a moderate interaction that could exacerbate diseases when taken with Gemtuzumab ozogamicin and Gemtuzumab ozogamicin may cause a moderate interaction that could exacerbate diseases when taken with Candida albicans Pegaspargase may lead to a major life threatening interaction when taken with Etanercept and Etanercept may cause a moderate interaction that could exacerbate diseases when taken with Candida albicans Pegaspargase may lead to a major life threatening interaction when taken with Upadacitinib and Upadacitinib may cause a moderate interaction that could exacerbate diseases when taken with Candida albicans Pegaspargase may lead to a major life threatening interaction when taken with Tofacitinib and Tofacitinib may lead to a major life threatening interaction when taken with Mycophenolic acid and Mycophenolic acid may cause a moderate interaction that could exacerbate diseases when taken with Candida albicans Pegaspargase may cause a moderate interaction that could exacerbate diseases when taken with Bortezomib and Bortezomib may cause a moderate interaction that could exacerbate diseases when taken with Ustekinumab and Ustekinumab may cause a moderate interaction that could exacerbate diseases when taken with Candida albicans Pegaspargase may cause a moderate interaction that could exacerbate diseases when taken with Deflazacort and Deflazacort may cause a moderate interaction that could exacerbate diseases when taken with Ustekinumab and Ustekinumab may cause a moderate interaction that could exacerbate diseases when taken with Candida albicans
DB00344
DB11837
1,302
1,297
[ "DDInter1543", "DDInter1351" ]
Protriptyline
Osilodrostat
Protriptyline hydrochloride is a dibenzocycloheptene-derivative tricyclic antidepressant (TCA). TCAs are structurally similar to phenothiazines. They contain a tricyclic ring system with an alkyl amine substituent on the central ring. In non-depressed individuals, protriptyline does not affect mood or arousal, but may cause sedation. In depressed individuals, protriptyline exerts a positive effect on mood. TCAs are potent inhibitors of serotonin and norepinephrine reuptake. In addition, TCAs down-regulate cerebral cortical &beta;-adrenergic receptors and sensitize post-synaptic serotonergic receptors with chronic use. The antidepressant effects of TCAs are thought to be due to an overall increase in serotonergic neurotransmission. TCAs also block histamine H<sub>1</sub> receptors, alpha<sub>1</sub
Osilodrostat is an inhibitor of 11β-hydroxylase (also referred to as CYP11B1), the enzyme that catalyzes the final step in the biosynthesis of endogenous cortisol. It is used to lower circulating cortisol levels in the treatment of Cushing's disease, a disorder in which cortisol levels are chronically and supraphysiologically elevated. Cushing's disease is often the result of ACTH hypersecretion secondary to a pituitary tumor, and surgical resection of the tumour is generally the treatment of choice. As an orally bioavailable drug therapy, osilodrostat provides a novel treatment option for patients in whom removal of the causative tumor is not an option or for whom previous pituitary surgery has not been curative. Osilodrostat is manufactured by Novartis under the brand name Isturisa. It has undergone phase II clinical trials for the treatment of solid tumours, hypertension, and heart failure, but development for these indications was discontinued by Novartis in January 2013. Osilodrostat was approved for use in the EU in January 2020 for the treatment of endogenous Cushing's syndrome (i.e. Cushing's disease), and was granted FDA approval and Orphan Drug designation in the US in March 2020 for the same indication.
Moderate
1
[ [ [ 1302, 24, 1297 ] ], [ [ 1302, 23, 112 ], [ 112, 23, 1297 ] ], [ [ 1302, 25, 222 ], [ 222, 23, 1297 ] ], [ [ 1302, 24, 401 ], [ 401, 24, 1297 ] ], [ [ 1302, 24, 971 ], [ 971, 63, 1297 ] ], [ [ 1302, 63, 1181 ], [ 1181, 24, 1297 ] ], [ [ 1302, 25, 1133 ], [ 1133, 24, 1297 ] ], [ [ 1302, 1, 1405 ], [ 1405, 24, 1297 ] ], [ [ 1302, 40, 998 ], [ 998, 24, 1297 ] ], [ [ 1302, 25, 351 ], [ 351, 25, 1297 ] ] ]
[ [ [ "Protriptyline", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Osilodrostat" ] ], [ [ "Protriptyline", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Metronidazole" ], [ "Metronidazole", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Osilodrostat" ] ], [ [ "Protriptyline", "{u} may lead to a major life threatening interaction when taken with {v}", "Sibutramine" ], [ "Sibutramine", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Osilodrostat" ] ], [ [ "Protriptyline", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Promethazine" ], [ "Promethazine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Osilodrostat" ] ], [ [ "Protriptyline", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Gilteritinib" ], [ "Gilteritinib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Osilodrostat" ] ], [ [ "Protriptyline", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Terfenadine" ], [ "Terfenadine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Osilodrostat" ] ], [ [ "Protriptyline", "{u} may lead to a major life threatening interaction when taken with {v}", "Granisetron" ], [ "Granisetron", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Osilodrostat" ] ], [ [ "Protriptyline", "{u} (Compound) resembles {v} (Compound)", "Cyclobenzaprine" ], [ "Cyclobenzaprine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Osilodrostat" ] ], [ [ "Protriptyline", "{u} (Compound) resembles {v} (Compound)", "Phenylbutazone" ], [ "Phenylbutazone", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Osilodrostat" ] ], [ [ "Protriptyline", "{u} may lead to a major life threatening interaction when taken with {v}", "Ribociclib" ], [ "Ribociclib", "{u} may lead to a major life threatening interaction when taken with {v}", "Osilodrostat" ] ] ]
Protriptyline may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Osilodrostat Protriptyline may lead to a major life threatening interaction when taken with Sibutramine and Sibutramine may cause a minor interaction that can limit clinical effects when taken with Osilodrostat Protriptyline may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Osilodrostat Protriptyline may cause a moderate interaction that could exacerbate diseases when taken with Gilteritinib and Gilteritinib may cause a moderate interaction that could exacerbate diseases when taken with Osilodrostat Protriptyline may cause a moderate interaction that could exacerbate diseases when taken with Terfenadine and Terfenadine may cause a moderate interaction that could exacerbate diseases when taken with Osilodrostat Protriptyline may lead to a major life threatening interaction when taken with Granisetron and Granisetron may cause a moderate interaction that could exacerbate diseases when taken with Osilodrostat Protriptyline (Compound) resembles Cyclobenzaprine (Compound) and Cyclobenzaprine may cause a moderate interaction that could exacerbate diseases when taken with Osilodrostat Protriptyline (Compound) resembles Phenylbutazone (Compound) and Phenylbutazone may cause a moderate interaction that could exacerbate diseases when taken with Osilodrostat Protriptyline may lead to a major life threatening interaction when taken with Ribociclib and Ribociclib may lead to a major life threatening interaction when taken with Osilodrostat
DB01225
DB01294
500
266
[ "DDInter645", "DDInter215" ]
Enoxaparin
Bismuth subsalicylate
Enoxaparin is a common low-molecular-weight heparin (LMWH) used in the prevention and management of various thromboembolic disorders. Initially approved by the FDA in 1993, it is administered by a subcutaneous or intravenous injection and marketed by several pharmaceutical companies. Enoxaparin markedly reduces the incidence of venous thromboembolism in hospitalized patients when compared to unfractionated [heparin], without increasing the risk of serious bleeding.[A228178,A228313]
Bismuth subsalicylate is an antacid and anti-diarrheal agent. Exhibiting antibacterial and gastroprotective properties, bismuth subsalicylate is an insoluble salt of [salicylic acid] linked to trivalent [bismuth cation]. Each molecule of bismuth subsalicylate contains 58% bismuth and 42% salicylate by weight. Bismuth subsalicylate has been around for over 100 years: it was originally developed in 1901 for hygienic use and sanitation for cholera infection.[A230728, A230773] Bismuth subsalicylate was first approved by the FDA in 1939 and is now mainly used to relieve nausea, diarrhea, and gastrointestinal discomfort. It is an active ingredient found in Pepto-Bismol, a common over-the-counter medication that is used to temporarily treat discomforts of the stomach and gastrointestinal tract. Bismuth subsalicylate is a component of HELIDAC Therapy (bismuth subsalicylate, [metronidazole], and [tetracycline]), which is a treatment regimen indicated for the eradication of _H. pylori_ for treatment of patients with _H. pylori_ infection and duodenal ulcer disease.
Moderate
1
[ [ [ 500, 24, 266 ] ], [ [ 500, 21, 28929 ], [ 28929, 60, 266 ] ], [ [ 500, 64, 1347 ], [ 1347, 24, 266 ] ], [ [ 500, 25, 235 ], [ 235, 63, 266 ] ], [ [ 500, 25, 885 ], [ 885, 24, 266 ] ], [ [ 500, 63, 121 ], [ 121, 24, 266 ] ], [ [ 500, 25, 330 ], [ 330, 64, 266 ] ], [ [ 500, 21, 28929 ], [ 28929, 60, 1347 ], [ 1347, 24, 266 ] ], [ [ 500, 21, 29547 ], [ 29547, 60, 663 ], [ 663, 25, 266 ] ], [ [ 500, 64, 1347 ], [ 1347, 21, 28643 ], [ 28643, 60, 266 ] ] ]
[ [ [ "Enoxaparin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Bismuth subsalicylate" ] ], [ [ "Enoxaparin", "{u} (Compound) causes {v} (Side Effect)", "Confusional state" ], [ "Confusional state", "{u} (Side Effect) is caused by {v} (Compound)", "Bismuth subsalicylate" ] ], [ [ "Enoxaparin", "{u} may lead to a major life threatening interaction when taken with {v}", "Clopidogrel" ], [ "Clopidogrel", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Bismuth subsalicylate" ] ], [ [ "Enoxaparin", "{u} may lead to a major life threatening interaction when taken with {v}", "Desirudin" ], [ "Desirudin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Bismuth subsalicylate" ] ], [ [ "Enoxaparin", "{u} may lead to a major life threatening interaction when taken with {v}", "Epoprostenol" ], [ "Epoprostenol", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Bismuth subsalicylate" ] ], [ [ "Enoxaparin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Fenfluramine" ], [ "Fenfluramine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Bismuth subsalicylate" ] ], [ [ "Enoxaparin", "{u} may lead to a major life threatening interaction when taken with {v}", "Ramucirumab" ], [ "Ramucirumab", "{u} may lead to a major life threatening interaction when taken with {v}", "Bismuth subsalicylate" ] ], [ [ "Enoxaparin", "{u} (Compound) causes {v} (Side Effect)", "Confusional state" ], [ "Confusional state", "{u} (Side Effect) is caused by {v} (Compound)", "Clopidogrel" ], [ "Clopidogrel", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Bismuth subsalicylate" ] ], [ [ "Enoxaparin", "{u} (Compound) causes {v} (Side Effect)", "Skin exfoliation" ], [ "Skin exfoliation", "{u} (Side Effect) is caused by {v} (Compound)", "Methotrexate" ], [ "Methotrexate", "{u} may lead to a major life threatening interaction when taken with {v}", "Bismuth subsalicylate" ] ], [ [ "Enoxaparin", "{u} may lead to a major life threatening interaction when taken with {v}", "Clopidogrel" ], [ "Clopidogrel", "{u} (Compound) causes {v} (Side Effect)", "Infection" ], [ "Infection", "{u} (Side Effect) is caused by {v} (Compound)", "Bismuth subsalicylate" ] ] ]
Enoxaparin (Compound) causes Confusional state (Side Effect) and Confusional state (Side Effect) is caused by Bismuth subsalicylate (Compound) Enoxaparin may lead to a major life threatening interaction when taken with Clopidogrel and Clopidogrel may cause a moderate interaction that could exacerbate diseases when taken with Bismuth subsalicylate Enoxaparin may lead to a major life threatening interaction when taken with Desirudin and Desirudin may cause a moderate interaction that could exacerbate diseases when taken with Bismuth subsalicylate Enoxaparin may lead to a major life threatening interaction when taken with Epoprostenol and Epoprostenol may cause a moderate interaction that could exacerbate diseases when taken with Bismuth subsalicylate Enoxaparin may cause a moderate interaction that could exacerbate diseases when taken with Fenfluramine and Fenfluramine may cause a moderate interaction that could exacerbate diseases when taken with Bismuth subsalicylate Enoxaparin may lead to a major life threatening interaction when taken with Ramucirumab and Ramucirumab may lead to a major life threatening interaction when taken with Bismuth subsalicylate Enoxaparin (Compound) causes Confusional state (Side Effect) and Confusional state (Side Effect) is caused by Clopidogrel (Compound) and Clopidogrel may cause a moderate interaction that could exacerbate diseases when taken with Bismuth subsalicylate Enoxaparin (Compound) causes Skin exfoliation (Side Effect) and Skin exfoliation (Side Effect) is caused by Methotrexate (Compound) and Methotrexate may lead to a major life threatening interaction when taken with Bismuth subsalicylate Enoxaparin may lead to a major life threatening interaction when taken with Clopidogrel and Clopidogrel (Compound) causes Infection (Side Effect) and Infection (Side Effect) is caused by Bismuth subsalicylate (Compound)
DB00557
DB13074
252
877
[ "DDInter895", "DDInter1110" ]
Hydroxyzine
Macimorelin
Hydroxyzine is a first-generation histamine H<sub>1</sub>-receptor antagonist of the dephenylmethane and piperazine classes that exhibits sedative, anxiolytic, and antiemetic properties.[A1257,A187589] It was first developed in 1955, and has since remained a relatively common treatment for allergic conditions such as pruritus, urticaria, dermatoses, and histamine-mediated pruritus. The active metabolite of hydroxyzine, [cetirizine], is also available as an active ingredient in allergic medications, and is responsible for much of its hydroxyzine's antihistaminic effect. Hydroxyzine is also used for generalized anxiety disorder, tension caused by psychoneurosis, and other conditions with manifestations of anxiety.
Macimorelin, a novel and orally active ghrelin mimetic that stimulates GH secretion, is used in the diagnosis of adult GH deficiency (AGHD). More specifically, macimorelin is a peptidomimetic growth hormone secretagogue (GHS) that acts as an agonist of GH secretagogue receptor, or ghrelin receptor (GHS-R1a) to dose-dependently increase GH levels . Growth hormone secretagogues (GHS) represent a new class of pharmacological agents which have the potential to be used in numerous clinical applications. They include treatment for growth retardation in children and cachexia associated with chronic disease such as AIDS and cancer. Growth hormone (GH) is classically linked with linear growth during childhood. In deficiency of this hormone, AGHD is commonly associated with increased fat mass (particularly in the abdominal region), decreased lean body mass, osteopenia, dyslipidemia, insulin resistance, and/or glucose intolerance overtime. In addition, individuals with may be susceptible to cardiovascular complications from altered structures and function . Risk factors of AGHD include a history of childhood-onset GH deficiency or with hypothalamic/pituitary disease, surgery, or irradiation to these areas, head trauma, or evidence of other pituitary hormone deficiencies . While there are various therapies available such as GH replacement therapy, the absence of panhypopituitarism and low serum IGF-I levels with nonspecific clinical symptoms pose challenges to the detection and diagnosis of AGHD. The diagnosis of AGHD requires biochemical confirmation with at least 1 GH stimulation test . Macimorelin is clinically useful since it displays good stability and oral bioavailability with comparable affinity to ghrelin receptor as its endogenous ligand. In clinical studies involving healthy subjects, macimorelin stimulated GH release in a dose-dependent manner with good tolerability . Macimorelin, developed by Aeterna Zentaris, was approved by the FDA in December 2017 under the market name Macrilen for oral solution.
Major
2
[ [ [ 252, 25, 877 ] ], [ [ 252, 23, 112 ], [ 112, 23, 877 ] ], [ [ 252, 24, 85 ], [ 85, 24, 877 ] ], [ [ 252, 24, 485 ], [ 485, 25, 877 ] ], [ [ 252, 25, 478 ], [ 478, 25, 877 ] ], [ [ 252, 63, 1424 ], [ 1424, 25, 877 ] ], [ [ 252, 40, 1630 ], [ 1630, 25, 877 ] ], [ [ 252, 25, 982 ], [ 982, 64, 877 ] ], [ [ 252, 64, 702 ], [ 702, 25, 877 ] ], [ [ 252, 1, 623 ], [ 623, 25, 877 ] ] ]
[ [ [ "Hydroxyzine", "{u} may lead to a major life threatening interaction when taken with {v}", "Macimorelin" ] ], [ [ "Hydroxyzine", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Metronidazole" ], [ "Metronidazole", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Macimorelin" ] ], [ [ "Hydroxyzine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Atropine" ], [ "Atropine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Macimorelin" ] ], [ [ "Hydroxyzine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Pentamidine" ], [ "Pentamidine", "{u} may lead to a major life threatening interaction when taken with {v}", "Macimorelin" ] ], [ [ "Hydroxyzine", "{u} may lead to a major life threatening interaction when taken with {v}", "Nilotinib" ], [ "Nilotinib", "{u} may lead to a major life threatening interaction when taken with {v}", "Macimorelin" ] ], [ [ "Hydroxyzine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Quinine" ], [ "Quinine", "{u} may lead to a major life threatening interaction when taken with {v}", "Macimorelin" ] ], [ [ "Hydroxyzine", "{u} (Compound) resembles {v} (Compound)", "Perphenazine" ], [ "Perphenazine", "{u} may lead to a major life threatening interaction when taken with {v}", "Macimorelin" ] ], [ [ "Hydroxyzine", "{u} may lead to a major life threatening interaction when taken with {v}", "Ivosidenib" ], [ "Ivosidenib", "{u} may lead to a major life threatening interaction when taken with {v}", "Macimorelin" ] ], [ [ "Hydroxyzine", "{u} may lead to a major life threatening interaction when taken with {v}", "Anagrelide" ], [ "Anagrelide", "{u} may lead to a major life threatening interaction when taken with {v}", "Macimorelin" ] ], [ [ "Hydroxyzine", "{u} (Compound) resembles {v} (Compound)", "Quetiapine" ], [ "Quetiapine", "{u} may lead to a major life threatening interaction when taken with {v}", "Macimorelin" ] ] ]
Hydroxyzine may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Macimorelin Hydroxyzine may cause a moderate interaction that could exacerbate diseases when taken with Atropine and Atropine may cause a moderate interaction that could exacerbate diseases when taken with Macimorelin Hydroxyzine may cause a moderate interaction that could exacerbate diseases when taken with Pentamidine and Pentamidine may lead to a major life threatening interaction when taken with Macimorelin Hydroxyzine may lead to a major life threatening interaction when taken with Nilotinib and Nilotinib may lead to a major life threatening interaction when taken with Macimorelin Hydroxyzine may cause a moderate interaction that could exacerbate diseases when taken with Quinine and Quinine may lead to a major life threatening interaction when taken with Macimorelin Hydroxyzine (Compound) resembles Perphenazine (Compound) and Perphenazine may lead to a major life threatening interaction when taken with Macimorelin Hydroxyzine may lead to a major life threatening interaction when taken with Ivosidenib and Ivosidenib may lead to a major life threatening interaction when taken with Macimorelin Hydroxyzine may lead to a major life threatening interaction when taken with Anagrelide and Anagrelide may lead to a major life threatening interaction when taken with Macimorelin Hydroxyzine (Compound) resembles Quetiapine (Compound) and Quetiapine may lead to a major life threatening interaction when taken with Macimorelin
DB00026
DB11767
1,184
1,583
[ "DDInter94", "DDInter1643" ]
Anakinra
Sarilumab
Anakinra is a recombinant human interleukin-1 (IL-1) receptor antagonist (IL-1Ra) composed of 153 amino acid residues. Unlike native human IL-1Ra, anakinra has an additional methionine residue at the amino terminus. This drug binds to the IL-1 receptor, competing with and inhibiting the activity of IL-1 alpha and beta. Anakinra is indicated for the management of rheumatoid arthritis (RA) in patients 18 years of age or older who have failed one or more disease-modifying antirheumatic drugs (DMARDs), as well as the treatment of neonatal-onset multisystem inflammatory disease (NOMID) and deficiency of interleukin-1 receptor antagonist (DIRA). Since IL-1 has an important role in inflammation and immunological responses, anakinra is also used for the off-label treatment of inflammatory diseases. Anakinra is produced using the _
Sarilumab is a fully human anti-interleukin 6 (IL-6) receptor monoclonal IgG1 antibody that binds to both membrane-bound and soluble IL-6 receptor forms, thus blocking the cis- and trans-inflammatory signalling cascades of IL-6. Sarilumab was developed by Sanofi and Regeneron Pharmaceuticals, Inc; it was US FDA-approved in May 2017 and followed by EU approval in June 2017 for the treatment of moderate to severe rheumatoid arthritis (RA) in combination with methotrexate. RA is a chronic inflammatory disease characterized by polyarthritis, and its treatment has been challenged by the different responses in every patient. Subcutaneous administration of sarilumab has been shown to decrease acute-phase reactant levels and improve clinical RA symptoms.
Major
2
[ [ [ 1184, 25, 1583 ] ], [ [ 1184, 23, 1461 ], [ 1461, 23, 1583 ] ], [ [ 1184, 24, 362 ], [ 362, 24, 1583 ] ], [ [ 1184, 24, 287 ], [ 287, 63, 1583 ] ], [ [ 1184, 63, 305 ], [ 305, 24, 1583 ] ], [ [ 1184, 25, 1064 ], [ 1064, 25, 1583 ] ], [ [ 1184, 24, 1683 ], [ 1683, 25, 1583 ] ], [ [ 1184, 25, 779 ], [ 779, 64, 1583 ] ], [ [ 1184, 64, 1057 ], [ 1057, 25, 1583 ] ], [ [ 1184, 23, 1461 ], [ 1461, 24, 372 ], [ 372, 24, 1583 ] ] ]
[ [ [ "Anakinra", "{u} may lead to a major life threatening interaction when taken with {v}", "Sarilumab" ] ], [ [ "Anakinra", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Vitamin E" ], [ "Vitamin E", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Sarilumab" ] ], [ [ "Anakinra", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Phenytoin" ], [ "Phenytoin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Sarilumab" ] ], [ [ "Anakinra", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Diroximel fumarate" ], [ "Diroximel fumarate", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Sarilumab" ] ], [ [ "Anakinra", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Asparaginase Escherichia coli" ], [ "Asparaginase Escherichia coli", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Sarilumab" ] ], [ [ "Anakinra", "{u} may lead to a major life threatening interaction when taken with {v}", "Cladribine" ], [ "Cladribine", "{u} may lead to a major life threatening interaction when taken with {v}", "Sarilumab" ] ], [ [ "Anakinra", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Ustekinumab" ], [ "Ustekinumab", "{u} may lead to a major life threatening interaction when taken with {v}", "Sarilumab" ] ], [ [ "Anakinra", "{u} may lead to a major life threatening interaction when taken with {v}", "Smallpox (Vaccinia) Vaccine, Live" ], [ "Smallpox (Vaccinia) Vaccine, Live", "{u} may lead to a major life threatening interaction when taken with {v}", "Sarilumab" ] ], [ [ "Anakinra", "{u} may lead to a major life threatening interaction when taken with {v}", "Etanercept" ], [ "Etanercept", "{u} may lead to a major life threatening interaction when taken with {v}", "Sarilumab" ] ], [ [ "Anakinra", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Vitamin E" ], [ "Vitamin E", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Clofarabine" ], [ "Clofarabine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Sarilumab" ] ] ]
Anakinra may cause a minor interaction that can limit clinical effects when taken with Vitamin E and Vitamin E may cause a minor interaction that can limit clinical effects when taken with Sarilumab Anakinra may cause a moderate interaction that could exacerbate diseases when taken with Phenytoin and Phenytoin may cause a moderate interaction that could exacerbate diseases when taken with Sarilumab Anakinra may cause a moderate interaction that could exacerbate diseases when taken with Diroximel fumarate and Diroximel fumarate may cause a moderate interaction that could exacerbate diseases when taken with Sarilumab Anakinra may cause a moderate interaction that could exacerbate diseases when taken with Asparaginase Escherichia coli and Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate diseases when taken with Sarilumab Anakinra may lead to a major life threatening interaction when taken with Cladribine and Cladribine may lead to a major life threatening interaction when taken with Sarilumab Anakinra may cause a moderate interaction that could exacerbate diseases when taken with Ustekinumab and Ustekinumab may lead to a major life threatening interaction when taken with Sarilumab Anakinra may lead to a major life threatening interaction when taken with Smallpox (Vaccinia) Vaccine, Live and Smallpox (Vaccinia) Vaccine, Live may lead to a major life threatening interaction when taken with Sarilumab Anakinra may lead to a major life threatening interaction when taken with Etanercept and Etanercept may lead to a major life threatening interaction when taken with Sarilumab Anakinra may cause a minor interaction that can limit clinical effects when taken with Vitamin E and Vitamin E may cause a moderate interaction that could exacerbate diseases when taken with Clofarabine and Clofarabine may cause a moderate interaction that could exacerbate diseases when taken with Sarilumab
DB00106
DB08865
618
1,593
[ "DDInter4", "DDInter448" ]
Abarelix
Crizotinib
Synthetic decapeptide antagonist to gonadotropin releasing hormone (GnRH). It is marketed by Praecis Pharmaceuticals as Plenaxis. Praecis announced in June 2006 that it was voluntarily withdrawing the drug from the market.
Crizotinib is a tyrosine kinase receptor inhibitor used for the treatment of anaplastic lymphoma kinase (ALK) or ROS1-positive non-small cell lung cancer (NSCLC) tumors, as well as ALK-positive anaplastic large cell lymphoma (ALCL) and inflammatory myofibroblastic tumor (IMT). By targeting the echinoderm microtubule-associated protein-like 4 (EML4)-ALK fusion protein, crizotinib offers robust effectiveness in treating NSCLC in patients with this type of rearrangement. Crizotinib was the first-in-class drug used to treat ALK-positive tumors. Second- and third-generation ALK-tyrosine kinase-inhibitors have overcome many of the pharmacodynamic and genetic resistance mechanisms crizotinib is prone to. Crizotinib was approved by the FDA in 2011, and its use is accompanied by FDA-approved tests used to detect ALK and ROS1 rearrangements.
Major
2
[ [ [ 618, 25, 1593 ] ], [ [ 618, 24, 479 ], [ 479, 23, 1593 ] ], [ [ 618, 23, 1247 ], [ 1247, 23, 1593 ] ], [ [ 618, 24, 286 ], [ 286, 63, 1593 ] ], [ [ 618, 24, 898 ], [ 898, 24, 1593 ] ], [ [ 618, 23, 112 ], [ 112, 24, 1593 ] ], [ [ 618, 25, 684 ], [ 684, 25, 1593 ] ], [ [ 618, 24, 1494 ], [ 1494, 25, 1593 ] ], [ [ 618, 24, 36 ], [ 36, 64, 1593 ] ], [ [ 618, 25, 1618 ], [ 1618, 64, 1593 ] ] ]
[ [ [ "Abarelix", "{u} may lead to a major life threatening interaction when taken with {v}", "Crizotinib" ] ], [ [ "Abarelix", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Donepezil" ], [ "Donepezil", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Crizotinib" ] ], [ [ "Abarelix", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Sulfamethoxazole" ], [ "Sulfamethoxazole", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Crizotinib" ] ], [ [ "Abarelix", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Magnesium hydroxide" ], [ "Magnesium hydroxide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Crizotinib" ] ], [ [ "Abarelix", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Propofol" ], [ "Propofol", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Crizotinib" ] ], [ [ "Abarelix", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Metronidazole" ], [ "Metronidazole", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Crizotinib" ] ], [ [ "Abarelix", "{u} may lead to a major life threatening interaction when taken with {v}", "Thioridazine" ], [ "Thioridazine", "{u} may lead to a major life threatening interaction when taken with {v}", "Crizotinib" ] ], [ [ "Abarelix", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Palonosetron" ], [ "Palonosetron", "{u} may lead to a major life threatening interaction when taken with {v}", "Crizotinib" ] ], [ [ "Abarelix", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Eribulin" ], [ "Eribulin", "{u} may lead to a major life threatening interaction when taken with {v}", "Crizotinib" ] ], [ [ "Abarelix", "{u} may lead to a major life threatening interaction when taken with {v}", "Cabozantinib" ], [ "Cabozantinib", "{u} may lead to a major life threatening interaction when taken with {v}", "Crizotinib" ] ] ]
Abarelix may cause a moderate interaction that could exacerbate diseases when taken with Donepezil and Donepezil may cause a minor interaction that can limit clinical effects when taken with Crizotinib Abarelix may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole and Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Crizotinib Abarelix may cause a moderate interaction that could exacerbate diseases when taken with Magnesium hydroxide and Magnesium hydroxide may cause a moderate interaction that could exacerbate diseases when taken with Crizotinib Abarelix may cause a moderate interaction that could exacerbate diseases when taken with Propofol and Propofol may cause a moderate interaction that could exacerbate diseases when taken with Crizotinib Abarelix may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a moderate interaction that could exacerbate diseases when taken with Crizotinib Abarelix may lead to a major life threatening interaction when taken with Thioridazine and Thioridazine may lead to a major life threatening interaction when taken with Crizotinib Abarelix may cause a moderate interaction that could exacerbate diseases when taken with Palonosetron and Palonosetron may lead to a major life threatening interaction when taken with Crizotinib Abarelix may cause a moderate interaction that could exacerbate diseases when taken with Eribulin and Eribulin may lead to a major life threatening interaction when taken with Crizotinib Abarelix may lead to a major life threatening interaction when taken with Cabozantinib and Cabozantinib may lead to a major life threatening interaction when taken with Crizotinib
DB00344
DB08899
1,302
129
[ "DDInter1543", "DDInter649" ]
Protriptyline
Enzalutamide
Protriptyline hydrochloride is a dibenzocycloheptene-derivative tricyclic antidepressant (TCA). TCAs are structurally similar to phenothiazines. They contain a tricyclic ring system with an alkyl amine substituent on the central ring. In non-depressed individuals, protriptyline does not affect mood or arousal, but may cause sedation. In depressed individuals, protriptyline exerts a positive effect on mood. TCAs are potent inhibitors of serotonin and norepinephrine reuptake. In addition, TCAs down-regulate cerebral cortical &beta;-adrenergic receptors and sensitize post-synaptic serotonergic receptors with chronic use. The antidepressant effects of TCAs are thought to be due to an overall increase in serotonergic neurotransmission. TCAs also block histamine H<sub>1</sub> receptors, alpha<sub>1</sub
Enzalutamide is an androgen receptor (AR) inhibitor for the treatment of castration-resistant prostate cancer (CRPC), both metastatic and non-metastatic. It is a second-generation antiandrogen agent that the FDA approved on August 31, 2012.[L40639, A252667] Although androgen deprivation therapy (ADT) is the first-line treatment of prostate cancer and remission can be achieved, arising resistance is inevitable, becoming castration-resistant prostate cancer. Until recently, docetaxel is the only treatment available for metastatic CRPC; however, AR inhibitors have been developed for more targeted therapy, although first-generation AR inhibitors like bicalutamide did not substantially increase the survival rate. Second-generation such as enzalutamide is more efficacious due to a higher affinity to AR and no partial agonist activity compared to bicalutamide.[A252667,A252642] Due to a favorable pharmacological profile, a phase 1 study of enzalutamide was initiated in July 2007. Compared to the average time of 10 to 15 years for a drug to go from pre-clinical to clinical studies, enzalutamide was developed relatively rapidly.
Moderate
1
[ [ [ 1302, 24, 129 ] ], [ [ 1302, 24, 918 ], [ 918, 1, 129 ] ], [ [ 1302, 6, 12523 ], [ 12523, 45, 129 ] ], [ [ 1302, 21, 28703 ], [ 28703, 60, 129 ] ], [ [ 1302, 23, 112 ], [ 112, 23, 129 ] ], [ [ 1302, 24, 79 ], [ 79, 24, 129 ] ], [ [ 1302, 24, 659 ], [ 659, 63, 129 ] ], [ [ 1302, 25, 1133 ], [ 1133, 24, 129 ] ], [ [ 1302, 40, 413 ], [ 413, 24, 129 ] ], [ [ 1302, 63, 600 ], [ 600, 24, 129 ] ] ]
[ [ [ "Protriptyline", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Enzalutamide" ] ], [ [ "Protriptyline", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Bicalutamide" ], [ "Bicalutamide", "{u} (Compound) resembles {v} (Compound)", "Enzalutamide" ] ], [ [ "Protriptyline", "{u} (Compound) binds {v} (Gene)", "CYP2D6" ], [ "CYP2D6", "{u} (Gene) is bound by {v} (Compound)", "Enzalutamide" ] ], [ [ "Protriptyline", "{u} (Compound) causes {v} (Side Effect)", "Pruritus" ], [ "Pruritus", "{u} (Side Effect) is caused by {v} (Compound)", "Enzalutamide" ] ], [ [ "Protriptyline", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Metronidazole" ], [ "Metronidazole", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Enzalutamide" ] ], [ [ "Protriptyline", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Sorafenib" ], [ "Sorafenib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Enzalutamide" ] ], [ [ "Protriptyline", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Vilanterol" ], [ "Vilanterol", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Enzalutamide" ] ], [ [ "Protriptyline", "{u} may lead to a major life threatening interaction when taken with {v}", "Granisetron" ], [ "Granisetron", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Enzalutamide" ] ], [ [ "Protriptyline", "{u} (Compound) resembles {v} (Compound)", "Maprotiline" ], [ "Maprotiline", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Enzalutamide" ] ], [ [ "Protriptyline", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Fluconazole" ], [ "Fluconazole", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Enzalutamide" ] ] ]
Protriptyline may cause a moderate interaction that could exacerbate diseases when taken with Bicalutamide and Bicalutamide (Compound) resembles Enzalutamide (Compound) Protriptyline (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Enzalutamide (Compound) Protriptyline (Compound) causes Pruritus (Side Effect) and Pruritus (Side Effect) is caused by Enzalutamide (Compound) Protriptyline may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Enzalutamide Protriptyline may cause a moderate interaction that could exacerbate diseases when taken with Sorafenib and Sorafenib may cause a moderate interaction that could exacerbate diseases when taken with Enzalutamide Protriptyline may cause a moderate interaction that could exacerbate diseases when taken with Vilanterol and Vilanterol may cause a moderate interaction that could exacerbate diseases when taken with Enzalutamide Protriptyline may lead to a major life threatening interaction when taken with Granisetron and Granisetron may cause a moderate interaction that could exacerbate diseases when taken with Enzalutamide Protriptyline (Compound) resembles Maprotiline (Compound) and Maprotiline may cause a moderate interaction that could exacerbate diseases when taken with Enzalutamide Protriptyline may cause a moderate interaction that could exacerbate diseases when taken with Fluconazole and Fluconazole may cause a moderate interaction that could exacerbate diseases when taken with Enzalutamide
DB09322
DB14491
1,114
428
[ "DDInter1966", "DDInter725" ]
Zinc sulfate
Ferrous fumarate
Zinc sulfate is the inorganic compound with the formula ZnSO4 and historically known as "white vitriol". It is on the World Health Organization's List of Essential Medicines, a list of the most important medication needed in a basic health system.
Used in treatment of iron deficiency anemia.
Minor
0
[ [ [ 1114, 23, 428 ] ], [ [ 1114, 62, 1096 ], [ 1096, 23, 428 ] ], [ [ 1114, 63, 1008 ], [ 1008, 24, 428 ] ], [ [ 1114, 24, 133 ], [ 133, 24, 428 ] ], [ [ 1114, 62, 29 ], [ 29, 24, 428 ] ], [ [ 1114, 64, 1459 ], [ 1459, 25, 428 ] ], [ [ 1114, 62, 1096 ], [ 1096, 23, 1193 ], [ 1193, 23, 428 ] ], [ [ 1114, 62, 955 ], [ 955, 1, 1096 ], [ 1096, 23, 428 ] ], [ [ 1114, 63, 1008 ], [ 1008, 24, 1193 ], [ 1193, 23, 428 ] ], [ [ 1114, 63, 246 ], [ 246, 63, 1096 ], [ 1096, 23, 428 ] ] ]
[ [ [ "Zinc sulfate", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Ferrous fumarate" ] ], [ [ "Zinc sulfate", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Mycophenolic acid" ], [ "Mycophenolic acid", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Ferrous fumarate" ] ], [ [ "Zinc sulfate", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Risedronic acid" ], [ "Risedronic acid", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Ferrous fumarate" ] ], [ [ "Zinc sulfate", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Baloxavir marboxil" ], [ "Baloxavir marboxil", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Ferrous fumarate" ] ], [ [ "Zinc sulfate", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Triethylenetetramine" ], [ "Triethylenetetramine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Ferrous fumarate" ] ], [ [ "Zinc sulfate", "{u} may lead to a major life threatening interaction when taken with {v}", "Dolutegravir" ], [ "Dolutegravir", "{u} may lead to a major life threatening interaction when taken with {v}", "Ferrous fumarate" ] ], [ [ "Zinc sulfate", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Mycophenolic acid" ], [ "Mycophenolic acid", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Zinc gluconate" ], [ "Zinc gluconate", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Ferrous fumarate" ] ], [ [ "Zinc sulfate", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Mycophenolate mofetil" ], [ "Mycophenolate mofetil", "{u} (Compound) resembles {v} (Compound)", "Mycophenolic acid" ], [ "Mycophenolic acid", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Ferrous fumarate" ] ], [ [ "Zinc sulfate", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Risedronic acid" ], [ "Risedronic acid", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Zinc gluconate" ], [ "Zinc gluconate", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Ferrous fumarate" ] ], [ [ "Zinc sulfate", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Gatifloxacin" ], [ "Gatifloxacin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Mycophenolic acid" ], [ "Mycophenolic acid", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Ferrous fumarate" ] ] ]
Zinc sulfate may cause a minor interaction that can limit clinical effects when taken with Mycophenolic acid and Mycophenolic acid may cause a minor interaction that can limit clinical effects when taken with Ferrous fumarate Zinc sulfate may cause a moderate interaction that could exacerbate diseases when taken with Risedronic acid and Risedronic acid may cause a moderate interaction that could exacerbate diseases when taken with Ferrous fumarate Zinc sulfate may cause a moderate interaction that could exacerbate diseases when taken with Baloxavir marboxil and Baloxavir marboxil may cause a moderate interaction that could exacerbate diseases when taken with Ferrous fumarate Zinc sulfate may cause a minor interaction that can limit clinical effects when taken with Triethylenetetramine and Triethylenetetramine may cause a moderate interaction that could exacerbate diseases when taken with Ferrous fumarate Zinc sulfate may lead to a major life threatening interaction when taken with Dolutegravir and Dolutegravir may lead to a major life threatening interaction when taken with Ferrous fumarate Zinc sulfate may cause a minor interaction that can limit clinical effects when taken with Mycophenolic acid and Mycophenolic acid may cause a minor interaction that can limit clinical effects when taken with Zinc gluconate and Zinc gluconate may cause a minor interaction that can limit clinical effects when taken with Ferrous fumarate Zinc sulfate may cause a minor interaction that can limit clinical effects when taken with Mycophenolate mofetil and Mycophenolate mofetil (Compound) resembles Mycophenolic acid (Compound) and Mycophenolic acid may cause a minor interaction that can limit clinical effects when taken with Ferrous fumarate Zinc sulfate may cause a moderate interaction that could exacerbate diseases when taken with Risedronic acid and Risedronic acid may cause a moderate interaction that could exacerbate diseases when taken with Zinc gluconate and Zinc gluconate may cause a minor interaction that can limit clinical effects when taken with Ferrous fumarate Zinc sulfate may cause a moderate interaction that could exacerbate diseases when taken with Gatifloxacin and Gatifloxacin may cause a moderate interaction that could exacerbate diseases when taken with Mycophenolic acid and Mycophenolic acid may cause a minor interaction that can limit clinical effects when taken with Ferrous fumarate
DB00059
DB09052
1,560
250
[ "DDInter1404", "DDInter220" ]
Pegaspargase
Blinatumomab
Pegaspargase is a conjugate of monomethoxypolyethylene glycol (mPEG) and L-asparaginase (L-asparagine amidohydrolase), an asparagine-specific enzyme that converts L-asparagine into aspartic acid and ammonia. Asparagine is an amino acid that is vital for cell survival. In humans, most normal tissues can produce asparagine through the action of asparagine synthetase. However, leukemia cells have low levels of this enzyme and depend on exogenous sources. Therefore, the use of pegaspargase results in leukemic cell death.[A103,A255912,L44667] Pegaspargase has the same mechanism of action as [L-asparaginase] derived from _Escherichia coli_, a previously developed enzyme used for the treatment of acute lymphoblastic leukemia (ALL). However, using L-asparaginase derived from _Escherich
Blinatumomab is a BiTE-class (bi-specific T-cell engager) constructed monoclonal antibody formed by the recombinant fusion of an anti-CD3 single-chain variable fragment (scFV) and an anti-CD19 scFV through a short peptide linker.[A254836,L44311] CD3 is an antigen expressed on the surface of T-cells, while CD19 is mostly expressed on the surface of malignant B-cells. Since blinatumomab has an affinity to both antigens, it redirects T-cells to tumor cells expressing CD19 and promotes tumor cell lysis and apoptosis.[A7659,A7660,A254831] Blinatumomab is manufactured by Amgen Inc. and marketed under the brand Blincyto. It was first approved by the FDA in December 2014 for the treatment of CD19-positive B-cell precursor acute lymphoblastic leukemia (ALL) in relapsed and refractory patients. In March 2018, it was approved under the FDA’s accelerated approval program for the treatment of CD19-positive B-cell precursor ALL in first or second complete remission with minimal residual disease (MRD) greater than or equal to 0.1% in adults and children. Full approval for this indication was granted in June 2023.[L46991,L46996] Blinatumomab has a short half-life, requiring patients to receive a continuous infusion over 4-week cycles using a portable mini-pump for optimum delivery.
Moderate
1
[ [ [ 1560, 24, 250 ] ], [ [ 1560, 24, 949 ], [ 949, 63, 250 ] ], [ [ 1560, 24, 1236 ], [ 1236, 24, 250 ] ], [ [ 1560, 63, 1257 ], [ 1257, 24, 250 ] ], [ [ 1560, 25, 581 ], [ 581, 25, 250 ] ], [ [ 1560, 24, 593 ], [ 593, 25, 250 ] ], [ [ 1560, 64, 1057 ], [ 1057, 25, 250 ] ], [ [ 1560, 25, 1137 ], [ 1137, 64, 250 ] ], [ [ 1560, 24, 949 ], [ 949, 63, 1362 ], [ 1362, 63, 250 ] ], [ [ 1560, 24, 1236 ], [ 1236, 25, 1362 ], [ 1362, 63, 250 ] ] ]
[ [ [ "Pegaspargase", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Blinatumomab" ] ], [ [ "Pegaspargase", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Clostridium tetani toxoid antigen (formaldehyde inactivated)" ], [ "Clostridium tetani toxoid antigen (formaldehyde inactivated)", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Blinatumomab" ] ], [ [ "Pegaspargase", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Carbamazepine" ], [ "Carbamazepine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Blinatumomab" ] ], [ [ "Pegaspargase", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Pegfilgrastim" ], [ "Pegfilgrastim", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Blinatumomab" ] ], [ [ "Pegaspargase", "{u} may lead to a major life threatening interaction when taken with {v}", "Infliximab" ], [ "Infliximab", "{u} may lead to a major life threatening interaction when taken with {v}", "Blinatumomab" ] ], [ [ "Pegaspargase", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Bupropion" ], [ "Bupropion", "{u} may lead to a major life threatening interaction when taken with {v}", "Blinatumomab" ] ], [ [ "Pegaspargase", "{u} may lead to a major life threatening interaction when taken with {v}", "Etanercept" ], [ "Etanercept", "{u} may lead to a major life threatening interaction when taken with {v}", "Blinatumomab" ] ], [ [ "Pegaspargase", "{u} may lead to a major life threatening interaction when taken with {v}", "Measles virus vaccine live attenuated" ], [ "Measles virus vaccine live attenuated", "{u} may lead to a major life threatening interaction when taken with {v}", "Blinatumomab" ] ], [ [ "Pegaspargase", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Clostridium tetani toxoid antigen (formaldehyde inactivated)" ], [ "Clostridium tetani toxoid antigen (formaldehyde inactivated)", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Olaparib" ], [ "Olaparib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Blinatumomab" ] ], [ [ "Pegaspargase", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Carbamazepine" ], [ "Carbamazepine", "{u} may lead to a major life threatening interaction when taken with {v}", "Olaparib" ], [ "Olaparib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Blinatumomab" ] ] ]
Pegaspargase may cause a moderate interaction that could exacerbate diseases when taken with Clostridium tetani toxoid antigen (formaldehyde inactivated) and Clostridium tetani toxoid antigen (formaldehyde inactivated) may cause a moderate interaction that could exacerbate diseases when taken with Blinatumomab Pegaspargase may cause a moderate interaction that could exacerbate diseases when taken with Carbamazepine and Carbamazepine may cause a moderate interaction that could exacerbate diseases when taken with Blinatumomab Pegaspargase may cause a moderate interaction that could exacerbate diseases when taken with Pegfilgrastim and Pegfilgrastim may cause a moderate interaction that could exacerbate diseases when taken with Blinatumomab Pegaspargase may lead to a major life threatening interaction when taken with Infliximab and Infliximab may lead to a major life threatening interaction when taken with Blinatumomab Pegaspargase may cause a moderate interaction that could exacerbate diseases when taken with Bupropion and Bupropion may lead to a major life threatening interaction when taken with Blinatumomab Pegaspargase may lead to a major life threatening interaction when taken with Etanercept and Etanercept may lead to a major life threatening interaction when taken with Blinatumomab Pegaspargase may lead to a major life threatening interaction when taken with Measles virus vaccine live attenuated and Measles virus vaccine live attenuated may lead to a major life threatening interaction when taken with Blinatumomab Pegaspargase may cause a moderate interaction that could exacerbate diseases when taken with Clostridium tetani toxoid antigen (formaldehyde inactivated) and Clostridium tetani toxoid antigen (formaldehyde inactivated) may cause a moderate interaction that could exacerbate diseases when taken with Olaparib and Olaparib may cause a moderate interaction that could exacerbate diseases when taken with Blinatumomab Pegaspargase may cause a moderate interaction that could exacerbate diseases when taken with Carbamazepine and Carbamazepine may lead to a major life threatening interaction when taken with Olaparib and Olaparib may cause a moderate interaction that could exacerbate diseases when taken with Blinatumomab
DB00620
DB01203
175
699
[ "DDInter1855", "DDInter1255" ]
Triamcinolone
Nadolol
Triamcinolone is a corticosteroid used to treat various inflammatory conditions in the body from allergic rhinitis to acute exacerbations of multiple sclerosis. Triamcinolone can be used as a one time adjunct treatment of osteoarthritic knee pain, or first line as a topical treatment of corticosteroid responsive dermatoses. Triamcinolone is more commonly seen in the forms triamcinolone hexacetonide, triamcinolone acetonide, and triamcinolone diacetate.[L8246,L8249,L8252,L8255,L8258,L8261,L8264] Triamcinolone was granted FDA approval on 3 December 1957. In October 2021, a suspension of triamcinolone acetonide was approved for suprachoroidal injection - the first suprachoroidal injection to receive FDA approval - for the treatment of patients with macular
Nadolol is a nonselective beta adrenal receptor blocker that is used to lower blood pressure.[L7922,L7925] Nonselective beta adrenal receptor blockers may no longer be first line in the treatment of hypertension as newer generations of beta adrenal receptor blockers have higher selectivity and offer better rates of adverse effects. Nadolol was granted FDA approval on 10 December 1979.
Moderate
1
[ [ [ 175, 24, 699 ] ], [ [ 175, 24, 729 ], [ 729, 1, 699 ] ], [ [ 175, 18, 20113 ], [ 20113, 57, 699 ] ], [ [ 175, 21, 28882 ], [ 28882, 60, 699 ] ], [ [ 175, 23, 1384 ], [ 1384, 62, 699 ] ], [ [ 175, 25, 609 ], [ 609, 62, 699 ] ], [ [ 175, 24, 1479 ], [ 1479, 23, 699 ] ], [ [ 175, 24, 286 ], [ 286, 62, 699 ] ], [ [ 175, 40, 251 ], [ 251, 24, 699 ] ], [ [ 175, 25, 976 ], [ 976, 63, 699 ] ] ]
[ [ [ "Triamcinolone", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Nadolol" ] ], [ [ "Triamcinolone", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Penbutolol" ], [ "Penbutolol", "{u} (Compound) resembles {v} (Compound)", "Nadolol" ] ], [ [ "Triamcinolone", "{u} (Compound) downregulates {v} (Gene)", "IER3" ], [ "IER3", "{u} (Gene) is downregulated by {v} (Compound)", "Nadolol" ] ], [ [ "Triamcinolone", "{u} (Compound) causes {v} (Side Effect)", "Body temperature increased" ], [ "Body temperature increased", "{u} (Side Effect) is caused by {v} (Compound)", "Nadolol" ] ], [ [ "Triamcinolone", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Magaldrate" ], [ "Magaldrate", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Nadolol" ] ], [ [ "Triamcinolone", "{u} may lead to a major life threatening interaction when taken with {v}", "Clarithromycin" ], [ "Clarithromycin", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Nadolol" ] ], [ [ "Triamcinolone", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Acetylsalicylic acid" ], [ "Acetylsalicylic acid", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Nadolol" ] ], [ [ "Triamcinolone", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Magnesium hydroxide" ], [ "Magnesium hydroxide", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Nadolol" ] ], [ [ "Triamcinolone", "{u} (Compound) resembles {v} (Compound)", "Betamethasone" ], [ "Betamethasone", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Nadolol" ] ], [ [ "Triamcinolone", "{u} may lead to a major life threatening interaction when taken with {v}", "Tofacitinib" ], [ "Tofacitinib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Nadolol" ] ] ]
Triamcinolone may cause a moderate interaction that could exacerbate diseases when taken with Penbutolol and Penbutolol (Compound) resembles Nadolol (Compound) Triamcinolone (Compound) downregulates IER3 (Gene) and IER3 (Gene) is downregulated by Nadolol (Compound) Triamcinolone (Compound) causes Body temperature increased (Side Effect) and Body temperature increased (Side Effect) is caused by Nadolol (Compound) Triamcinolone may cause a minor interaction that can limit clinical effects when taken with Magaldrate and Magaldrate may cause a minor interaction that can limit clinical effects when taken with Nadolol Triamcinolone may lead to a major life threatening interaction when taken with Clarithromycin and Clarithromycin may cause a minor interaction that can limit clinical effects when taken with Nadolol Triamcinolone may cause a moderate interaction that could exacerbate diseases when taken with Acetylsalicylic acid and Acetylsalicylic acid may cause a minor interaction that can limit clinical effects when taken with Nadolol Triamcinolone may cause a moderate interaction that could exacerbate diseases when taken with Magnesium hydroxide and Magnesium hydroxide may cause a minor interaction that can limit clinical effects when taken with Nadolol Triamcinolone (Compound) resembles Betamethasone (Compound) and Betamethasone may cause a moderate interaction that could exacerbate diseases when taken with Nadolol Triamcinolone may lead to a major life threatening interaction when taken with Tofacitinib and Tofacitinib may cause a moderate interaction that could exacerbate diseases when taken with Nadolol
DB01039
DB01067
535
959
[ "DDInter718", "DDInter826" ]
Fenofibrate
Glipizide
Fenofibrate is a fibric acid derivative like [clofibrate] and [gemfibrozil]. Fenofibrate is used to treat primary hypercholesterolemia, mixed dyslipidemia, severe hypertriglyceridemia.[L8588,L8591] Fenofibrate was granted FDA approval on 31 December 1993.
Glipizide is an oral hypoglycemic agent in the second-generation sulfonylurea drug class that is used to control blood sugar levels in patients with type 2 diabetes mellitus. It was first introduced in 1984 and is available in various countries including Canada and the U.S. According to the 2018 Clinical Practice Guidelines by Diabetes Canada, sulfonylurea drugs are considered a second-line glucose-lowering therapy following metformin. Because sulfonylureas require functional pancreatic beta cells for their therapeutic effectiveness, sulfonylureas are more commonly used for early-stage type 2 diabetes when there is no progressed pancreatic failure. Compared to the first-generation sulfonylureas, such as [tolbutamide] and [chlorpropamide], second-generation sulfonylureas contain a more non-polar side chain in their chemical structure, which enhances their hypoglycemic potency. Compared to other members of the sulfonylurea drug group, glipizide displays rapid absorption and onset of action with the shortest half-life and duration of action, reducing the risk for long-lasting hypoglycemia that is often observed with blood glucose-lowering agents. Glipizide was first approved by the FDA in 1994 and is available in extended-release tablets under the brand name Glucotrol®, as well as in combination with metformin under the brand name Metaglip®.
Moderate
1
[ [ [ 535, 24, 959 ] ], [ [ 535, 63, 245 ], [ 245, 40, 959 ] ], [ [ 535, 24, 1411 ], [ 1411, 1, 959 ] ], [ [ 535, 6, 8374 ], [ 8374, 45, 959 ] ], [ [ 535, 21, 29442 ], [ 29442, 60, 959 ] ], [ [ 535, 63, 660 ], [ 660, 23, 959 ] ], [ [ 535, 64, 126 ], [ 126, 24, 959 ] ], [ [ 535, 63, 1560 ], [ 1560, 24, 959 ] ], [ [ 535, 24, 848 ], [ 848, 24, 959 ] ], [ [ 535, 25, 1377 ], [ 1377, 63, 959 ] ] ]
[ [ [ "Fenofibrate", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Glipizide" ] ], [ [ "Fenofibrate", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Glimepiride" ], [ "Glimepiride", "{u} (Compound) resembles {v} (Compound)", "Glipizide" ] ], [ [ "Fenofibrate", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Tolbutamide" ], [ "Tolbutamide", "{u} (Compound) resembles {v} (Compound)", "Glipizide" ] ], [ [ "Fenofibrate", "{u} (Compound) binds {v} (Gene)", "CYP3A4" ], [ "CYP3A4", "{u} (Gene) is bound by {v} (Compound)", "Glipizide" ] ], [ [ "Fenofibrate", "{u} (Compound) causes {v} (Side Effect)", "Abnormal vision" ], [ "Abnormal vision", "{u} (Side Effect) is caused by {v} (Compound)", "Glipizide" ] ], [ [ "Fenofibrate", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Esomeprazole" ], [ "Esomeprazole", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Glipizide" ] ], [ [ "Fenofibrate", "{u} may lead to a major life threatening interaction when taken with {v}", "Warfarin" ], [ "Warfarin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Glipizide" ] ], [ [ "Fenofibrate", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Pegaspargase" ], [ "Pegaspargase", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Glipizide" ] ], [ [ "Fenofibrate", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Ibuprofen" ], [ "Ibuprofen", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Glipizide" ] ], [ [ "Fenofibrate", "{u} may lead to a major life threatening interaction when taken with {v}", "Leflunomide" ], [ "Leflunomide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Glipizide" ] ] ]
Fenofibrate may cause a moderate interaction that could exacerbate diseases when taken with Glimepiride and Glimepiride (Compound) resembles Glipizide (Compound) Fenofibrate may cause a moderate interaction that could exacerbate diseases when taken with Tolbutamide and Tolbutamide (Compound) resembles Glipizide (Compound) Fenofibrate (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Glipizide (Compound) Fenofibrate (Compound) causes Abnormal vision (Side Effect) and Abnormal vision (Side Effect) is caused by Glipizide (Compound) Fenofibrate may cause a moderate interaction that could exacerbate diseases when taken with Esomeprazole and Esomeprazole may cause a minor interaction that can limit clinical effects when taken with Glipizide Fenofibrate may lead to a major life threatening interaction when taken with Warfarin and Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Glipizide Fenofibrate may cause a moderate interaction that could exacerbate diseases when taken with Pegaspargase and Pegaspargase may cause a moderate interaction that could exacerbate diseases when taken with Glipizide Fenofibrate may cause a moderate interaction that could exacerbate diseases when taken with Ibuprofen and Ibuprofen may cause a moderate interaction that could exacerbate diseases when taken with Glipizide Fenofibrate may lead to a major life threatening interaction when taken with Leflunomide and Leflunomide may cause a moderate interaction that could exacerbate diseases when taken with Glipizide
DB00745
DB11828
307
1,406
[ "DDInter1236", "DDInter1281" ]
Modafinil
Neratinib
Modafinil is a stimulant drug marketed as a 'wakefulness promoting agent' and is one of the stimulants used in the treatment of narcolepsy. Narcolepsy is caused by dysfunction of a family of wakefulness-promoting and sleep-suppressing peptides, the orexins, whose neurons are activated by modafinil. The prexin neuron activation is associated with psychoactivation and euphoria. The exact mechanism of action is unclear, although in vitro studies have shown it to inhibit the reuptake of dopamine by binding to the dopamine reuptake pump, and lead to an increase in extracellular dopamine. Modafinil activates glutamatergic circuits while inhibiting GABA.
Neratinib was approved in July 2017 for use as an extended adjuvant therapy in Human Epidermal Growth Factor Receptor 2 (HER2) positive breast cancer. Approval was granted to Puma Biotechnology Inc. for the tradename Nerlynx. Neratinib is currently under investigation for use in many other forms of cancer.
Major
2
[ [ [ 307, 25, 1406 ] ], [ [ 307, 23, 1135 ], [ 1135, 23, 1406 ] ], [ [ 307, 24, 392 ], [ 392, 24, 1406 ] ], [ [ 307, 62, 1195 ], [ 1195, 24, 1406 ] ], [ [ 307, 24, 710 ], [ 710, 63, 1406 ] ], [ [ 307, 23, 1499 ], [ 1499, 24, 1406 ] ], [ [ 307, 25, 1456 ], [ 1456, 24, 1406 ] ], [ [ 307, 63, 1181 ], [ 1181, 24, 1406 ] ], [ [ 307, 23, 1619 ], [ 1619, 63, 1406 ] ], [ [ 307, 23, 1593 ], [ 1593, 25, 1406 ] ] ]
[ [ [ "Modafinil", "{u} may lead to a major life threatening interaction when taken with {v}", "Neratinib" ] ], [ [ "Modafinil", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Naloxegol" ], [ "Naloxegol", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Neratinib" ] ], [ [ "Modafinil", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Lapatinib" ], [ "Lapatinib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Neratinib" ] ], [ [ "Modafinil", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Erlotinib" ], [ "Erlotinib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Neratinib" ] ], [ [ "Modafinil", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Binimetinib" ], [ "Binimetinib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Neratinib" ] ], [ [ "Modafinil", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Naldemedine" ], [ "Naldemedine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Neratinib" ] ], [ [ "Modafinil", "{u} may lead to a major life threatening interaction when taken with {v}", "Venetoclax" ], [ "Venetoclax", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Neratinib" ] ], [ [ "Modafinil", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Terfenadine" ], [ "Terfenadine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Neratinib" ] ], [ [ "Modafinil", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Rucaparib" ], [ "Rucaparib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Neratinib" ] ], [ [ "Modafinil", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Crizotinib" ], [ "Crizotinib", "{u} may lead to a major life threatening interaction when taken with {v}", "Neratinib" ] ] ]
Modafinil may cause a minor interaction that can limit clinical effects when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Neratinib Modafinil may cause a moderate interaction that could exacerbate diseases when taken with Lapatinib and Lapatinib may cause a moderate interaction that could exacerbate diseases when taken with Neratinib Modafinil may cause a minor interaction that can limit clinical effects when taken with Erlotinib and Erlotinib may cause a moderate interaction that could exacerbate diseases when taken with Neratinib Modafinil may cause a moderate interaction that could exacerbate diseases when taken with Binimetinib and Binimetinib may cause a moderate interaction that could exacerbate diseases when taken with Neratinib Modafinil may cause a minor interaction that can limit clinical effects when taken with Naldemedine and Naldemedine may cause a moderate interaction that could exacerbate diseases when taken with Neratinib Modafinil may lead to a major life threatening interaction when taken with Venetoclax and Venetoclax may cause a moderate interaction that could exacerbate diseases when taken with Neratinib Modafinil may cause a moderate interaction that could exacerbate diseases when taken with Terfenadine and Terfenadine may cause a moderate interaction that could exacerbate diseases when taken with Neratinib Modafinil may cause a minor interaction that can limit clinical effects when taken with Rucaparib and Rucaparib may cause a moderate interaction that could exacerbate diseases when taken with Neratinib Modafinil may cause a minor interaction that can limit clinical effects when taken with Crizotinib and Crizotinib may lead to a major life threatening interaction when taken with Neratinib
DB08881
DB11560
868
1,678
[ "DDInter1925", "DDInter1038" ]
Vemurafenib
Lesinurad
Vemurafenib is a competitive kinase inhibitor with activity against BRAF kinase with mutations like V600E. It exerts its function by binding to the ATP-binding domain of the mutant BRAF. Vemurafenib was co-developed by Roche and Plexxikon and it obtained its FDA approval on August 17, 2011, under the company Hoffmann La Roche. After approval, Roche in collaboration with Genentech launched a broad development program.
Lesinurad is an oral uric acid transporter 1 (URAT1) inhibitor indicated for the treatment of hyperuricemia associated with gout. It reduces serum uric acid concentration through the inhibition of URAT1, an enzyme responsible for reuptake of uric acid from the renal tubule, and OAT4, another uric acid transporter associated with diuretic-induced hyperuricemia. Marketed as the product Zurampic, it is indicated for use in combination with a xanthine oxidase inhibitor for the treatment of hyperuricemia associated with gout in patients who have not achieved target serum uric acid levels with a xanthine oxidase inhibitor alone. In August 2017, a combination oral therapy consisting of lesinurad and was FDA-approved under the brand name Duzallo indicated for the treatment of gout-related hyperuricemia in patients with uncontrolled gout.
Moderate
1
[ [ [ 868, 24, 1678 ] ], [ [ 868, 62, 168 ], [ 168, 23, 1678 ] ], [ [ 868, 24, 466 ], [ 466, 63, 1678 ] ], [ [ 868, 64, 1374 ], [ 1374, 24, 1678 ] ], [ [ 868, 25, 877 ], [ 877, 63, 1678 ] ], [ [ 868, 63, 263 ], [ 263, 24, 1678 ] ], [ [ 868, 24, 1040 ], [ 1040, 24, 1678 ] ], [ [ 868, 62, 112 ], [ 112, 24, 1678 ] ], [ [ 868, 25, 129 ], [ 129, 24, 1678 ] ], [ [ 868, 62, 168 ], [ 168, 24, 522 ], [ 522, 24, 1678 ] ] ]
[ [ [ "Vemurafenib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Lesinurad" ] ], [ [ "Vemurafenib", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Bortezomib" ], [ "Bortezomib", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Lesinurad" ] ], [ [ "Vemurafenib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Darolutamide" ], [ "Darolutamide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Lesinurad" ] ], [ [ "Vemurafenib", "{u} may lead to a major life threatening interaction when taken with {v}", "Abiraterone" ], [ "Abiraterone", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Lesinurad" ] ], [ [ "Vemurafenib", "{u} may lead to a major life threatening interaction when taken with {v}", "Macimorelin" ], [ "Macimorelin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Lesinurad" ] ], [ [ "Vemurafenib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Axitinib" ], [ "Axitinib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Lesinurad" ] ], [ [ "Vemurafenib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Dabrafenib" ], [ "Dabrafenib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Lesinurad" ] ], [ [ "Vemurafenib", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Metronidazole" ], [ "Metronidazole", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Lesinurad" ] ], [ [ "Vemurafenib", "{u} may lead to a major life threatening interaction when taken with {v}", "Enzalutamide" ], [ "Enzalutamide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Lesinurad" ] ], [ [ "Vemurafenib", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Bortezomib" ], [ "Bortezomib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Zafirlukast" ], [ "Zafirlukast", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Lesinurad" ] ] ]
Vemurafenib may cause a minor interaction that can limit clinical effects when taken with Bortezomib and Bortezomib may cause a minor interaction that can limit clinical effects when taken with Lesinurad Vemurafenib may cause a moderate interaction that could exacerbate diseases when taken with Darolutamide and Darolutamide may cause a moderate interaction that could exacerbate diseases when taken with Lesinurad Vemurafenib may lead to a major life threatening interaction when taken with Abiraterone and Abiraterone may cause a moderate interaction that could exacerbate diseases when taken with Lesinurad Vemurafenib may lead to a major life threatening interaction when taken with Macimorelin and Macimorelin may cause a moderate interaction that could exacerbate diseases when taken with Lesinurad Vemurafenib may cause a moderate interaction that could exacerbate diseases when taken with Axitinib and Axitinib may cause a moderate interaction that could exacerbate diseases when taken with Lesinurad Vemurafenib may cause a moderate interaction that could exacerbate diseases when taken with Dabrafenib and Dabrafenib may cause a moderate interaction that could exacerbate diseases when taken with Lesinurad Vemurafenib may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a moderate interaction that could exacerbate diseases when taken with Lesinurad Vemurafenib may lead to a major life threatening interaction when taken with Enzalutamide and Enzalutamide may cause a moderate interaction that could exacerbate diseases when taken with Lesinurad Vemurafenib may cause a minor interaction that can limit clinical effects when taken with Bortezomib and Bortezomib may cause a moderate interaction that could exacerbate diseases when taken with Zafirlukast and Zafirlukast may cause a moderate interaction that could exacerbate diseases when taken with Lesinurad
DB08871
DB11113
36
657
[ "DDInter666", "DDInter307" ]
Eribulin
Castor oil
Eribulin is a microtubule inhibitor indicated for the treatment of patients with metastatic breast cancer who have previously received at least two chemotherapeutic regimens for the treatment of metastatic disease. Eribulin was isolated from the marine sponge Halichondria okadai. Eribulin is also being investigated for use in the treatment of advanced solid tumors.
Castor oil is a vegetable oil obtained by pressing the seeds of the castor oil plant (_Ricinus communis_ L.) mainly cultivated in India, South America, Africa, and China. Castor oil is a rich source of , which represents up to 90% of the total castor oil content. It also consists up to 4% linoleic, 3% oleic, 1% stearic, and less than 1% linolenic fatty acids . has a hydroxyl group that provides a functional group location for various chemical reactions, making it a favourable substance in industrial applications . Castor oil does not contain ricin, which is a natural poison found in the castor oil plant; the toxic lectin remains in the bean pulp following oil isolation . Due to its renewability and high versatility in addition to being the only commercial source of a hydroxylated fatty acid , castor oil has been used as a vital raw material for the chemical industry . Castor oil was mainly used in the manufacturing of soaps, lubricants, and coatings . It is an FDA-approved food additive directly added to food products for human consumption. It can also be found in hard candies as a release agent and anti-sticking agent, or supplementary vitamins and mineral oral tablets as an ingredient for protective coatings. Castor oil is found in over-the-counter oral liquids as a stimulant laxative, and is also added in commercial cosmetic, hair, and skincare products.
Moderate
1
[ [ [ 36, 24, 657 ] ], [ [ 36, 63, 1079 ], [ 1079, 24, 657 ] ], [ [ 36, 24, 927 ], [ 927, 63, 657 ] ], [ [ 36, 64, 540 ], [ 540, 24, 657 ] ], [ [ 36, 25, 985 ], [ 985, 24, 657 ] ], [ [ 36, 24, 1228 ], [ 1228, 24, 657 ] ], [ [ 36, 25, 982 ], [ 982, 63, 657 ] ], [ [ 36, 63, 1079 ], [ 1079, 24, 927 ], [ 927, 63, 657 ] ], [ [ 36, 24, 927 ], [ 927, 63, 1079 ], [ 1079, 24, 657 ] ], [ [ 36, 64, 540 ], [ 540, 25, 927 ], [ 927, 63, 657 ] ] ]
[ [ [ "Eribulin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Castor oil" ] ], [ [ "Eribulin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Telavancin" ], [ "Telavancin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Castor oil" ] ], [ [ "Eribulin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Encorafenib" ], [ "Encorafenib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Castor oil" ] ], [ [ "Eribulin", "{u} may lead to a major life threatening interaction when taken with {v}", "Dronedarone" ], [ "Dronedarone", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Castor oil" ] ], [ [ "Eribulin", "{u} may lead to a major life threatening interaction when taken with {v}", "Osimertinib" ], [ "Osimertinib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Castor oil" ] ], [ [ "Eribulin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Lenvatinib" ], [ "Lenvatinib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Castor oil" ] ], [ [ "Eribulin", "{u} may lead to a major life threatening interaction when taken with {v}", "Ivosidenib" ], [ "Ivosidenib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Castor oil" ] ], [ [ "Eribulin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Telavancin" ], [ "Telavancin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Encorafenib" ], [ "Encorafenib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Castor oil" ] ], [ [ "Eribulin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Encorafenib" ], [ "Encorafenib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Telavancin" ], [ "Telavancin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Castor oil" ] ], [ [ "Eribulin", "{u} may lead to a major life threatening interaction when taken with {v}", "Dronedarone" ], [ "Dronedarone", "{u} may lead to a major life threatening interaction when taken with {v}", "Encorafenib" ], [ "Encorafenib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Castor oil" ] ] ]
Eribulin may cause a moderate interaction that could exacerbate diseases when taken with Telavancin and Telavancin may cause a moderate interaction that could exacerbate diseases when taken with Castor oil Eribulin may cause a moderate interaction that could exacerbate diseases when taken with Encorafenib and Encorafenib may cause a moderate interaction that could exacerbate diseases when taken with Castor oil Eribulin may lead to a major life threatening interaction when taken with Dronedarone and Dronedarone may cause a moderate interaction that could exacerbate diseases when taken with Castor oil Eribulin may lead to a major life threatening interaction when taken with Osimertinib and Osimertinib may cause a moderate interaction that could exacerbate diseases when taken with Castor oil Eribulin may cause a moderate interaction that could exacerbate diseases when taken with Lenvatinib and Lenvatinib may cause a moderate interaction that could exacerbate diseases when taken with Castor oil Eribulin may lead to a major life threatening interaction when taken with Ivosidenib and Ivosidenib may cause a moderate interaction that could exacerbate diseases when taken with Castor oil Eribulin may cause a moderate interaction that could exacerbate diseases when taken with Telavancin and Telavancin may cause a moderate interaction that could exacerbate diseases when taken with Encorafenib and Encorafenib may cause a moderate interaction that could exacerbate diseases when taken with Castor oil Eribulin may cause a moderate interaction that could exacerbate diseases when taken with Encorafenib and Encorafenib may cause a moderate interaction that could exacerbate diseases when taken with Telavancin and Telavancin may cause a moderate interaction that could exacerbate diseases when taken with Castor oil Eribulin may lead to a major life threatening interaction when taken with Dronedarone and Dronedarone may lead to a major life threatening interaction when taken with Encorafenib and Encorafenib may cause a moderate interaction that could exacerbate diseases when taken with Castor oil
DB01764
DB12941
805
466
[ "DDInter469", "DDInter481" ]
Dalfopristin
Darolutamide
Dalfopristin is a combination of two antibiotics (Dalfopristin and quinupristin) used to treat infections by staphylococci and by vancomycin-resistant Enterococcus faecium. It is not effective against Enterococcus faecalis infections. Dalfopristin inhibits the early phase of protein synthesis in the bacterial ribosome and quinupristin inhibits the late phase of protein synthesis.
Darolutamide is a nonsteroidal androgen receptor antagonist for the treatment of castrate-resistant, non-metastatic prostate cancer (nmCRPC). This condition occurs in the majority of patients with advanced prostate cancer who have been treated with androgen receptor antagonists. Though prior treatment for prostate cancer has been successful for these patients, the cancer eventually progresses to become resistant to existing therapies. This warrants further treatment. The goal of treatment with darolutamide is to delay the progression of prostate cancer to metastatic disease, increasing quality of life and life expectancy for those with advanced prostate cancer.[A189054,A189063] Darolutamide was developed by Bayer HealthCare Pharmaceuticals Inc. and approved by the FDA on July 30th, 2019.
Minor
0
[ [ [ 805, 23, 466 ] ], [ [ 805, 24, 351 ], [ 351, 23, 466 ] ], [ [ 805, 23, 283 ], [ 283, 23, 466 ] ], [ [ 805, 63, 86 ], [ 86, 23, 466 ] ], [ [ 805, 25, 484 ], [ 484, 23, 466 ] ], [ [ 805, 24, 159 ], [ 159, 62, 466 ] ], [ [ 805, 63, 392 ], [ 392, 24, 466 ] ], [ [ 805, 24, 792 ], [ 792, 24, 466 ] ], [ [ 805, 25, 1456 ], [ 1456, 24, 466 ] ], [ [ 805, 25, 982 ], [ 982, 63, 466 ] ] ]
[ [ [ "Dalfopristin", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Darolutamide" ] ], [ [ "Dalfopristin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Ribociclib" ], [ "Ribociclib", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Darolutamide" ] ], [ [ "Dalfopristin", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Fedratinib" ], [ "Fedratinib", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Darolutamide" ] ], [ [ "Dalfopristin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Miconazole" ], [ "Miconazole", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Darolutamide" ] ], [ [ "Dalfopristin", "{u} may lead to a major life threatening interaction when taken with {v}", "Entrectinib" ], [ "Entrectinib", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Darolutamide" ] ], [ [ "Dalfopristin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Larotrectinib" ], [ "Larotrectinib", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Darolutamide" ] ], [ [ "Dalfopristin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Lapatinib" ], [ "Lapatinib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Darolutamide" ] ], [ [ "Dalfopristin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Rivaroxaban" ], [ "Rivaroxaban", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Darolutamide" ] ], [ [ "Dalfopristin", "{u} may lead to a major life threatening interaction when taken with {v}", "Venetoclax" ], [ "Venetoclax", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Darolutamide" ] ], [ [ "Dalfopristin", "{u} may lead to a major life threatening interaction when taken with {v}", "Ivosidenib" ], [ "Ivosidenib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Darolutamide" ] ] ]
Dalfopristin may cause a moderate interaction that could exacerbate diseases when taken with Ribociclib and Ribociclib may cause a minor interaction that can limit clinical effects when taken with Darolutamide Dalfopristin may cause a minor interaction that can limit clinical effects when taken with Fedratinib and Fedratinib may cause a minor interaction that can limit clinical effects when taken with Darolutamide Dalfopristin may cause a moderate interaction that could exacerbate diseases when taken with Miconazole and Miconazole may cause a minor interaction that can limit clinical effects when taken with Darolutamide Dalfopristin may lead to a major life threatening interaction when taken with Entrectinib and Entrectinib may cause a minor interaction that can limit clinical effects when taken with Darolutamide Dalfopristin may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib and Larotrectinib may cause a minor interaction that can limit clinical effects when taken with Darolutamide Dalfopristin may cause a moderate interaction that could exacerbate diseases when taken with Lapatinib and Lapatinib may cause a moderate interaction that could exacerbate diseases when taken with Darolutamide Dalfopristin may cause a moderate interaction that could exacerbate diseases when taken with Rivaroxaban and Rivaroxaban may cause a moderate interaction that could exacerbate diseases when taken with Darolutamide Dalfopristin may lead to a major life threatening interaction when taken with Venetoclax and Venetoclax may cause a moderate interaction that could exacerbate diseases when taken with Darolutamide Dalfopristin may lead to a major life threatening interaction when taken with Ivosidenib and Ivosidenib may cause a moderate interaction that could exacerbate diseases when taken with Darolutamide
DB00069
DB01229
367
973
[ "DDInter946", "DDInter1378" ]
Interferon alfacon-1
Paclitaxel (protein-bound)
Interferon alfacon-1 is a recombinant non-naturally occurring type-I interferon. The 166-amino acid sequence of Interferon alfacon-1 was derived by scanning the sequences of several natural interferon alpha subtypes and assigning the most frequently observed amino acid in each corresponding position. Four additional amino acid changes were made to facilitate the molecular construction, and a corresponding synthetic DNA sequence was constructed using chemical synthesis methodology. Interferon alfacon-1 differs from interferon alfa-2b at 20/166 amino acids (88% homology), and comparison with interferon-beta shows identity at over 30% of the amino acid positions. Interferon alfacon-1 is produced in Escherichia coli (E. coli) cells that have been genetically altered by insertion of a synthetically constructed sequence that codes for Interferon alfacon-1. Prior to final purification, Interferon alfacon-
Paclitaxel can cause developmental toxicity, female reproductive toxicity and male reproductive toxicity according to state or federal government labeling requirements.
Moderate
1
[ [ [ 367, 24, 973 ] ], [ [ 367, 24, 310 ], [ 310, 63, 973 ] ], [ [ 367, 24, 134 ], [ 134, 24, 973 ] ], [ [ 367, 25, 990 ], [ 990, 63, 973 ] ], [ [ 367, 63, 491 ], [ 491, 24, 973 ] ], [ [ 367, 25, 139 ], [ 139, 24, 973 ] ], [ [ 367, 25, 1011 ], [ 1011, 64, 973 ] ], [ [ 367, 63, 581 ], [ 581, 25, 973 ] ], [ [ 367, 25, 1066 ], [ 1066, 25, 973 ] ], [ [ 367, 24, 770 ], [ 770, 25, 973 ] ] ]
[ [ [ "Interferon alfacon-1", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Paclitaxel" ] ], [ [ "Interferon alfacon-1", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Cabazitaxel" ], [ "Cabazitaxel", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Paclitaxel" ] ], [ [ "Interferon alfacon-1", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Vinorelbine" ], [ "Vinorelbine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Paclitaxel" ] ], [ [ "Interferon alfacon-1", "{u} may lead to a major life threatening interaction when taken with {v}", "Lomitapide" ], [ "Lomitapide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Paclitaxel" ] ], [ [ "Interferon alfacon-1", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Peginterferon alfa-2a" ], [ "Peginterferon alfa-2a", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Paclitaxel" ] ], [ [ "Interferon alfacon-1", "{u} may lead to a major life threatening interaction when taken with {v}", "Zidovudine" ], [ "Zidovudine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Paclitaxel" ] ], [ [ "Interferon alfacon-1", "{u} may lead to a major life threatening interaction when taken with {v}", "Fingolimod" ], [ "Fingolimod", "{u} may lead to a major life threatening interaction when taken with {v}", "Paclitaxel" ] ], [ [ "Interferon alfacon-1", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Infliximab" ], [ "Infliximab", "{u} may lead to a major life threatening interaction when taken with {v}", "Paclitaxel" ] ], [ [ "Interferon alfacon-1", "{u} may lead to a major life threatening interaction when taken with {v}", "Natalizumab" ], [ "Natalizumab", "{u} may lead to a major life threatening interaction when taken with {v}", "Paclitaxel" ] ], [ [ "Interferon alfacon-1", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Thalidomide" ], [ "Thalidomide", "{u} may lead to a major life threatening interaction when taken with {v}", "Paclitaxel" ] ] ]
Interferon alfacon-1 may cause a moderate interaction that could exacerbate diseases when taken with Paclitaxel Interferon alfacon-1 may cause a moderate interaction that could exacerbate diseases when taken with Cabazitaxel and Cabazitaxel may cause a moderate interaction that could exacerbate diseases when taken with Paclitaxel Interferon alfacon-1 may cause a moderate interaction that could exacerbate diseases when taken with Vinorelbine and Vinorelbine may cause a moderate interaction that could exacerbate diseases when taken with Paclitaxel Interferon alfacon-1 may lead to a major life threatening interaction when taken with Lomitapide and Lomitapide may cause a moderate interaction that could exacerbate diseases when taken with Paclitaxel Interferon alfacon-1 may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon alfa-2a and Peginterferon alfa-2a may cause a moderate interaction that could exacerbate diseases when taken with Paclitaxel Interferon alfacon-1 may lead to a major life threatening interaction when taken with Zidovudine and Zidovudine may cause a moderate interaction that could exacerbate diseases when taken with Paclitaxel Interferon alfacon-1 may lead to a major life threatening interaction when taken with Fingolimod and Fingolimod may lead to a major life threatening interaction when taken with Paclitaxel Interferon alfacon-1 may cause a moderate interaction that could exacerbate diseases when taken with Infliximab and Infliximab may lead to a major life threatening interaction when taken with Paclitaxel Interferon alfacon-1 may lead to a major life threatening interaction when taken with Natalizumab and Natalizumab may lead to a major life threatening interaction when taken with Paclitaxel Interferon alfacon-1 may cause a moderate interaction that could exacerbate diseases when taken with Thalidomide and Thalidomide may lead to a major life threatening interaction when taken with Paclitaxel
DB00238
DB00468
188
1,424
[ "DDInter1285", "DDInter1557" ]
Nevirapine
Quinine
A potent, non-nucleoside reverse transcriptase inhibitor (NNRTI) used in combination with nucleoside analogues for treatment of Human Immunodeficiency Virus Type 1 (HIV-1) infection and AIDS. Structurally, nevirapine belongs to the dipyridodiazepinone chemical class.
An alkaloid derived from the bark of the cinchona tree. It is used as an antimalarial drug, and is the active ingredient in extracts of the cinchona that have been used for that purpose since before 1633. Quinine is also a mild antipyretic and analgesic and has been used in common cold preparations for that purpose. It was used commonly and as a bitter and flavoring agent, and is still useful for the treatment of babesiosis. Quinine is also useful in some muscular disorders, especially nocturnal leg cramps and myotonia congenita, because of its direct effects on muscle membrane and sodium channels. The mechanisms of its antimalarial effects are not well understood.
Moderate
1
[ [ [ 188, 24, 1424 ] ], [ [ 188, 6, 6017 ], [ 6017, 45, 1424 ] ], [ [ 188, 21, 28709 ], [ 28709, 60, 1424 ] ], [ [ 188, 24, 1135 ], [ 1135, 62, 1424 ] ], [ [ 188, 24, 723 ], [ 723, 63, 1424 ] ], [ [ 188, 25, 124 ], [ 124, 63, 1424 ] ], [ [ 188, 24, 79 ], [ 79, 24, 1424 ] ], [ [ 188, 23, 1101 ], [ 1101, 24, 1424 ] ], [ [ 188, 63, 1324 ], [ 1324, 24, 1424 ] ], [ [ 188, 24, 868 ], [ 868, 64, 1424 ] ] ]
[ [ [ "Nevirapine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Quinine" ] ], [ [ "Nevirapine", "{u} (Compound) binds {v} (Gene)", "CYP2C9" ], [ "CYP2C9", "{u} (Gene) is bound by {v} (Compound)", "Quinine" ] ], [ [ "Nevirapine", "{u} (Compound) causes {v} (Side Effect)", "Decreased appetite" ], [ "Decreased appetite", "{u} (Side Effect) is caused by {v} (Compound)", "Quinine" ] ], [ [ "Nevirapine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Naloxegol" ], [ "Naloxegol", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Quinine" ] ], [ [ "Nevirapine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Aprepitant" ], [ "Aprepitant", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Quinine" ] ], [ [ "Nevirapine", "{u} may lead to a major life threatening interaction when taken with {v}", "Glasdegib" ], [ "Glasdegib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Quinine" ] ], [ [ "Nevirapine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Sorafenib" ], [ "Sorafenib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Quinine" ] ], [ [ "Nevirapine", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Bexarotene" ], [ "Bexarotene", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Quinine" ] ], [ [ "Nevirapine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Troglitazone" ], [ "Troglitazone", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Quinine" ] ], [ [ "Nevirapine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Vemurafenib" ], [ "Vemurafenib", "{u} may lead to a major life threatening interaction when taken with {v}", "Quinine" ] ] ]
Nevirapine (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Quinine (Compound) Nevirapine (Compound) causes Decreased appetite (Side Effect) and Decreased appetite (Side Effect) is caused by Quinine (Compound) Nevirapine may cause a moderate interaction that could exacerbate diseases when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Quinine Nevirapine may cause a moderate interaction that could exacerbate diseases when taken with Aprepitant and Aprepitant may cause a moderate interaction that could exacerbate diseases when taken with Quinine Nevirapine may lead to a major life threatening interaction when taken with Glasdegib and Glasdegib may cause a moderate interaction that could exacerbate diseases when taken with Quinine Nevirapine may cause a moderate interaction that could exacerbate diseases when taken with Sorafenib and Sorafenib may cause a moderate interaction that could exacerbate diseases when taken with Quinine Nevirapine may cause a minor interaction that can limit clinical effects when taken with Bexarotene and Bexarotene may cause a moderate interaction that could exacerbate diseases when taken with Quinine Nevirapine may cause a moderate interaction that could exacerbate diseases when taken with Troglitazone and Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Quinine Nevirapine may cause a moderate interaction that could exacerbate diseases when taken with Vemurafenib and Vemurafenib may lead to a major life threatening interaction when taken with Quinine
DB01612
DB09117
1,637
957
[ "DDInter92", "DDInter1391" ]
Amyl Nitrite
Paraldehyde
Amyl Nitrite is an antihypertensive medicine. Amyl nitrite is employed medically to treat heart diseases such as angina and to treat cyanide poisoning. Its use as a prescription medicine comes from its ability to lower blood pressure. As an inhalant, it also has psychoactive effect which has led to illegal drug use.
Paraldehyde was initially introduced into medical practice in the United Kingdom in 1882 by the Italian physician Vincenzo Cervello. It is classified as a central nervous system (CNS) depressant and has also been found to be an effective anticonvulsant, hypnotic and sedative agent due to its CNS depressant properties. Paraldehyde is used as an ingredient in some cough medicines as an expectorant, but its efficacy for this indication has not been confirmed and its use as an expectorant may possibly be due to a placebo effect.
Moderate
1
[ [ [ 1637, 24, 957 ] ], [ [ 1637, 63, 1264 ], [ 1264, 24, 957 ] ], [ [ 1637, 24, 407 ], [ 407, 63, 957 ] ], [ [ 1637, 24, 849 ], [ 849, 24, 957 ] ], [ [ 1637, 63, 475 ], [ 475, 25, 957 ] ], [ [ 1637, 63, 1264 ], [ 1264, 63, 126 ], [ 126, 23, 957 ] ], [ [ 1637, 63, 401 ], [ 401, 24, 1264 ], [ 1264, 24, 957 ] ], [ [ 1637, 63, 1376 ], [ 1376, 40, 126 ], [ 126, 23, 957 ] ], [ [ 1637, 24, 407 ], [ 407, 63, 1264 ], [ 1264, 24, 957 ] ], [ [ 1637, 63, 1264 ], [ 1264, 63, 1648 ], [ 1648, 24, 957 ] ] ]
[ [ [ "Amyl Nitrite", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Paraldehyde" ] ], [ [ "Amyl Nitrite", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Doxepin" ], [ "Doxepin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Paraldehyde" ] ], [ [ "Amyl Nitrite", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Opium" ], [ "Opium", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Paraldehyde" ] ], [ [ "Amyl Nitrite", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Mepyramine" ], [ "Mepyramine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Paraldehyde" ] ], [ [ "Amyl Nitrite", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Morphine" ], [ "Morphine", "{u} may lead to a major life threatening interaction when taken with {v}", "Paraldehyde" ] ], [ [ "Amyl Nitrite", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Doxepin" ], [ "Doxepin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Warfarin" ], [ "Warfarin", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Paraldehyde" ] ], [ [ "Amyl Nitrite", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Promethazine" ], [ "Promethazine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Doxepin" ], [ "Doxepin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Paraldehyde" ] ], [ [ "Amyl Nitrite", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Diphenhydramine" ], [ "Diphenhydramine", "{u} (Compound) resembles {v} (Compound)", "Warfarin" ], [ "Warfarin", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Paraldehyde" ] ], [ [ "Amyl Nitrite", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Opium" ], [ "Opium", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Doxepin" ], [ "Doxepin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Paraldehyde" ] ], [ [ "Amyl Nitrite", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Doxepin" ], [ "Doxepin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Aldesleukin" ], [ "Aldesleukin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Paraldehyde" ] ] ]
Amyl Nitrite may cause a moderate interaction that could exacerbate diseases when taken with Doxepin and Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Paraldehyde Amyl Nitrite may cause a moderate interaction that could exacerbate diseases when taken with Opium and Opium may cause a moderate interaction that could exacerbate diseases when taken with Paraldehyde Amyl Nitrite may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine and Mepyramine may cause a moderate interaction that could exacerbate diseases when taken with Paraldehyde Amyl Nitrite may cause a moderate interaction that could exacerbate diseases when taken with Morphine and Morphine may lead to a major life threatening interaction when taken with Paraldehyde Amyl Nitrite may cause a moderate interaction that could exacerbate diseases when taken with Doxepin and Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Warfarin and Warfarin may cause a minor interaction that can limit clinical effects when taken with Paraldehyde Amyl Nitrite may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Doxepin and Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Paraldehyde Amyl Nitrite may cause a moderate interaction that could exacerbate diseases when taken with Diphenhydramine and Diphenhydramine (Compound) resembles Warfarin (Compound) and Warfarin may cause a minor interaction that can limit clinical effects when taken with Paraldehyde Amyl Nitrite may cause a moderate interaction that could exacerbate diseases when taken with Opium and Opium may cause a moderate interaction that could exacerbate diseases when taken with Doxepin and Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Paraldehyde Amyl Nitrite may cause a moderate interaction that could exacerbate diseases when taken with Doxepin and Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Aldesleukin and Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Paraldehyde
DB01124
DB01611
1,411
1,487
[ "DDInter1828", "DDInter893" ]
Tolbutamide
Hydroxychloroquine
Tolbutamide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It is structurally similar to acetohexamide, chlorpropamide and tolazamide and belongs to the sulfonylurea class of insulin secretagogues, which act by stimulating β cells of the pancreas to release insulin. Sulfonylureas increase both basal insulin secretion and meal-stimulated insulin release. Medications in this class differ in their dose, rate of absorption, duration of action, route of elimination and binding site on their target pancreatic β cell receptor. Sulfonylureas also increase peripheral glucose utilization, decrease hepatic gluconeogenesis and may increase the number and sensitivity of insulin receptors. Sulfonylureas are associated with weight gain, though less so than insulin. Due to their mechanism of action, sulfonylureas may cause hypoglycemia and require consistent food intake to
Hydroxychloroquine is a racemic mixture consisting of an R and S enantiomer. Hydroxychloroquine is an aminoquinoline like [chloroquine]. It is a commonly prescribed medication in the treatment of uncomplicated malaria, rheumatoid arthritis, chronic discoid lupus erythematosus, and systemic lupus erythematosus. Hydroxychloroquine is also used for the prophylaxis of malaria in regions where chloroquine resistance is unlikely. It was developed during World War II as a derivative of [quinacrine] with less severe side effects. Chloroquine and hydroxychloroquine are both being investigated for the treatment of SARS-CoV-2. **The FDA emergency use authorization for hydroxychloroquine and [chloroquine] in the treatment of COVID-19 was revoked on 15 June 2020.** Hydroxychloroquine was granted FDA approval on 18 April 1955. A recent study reported a fatality in the group being treated with hydroxychloroquine for COVID-19.
Moderate
1
[ [ [ 1411, 24, 1487 ] ], [ [ 1411, 21, 29232 ], [ 29232, 60, 1487 ] ], [ [ 1411, 63, 1247 ], [ 1247, 23, 1487 ] ], [ [ 1411, 63, 723 ], [ 723, 24, 1487 ] ], [ [ 1411, 1, 245 ], [ 245, 24, 1487 ] ], [ [ 1411, 24, 116 ], [ 116, 63, 1487 ] ], [ [ 1411, 24, 1283 ], [ 1283, 24, 1487 ] ], [ [ 1411, 62, 556 ], [ 556, 24, 1487 ] ], [ [ 1411, 23, 801 ], [ 801, 63, 1487 ] ], [ [ 1411, 64, 839 ], [ 839, 25, 1487 ] ] ]
[ [ [ "Tolbutamide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Hydroxychloroquine" ] ], [ [ "Tolbutamide", "{u} (Compound) causes {v} (Side Effect)", "Urticaria" ], [ "Urticaria", "{u} (Side Effect) is caused by {v} (Compound)", "Hydroxychloroquine" ] ], [ [ "Tolbutamide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Sulfamethoxazole" ], [ "Sulfamethoxazole", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Hydroxychloroquine" ] ], [ [ "Tolbutamide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Aprepitant" ], [ "Aprepitant", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Hydroxychloroquine" ] ], [ [ "Tolbutamide", "{u} (Compound) resembles {v} (Compound)", "Glimepiride" ], [ "Glimepiride", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Hydroxychloroquine" ] ], [ [ "Tolbutamide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Iodide I-131" ], [ "Iodide I-131", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Hydroxychloroquine" ] ], [ [ "Tolbutamide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Magnesium oxide" ], [ "Magnesium oxide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Hydroxychloroquine" ] ], [ [ "Tolbutamide", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Valproic acid" ], [ "Valproic acid", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Hydroxychloroquine" ] ], [ [ "Tolbutamide", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Brivaracetam" ], [ "Brivaracetam", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Hydroxychloroquine" ] ], [ [ "Tolbutamide", "{u} may lead to a major life threatening interaction when taken with {v}", "Grepafloxacin" ], [ "Grepafloxacin", "{u} may lead to a major life threatening interaction when taken with {v}", "Hydroxychloroquine" ] ] ]
Tolbutamide (Compound) causes Urticaria (Side Effect) and Urticaria (Side Effect) is caused by Hydroxychloroquine (Compound) Tolbutamide may cause a moderate interaction that could exacerbate diseases when taken with Sulfamethoxazole and Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Hydroxychloroquine Tolbutamide may cause a moderate interaction that could exacerbate diseases when taken with Aprepitant and Aprepitant may cause a moderate interaction that could exacerbate diseases when taken with Hydroxychloroquine Tolbutamide (Compound) resembles Glimepiride (Compound) and Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Hydroxychloroquine Tolbutamide may cause a moderate interaction that could exacerbate diseases when taken with Iodide I-131 and Iodide I-131 may cause a moderate interaction that could exacerbate diseases when taken with Hydroxychloroquine Tolbutamide may cause a moderate interaction that could exacerbate diseases when taken with Magnesium oxide and Magnesium oxide may cause a moderate interaction that could exacerbate diseases when taken with Hydroxychloroquine Tolbutamide may cause a minor interaction that can limit clinical effects when taken with Valproic acid and Valproic acid may cause a moderate interaction that could exacerbate diseases when taken with Hydroxychloroquine Tolbutamide may cause a minor interaction that can limit clinical effects when taken with Brivaracetam and Brivaracetam may cause a moderate interaction that could exacerbate diseases when taken with Hydroxychloroquine Tolbutamide may lead to a major life threatening interaction when taken with Grepafloxacin and Grepafloxacin may lead to a major life threatening interaction when taken with Hydroxychloroquine
DB00741
DB11936
167
1,030
[ "DDInter885", "DDInter176" ]
Hydrocortisone
Bempedoic acid
Hydrocortisone, or cortisol, is a glucocorticoid secreted by the adrenal cortex. Hydrocortisone is used to treat immune, inflammatory, and neoplastic conditions.[L10529,L10532,L10535,L10538,L7772,L7321] It was discovered in the 1930s by Edward Kendall and named Compound F, or 17-hydroxycorticosterone. Hydrocortisone was granted FDA approval on 5 August 1952.
High levels of LDL cholesterol (LDL-C) are a major risk factor for cardiovascular events. Caused by genetic mutations or lifestyle factors, hypercholesterolemia can significantly reduce quality of life and increase the risk of mortality from cardiovascular disease. About 1 in 4 patients, or 15 million Americans with elevated LDL-C, are insufficiently managed with maximally tolerated statin therapy alone, requiring additional treatment for hypercholesterolemia. Bempedoic acid is first-in-class adenosine triphosphate-citrate lyase (ACL) inhibitor used once a day for reducing LDL cholesterol levels in statin-refractory patients.[L12144,L12147] It was developed by Esperion Therapeutics Inc. and approved by the FDA on February 21, 2020. A combination product of bempedoic acid and [ezetimibe] was approved on February 26, 2020 for increased control of LDL cholesterol levels in patients experiencing refractory elevations despite previous statin treatment.[L12144,L12150]
Major
2
[ [ [ 167, 25, 1030 ] ], [ [ 167, 24, 473 ], [ 473, 24, 1030 ] ], [ [ 167, 63, 663 ], [ 663, 24, 1030 ] ], [ [ 167, 1, 891 ], [ 891, 25, 1030 ] ], [ [ 167, 40, 870 ], [ 870, 25, 1030 ] ], [ [ 167, 24, 473 ], [ 473, 24, 1450 ], [ 1450, 24, 1030 ] ], [ [ 167, 63, 663 ], [ 663, 24, 14 ], [ 14, 24, 1030 ] ], [ [ 167, 24, 1450 ], [ 1450, 63, 473 ], [ 473, 24, 1030 ] ], [ [ 167, 1, 891 ], [ 891, 24, 473 ], [ 473, 24, 1030 ] ], [ [ 167, 1, 617 ], [ 617, 63, 663 ], [ 663, 24, 1030 ] ] ]
[ [ [ "Hydrocortisone", "{u} may lead to a major life threatening interaction when taken with {v}", "Bempedoic acid" ] ], [ [ "Hydrocortisone", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Repaglinide" ], [ "Repaglinide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Bempedoic acid" ] ], [ [ "Hydrocortisone", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Methotrexate" ], [ "Methotrexate", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Bempedoic acid" ] ], [ [ "Hydrocortisone", "{u} (Compound) resembles {v} (Compound)", "Prednisolone" ], [ "Prednisolone", "{u} may lead to a major life threatening interaction when taken with {v}", "Bempedoic acid" ] ], [ [ "Hydrocortisone", "{u} (Compound) resembles {v} (Compound)", "Fludrocortisone" ], [ "Fludrocortisone", "{u} may lead to a major life threatening interaction when taken with {v}", "Bempedoic acid" ] ], [ [ "Hydrocortisone", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Repaglinide" ], [ "Repaglinide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Empagliflozin" ], [ "Empagliflozin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Bempedoic acid" ] ], [ [ "Hydrocortisone", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Methotrexate" ], [ "Methotrexate", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Rosuvastatin" ], [ "Rosuvastatin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Bempedoic acid" ] ], [ [ "Hydrocortisone", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Empagliflozin" ], [ "Empagliflozin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Repaglinide" ], [ "Repaglinide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Bempedoic acid" ] ], [ [ "Hydrocortisone", "{u} (Compound) resembles {v} (Compound)", "Prednisolone" ], [ "Prednisolone", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Repaglinide" ], [ "Repaglinide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Bempedoic acid" ] ], [ [ "Hydrocortisone", "{u} (Compound) resembles {v} (Compound)", "Budesonide" ], [ "Budesonide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Methotrexate" ], [ "Methotrexate", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Bempedoic acid" ] ] ]
Hydrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Repaglinide and Repaglinide may cause a moderate interaction that could exacerbate diseases when taken with Bempedoic acid Hydrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Methotrexate and Methotrexate may cause a moderate interaction that could exacerbate diseases when taken with Bempedoic acid Hydrocortisone (Compound) resembles Prednisolone (Compound) and Prednisolone may lead to a major life threatening interaction when taken with Bempedoic acid Hydrocortisone (Compound) resembles Fludrocortisone (Compound) and Fludrocortisone may lead to a major life threatening interaction when taken with Bempedoic acid Hydrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Repaglinide and Repaglinide may cause a moderate interaction that could exacerbate diseases when taken with Empagliflozin and Empagliflozin may cause a moderate interaction that could exacerbate diseases when taken with Bempedoic acid Hydrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Methotrexate and Methotrexate may cause a moderate interaction that could exacerbate diseases when taken with Rosuvastatin and Rosuvastatin may cause a moderate interaction that could exacerbate diseases when taken with Bempedoic acid Hydrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Empagliflozin and Empagliflozin may cause a moderate interaction that could exacerbate diseases when taken with Repaglinide and Repaglinide may cause a moderate interaction that could exacerbate diseases when taken with Bempedoic acid Hydrocortisone (Compound) resembles Prednisolone (Compound) and Prednisolone may cause a moderate interaction that could exacerbate diseases when taken with Repaglinide and Repaglinide may cause a moderate interaction that could exacerbate diseases when taken with Bempedoic acid Hydrocortisone (Compound) resembles Budesonide (Compound) and Budesonide may cause a moderate interaction that could exacerbate diseases when taken with Methotrexate and Methotrexate may cause a moderate interaction that could exacerbate diseases when taken with Bempedoic acid
DB00703
DB09104
997
286
[ "DDInter1167", "DDInter1118" ]
Methazolamide
Magnesium hydroxide
A carbonic anhydrase inhibitor that is used as a diuretic and in the treatment of glaucoma.
Magnesium hydroxide is an inorganic compound. It is naturally found as the mineral brucite. Magnesium hydroxide can be used as an antacid or a laxative in either an oral liquid suspension or chewable tablet form. Additionally, magnesium hydroxide has smoke suppressing and flame retardant properties and is thus used commercially as a fire retardant. It can also be used topically as a deodorant or for the relief of canker sores (aphthous ulcers).
Moderate
1
[ [ [ 997, 24, 286 ] ], [ [ 997, 63, 355 ], [ 355, 23, 286 ] ], [ [ 997, 24, 688 ], [ 688, 24, 286 ] ], [ [ 997, 40, 471 ], [ 471, 24, 286 ] ], [ [ 997, 23, 1669 ], [ 1669, 24, 286 ] ], [ [ 997, 62, 1572 ], [ 1572, 24, 286 ] ], [ [ 997, 24, 1019 ], [ 1019, 63, 286 ] ], [ [ 997, 63, 251 ], [ 251, 24, 286 ] ], [ [ 997, 25, 57 ], [ 57, 24, 286 ] ], [ [ 997, 64, 1425 ], [ 1425, 24, 286 ] ] ]
[ [ [ "Methazolamide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Magnesium hydroxide" ] ], [ [ "Methazolamide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Lactulose" ], [ "Lactulose", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Magnesium hydroxide" ] ], [ [ "Methazolamide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Salbutamol" ], [ "Salbutamol", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Magnesium hydroxide" ] ], [ [ "Methazolamide", "{u} (Compound) resembles {v} (Compound)", "Acetazolamide" ], [ "Acetazolamide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Magnesium hydroxide" ] ], [ [ "Methazolamide", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Minocycline" ], [ "Minocycline", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Magnesium hydroxide" ] ], [ [ "Methazolamide", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Demeclocycline" ], [ "Demeclocycline", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Magnesium hydroxide" ] ], [ [ "Methazolamide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Deflazacort" ], [ "Deflazacort", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Magnesium hydroxide" ] ], [ [ "Methazolamide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Betamethasone" ], [ "Betamethasone", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Magnesium hydroxide" ] ], [ [ "Methazolamide", "{u} may lead to a major life threatening interaction when taken with {v}", "Arsenic trioxide" ], [ "Arsenic trioxide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Magnesium hydroxide" ] ], [ [ "Methazolamide", "{u} may lead to a major life threatening interaction when taken with {v}", "Cisapride" ], [ "Cisapride", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Magnesium hydroxide" ] ] ]
Methazolamide may cause a moderate interaction that could exacerbate diseases when taken with Lactulose and Lactulose may cause a minor interaction that can limit clinical effects when taken with Magnesium hydroxide Methazolamide may cause a moderate interaction that could exacerbate diseases when taken with Salbutamol and Salbutamol may cause a moderate interaction that could exacerbate diseases when taken with Magnesium hydroxide Methazolamide (Compound) resembles Acetazolamide (Compound) and Acetazolamide may cause a moderate interaction that could exacerbate diseases when taken with Magnesium hydroxide Methazolamide may cause a minor interaction that can limit clinical effects when taken with Minocycline and Minocycline may cause a moderate interaction that could exacerbate diseases when taken with Magnesium hydroxide Methazolamide may cause a minor interaction that can limit clinical effects when taken with Demeclocycline and Demeclocycline may cause a moderate interaction that could exacerbate diseases when taken with Magnesium hydroxide Methazolamide may cause a moderate interaction that could exacerbate diseases when taken with Deflazacort and Deflazacort may cause a moderate interaction that could exacerbate diseases when taken with Magnesium hydroxide Methazolamide may cause a moderate interaction that could exacerbate diseases when taken with Betamethasone and Betamethasone may cause a moderate interaction that could exacerbate diseases when taken with Magnesium hydroxide Methazolamide may lead to a major life threatening interaction when taken with Arsenic trioxide and Arsenic trioxide may cause a moderate interaction that could exacerbate diseases when taken with Magnesium hydroxide Methazolamide may lead to a major life threatening interaction when taken with Cisapride and Cisapride may cause a moderate interaction that could exacerbate diseases when taken with Magnesium hydroxide
DB00436
DB06335
323
761
[ "DDInter179", "DDInter1646" ]
Bendroflumethiazide
Saxagliptin
A thiazide diuretic with actions and uses similar to those of hydrochlorothiazide. It has been used in the treatment of familial hyperkalemia, hypertension, edema, and urinary tract disorders. (From Martindale, The Extra Pharmacopoeia, 30th ed, p810)
Saxagliptin (rINN) is an orally active hypoglycemic (anti-diabetic drug) of the new dipeptidyl peptidase-4 (DPP-4) inhibitor class of drugs. FDA approved on July 31, 2009.
Moderate
1
[ [ [ 323, 24, 761 ] ], [ [ 323, 21, 28722 ], [ 28722, 60, 761 ] ], [ [ 323, 40, 1577 ], [ 1577, 24, 761 ] ], [ [ 323, 24, 1573 ], [ 1573, 24, 761 ] ], [ [ 323, 24, 1296 ], [ 1296, 63, 761 ] ], [ [ 323, 63, 1179 ], [ 1179, 24, 761 ] ], [ [ 323, 21, 28722 ], [ 28722, 60, 11525 ], [ 11525, 1, 761 ] ], [ [ 323, 21, 28784 ], [ 28784, 60, 1577 ], [ 1577, 24, 761 ] ], [ [ 323, 21, 28658 ], [ 28658, 60, 307 ], [ 307, 23, 761 ] ], [ [ 323, 40, 1577 ], [ 1577, 21, 28722 ], [ 28722, 60, 761 ] ] ]
[ [ [ "Bendroflumethiazide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Saxagliptin" ] ], [ [ "Bendroflumethiazide", "{u} (Compound) causes {v} (Side Effect)", "Nausea" ], [ "Nausea", "{u} (Side Effect) is caused by {v} (Compound)", "Saxagliptin" ] ], [ [ "Bendroflumethiazide", "{u} (Compound) resembles {v} (Compound)", "Hydroflumethiazide" ], [ "Hydroflumethiazide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Saxagliptin" ] ], [ [ "Bendroflumethiazide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Prednisone" ], [ "Prednisone", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Saxagliptin" ] ], [ [ "Bendroflumethiazide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Insulin degludec" ], [ "Insulin degludec", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Saxagliptin" ] ], [ [ "Bendroflumethiazide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Insulin lispro" ], [ "Insulin lispro", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Saxagliptin" ] ], [ [ "Bendroflumethiazide", "{u} (Compound) causes {v} (Side Effect)", "Nausea" ], [ "Nausea", "{u} (Side Effect) is caused by {v} (Compound)", "Vildagliptin" ], [ "Vildagliptin", "{u} (Compound) resembles {v} (Compound)", "Saxagliptin" ] ], [ [ "Bendroflumethiazide", "{u} (Compound) causes {v} (Side Effect)", "Thrombocytopenia" ], [ "Thrombocytopenia", "{u} (Side Effect) is caused by {v} (Compound)", "Hydroflumethiazide" ], [ "Hydroflumethiazide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Saxagliptin" ] ], [ [ "Bendroflumethiazide", "{u} (Compound) causes {v} (Side Effect)", "Vomiting" ], [ "Vomiting", "{u} (Side Effect) is caused by {v} (Compound)", "Modafinil" ], [ "Modafinil", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Saxagliptin" ] ], [ [ "Bendroflumethiazide", "{u} (Compound) resembles {v} (Compound)", "Hydroflumethiazide" ], [ "Hydroflumethiazide", "{u} (Compound) causes {v} (Side Effect)", "Nausea" ], [ "Nausea", "{u} (Side Effect) is caused by {v} (Compound)", "Saxagliptin" ] ] ]
Bendroflumethiazide (Compound) causes Nausea (Side Effect) and Nausea (Side Effect) is caused by Saxagliptin (Compound) Bendroflumethiazide (Compound) resembles Hydroflumethiazide (Compound) and Hydroflumethiazide may cause a moderate interaction that could exacerbate diseases when taken with Saxagliptin Bendroflumethiazide may cause a moderate interaction that could exacerbate diseases when taken with Prednisone and Prednisone may cause a moderate interaction that could exacerbate diseases when taken with Saxagliptin Bendroflumethiazide may cause a moderate interaction that could exacerbate diseases when taken with Insulin degludec and Insulin degludec may cause a moderate interaction that could exacerbate diseases when taken with Saxagliptin Bendroflumethiazide may cause a moderate interaction that could exacerbate diseases when taken with Insulin lispro and Insulin lispro may cause a moderate interaction that could exacerbate diseases when taken with Saxagliptin Bendroflumethiazide (Compound) causes Nausea (Side Effect) and Nausea (Side Effect) is caused by Vildagliptin (Compound) and Vildagliptin (Compound) resembles Saxagliptin (Compound) Bendroflumethiazide (Compound) causes Thrombocytopenia (Side Effect) and Thrombocytopenia (Side Effect) is caused by Hydroflumethiazide (Compound) and Hydroflumethiazide may cause a moderate interaction that could exacerbate diseases when taken with Saxagliptin Bendroflumethiazide (Compound) causes Vomiting (Side Effect) and Vomiting (Side Effect) is caused by Modafinil (Compound) and Modafinil may cause a minor interaction that can limit clinical effects when taken with Saxagliptin Bendroflumethiazide (Compound) resembles Hydroflumethiazide (Compound) and Hydroflumethiazide (Compound) causes Nausea (Side Effect) and Nausea (Side Effect) is caused by Saxagliptin (Compound)
DB00791
DB15091
132
676
[ "DDInter1902", "DDInter1901" ]
Uracil mustard
Upadacitinib
Nitrogen mustard derivative of uracil. It is a alkylating antineoplastic agent that is used in lymphatic malignancies, and causes mainly gastrointestinal and bone marrow damage.
Upadacitinib is an oral Janus kinase (JAK)1-selective inhibitor and a disease-modifying antirheumatic drug (DMARD) used in the treatment of rheumatoid arthritis to slow down disease progression. Rheumatoid arthritis is a chronic autoimmune inflammatory disease affecting the peripheral joints. It is characterized by synovial inflammation and hyperplasia, autoantibody production, cartilage damage and bone destruction, leading to co-morbidities. Despite a variety of therapeutic agents available for treatment, up to 40% of the patients do not respond to current therapies, including biological therapies. The etiology of the disease is mostly unknown; however, the role of JAK as a driver of immune-mediated conditions was discovered, leading to the use of JAK as therapeutic targets for rheumatoid arthritis. To reduce dose-related toxicity (as seen with some pan-JAK inhibitors) without significantly affecting efficacy, more selective JAK1 inhibitors, upadacitinib and [filgotinib], were developed. The FDA approved upadacitinib in August 2019 and it is used for the treatment of active rheumatoid arthritis, psoriatic arthritis, atopic dermatitis, ulcerative colitis, and ankylosing spondylitis. In December 2019, it was additionally approved by the European Commission and Health Canada.[L10899,L42540] Upadacitinib is marketed under the brand name RINVOQ for oral administration.
Major
2
[ [ [ 132, 25, 676 ] ], [ [ 132, 63, 1461 ], [ 1461, 23, 676 ] ], [ [ 132, 24, 1430 ], [ 1430, 24, 676 ] ], [ [ 132, 63, 597 ], [ 597, 24, 676 ] ], [ [ 132, 63, 1184 ], [ 1184, 25, 676 ] ], [ [ 132, 24, 869 ], [ 869, 25, 676 ] ], [ [ 132, 64, 1064 ], [ 1064, 25, 676 ] ], [ [ 132, 25, 1137 ], [ 1137, 25, 676 ] ], [ [ 132, 1, 970 ], [ 970, 25, 676 ] ], [ [ 132, 63, 1461 ], [ 1461, 62, 1184 ], [ 1184, 25, 676 ] ] ]
[ [ [ "Uracil mustard", "{u} may lead to a major life threatening interaction when taken with {v}", "Upadacitinib" ] ], [ [ "Uracil mustard", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Vitamin E" ], [ "Vitamin E", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Upadacitinib" ] ], [ [ "Uracil mustard", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Sipuleucel-T" ], [ "Sipuleucel-T", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Upadacitinib" ] ], [ [ "Uracil mustard", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Chloramphenicol" ], [ "Chloramphenicol", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Upadacitinib" ] ], [ [ "Uracil mustard", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Anakinra" ], [ "Anakinra", "{u} may lead to a major life threatening interaction when taken with {v}", "Upadacitinib" ] ], [ [ "Uracil mustard", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Topotecan" ], [ "Topotecan", "{u} may lead to a major life threatening interaction when taken with {v}", "Upadacitinib" ] ], [ [ "Uracil mustard", "{u} may lead to a major life threatening interaction when taken with {v}", "Cladribine" ], [ "Cladribine", "{u} may lead to a major life threatening interaction when taken with {v}", "Upadacitinib" ] ], [ [ "Uracil mustard", "{u} may lead to a major life threatening interaction when taken with {v}", "Measles virus vaccine live attenuated" ], [ "Measles virus vaccine live attenuated", "{u} may lead to a major life threatening interaction when taken with {v}", "Upadacitinib" ] ], [ [ "Uracil mustard", "{u} (Compound) resembles {v} (Compound)", "Fluorouracil" ], [ "Fluorouracil", "{u} may lead to a major life threatening interaction when taken with {v}", "Upadacitinib" ] ], [ [ "Uracil mustard", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Vitamin E" ], [ "Vitamin E", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Anakinra" ], [ "Anakinra", "{u} may lead to a major life threatening interaction when taken with {v}", "Upadacitinib" ] ] ]
Uracil mustard may cause a moderate interaction that could exacerbate diseases when taken with Vitamin E and Vitamin E may cause a minor interaction that can limit clinical effects when taken with Upadacitinib Uracil mustard may cause a moderate interaction that could exacerbate diseases when taken with Sipuleucel-T and Sipuleucel-T may cause a moderate interaction that could exacerbate diseases when taken with Upadacitinib Uracil mustard may cause a moderate interaction that could exacerbate diseases when taken with Chloramphenicol and Chloramphenicol may cause a moderate interaction that could exacerbate diseases when taken with Upadacitinib Uracil mustard may cause a moderate interaction that could exacerbate diseases when taken with Anakinra and Anakinra may lead to a major life threatening interaction when taken with Upadacitinib Uracil mustard may cause a moderate interaction that could exacerbate diseases when taken with Topotecan and Topotecan may lead to a major life threatening interaction when taken with Upadacitinib Uracil mustard may lead to a major life threatening interaction when taken with Cladribine and Cladribine may lead to a major life threatening interaction when taken with Upadacitinib Uracil mustard may lead to a major life threatening interaction when taken with Measles virus vaccine live attenuated and Measles virus vaccine live attenuated may lead to a major life threatening interaction when taken with Upadacitinib Uracil mustard (Compound) resembles Fluorouracil (Compound) and Fluorouracil may lead to a major life threatening interaction when taken with Upadacitinib Uracil mustard may cause a moderate interaction that could exacerbate diseases when taken with Vitamin E and Vitamin E may cause a minor interaction that can limit clinical effects when taken with Anakinra and Anakinra may lead to a major life threatening interaction when taken with Upadacitinib
DB09122
DB11791
1,613
785
[ "DDInter1409", "DDInter287" ]
Peginterferon beta-1a
Capmatinib
Multiple Sclerosis (MS) is a chronic and inflammatory autoimmune disease of the central nervous system, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years of life. Symptoms may include but are not limited to fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and depressing or mood swings. MS is one of the most common causes of neurological disability in young adults and is found to occur more frequently in women than in men.[A176474,L5792] Peginterferon beta-1a is an interferon therapy used for the management of relapsing forms of MS. It was originally approved by the FDA in 2014 for subcutaneous use, and was approved for intramuscular use in January 2021. Currently, it is the only approved pegylated interferon for the management of
Capmatinib is a small molecule kinase inhibitor targeted against c-Met (a.k.a. hepatocyte growth factor receptor [HGFR]), a receptor tyrosine kinase that, in healthy humans, activates signaling cascades involved in organ regeneration and tissue repair. Aberrant c-Met activation - via mutations, amplification, and/or overexpression - is known to occur in many types of cancer, and leads to overactivation of multiple downstream signaling pathways such as STAT3, PI3K/ATK, and RAS/MAPK. Mutations in _MET_ have been detected in non-small cell lung cancer (NSCLC), and the prevalence of _MET_ amplification in epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI)-naive patients with NSCLC has been reported to be 1.4% - 21%. This co-occurrence has made c-Met a desirable target in the treatment of NSCLC. Manufactured by Novartis and marketed under the brand name Tabrecta, capmatinib was granted accelerated approval by the FDA on May 6, 2020, for the treatment of NSCLC in patients whose tumors have a mutation that leads to mesenchymal-epithelial transition (MET) exon 14 skipping. The presence of the mutation must be confirmed by an FDA-approved test, such as the FoundationOne CDx assay (manufactured by Foundation Medicine, Inc.), which was approved by the FDA on the same day. As this indication was granted under an accelerated approval, its continued approval is contingent upon verification of capmatinib's benefit in confirmatory trials. Capmatinib was approved by Health Canada on June 8, 2022.
Moderate
1
[ [ [ 1613, 24, 785 ] ], [ [ 1613, 63, 1324 ], [ 1324, 24, 785 ] ], [ [ 1613, 24, 1320 ], [ 1320, 63, 785 ] ], [ [ 1613, 24, 351 ], [ 351, 24, 785 ] ], [ [ 1613, 63, 384 ], [ 384, 25, 785 ] ], [ [ 1613, 64, 1510 ], [ 1510, 25, 785 ] ], [ [ 1613, 63, 1324 ], [ 1324, 24, 1215 ], [ 1215, 23, 785 ] ], [ [ 1613, 63, 868 ], [ 868, 23, 1135 ], [ 1135, 23, 785 ] ], [ [ 1613, 63, 482 ], [ 482, 63, 1324 ], [ 1324, 24, 785 ] ], [ [ 1613, 63, 322 ], [ 322, 25, 868 ], [ 868, 24, 785 ] ] ]
[ [ [ "Peginterferon beta-1a", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Capmatinib" ] ], [ [ "Peginterferon beta-1a", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Troglitazone" ], [ "Troglitazone", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Capmatinib" ] ], [ [ "Peginterferon beta-1a", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Elagolix" ], [ "Elagolix", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Capmatinib" ] ], [ [ "Peginterferon beta-1a", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Ribociclib" ], [ "Ribociclib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Capmatinib" ] ], [ [ "Peginterferon beta-1a", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Idelalisib" ], [ "Idelalisib", "{u} may lead to a major life threatening interaction when taken with {v}", "Capmatinib" ] ], [ [ "Peginterferon beta-1a", "{u} may lead to a major life threatening interaction when taken with {v}", "Teriflunomide" ], [ "Teriflunomide", "{u} may lead to a major life threatening interaction when taken with {v}", "Capmatinib" ] ], [ [ "Peginterferon beta-1a", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Troglitazone" ], [ "Troglitazone", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Lansoprazole" ], [ "Lansoprazole", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Capmatinib" ] ], [ [ "Peginterferon beta-1a", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Vemurafenib" ], [ "Vemurafenib", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Naloxegol" ], [ "Naloxegol", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Capmatinib" ] ], [ [ "Peginterferon beta-1a", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Tioguanine" ], [ "Tioguanine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Troglitazone" ], [ "Troglitazone", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Capmatinib" ] ], [ [ "Peginterferon beta-1a", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Epirubicin" ], [ "Epirubicin", "{u} may lead to a major life threatening interaction when taken with {v}", "Vemurafenib" ], [ "Vemurafenib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Capmatinib" ] ] ]
Peginterferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Troglitazone and Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Capmatinib Peginterferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Elagolix and Elagolix may cause a moderate interaction that could exacerbate diseases when taken with Capmatinib Peginterferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Ribociclib and Ribociclib may cause a moderate interaction that could exacerbate diseases when taken with Capmatinib Peginterferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib and Idelalisib may lead to a major life threatening interaction when taken with Capmatinib Peginterferon beta-1a may lead to a major life threatening interaction when taken with Teriflunomide and Teriflunomide may lead to a major life threatening interaction when taken with Capmatinib Peginterferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Troglitazone and Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Lansoprazole and Lansoprazole may cause a minor interaction that can limit clinical effects when taken with Capmatinib Peginterferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Vemurafenib and Vemurafenib may cause a minor interaction that can limit clinical effects when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Capmatinib Peginterferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Tioguanine and Tioguanine may cause a moderate interaction that could exacerbate diseases when taken with Troglitazone and Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Capmatinib Peginterferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Epirubicin and Epirubicin may lead to a major life threatening interaction when taken with Vemurafenib and Vemurafenib may cause a moderate interaction that could exacerbate diseases when taken with Capmatinib
DB09101
DB09481
70
460
[ "DDInter633", "DDInter1113" ]
Elvitegravir
Magnesium carbonate
Elvitegravir is a human immunodeficiency virus type 1 (HIV-1) integrase strand transfer inhibitor (INSTI) used for the treatment of HIV-1 infection in antiretroviral treatment-experienced adults. Because integrase is necessary for viral replication, inhibition prevents the integration of HIV-1 DNA into the host genome and thereby blocks the formation of the HIV-1 provirus and resulting propagation of the viral infection. Although available as a single dose tablet, elvitegravir must be used in combination with an HIV protease inhibitor coadministered with ritonavir and another antiretroviral drug. Elvitegravir was first licensed from Japan Tobacco in 2008 and developed by Gilead Sciences. It was FDA approved on August 27, 2012. On September 24, 2014, the FDA approved the single pill form of elvitegravir.
Magnesium carbonate, also known as magnesite, is a common over the counter remedy for heartburn and upset stomach caused by overproduction of acid in the stomach [FDA Label].
Moderate
1
[ [ [ 70, 24, 460 ] ], [ [ 70, 63, 1040 ], [ 1040, 24, 460 ] ], [ [ 70, 24, 286 ], [ 286, 24, 460 ] ], [ [ 70, 63, 1040 ], [ 1040, 63, 1382 ], [ 1382, 23, 460 ] ], [ [ 70, 63, 1283 ], [ 1283, 62, 664 ], [ 664, 23, 460 ] ], [ [ 70, 24, 286 ], [ 286, 62, 664 ], [ 664, 23, 460 ] ], [ [ 70, 63, 1283 ], [ 1283, 23, 1592 ], [ 1592, 23, 460 ] ], [ [ 70, 24, 1017 ], [ 1017, 62, 1459 ], [ 1459, 25, 460 ] ], [ [ 70, 63, 868 ], [ 868, 23, 1459 ], [ 1459, 25, 460 ] ], [ [ 70, 24, 1017 ], [ 1017, 63, 1252 ], [ 1252, 23, 460 ] ] ]
[ [ [ "Elvitegravir", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Magnesium carbonate" ] ], [ [ "Elvitegravir", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Dabrafenib" ], [ "Dabrafenib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Magnesium carbonate" ] ], [ [ "Elvitegravir", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Magnesium hydroxide" ], [ "Magnesium hydroxide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Magnesium carbonate" ] ], [ [ "Elvitegravir", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Dabrafenib" ], [ "Dabrafenib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Midazolam" ], [ "Midazolam", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Magnesium carbonate" ] ], [ [ "Elvitegravir", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Magnesium oxide" ], [ "Magnesium oxide", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Perindopril" ], [ "Perindopril", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Magnesium carbonate" ] ], [ [ "Elvitegravir", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Magnesium hydroxide" ], [ "Magnesium hydroxide", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Perindopril" ], [ "Perindopril", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Magnesium carbonate" ] ], [ [ "Elvitegravir", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Magnesium oxide" ], [ "Magnesium oxide", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Nebivolol" ], [ "Nebivolol", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Magnesium carbonate" ] ], [ [ "Elvitegravir", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Lorlatinib" ], [ "Lorlatinib", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Dolutegravir" ], [ "Dolutegravir", "{u} may lead to a major life threatening interaction when taken with {v}", "Magnesium carbonate" ] ], [ [ "Elvitegravir", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Vemurafenib" ], [ "Vemurafenib", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Dolutegravir" ], [ "Dolutegravir", "{u} may lead to a major life threatening interaction when taken with {v}", "Magnesium carbonate" ] ], [ [ "Elvitegravir", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Lorlatinib" ], [ "Lorlatinib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Digoxin" ], [ "Digoxin", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Magnesium carbonate" ] ] ]
Elvitegravir may cause a moderate interaction that could exacerbate diseases when taken with Dabrafenib and Dabrafenib may cause a moderate interaction that could exacerbate diseases when taken with Magnesium carbonate Elvitegravir may cause a moderate interaction that could exacerbate diseases when taken with Magnesium hydroxide and Magnesium hydroxide may cause a moderate interaction that could exacerbate diseases when taken with Magnesium carbonate Elvitegravir may cause a moderate interaction that could exacerbate diseases when taken with Dabrafenib and Dabrafenib may cause a moderate interaction that could exacerbate diseases when taken with Midazolam and Midazolam may cause a minor interaction that can limit clinical effects when taken with Magnesium carbonate Elvitegravir may cause a moderate interaction that could exacerbate diseases when taken with Magnesium oxide and Magnesium oxide may cause a minor interaction that can limit clinical effects when taken with Perindopril and Perindopril may cause a minor interaction that can limit clinical effects when taken with Magnesium carbonate Elvitegravir may cause a moderate interaction that could exacerbate diseases when taken with Magnesium hydroxide and Magnesium hydroxide may cause a minor interaction that can limit clinical effects when taken with Perindopril and Perindopril may cause a minor interaction that can limit clinical effects when taken with Magnesium carbonate Elvitegravir may cause a moderate interaction that could exacerbate diseases when taken with Magnesium oxide and Magnesium oxide may cause a minor interaction that can limit clinical effects when taken with Nebivolol and Nebivolol may cause a minor interaction that can limit clinical effects when taken with Magnesium carbonate Elvitegravir may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib and Lorlatinib may cause a minor interaction that can limit clinical effects when taken with Dolutegravir and Dolutegravir may lead to a major life threatening interaction when taken with Magnesium carbonate Elvitegravir may cause a moderate interaction that could exacerbate diseases when taken with Vemurafenib and Vemurafenib may cause a minor interaction that can limit clinical effects when taken with Dolutegravir and Dolutegravir may lead to a major life threatening interaction when taken with Magnesium carbonate Elvitegravir may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib and Lorlatinib may cause a moderate interaction that could exacerbate diseases when taken with Digoxin and Digoxin may cause a minor interaction that can limit clinical effects when taken with Magnesium carbonate
DB00831
DB01276
1,178
123
[ "DDInter1866", "DDInter706" ]
Trifluoperazine
Exenatide
A phenothiazine with actions similar to chlorpromazine. It is used as an antipsychotic and an antiemetic.
Exenatide is a glucagon-like peptide-1 (GLP-1) analog. It activates the GLP-1 receptor and increases insulin secretion, decreases glucagon secretion, and slows gastric emptying to improve glycemic control. Exenatide was given FDA approval on April 28, 2005. It is available as immediate- and extended-release formulations.[L42685,L42690] Bydureon, the brand name product of extended-release exenatide in an injectable suspension, was discontinued in 2021. Bydureon BCise, an auto-injector extended-release formulation, remains available.
Moderate
1
[ [ [ 1178, 24, 123 ] ], [ [ 1178, 35, 820 ], [ 820, 24, 123 ] ], [ [ 1178, 40, 1630 ], [ 1630, 24, 123 ] ], [ [ 1178, 63, 1685 ], [ 1685, 24, 123 ] ], [ [ 1178, 24, 222 ], [ 222, 24, 123 ] ], [ [ 1178, 24, 1042 ], [ 1042, 63, 123 ] ], [ [ 1178, 1, 216 ], [ 216, 24, 123 ] ], [ [ 1178, 25, 1154 ], [ 1154, 63, 123 ] ], [ [ 1178, 62, 417 ], [ 417, 24, 123 ] ], [ [ 1178, 40, 9 ], [ 9, 63, 123 ] ] ]
[ [ [ "Trifluoperazine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Exenatide" ] ], [ [ "Trifluoperazine", "{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Alimemazine" ], [ "Alimemazine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Exenatide" ] ], [ [ "Trifluoperazine", "{u} (Compound) resembles {v} (Compound)", "Perphenazine" ], [ "Perphenazine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Exenatide" ] ], [ [ "Trifluoperazine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Insulin human" ], [ "Insulin human", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Exenatide" ] ], [ [ "Trifluoperazine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Sibutramine" ], [ "Sibutramine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Exenatide" ] ], [ [ "Trifluoperazine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Tetracosactide" ], [ "Tetracosactide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Exenatide" ] ], [ [ "Trifluoperazine", "{u} (Compound) resembles {v} (Compound)", "Chlorpromazine" ], [ "Chlorpromazine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Exenatide" ] ], [ [ "Trifluoperazine", "{u} may lead to a major life threatening interaction when taken with {v}", "Pasireotide" ], [ "Pasireotide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Exenatide" ] ], [ [ "Trifluoperazine", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Sucralfate" ], [ "Sucralfate", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Exenatide" ] ], [ [ "Trifluoperazine", "{u} (Compound) resembles {v} (Compound)", "Methotrimeprazine" ], [ "Methotrimeprazine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Exenatide" ] ] ]
Trifluoperazine (Compound) resembles Alimemazine (Compound) and Trifluoperazine may cause a moderate interaction that could exacerbate diseases when taken with Alimemazine and Alimemazine may cause a moderate interaction that could exacerbate diseases when taken with Exenatide Trifluoperazine (Compound) resembles Perphenazine (Compound) and Perphenazine may cause a moderate interaction that could exacerbate diseases when taken with Exenatide Trifluoperazine may cause a moderate interaction that could exacerbate diseases when taken with Insulin human and Insulin human may cause a moderate interaction that could exacerbate diseases when taken with Exenatide Trifluoperazine may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine and Sibutramine may cause a moderate interaction that could exacerbate diseases when taken with Exenatide Trifluoperazine may cause a moderate interaction that could exacerbate diseases when taken with Tetracosactide and Tetracosactide may cause a moderate interaction that could exacerbate diseases when taken with Exenatide Trifluoperazine (Compound) resembles Chlorpromazine (Compound) and Chlorpromazine may cause a moderate interaction that could exacerbate diseases when taken with Exenatide Trifluoperazine may lead to a major life threatening interaction when taken with Pasireotide and Pasireotide may cause a moderate interaction that could exacerbate diseases when taken with Exenatide Trifluoperazine may cause a minor interaction that can limit clinical effects when taken with Sucralfate and Sucralfate may cause a moderate interaction that could exacerbate diseases when taken with Exenatide Trifluoperazine (Compound) resembles Methotrimeprazine (Compound) and Methotrimeprazine may cause a moderate interaction that could exacerbate diseases when taken with Exenatide
DB00641
DB00911
467
458
[ "DDInter1675", "DDInter1811" ]
Simvastatin
Tinidazole
Simvastatin, also known as the brand name product Zocor, is a lipid-lowering drug derived synthetically from a fermentation product of _Aspergillus terreus_. It belongs to the statin class of medications, which are used to lower the risk of cardiovascular disease and manage abnormal lipid levels by inhibiting the endogenous production of cholesterol in the liver. More specifically, statin medications competitively inhibit the enzyme hydroxymethylglutaryl-coenzyme A (HMG-CoA) Reductase, which catalyzes the conversion of HMG-CoA to mevalonic acid and is the third step in a sequence of metabolic reactions involved in the production of several compounds involved in lipid metabolism and transport including cholesterol, low-density lipoprotein (LDL) (sometimes referred to as "bad cholesterol"), and very low-density lipoprotein (VLDL). Prescribing of statin medications is considered standard practice following any cardiovascular events and for people with a
A nitroimidazole antitrichomonal agent effective against _Trichomonas vaginalis_, _Entamoeba histolytica_, and _Giardia lamblia_ infections.
Moderate
1
[ [ [ 467, 24, 458 ] ], [ [ 467, 24, 112 ], [ 112, 1, 458 ] ], [ [ 467, 6, 8374 ], [ 8374, 45, 458 ] ], [ [ 467, 7, 4634 ], [ 4634, 46, 458 ] ], [ [ 467, 21, 29340 ], [ 29340, 60, 458 ] ], [ [ 467, 63, 752 ], [ 752, 23, 458 ] ], [ [ 467, 63, 238 ], [ 238, 24, 458 ] ], [ [ 467, 24, 310 ], [ 310, 63, 458 ] ], [ [ 467, 25, 1554 ], [ 1554, 63, 458 ] ], [ [ 467, 25, 1080 ], [ 1080, 24, 458 ] ] ]
[ [ [ "Simvastatin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Tinidazole" ] ], [ [ "Simvastatin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Metronidazole" ], [ "Metronidazole", "{u} (Compound) resembles {v} (Compound)", "Tinidazole" ] ], [ [ "Simvastatin", "{u} (Compound) binds {v} (Gene)", "CYP3A4" ], [ "CYP3A4", "{u} (Gene) is bound by {v} (Compound)", "Tinidazole" ] ], [ [ "Simvastatin", "{u} (Compound) upregulates {v} (Gene)", "FOXO4" ], [ "FOXO4", "{u} (Gene) is upregulated by {v} (Compound)", "Tinidazole" ] ], [ [ "Simvastatin", "{u} (Compound) causes {v} (Side Effect)", "Stevens-Johnson syndrome" ], [ "Stevens-Johnson syndrome", "{u} (Side Effect) is caused by {v} (Compound)", "Tinidazole" ] ], [ [ "Simvastatin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Cimetidine" ], [ "Cimetidine", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Tinidazole" ] ], [ [ "Simvastatin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Ethambutol" ], [ "Ethambutol", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Tinidazole" ] ], [ [ "Simvastatin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Cabazitaxel" ], [ "Cabazitaxel", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Tinidazole" ] ], [ [ "Simvastatin", "{u} may lead to a major life threatening interaction when taken with {v}", "Colchicine" ], [ "Colchicine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Tinidazole" ] ], [ [ "Simvastatin", "{u} may lead to a major life threatening interaction when taken with {v}", "Conivaptan" ], [ "Conivaptan", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Tinidazole" ] ] ]
Simvastatin may cause a moderate interaction that could exacerbate diseases when taken with Metronidazole and Metronidazole (Compound) resembles Tinidazole (Compound) Simvastatin (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Tinidazole (Compound) Simvastatin (Compound) upregulates FOXO4 (Gene) and FOXO4 (Gene) is upregulated by Tinidazole (Compound) Simvastatin (Compound) causes Stevens-Johnson syndrome (Side Effect) and Stevens-Johnson syndrome (Side Effect) is caused by Tinidazole (Compound) Simvastatin may cause a moderate interaction that could exacerbate diseases when taken with Cimetidine and Cimetidine may cause a minor interaction that can limit clinical effects when taken with Tinidazole Simvastatin may cause a moderate interaction that could exacerbate diseases when taken with Ethambutol and Ethambutol may cause a moderate interaction that could exacerbate diseases when taken with Tinidazole Simvastatin may cause a moderate interaction that could exacerbate diseases when taken with Cabazitaxel and Cabazitaxel may cause a moderate interaction that could exacerbate diseases when taken with Tinidazole Simvastatin may lead to a major life threatening interaction when taken with Colchicine and Colchicine may cause a moderate interaction that could exacerbate diseases when taken with Tinidazole Simvastatin may lead to a major life threatening interaction when taken with Conivaptan and Conivaptan may cause a moderate interaction that could exacerbate diseases when taken with Tinidazole
DB00222
DB01309
245
1,254
[ "DDInter825", "DDInter933" ]
Glimepiride
Insulin glulisine
First introduced in 1995, glimepiride is a member of the second-generation sulfonylurea (SU) drug class used for the management of type 2 diabetes mellitus (T2DM) to improve glycemic control. Type 2 diabetes is a metabolic disorder with increasing prevalences worldwide; it is characterized by insulin resistance in accordance with progressive β cell failure and long-term microvascular and macrovascular complications that lead to co-morbidities and mortalities. Sulfonylureas are one of the insulin secretagogues widely used for the management of type 2 diabetes to lower blood glucose levels. The main effect of SUs is thought to be effective when residual pancreatic β-cells are present, as they work by stimulating the release of insulin from the pancreatic beta cells and they are also thought to exert extra-pancreatic effects, such as increasing the insulin-mediated peripheral glucose uptake. Glimepiride works by stimulating the secretion of insulin granules from
Insulin glulisine is a short-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Insulin is typically prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide hormone produced by beta cells of the pancreas that promotes glucose metabolism. Insulin is released from the pancreas following a meal to promote the uptake of glucose from the blood into internal organs and tissues such as the liver, fat cells, and skeletal muscle. Absorption of glucose into cells allows for its transformation into glycogen or fat for storage. Insulin also inhibits hepatic glucose production, enhances protein synthesis, and inhibits lipolysis and proteolysis among many other functions. Insulin is an important treatment in the management of Type 1 Diabetes (T1D) which is caused by an autoimmune reaction that destroys the beta cells of the pancreas, resulting in the body not being able to produce or synthesize the insulin needed to manage circulating blood sugar levels. As a result, people with T1D rely primarily on exogenous forms of insulin, such as insulin glulisine, to lower glucose levels in the blood. Insulin is also used in the treatment of Type 2 Diabetes (T2D), another form of diabetes mellitus that is a slowly progressing metabolic disorder caused by a combination of genetic and lifestyle factors that promote chronically elevated blood sugar levels. Without treatment or improvement in non-pharmacological measures such as diet and exercise to lower blood glucose, high blood sugar eventually causes cellular resistance to endogenous insulin, and in the long term, damage to pancreatic islet cells. Insulin is typically prescribed later in the course of T2D, after trying several oral medications such as , , or have been tried, when sufficient damage has been caused to pancreatic cells that the body is no longer able to produce insulin on its own. Marketed as the brand name product Apidra, insulin glulisine begins to exert its effects within 15 minutes of subcutaneous administration, while peak levels occur 30 to 90 minutes after administration. Due to its duration of action of around 5 hours, Apidra is considered "bolus insulin" as it provides high levels of insulin in a short period of time to mimic the release of endogenous insulin from the pancreas after meals. Bolus insulin is often combined with once daily, long-acting "basal insulin" such as , , and to provide low concentrations of background insulin that can keep blood sugar stable between meals or overnight. Use of basal and bolus insulin together is intended to mimic the pancreas' production of endogenous insulin, with a goal of avoiding any periods of hypoglycemia. Insulin glulisine is a biosynthetic, rapid-acting human insulin analogue produced in a non-pathogenic laboratory strain of _Escherichia coli_ (K12). This recombinant hormone differs from native human insulin in that the amino acid asparagine at position B3 is replaced by lysine and the lysine at position B29 is replaced by glutamic acid. These structural modifications decrease hexamer formation, stabilize insulin glulisine monomers and increase the rate of absorption and onset of action compared to human insulin. Without an adequate supply of insulin to promote absorption of glucose from the bloodstream, blood sugar levels can climb to dangerously high levels and can result in symptoms such as fatigue, headache, blurred vision, and increased thirst. If left untreated, the body starts to break down fat, instead of glucose, for energy which results in a build-up of ketone acids in the blood and a syndrome called ketoacidosis, which is a life-threatening medical emergency. In the long term, elevated blood sugar levels increase the risk of heart attack, stroke, and diabetic neuropathy.
Moderate
1
[ [ [ 245, 24, 1254 ] ], [ [ 245, 62, 333 ], [ 333, 23, 1254 ] ], [ [ 245, 23, 721 ], [ 721, 62, 1254 ] ], [ [ 245, 23, 1103 ], [ 1103, 23, 1254 ] ], [ [ 245, 24, 1033 ], [ 1033, 63, 1254 ] ], [ [ 245, 24, 1424 ], [ 1424, 24, 1254 ] ], [ [ 245, 63, 73 ], [ 73, 24, 1254 ] ], [ [ 245, 40, 1411 ], [ 1411, 24, 1254 ] ], [ [ 245, 25, 246 ], [ 246, 25, 1254 ] ], [ [ 245, 25, 255 ], [ 255, 64, 1254 ] ] ]
[ [ [ "Glimepiride", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Insulin glulisine" ] ], [ [ "Glimepiride", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Lipoic acid" ], [ "Lipoic acid", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Insulin glulisine" ] ], [ [ "Glimepiride", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Methylcellulose" ], [ "Methylcellulose", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Insulin glulisine" ] ], [ [ "Glimepiride", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Amcinonide" ], [ "Amcinonide", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Insulin glulisine" ] ], [ [ "Glimepiride", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Alpelisib" ], [ "Alpelisib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Insulin glulisine" ] ], [ [ "Glimepiride", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Quinine" ], [ "Quinine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Insulin glulisine" ] ], [ [ "Glimepiride", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Phentermine" ], [ "Phentermine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Insulin glulisine" ] ], [ [ "Glimepiride", "{u} (Compound) resembles {v} (Compound)", "Tolbutamide" ], [ "Tolbutamide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Insulin glulisine" ] ], [ [ "Glimepiride", "{u} may lead to a major life threatening interaction when taken with {v}", "Gatifloxacin" ], [ "Gatifloxacin", "{u} may lead to a major life threatening interaction when taken with {v}", "Insulin glulisine" ] ], [ [ "Glimepiride", "{u} may lead to a major life threatening interaction when taken with {v}", "Delafloxacin" ], [ "Delafloxacin", "{u} may lead to a major life threatening interaction when taken with {v}", "Insulin glulisine" ] ] ]
Glimepiride may cause a minor interaction that can limit clinical effects when taken with Lipoic acid and Lipoic acid may cause a minor interaction that can limit clinical effects when taken with Insulin glulisine Glimepiride may cause a minor interaction that can limit clinical effects when taken with Methylcellulose and Methylcellulose may cause a minor interaction that can limit clinical effects when taken with Insulin glulisine Glimepiride may cause a minor interaction that can limit clinical effects when taken with Amcinonide and Amcinonide may cause a minor interaction that can limit clinical effects when taken with Insulin glulisine Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Alpelisib and Alpelisib may cause a moderate interaction that could exacerbate diseases when taken with Insulin glulisine Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Quinine and Quinine may cause a moderate interaction that could exacerbate diseases when taken with Insulin glulisine Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Phentermine and Phentermine may cause a moderate interaction that could exacerbate diseases when taken with Insulin glulisine Glimepiride (Compound) resembles Tolbutamide (Compound) and Tolbutamide may cause a moderate interaction that could exacerbate diseases when taken with Insulin glulisine Glimepiride may lead to a major life threatening interaction when taken with Gatifloxacin and Gatifloxacin may lead to a major life threatening interaction when taken with Insulin glulisine Glimepiride may lead to a major life threatening interaction when taken with Delafloxacin and Delafloxacin may lead to a major life threatening interaction when taken with Insulin glulisine
DB00601
DB00983
453
480
[ "DDInter1073", "DDInter776" ]
Linezolid
Formoterol
Linezolid is a synthetic antibiotic which is used for the treatment of infections caused by aerobic Gram-positive bacteria. Its effects are bacteriostatic against both enterococci and staphylococci and bactericidal against most isolates of streptococci. Linezolid exerts its antibacterial activity by inhibiting the initiation of bacterial protein synthesis - more specifically, it binds to the 23S ribosomal RNA of the 50S subunit[A11227,A199050] and, in doing so, prevents the formation of the 70S initiation complex which is essential for bacterial reproduction. Linezolid was initially approved in 2000 and was the first member of the oxazolidinone antibiotic class. A second member of this class, [tedizolid], was approved by the FDA in 2014 and is considered generally more effective and tolerable than its predecessor.
Formoterol is an inhaled beta<sub>2</sub>-agonist used in the management of COPD and asthma that was first approved for use in the United States in 2001. It acts on bronchial smooth muscle to dilate and relax airways, and is administered as a racemic mixture of its active (R;R)- and inactive (S;S)-enantiomers. A major clinical advantage of formoterol over other inhaled beta-agonists is its rapid onset of action (2-3 minutes), which is at least as fast as [salbutamol], combined with a long duration of action (12 hours) - for this reason, treatment guidelines for asthma recommend its use as both a reliever and maintenance medication. It is available as a single-entity product [L10986,L11223] and in several formulations in combination with both inhaled corticosteroids [L10995,L10619] and long-acting muscarinic antagonists.[L10992,L10989]
Moderate
1
[ [ [ 453, 24, 480 ] ], [ [ 453, 24, 1148 ], [ 1148, 63, 480 ] ], [ [ 453, 21, 28719 ], [ 28719, 60, 480 ] ], [ [ 453, 25, 1053 ], [ 1053, 63, 480 ] ], [ [ 453, 24, 1674 ], [ 1674, 24, 480 ] ], [ [ 453, 64, 1636 ], [ 1636, 24, 480 ] ], [ [ 453, 25, 1133 ], [ 1133, 24, 480 ] ], [ [ 453, 63, 1555 ], [ 1555, 24, 480 ] ], [ [ 453, 37, 1090 ], [ 1090, 63, 480 ] ], [ [ 453, 25, 290 ], [ 290, 25, 480 ] ] ]
[ [ [ "Linezolid", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Formoterol" ] ], [ [ "Linezolid", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Isoprenaline" ], [ "Isoprenaline", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Formoterol" ] ], [ [ "Linezolid", "{u} (Compound) causes {v} (Side Effect)", "Pain" ], [ "Pain", "{u} (Side Effect) is caused by {v} (Compound)", "Formoterol" ] ], [ [ "Linezolid", "{u} may lead to a major life threatening interaction when taken with {v}", "Procarbazine" ], [ "Procarbazine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Formoterol" ] ], [ [ "Linezolid", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Orciprenaline" ], [ "Orciprenaline", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Formoterol" ] ], [ [ "Linezolid", "{u} may lead to a major life threatening interaction when taken with {v}", "Phenylephrine" ], [ "Phenylephrine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Formoterol" ] ], [ [ "Linezolid", "{u} may lead to a major life threatening interaction when taken with {v}", "Granisetron" ], [ "Granisetron", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Formoterol" ] ], [ [ "Linezolid", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Oxaliplatin" ], [ "Oxaliplatin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Formoterol" ] ], [ [ "Linezolid", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v} and {u} may lead to a major life threatening interaction when taken with {v}", "Tetryzoline" ], [ "Tetryzoline", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Formoterol" ] ], [ [ "Linezolid", "{u} may lead to a major life threatening interaction when taken with {v}", "Cocaine" ], [ "Cocaine", "{u} may lead to a major life threatening interaction when taken with {v}", "Formoterol" ] ] ]
Linezolid may cause a moderate interaction that could exacerbate diseases when taken with Isoprenaline and Isoprenaline may cause a moderate interaction that could exacerbate diseases when taken with Formoterol Linezolid (Compound) causes Pain (Side Effect) and Pain (Side Effect) is caused by Formoterol (Compound) Linezolid may lead to a major life threatening interaction when taken with Procarbazine and Procarbazine may cause a moderate interaction that could exacerbate diseases when taken with Formoterol Linezolid may cause a moderate interaction that could exacerbate diseases when taken with Orciprenaline and Orciprenaline may cause a moderate interaction that could exacerbate diseases when taken with Formoterol Linezolid may lead to a major life threatening interaction when taken with Phenylephrine and Phenylephrine may cause a moderate interaction that could exacerbate diseases when taken with Formoterol Linezolid may lead to a major life threatening interaction when taken with Granisetron and Granisetron may cause a moderate interaction that could exacerbate diseases when taken with Formoterol Linezolid may cause a moderate interaction that could exacerbate diseases when taken with Oxaliplatin and Oxaliplatin may cause a moderate interaction that could exacerbate diseases when taken with Formoterol Linezolid may cause a moderate interaction that could exacerbate diseases when taken with Tetryzoline and Linezolid may lead to a major life threatening interaction when taken with Tetryzoline and Tetryzoline may cause a moderate interaction that could exacerbate diseases when taken with Formoterol Linezolid may lead to a major life threatening interaction when taken with Cocaine and Cocaine may lead to a major life threatening interaction when taken with Formoterol
DB00033
DB09498
342
810
[ "DDInter949", "DDInter1715" ]
Interferon gamma-1b
Strontium chloride Sr-89
Human Interferon gamma-1b (140 residues), produced from E. coli. Production of Actimmune is achieved by fermentation of a genetically engineered Escherichia coli bacterium containing the DNA which encodes for the human protein. Purification of the product is achieved by conventional column chromatography. The sequence displayed is a cDNA sequence which codes for human interferon gamma, as described by Gray et. al. and not specifically interferon gamma 1b.
Strontium chloride (Sr-89), initially FDA-approved in 1993, is used as a paliative therapeutic option to help relieve the pain from bone metastases. Strontium chloride is mainly used in cases of metastatic castrate-resistant prostate cancer. Bone metastases is a common and severe complication presented in advanced stages of the disease. It is usually presented mainly in patients with prostatic and breast cancer, as well as in cancer of lung, bladder and thyroid. There has been some cases of apparent tumor regression which has given it a potential tumoricidal effect.
Moderate
1
[ [ [ 342, 24, 810 ] ], [ [ 342, 24, 597 ], [ 597, 24, 810 ] ], [ [ 342, 24, 738 ], [ 738, 63, 810 ] ], [ [ 342, 25, 976 ], [ 976, 24, 810 ] ], [ [ 342, 25, 1259 ], [ 1259, 63, 810 ] ], [ [ 342, 25, 1064 ], [ 1064, 25, 810 ] ], [ [ 342, 24, 597 ], [ 597, 63, 552 ], [ 552, 24, 810 ] ], [ [ 342, 25, 976 ], [ 976, 64, 552 ], [ 552, 24, 810 ] ], [ [ 342, 24, 599 ], [ 599, 24, 552 ], [ 552, 24, 810 ] ], [ [ 342, 25, 1101 ], [ 1101, 23, 597 ], [ 597, 24, 810 ] ] ]
[ [ [ "Interferon gamma-1b", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Strontium chloride Sr-89" ] ], [ [ "Interferon gamma-1b", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Chloramphenicol" ], [ "Chloramphenicol", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Strontium chloride Sr-89" ] ], [ [ "Interferon gamma-1b", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Niraparib" ], [ "Niraparib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Strontium chloride Sr-89" ] ], [ [ "Interferon gamma-1b", "{u} may lead to a major life threatening interaction when taken with {v}", "Tofacitinib" ], [ "Tofacitinib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Strontium chloride Sr-89" ] ], [ [ "Interferon gamma-1b", "{u} may lead to a major life threatening interaction when taken with {v}", "Baricitinib" ], [ "Baricitinib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Strontium chloride Sr-89" ] ], [ [ "Interferon gamma-1b", "{u} may lead to a major life threatening interaction when taken with {v}", "Cladribine" ], [ "Cladribine", "{u} may lead to a major life threatening interaction when taken with {v}", "Strontium chloride Sr-89" ] ], [ [ "Interferon gamma-1b", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Chloramphenicol" ], [ "Chloramphenicol", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Carmustine" ], [ "Carmustine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Strontium chloride Sr-89" ] ], [ [ "Interferon gamma-1b", "{u} may lead to a major life threatening interaction when taken with {v}", "Tofacitinib" ], [ "Tofacitinib", "{u} may lead to a major life threatening interaction when taken with {v}", "Carmustine" ], [ "Carmustine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Strontium chloride Sr-89" ] ], [ [ "Interferon gamma-1b", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Alemtuzumab" ], [ "Alemtuzumab", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Carmustine" ], [ "Carmustine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Strontium chloride Sr-89" ] ], [ [ "Interferon gamma-1b", "{u} may lead to a major life threatening interaction when taken with {v}", "Bexarotene" ], [ "Bexarotene", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Chloramphenicol" ], [ "Chloramphenicol", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Strontium chloride Sr-89" ] ] ]
Interferon gamma-1b may cause a moderate interaction that could exacerbate diseases when taken with Chloramphenicol and Chloramphenicol may cause a moderate interaction that could exacerbate diseases when taken with Strontium chloride Sr-89 Interferon gamma-1b may cause a moderate interaction that could exacerbate diseases when taken with Niraparib and Niraparib may cause a moderate interaction that could exacerbate diseases when taken with Strontium chloride Sr-89 Interferon gamma-1b may lead to a major life threatening interaction when taken with Tofacitinib and Tofacitinib may cause a moderate interaction that could exacerbate diseases when taken with Strontium chloride Sr-89 Interferon gamma-1b may lead to a major life threatening interaction when taken with Baricitinib and Baricitinib may cause a moderate interaction that could exacerbate diseases when taken with Strontium chloride Sr-89 Interferon gamma-1b may lead to a major life threatening interaction when taken with Cladribine and Cladribine may lead to a major life threatening interaction when taken with Strontium chloride Sr-89 Interferon gamma-1b may cause a moderate interaction that could exacerbate diseases when taken with Chloramphenicol and Chloramphenicol may cause a moderate interaction that could exacerbate diseases when taken with Carmustine and Carmustine may cause a moderate interaction that could exacerbate diseases when taken with Strontium chloride Sr-89 Interferon gamma-1b may lead to a major life threatening interaction when taken with Tofacitinib and Tofacitinib may lead to a major life threatening interaction when taken with Carmustine and Carmustine may cause a moderate interaction that could exacerbate diseases when taken with Strontium chloride Sr-89 Interferon gamma-1b may cause a moderate interaction that could exacerbate diseases when taken with Alemtuzumab and Alemtuzumab may cause a moderate interaction that could exacerbate diseases when taken with Carmustine and Carmustine may cause a moderate interaction that could exacerbate diseases when taken with Strontium chloride Sr-89 Interferon gamma-1b may lead to a major life threatening interaction when taken with Bexarotene and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Chloramphenicol and Chloramphenicol may cause a moderate interaction that could exacerbate diseases when taken with Strontium chloride Sr-89
DB00022
DB00439
268
289
[ "DDInter1408", "DDInter341" ]
Peginterferon alfa-2b
Cerivastatin
Peginterferon alfa-2b is a form of recombinant interferon used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). HCV is a single-stranded RNA virus that is categorized into nine distinct genotypes, with genotype 1 being the most common in the United States, and affecting 72% of all chronic HCV patients. Treatment options for chronic Hepatitis C have advanced significantly since 2011, with the development of Direct Acting Antivirals (DAAs) resulting in less use of Peginterferon alfa-2b. Peginterferon alfa-2b is derived from the alfa-2b moeity of recombinant human interferon and acts by binding to human type 1 interferon receptors. Activation and dimerization of this receptor induces the body's innate antiviral response by activating the janus kinase
On August 8, 2001 the U.S. Food and Drug Administration (FDA) announced that Bayer Pharmaceutical Division voluntarily withdrew Baycol from the U.S. market, due to reports of fatal rhabdomyolysis, a severe adverse reaction from this cholesterol-lowering (lipid-lowering) product. It has also been withdrawn from the Canadian market.[A669,L43942]
Moderate
1
[ [ [ 268, 24, 289 ] ], [ [ 268, 24, 1560 ], [ 1560, 24, 289 ] ], [ [ 268, 24, 384 ], [ 384, 63, 289 ] ], [ [ 268, 25, 72 ], [ 72, 63, 289 ] ], [ [ 268, 63, 491 ], [ 491, 24, 289 ] ], [ [ 268, 25, 1377 ], [ 1377, 64, 289 ] ], [ [ 268, 24, 1560 ], [ 1560, 24, 384 ], [ 384, 63, 289 ] ], [ [ 268, 24, 384 ], [ 384, 64, 1491 ], [ 1491, 63, 289 ] ], [ [ 268, 25, 72 ], [ 72, 24, 1491 ], [ 1491, 63, 289 ] ], [ [ 268, 24, 1434 ], [ 1434, 63, 1555 ], [ 1555, 63, 289 ] ] ]
[ [ [ "Peginterferon alfa-2b", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Cerivastatin" ] ], [ [ "Peginterferon alfa-2b", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Pegaspargase" ], [ "Pegaspargase", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Cerivastatin" ] ], [ [ "Peginterferon alfa-2b", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Idelalisib" ], [ "Idelalisib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Cerivastatin" ] ], [ [ "Peginterferon alfa-2b", "{u} may lead to a major life threatening interaction when taken with {v}", "Eltrombopag" ], [ "Eltrombopag", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Cerivastatin" ] ], [ [ "Peginterferon alfa-2b", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Peginterferon alfa-2a" ], [ "Peginterferon alfa-2a", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Cerivastatin" ] ], [ [ "Peginterferon alfa-2b", "{u} may lead to a major life threatening interaction when taken with {v}", "Leflunomide" ], [ "Leflunomide", "{u} may lead to a major life threatening interaction when taken with {v}", "Cerivastatin" ] ], [ [ "Peginterferon alfa-2b", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Pegaspargase" ], [ "Pegaspargase", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Idelalisib" ], [ "Idelalisib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Cerivastatin" ] ], [ [ "Peginterferon alfa-2b", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Idelalisib" ], [ "Idelalisib", "{u} may lead to a major life threatening interaction when taken with {v}", "Midostaurin" ], [ "Midostaurin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Cerivastatin" ] ], [ [ "Peginterferon alfa-2b", "{u} may lead to a major life threatening interaction when taken with {v}", "Eltrombopag" ], [ "Eltrombopag", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Midostaurin" ], [ "Midostaurin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Cerivastatin" ] ], [ [ "Peginterferon alfa-2b", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Benznidazole" ], [ "Benznidazole", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Oxaliplatin" ], [ "Oxaliplatin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Cerivastatin" ] ] ]
Peginterferon alfa-2b may cause a moderate interaction that could exacerbate diseases when taken with Pegaspargase and Pegaspargase may cause a moderate interaction that could exacerbate diseases when taken with Cerivastatin Peginterferon alfa-2b may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib and Idelalisib may cause a moderate interaction that could exacerbate diseases when taken with Cerivastatin Peginterferon alfa-2b may lead to a major life threatening interaction when taken with Eltrombopag and Eltrombopag may cause a moderate interaction that could exacerbate diseases when taken with Cerivastatin Peginterferon alfa-2b may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon alfa-2a and Peginterferon alfa-2a may cause a moderate interaction that could exacerbate diseases when taken with Cerivastatin Peginterferon alfa-2b may lead to a major life threatening interaction when taken with Leflunomide and Leflunomide may lead to a major life threatening interaction when taken with Cerivastatin Peginterferon alfa-2b may cause a moderate interaction that could exacerbate diseases when taken with Pegaspargase and Pegaspargase may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib and Idelalisib may cause a moderate interaction that could exacerbate diseases when taken with Cerivastatin Peginterferon alfa-2b may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib and Idelalisib may lead to a major life threatening interaction when taken with Midostaurin and Midostaurin may cause a moderate interaction that could exacerbate diseases when taken with Cerivastatin Peginterferon alfa-2b may lead to a major life threatening interaction when taken with Eltrombopag and Eltrombopag may cause a moderate interaction that could exacerbate diseases when taken with Midostaurin and Midostaurin may cause a moderate interaction that could exacerbate diseases when taken with Cerivastatin Peginterferon alfa-2b may cause a moderate interaction that could exacerbate diseases when taken with Benznidazole and Benznidazole may cause a moderate interaction that could exacerbate diseases when taken with Oxaliplatin and Oxaliplatin may cause a moderate interaction that could exacerbate diseases when taken with Cerivastatin
DB00910
DB01263
1,041
859
[ "DDInter1394", "DDInter1494" ]
Paricalcitol
Posaconazole
Paricalcitol is a synthetic vitamin D analog. Paricalcitol has been used to reduce parathyroid hormone levels. Paricalcitol is indicated for the prevention and treatment of secondary hyperparathyroidism associated with chronic renal failure.
Posaconazole is a triazole antifungal drug that is used to treat invasive infections by Candida species and Aspergillus species in severely immunocompromised patients.
Moderate
1
[ [ [ 1041, 24, 859 ] ], [ [ 1041, 6, 8374 ], [ 8374, 45, 859 ] ], [ [ 1041, 21, 28762 ], [ 28762, 60, 859 ] ], [ [ 1041, 24, 286 ], [ 286, 63, 859 ] ], [ [ 1041, 24, 609 ], [ 609, 24, 859 ] ], [ [ 1041, 24, 1017 ], [ 1017, 64, 859 ] ], [ [ 1041, 6, 8374 ], [ 8374, 45, 981 ], [ 981, 1, 859 ] ], [ [ 1041, 21, 28762 ], [ 28762, 60, 981 ], [ 981, 1, 859 ] ], [ [ 1041, 21, 29279 ], [ 29279, 60, 112 ], [ 112, 23, 859 ] ], [ [ 1041, 21, 29758 ], [ 29758, 60, 267 ], [ 267, 24, 859 ] ] ]
[ [ [ "Paricalcitol", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Posaconazole" ] ], [ [ "Paricalcitol", "{u} (Compound) binds {v} (Gene)", "CYP3A4" ], [ "CYP3A4", "{u} (Gene) is bound by {v} (Compound)", "Posaconazole" ] ], [ [ "Paricalcitol", "{u} (Compound) causes {v} (Side Effect)", "Headache" ], [ "Headache", "{u} (Side Effect) is caused by {v} (Compound)", "Posaconazole" ] ], [ [ "Paricalcitol", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Magnesium hydroxide" ], [ "Magnesium hydroxide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Posaconazole" ] ], [ [ "Paricalcitol", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Clarithromycin" ], [ "Clarithromycin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Posaconazole" ] ], [ [ "Paricalcitol", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Lorlatinib" ], [ "Lorlatinib", "{u} may lead to a major life threatening interaction when taken with {v}", "Posaconazole" ] ], [ [ "Paricalcitol", "{u} (Compound) binds {v} (Gene)", "CYP3A4" ], [ "CYP3A4", "{u} (Gene) is bound by {v} (Compound)", "Itraconazole" ], [ "Itraconazole", "{u} (Compound) resembles {v} (Compound)", "Posaconazole" ] ], [ [ "Paricalcitol", "{u} (Compound) causes {v} (Side Effect)", "Headache" ], [ "Headache", "{u} (Side Effect) is caused by {v} (Compound)", "Itraconazole" ], [ "Itraconazole", "{u} (Compound) resembles {v} (Compound)", "Posaconazole" ] ], [ [ "Paricalcitol", "{u} (Compound) causes {v} (Side Effect)", "Eructation" ], [ "Eructation", "{u} (Side Effect) is caused by {v} (Compound)", "Metronidazole" ], [ "Metronidazole", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Posaconazole" ] ], [ [ "Paricalcitol", "{u} (Compound) causes {v} (Side Effect)", "Night sweats" ], [ "Night sweats", "{u} (Side Effect) is caused by {v} (Compound)", "Naltrexone" ], [ "Naltrexone", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Posaconazole" ] ] ]
Paricalcitol (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Posaconazole (Compound) Paricalcitol (Compound) causes Headache (Side Effect) and Headache (Side Effect) is caused by Posaconazole (Compound) Paricalcitol may cause a moderate interaction that could exacerbate diseases when taken with Magnesium hydroxide and Magnesium hydroxide may cause a moderate interaction that could exacerbate diseases when taken with Posaconazole Paricalcitol may cause a moderate interaction that could exacerbate diseases when taken with Clarithromycin and Clarithromycin may cause a moderate interaction that could exacerbate diseases when taken with Posaconazole Paricalcitol may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib and Lorlatinib may lead to a major life threatening interaction when taken with Posaconazole Paricalcitol (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Itraconazole (Compound) and Itraconazole (Compound) resembles Posaconazole (Compound) Paricalcitol (Compound) causes Headache (Side Effect) and Headache (Side Effect) is caused by Itraconazole (Compound) and Itraconazole (Compound) resembles Posaconazole (Compound) Paricalcitol (Compound) causes Eructation (Side Effect) and Eructation (Side Effect) is caused by Metronidazole (Compound) and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Posaconazole Paricalcitol (Compound) causes Night sweats (Side Effect) and Night sweats (Side Effect) is caused by Naltrexone (Compound) and Naltrexone may cause a moderate interaction that could exacerbate diseases when taken with Posaconazole
DB00598
DB08895
1,523
976
[ "DDInter1013", "DDInter1825" ]
Labetalol
Tofacitinib
Labetalol is a racemic mixture of 2 diastereoisomers where dilevalol, the R,R' stereoisomer, makes up 25% of the mixture. Labetalol is formulated as an injection or tablets to treat hypertension.[L7727,L7730] Labetalol was granted FDA approval on 1 August 1984.
Tofacitinib is an inhibitor of Janus kinases, a group of intracellular enzymes involved in signalling pathways that affect hematopoiesis and immune cell function. It is approved by the FDA for treatment of moderate to severe rheumatoid arthritis that responds inadequately to methotrexate or in those who are intolerant to methotrexate. Besides rheumatoid arthritis, tofacitinib has also been studied in clinical trials for the prevention of organ transplant rejection, and is currently under investigation for the treatment of psoriasis. Known adverse effects include nausea and headache as well as more serious immunologic and hematological adverse effects. Tofacitinib is marketed under the brand name Xeljanz by Pfizer.
Moderate
1
[ [ [ 1523, 24, 976 ] ], [ [ 1523, 24, 407 ], [ 407, 63, 976 ] ], [ [ 1523, 63, 475 ], [ 475, 24, 976 ] ], [ [ 1523, 23, 1479 ], [ 1479, 24, 976 ] ], [ [ 1523, 40, 935 ], [ 935, 24, 976 ] ], [ [ 1523, 24, 1274 ], [ 1274, 24, 976 ] ], [ [ 1523, 25, 1011 ], [ 1011, 25, 976 ] ], [ [ 1523, 24, 175 ], [ 175, 25, 976 ] ], [ [ 1523, 63, 1648 ], [ 1648, 25, 976 ] ], [ [ 1523, 24, 1476 ], [ 1476, 64, 976 ] ] ]
[ [ [ "Labetalol", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Tofacitinib" ] ], [ [ "Labetalol", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Opium" ], [ "Opium", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Tofacitinib" ] ], [ [ "Labetalol", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Morphine" ], [ "Morphine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Tofacitinib" ] ], [ [ "Labetalol", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Acetylsalicylic acid" ], [ "Acetylsalicylic acid", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Tofacitinib" ] ], [ [ "Labetalol", "{u} (Compound) resembles {v} (Compound)", "Ketoprofen" ], [ "Ketoprofen", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Tofacitinib" ] ], [ [ "Labetalol", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Flurbiprofen" ], [ "Flurbiprofen", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Tofacitinib" ] ], [ [ "Labetalol", "{u} may lead to a major life threatening interaction when taken with {v}", "Fingolimod" ], [ "Fingolimod", "{u} may lead to a major life threatening interaction when taken with {v}", "Tofacitinib" ] ], [ [ "Labetalol", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Triamcinolone" ], [ "Triamcinolone", "{u} may lead to a major life threatening interaction when taken with {v}", "Tofacitinib" ] ], [ [ "Labetalol", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Aldesleukin" ], [ "Aldesleukin", "{u} may lead to a major life threatening interaction when taken with {v}", "Tofacitinib" ] ], [ [ "Labetalol", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Brigatinib" ], [ "Brigatinib", "{u} may lead to a major life threatening interaction when taken with {v}", "Tofacitinib" ] ] ]
Labetalol may cause a moderate interaction that could exacerbate diseases when taken with Opium and Opium may cause a moderate interaction that could exacerbate diseases when taken with Tofacitinib Labetalol may cause a moderate interaction that could exacerbate diseases when taken with Morphine and Morphine may cause a moderate interaction that could exacerbate diseases when taken with Tofacitinib Labetalol may cause a minor interaction that can limit clinical effects when taken with Acetylsalicylic acid and Acetylsalicylic acid may cause a moderate interaction that could exacerbate diseases when taken with Tofacitinib Labetalol (Compound) resembles Ketoprofen (Compound) and Ketoprofen may cause a moderate interaction that could exacerbate diseases when taken with Tofacitinib Labetalol may cause a moderate interaction that could exacerbate diseases when taken with Flurbiprofen and Flurbiprofen may cause a moderate interaction that could exacerbate diseases when taken with Tofacitinib Labetalol may lead to a major life threatening interaction when taken with Fingolimod and Fingolimod may lead to a major life threatening interaction when taken with Tofacitinib Labetalol may cause a moderate interaction that could exacerbate diseases when taken with Triamcinolone and Triamcinolone may lead to a major life threatening interaction when taken with Tofacitinib Labetalol may cause a moderate interaction that could exacerbate diseases when taken with Aldesleukin and Aldesleukin may lead to a major life threatening interaction when taken with Tofacitinib Labetalol may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib and Brigatinib may lead to a major life threatening interaction when taken with Tofacitinib
DB00413
DB00835
1,346
100
[ "DDInter1505", "DDInter245" ]
Pramipexole
Brompheniramine
Pramipexole is a drug used to treat the symptoms of Parkinson's Disease (PD). It is a _non-ergot dopamine agonist_ drug that is efficacious in treating various Parkinson's symptoms such as tremor, rigidity, and bradykinesia (slow movement). It was first approved by the FDA in 1997. Parkinson's Disease is one of the most common neurodegenerative disorders and causes a high level of disability in patients, leading to increased difficulty in performing activities of daily living due to symptoms that progress over time. The prevalence of Parkinson's Disease worldwide has increased from approximately 2.5 million in 1990 to about 6.1 million in 2016. This increase may be attributed to an aging population along with other contributing factors. In addition to the above FDA approval for Parkinson's Disease, pramipexole was also approved by the FDA in 2006 for the treatment of Restless Legs Syndrome (
Histamine H1 antagonist used in treatment of allergies, rhinitis, and urticaria.
Moderate
1
[ [ [ 1346, 24, 100 ] ], [ [ 1346, 24, 832 ], [ 832, 24, 100 ] ], [ [ 1346, 63, 128 ], [ 128, 24, 100 ] ], [ [ 1346, 24, 649 ], [ 649, 63, 100 ] ], [ [ 1346, 24, 662 ], [ 662, 35, 100 ] ], [ [ 1346, 24, 1376 ], [ 1376, 74, 100 ] ], [ [ 1346, 24, 832 ], [ 832, 40, 508 ], [ 508, 24, 100 ] ], [ [ 1346, 63, 128 ], [ 128, 24, 832 ], [ 832, 24, 100 ] ], [ [ 1346, 24, 649 ], [ 649, 1, 832 ], [ 832, 24, 100 ] ], [ [ 1346, 24, 1311 ], [ 1311, 63, 832 ], [ 832, 24, 100 ] ] ]
[ [ [ "Pramipexole", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Brompheniramine" ] ], [ [ "Pramipexole", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Tripelennamine" ], [ "Tripelennamine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Brompheniramine" ] ], [ [ "Pramipexole", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Dexbrompheniramine" ], [ "Dexbrompheniramine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Brompheniramine" ] ], [ [ "Pramipexole", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Clofedanol" ], [ "Clofedanol", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Brompheniramine" ] ], [ [ "Pramipexole", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Carbinoxamine" ], [ "Carbinoxamine", "{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Brompheniramine" ] ], [ [ "Pramipexole", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Diphenhydramine" ], [ "Diphenhydramine", "{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Brompheniramine" ] ], [ [ "Pramipexole", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Tripelennamine" ], [ "Tripelennamine", "{u} (Compound) resembles {v} (Compound)", "Promazine" ], [ "Promazine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Brompheniramine" ] ], [ [ "Pramipexole", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Dexbrompheniramine" ], [ "Dexbrompheniramine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Tripelennamine" ], [ "Tripelennamine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Brompheniramine" ] ], [ [ "Pramipexole", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Clofedanol" ], [ "Clofedanol", "{u} (Compound) resembles {v} (Compound)", "Tripelennamine" ], [ "Tripelennamine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Brompheniramine" ] ], [ [ "Pramipexole", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Metoclopramide" ], [ "Metoclopramide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Tripelennamine" ], [ "Tripelennamine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Brompheniramine" ] ] ]
Pramipexole may cause a moderate interaction that could exacerbate diseases when taken with Tripelennamine and Tripelennamine may cause a moderate interaction that could exacerbate diseases when taken with Brompheniramine Pramipexole may cause a moderate interaction that could exacerbate diseases when taken with Dexbrompheniramine and Dexbrompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Brompheniramine Pramipexole may cause a moderate interaction that could exacerbate diseases when taken with Clofedanol and Clofedanol may cause a moderate interaction that could exacerbate diseases when taken with Brompheniramine Pramipexole may cause a moderate interaction that could exacerbate diseases when taken with Carbinoxamine and Carbinoxamine (Compound) resembles Brompheniramine (Compound) and Carbinoxamine may cause a moderate interaction that could exacerbate diseases when taken with Brompheniramine Pramipexole may cause a moderate interaction that could exacerbate diseases when taken with Diphenhydramine and Diphenhydramine (Compound) resembles Brompheniramine (Compound) and Diphenhydramine may cause a moderate interaction that could exacerbate diseases when taken with Brompheniramine Pramipexole may cause a moderate interaction that could exacerbate diseases when taken with Tripelennamine and Tripelennamine (Compound) resembles Promazine (Compound) and Promazine may cause a moderate interaction that could exacerbate diseases when taken with Brompheniramine Pramipexole may cause a moderate interaction that could exacerbate diseases when taken with Dexbrompheniramine and Dexbrompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Tripelennamine and Tripelennamine may cause a moderate interaction that could exacerbate diseases when taken with Brompheniramine Pramipexole may cause a moderate interaction that could exacerbate diseases when taken with Clofedanol and Clofedanol (Compound) resembles Tripelennamine (Compound) and Tripelennamine may cause a moderate interaction that could exacerbate diseases when taken with Brompheniramine Pramipexole may cause a moderate interaction that could exacerbate diseases when taken with Metoclopramide and Metoclopramide may cause a moderate interaction that could exacerbate diseases when taken with Tripelennamine and Tripelennamine may cause a moderate interaction that could exacerbate diseases when taken with Brompheniramine
DB00357
DB00717
1,051
1,197
[ "DDInter71", "DDInter1312" ]
Aminoglutethimide
Norethisterone
An aromatase inhibitor that produces a state of "medical" adrenalectomy by blocking the production of adrenal steroids. It also blocks the conversion of androgens to estrogens. Aminoglutethimide has been used in the treatment of advanced breast and prostate cancer. It was formerly used for its weak anticonvulsant properties. (From Martindale, The Extra Pharmacopoeia, 30th ed, p454)
Norethisterone, also known as norethindrone, is a synthetic progestational hormone belonging to the 19-nortestosterone-derived class of progestins. It is further classified as a second-generation progestin, along with [levonorgestrel] and its derivatives, and is the active form of several other progestins including [norethynodrel] and [lynestrenol]. Norethisterone mimics the actions of endogenous [progesterone], albeit with a greater potency, and is used on its own or in combination with estrogen derivatives in a variety of applications including contraception and hormone replacement therapy.[L9527,L10301,L10304,L10307] First derived in 1951 in Mexico City, norethisterone was originally intended for use as a remedy for irregular menstruation and endometriosis, and was not marketed for use as an oral contraceptive until 1962.
Moderate
1
[ [ [ 1051, 24, 1197 ] ], [ [ 1051, 24, 989 ], [ 989, 1, 1197 ] ], [ [ 1051, 24, 566 ], [ 566, 40, 1197 ] ], [ [ 1051, 63, 1336 ], [ 1336, 40, 1197 ] ], [ [ 1051, 6, 10215 ], [ 10215, 45, 1197 ] ], [ [ 1051, 18, 5795 ], [ 5795, 57, 1197 ] ], [ [ 1051, 21, 29232 ], [ 29232, 60, 1197 ] ], [ [ 1051, 23, 1130 ], [ 1130, 62, 1197 ] ], [ [ 1051, 24, 484 ], [ 484, 63, 1197 ] ], [ [ 1051, 62, 245 ], [ 245, 24, 1197 ] ] ]
[ [ [ "Aminoglutethimide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Norethisterone" ] ], [ [ "Aminoglutethimide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Progesterone" ], [ "Progesterone", "{u} (Compound) resembles {v} (Compound)", "Norethisterone" ] ], [ [ "Aminoglutethimide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Levonorgestrel" ], [ "Levonorgestrel", "{u} (Compound) resembles {v} (Compound)", "Norethisterone" ] ], [ [ "Aminoglutethimide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Etonogestrel" ], [ "Etonogestrel", "{u} (Compound) resembles {v} (Compound)", "Norethisterone" ] ], [ [ "Aminoglutethimide", "{u} (Compound) binds {v} (Gene)", "CYP2C19" ], [ "CYP2C19", "{u} (Gene) is bound by {v} (Compound)", "Norethisterone" ] ], [ [ "Aminoglutethimide", "{u} (Compound) downregulates {v} (Gene)", "PSMB8" ], [ "PSMB8", "{u} (Gene) is downregulated by {v} (Compound)", "Norethisterone" ] ], [ [ "Aminoglutethimide", "{u} (Compound) causes {v} (Side Effect)", "Urticaria" ], [ "Urticaria", "{u} (Side Effect) is caused by {v} (Compound)", "Norethisterone" ] ], [ [ "Aminoglutethimide", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Pioglitazone" ], [ "Pioglitazone", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Norethisterone" ] ], [ [ "Aminoglutethimide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Entrectinib" ], [ "Entrectinib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Norethisterone" ] ], [ [ "Aminoglutethimide", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Glimepiride" ], [ "Glimepiride", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Norethisterone" ] ] ]
Aminoglutethimide may cause a moderate interaction that could exacerbate diseases when taken with Progesterone and Progesterone (Compound) resembles Norethisterone (Compound) Aminoglutethimide may cause a moderate interaction that could exacerbate diseases when taken with Levonorgestrel and Levonorgestrel (Compound) resembles Norethisterone (Compound) Aminoglutethimide may cause a moderate interaction that could exacerbate diseases when taken with Etonogestrel and Etonogestrel (Compound) resembles Norethisterone (Compound) Aminoglutethimide (Compound) binds CYP2C19 (Gene) and CYP2C19 (Gene) is bound by Norethisterone (Compound) Aminoglutethimide (Compound) downregulates PSMB8 (Gene) and PSMB8 (Gene) is downregulated by Norethisterone (Compound) Aminoglutethimide (Compound) causes Urticaria (Side Effect) and Urticaria (Side Effect) is caused by Norethisterone (Compound) Aminoglutethimide may cause a minor interaction that can limit clinical effects when taken with Pioglitazone and Pioglitazone may cause a minor interaction that can limit clinical effects when taken with Norethisterone Aminoglutethimide may cause a moderate interaction that could exacerbate diseases when taken with Entrectinib and Entrectinib may cause a moderate interaction that could exacerbate diseases when taken with Norethisterone Aminoglutethimide may cause a minor interaction that can limit clinical effects when taken with Glimepiride and Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Norethisterone
DB00959
DB09098
1,486
98
[ "DDInter1191", "DDInter1700" ]
Methylprednisolone
Somatrem
Methylprednisolone is a [prednisolone] derivative glucocorticoid with higher potency than [prednisone]. It was first described in the literature in the late 1950s.[A188811,A188814] Methylprednisolone was granted FDA approval on 24 October 1957. In the outbreak of COVID-19, low dose methylprednisolone-based therapy was successful in treating COVID-19-associated pneumonia in one patient with long-term immunosuppression. The efficacy of methylprednisolone in novel coronavirus pneumonia is being investigated further in clinical trials.
Despite the ability of almost all contemporary recombinant growth hormones to cause definite and demonstrable increases in growth rate in patients who are administered the drug, the use of these agents continues to be mired in persistent bioethical debate . Such discussion revolves around whether patients' natural disposition of short stature should be considered a medical condition justifying medical treatment with such hormone therapy - especially when these hormone agents have been proven effective at increasing the height of children with or without growth hormone deficiency .
Moderate
1
[ [ [ 1486, 24, 98 ] ], [ [ 1486, 24, 336 ], [ 336, 24, 98 ] ], [ [ 1486, 24, 159 ], [ 159, 63, 98 ] ], [ [ 1486, 40, 1573 ], [ 1573, 24, 98 ] ], [ [ 1486, 25, 609 ], [ 609, 24, 98 ] ], [ [ 1486, 63, 1433 ], [ 1433, 24, 98 ] ], [ [ 1486, 62, 455 ], [ 455, 24, 98 ] ], [ [ 1486, 1, 175 ], [ 175, 24, 98 ] ], [ [ 1486, 64, 1091 ], [ 1091, 24, 98 ] ], [ [ 1486, 25, 1155 ], [ 1155, 63, 98 ] ] ]
[ [ [ "Methylprednisolone", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Somatrem" ] ], [ [ "Methylprednisolone", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Nifedipine" ], [ "Nifedipine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Somatrem" ] ], [ [ "Methylprednisolone", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Larotrectinib" ], [ "Larotrectinib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Somatrem" ] ], [ [ "Methylprednisolone", "{u} (Compound) resembles {v} (Compound)", "Prednisone" ], [ "Prednisone", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Somatrem" ] ], [ [ "Methylprednisolone", "{u} may lead to a major life threatening interaction when taken with {v}", "Clarithromycin" ], [ "Clarithromycin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Somatrem" ] ], [ [ "Methylprednisolone", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Doxazosin" ], [ "Doxazosin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Somatrem" ] ], [ [ "Methylprednisolone", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Salmeterol" ], [ "Salmeterol", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Somatrem" ] ], [ [ "Methylprednisolone", "{u} (Compound) resembles {v} (Compound)", "Triamcinolone" ], [ "Triamcinolone", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Somatrem" ] ], [ [ "Methylprednisolone", "{u} may lead to a major life threatening interaction when taken with {v}", "Amprenavir" ], [ "Amprenavir", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Somatrem" ] ], [ [ "Methylprednisolone", "{u} may lead to a major life threatening interaction when taken with {v}", "Tucatinib" ], [ "Tucatinib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Somatrem" ] ] ]
Methylprednisolone may cause a moderate interaction that could exacerbate diseases when taken with Nifedipine and Nifedipine may cause a moderate interaction that could exacerbate diseases when taken with Somatrem Methylprednisolone may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib and Larotrectinib may cause a moderate interaction that could exacerbate diseases when taken with Somatrem Methylprednisolone (Compound) resembles Prednisone (Compound) and Prednisone may cause a moderate interaction that could exacerbate diseases when taken with Somatrem Methylprednisolone may lead to a major life threatening interaction when taken with Clarithromycin and Clarithromycin may cause a moderate interaction that could exacerbate diseases when taken with Somatrem Methylprednisolone may cause a moderate interaction that could exacerbate diseases when taken with Doxazosin and Doxazosin may cause a moderate interaction that could exacerbate diseases when taken with Somatrem Methylprednisolone may cause a minor interaction that can limit clinical effects when taken with Salmeterol and Salmeterol may cause a moderate interaction that could exacerbate diseases when taken with Somatrem Methylprednisolone (Compound) resembles Triamcinolone (Compound) and Triamcinolone may cause a moderate interaction that could exacerbate diseases when taken with Somatrem Methylprednisolone may lead to a major life threatening interaction when taken with Amprenavir and Amprenavir may cause a moderate interaction that could exacerbate diseases when taken with Somatrem Methylprednisolone may lead to a major life threatening interaction when taken with Tucatinib and Tucatinib may cause a moderate interaction that could exacerbate diseases when taken with Somatrem
DB00771
DB09128
262
1,241
[ "DDInter397", "DDInter231" ]
Clidinium
Brexpiprazole
Clidinium is a synthetic anticholinergic agent which has been shown in experimental and clinical studies to have a pronounced antispasmodic and antisecretory effect on the gastrointestinal tract. It inhibits muscarinic actions of acetylcholine at postganglionic parasympathetic neuroeffector sites. It is used for the treatment of peptic ulcer disease and also to help relieve abdominal or stomach spasms or cramps due to colicky abdominal pain, diverticulitis, and irritable bowel syndrome.
Brexpiprazole is an atypical antipsychotic and a novel D2 dopamine and serotonin 1A partial agonist called serotonin-dopamine activity modulator (SDAM). It has a high affinity for serotonin, dopamine and alpha (α)-adrenergic receptors. Although it is structurally similar to [aripiprazole], brexpiprazole has different binding affinities for dopamine and serotonin receptors. Compared to aripiprazole, brexpiprazole has less potential for partial agonist-mediated adverse effects such as extrapyramidal symptoms, which is attributed to lower intrinsic activity at the D2 receptor. It also displays stronger antagonism at the 5-HT1A and 5-HT2A receptors.[A182186, A38385, A259661] Brexpiprazole was first approved by the FDA on July 10, 2015. Currently approved for the treatment of depression, schizophrenia, and agitation associated with dementia due to Alzheimer’s disease, brexpiprazole has also been investigated in other psychiatric disorders, such as post-traumatic stress disorder.
Moderate
1
[ [ [ 262, 24, 1241 ] ], [ [ 262, 24, 407 ], [ 407, 63, 1241 ] ], [ [ 262, 24, 543 ], [ 543, 24, 1241 ] ], [ [ 262, 63, 1233 ], [ 1233, 24, 1241 ] ], [ [ 262, 74, 352 ], [ 352, 24, 1241 ] ], [ [ 262, 24, 1376 ], [ 1376, 25, 1241 ] ], [ [ 262, 63, 475 ], [ 475, 25, 1241 ] ], [ [ 262, 24, 407 ], [ 407, 63, 543 ], [ 543, 24, 1241 ] ], [ [ 262, 24, 543 ], [ 543, 24, 129 ], [ 129, 24, 1241 ] ], [ [ 262, 24, 832 ], [ 832, 24, 407 ], [ 407, 63, 1241 ] ] ]
[ [ [ "Clidinium", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Brexpiprazole" ] ], [ [ "Clidinium", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Opium" ], [ "Opium", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Brexpiprazole" ] ], [ [ "Clidinium", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Loperamide" ], [ "Loperamide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Brexpiprazole" ] ], [ [ "Clidinium", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Triprolidine" ], [ "Triprolidine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Brexpiprazole" ] ], [ [ "Clidinium", "{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Trospium" ], [ "Trospium", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Brexpiprazole" ] ], [ [ "Clidinium", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Diphenhydramine" ], [ "Diphenhydramine", "{u} may lead to a major life threatening interaction when taken with {v}", "Brexpiprazole" ] ], [ [ "Clidinium", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Morphine" ], [ "Morphine", "{u} may lead to a major life threatening interaction when taken with {v}", "Brexpiprazole" ] ], [ [ "Clidinium", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Opium" ], [ "Opium", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Loperamide" ], [ "Loperamide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Brexpiprazole" ] ], [ [ "Clidinium", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Loperamide" ], [ "Loperamide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Enzalutamide" ], [ "Enzalutamide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Brexpiprazole" ] ], [ [ "Clidinium", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Tripelennamine" ], [ "Tripelennamine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Opium" ], [ "Opium", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Brexpiprazole" ] ] ]
Clidinium may cause a moderate interaction that could exacerbate diseases when taken with Opium and Opium may cause a moderate interaction that could exacerbate diseases when taken with Brexpiprazole Clidinium may cause a moderate interaction that could exacerbate diseases when taken with Loperamide and Loperamide may cause a moderate interaction that could exacerbate diseases when taken with Brexpiprazole Clidinium may cause a moderate interaction that could exacerbate diseases when taken with Triprolidine and Triprolidine may cause a moderate interaction that could exacerbate diseases when taken with Brexpiprazole Clidinium (Compound) resembles Trospium (Compound) and Clidinium may cause a moderate interaction that could exacerbate diseases when taken with Trospium and Trospium may cause a moderate interaction that could exacerbate diseases when taken with Brexpiprazole Clidinium may cause a moderate interaction that could exacerbate diseases when taken with Diphenhydramine and Diphenhydramine may lead to a major life threatening interaction when taken with Brexpiprazole Clidinium may cause a moderate interaction that could exacerbate diseases when taken with Morphine and Morphine may lead to a major life threatening interaction when taken with Brexpiprazole Clidinium may cause a moderate interaction that could exacerbate diseases when taken with Opium and Opium may cause a moderate interaction that could exacerbate diseases when taken with Loperamide and Loperamide may cause a moderate interaction that could exacerbate diseases when taken with Brexpiprazole Clidinium may cause a moderate interaction that could exacerbate diseases when taken with Loperamide and Loperamide may cause a moderate interaction that could exacerbate diseases when taken with Enzalutamide and Enzalutamide may cause a moderate interaction that could exacerbate diseases when taken with Brexpiprazole Clidinium may cause a moderate interaction that could exacerbate diseases when taken with Tripelennamine and Tripelennamine may cause a moderate interaction that could exacerbate diseases when taken with Opium and Opium may cause a moderate interaction that could exacerbate diseases when taken with Brexpiprazole
DB00420
DB01612
508
1,637
[ "DDInter1532", "DDInter92" ]
Promazine
Amyl Nitrite
A phenothiazine with actions similar to chlorpromazine but with less antipsychotic activity. It is primarily used in short-term treatment of disturbed behavior and as an antiemetic. It is currently not approved for use in the United States.
Amyl Nitrite is an antihypertensive medicine. Amyl nitrite is employed medically to treat heart diseases such as angina and to treat cyanide poisoning. Its use as a prescription medicine comes from its ability to lower blood pressure. As an inhalant, it also has psychoactive effect which has led to illegal drug use.
Moderate
1
[ [ [ 508, 24, 1637 ] ], [ [ 508, 1, 358 ], [ 358, 24, 1637 ] ], [ [ 508, 64, 475 ], [ 475, 24, 1637 ] ], [ [ 508, 35, 401 ], [ 401, 24, 1637 ] ], [ [ 508, 25, 593 ], [ 593, 24, 1637 ] ], [ [ 508, 40, 21 ], [ 21, 24, 1637 ] ], [ [ 508, 24, 1053 ], [ 1053, 24, 1637 ] ], [ [ 508, 24, 407 ], [ 407, 63, 1637 ] ], [ [ 508, 1, 358 ], [ 358, 64, 475 ], [ 475, 24, 1637 ] ], [ [ 508, 64, 475 ], [ 475, 25, 946 ], [ 946, 24, 1637 ] ] ]
[ [ [ "Promazine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Amyl Nitrite" ] ], [ [ "Promazine", "{u} (Compound) resembles {v} (Compound)", "Orphenadrine" ], [ "Orphenadrine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Amyl Nitrite" ] ], [ [ "Promazine", "{u} may lead to a major life threatening interaction when taken with {v}", "Morphine" ], [ "Morphine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Amyl Nitrite" ] ], [ [ "Promazine", "{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Promethazine" ], [ "Promethazine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Amyl Nitrite" ] ], [ [ "Promazine", "{u} may lead to a major life threatening interaction when taken with {v}", "Bupropion" ], [ "Bupropion", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Amyl Nitrite" ] ], [ [ "Promazine", "{u} (Compound) resembles {v} (Compound)", "Amitriptyline" ], [ "Amitriptyline", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Amyl Nitrite" ] ], [ [ "Promazine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Procarbazine" ], [ "Procarbazine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Amyl Nitrite" ] ], [ [ "Promazine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Opium" ], [ "Opium", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Amyl Nitrite" ] ], [ [ "Promazine", "{u} (Compound) resembles {v} (Compound)", "Orphenadrine" ], [ "Orphenadrine", "{u} may lead to a major life threatening interaction when taken with {v}", "Morphine" ], [ "Morphine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Amyl Nitrite" ] ], [ [ "Promazine", "{u} may lead to a major life threatening interaction when taken with {v}", "Morphine" ], [ "Morphine", "{u} may lead to a major life threatening interaction when taken with {v}", "Buspirone" ], [ "Buspirone", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Amyl Nitrite" ] ] ]
Promazine (Compound) resembles Orphenadrine (Compound) and Orphenadrine may cause a moderate interaction that could exacerbate diseases when taken with Amyl Nitrite Promazine may lead to a major life threatening interaction when taken with Morphine and Morphine may cause a moderate interaction that could exacerbate diseases when taken with Amyl Nitrite Promazine (Compound) resembles Promethazine (Compound) and Promazine may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Amyl Nitrite Promazine may lead to a major life threatening interaction when taken with Bupropion and Bupropion may cause a moderate interaction that could exacerbate diseases when taken with Amyl Nitrite Promazine (Compound) resembles Amitriptyline (Compound) and Amitriptyline may cause a moderate interaction that could exacerbate diseases when taken with Amyl Nitrite Promazine may cause a moderate interaction that could exacerbate diseases when taken with Procarbazine and Procarbazine may cause a moderate interaction that could exacerbate diseases when taken with Amyl Nitrite Promazine may cause a moderate interaction that could exacerbate diseases when taken with Opium and Opium may cause a moderate interaction that could exacerbate diseases when taken with Amyl Nitrite Promazine (Compound) resembles Orphenadrine (Compound) and Orphenadrine may lead to a major life threatening interaction when taken with Morphine and Morphine may cause a moderate interaction that could exacerbate diseases when taken with Amyl Nitrite Promazine may lead to a major life threatening interaction when taken with Morphine and Morphine may lead to a major life threatening interaction when taken with Buspirone and Buspirone may cause a moderate interaction that could exacerbate diseases when taken with Amyl Nitrite
DB00865
DB01156
939
593
[ "DDInter187", "DDInter252" ]
Benzphetamine
Bupropion
A sympathomimetic agent with properties similar to dextroamphetamine. It is used in the treatment of obesity. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1222)
Bupropion (also known as the brand name product Wellbutrin®) is a norepinephrine/dopamine-reuptake inhibitor (NDRI) used most commonly for the management of Major Depressive Disorder (MDD), Seasonal Affective Disorder (SAD), and as an aid for smoking cessation. Bupropion exerts its pharmacological effects by weakly inhibiting the enzymes involved in the uptake of the neurotransmitters norepinephrine and dopamine from the synaptic cleft, therefore prolonging their duration of action within the neuronal synapse and the downstream effects of these neurotransmitters. More specifically, bupropion binds to the norepinephrine transporter (NET) and the dopamine transporter (DAT).[A6399,A178810] Bupropion was originally classified as an "atypical" antidepressant because it does not exert the same effects as the classical antidepressants such as Monoamine Oxidase Inhibitors (MAOIs), Tricyclic Antidepressants (TCAs), or Selective Serotonin Reuptake Inhibitors (SSRIs). While it has comparable effectiveness to typical first-line options for the treatment of depression such as SSRIs,[A178798,A178804] bupropion is a unique option for the treatment of MDD as it lacks any clinically relevant serotonergic effects, typical of other mood medications, or any effects on histamine or adrenaline receptors.[A6399,A178840] Lack of activity at these receptors results in a more tolerable side effect profile; bupropion is less likely to cause sexual side effects, sedation, or weight gain as compared to SSRIs or TCAs, for example.[A178804,A178807] When used as an aid to smoking cessation, bupropion is thought to confer its anti-craving and anti-withdrawal effects by inhibiting dopamine reuptake, which is thought to be involved in the reward pathways associated with nicotine, and through the antagonism of the nicotinic acetylcholinergic receptor.[A178825,A1966,A16508] A Cochrane Review of meta-analyses of available treatment modalities for smoking cessation found that abstinence rates approximately doubled when bupropion was used as compared to placebo, and was found to have similar rates of smoking cessation as [nicotine] replacement therapy (NRT). Bupropion is sometimes used as an add-on agent to first-line treatments of depression such as selective serotonin reuptake inhibitor (SSRI) medications when there is a treatment-failure or only partial response. Bupropion is also used off-label for the management of Attention/Deficit-Hyperactivity Disorder (ADHD) in adults with comorbid bipolar depression to avoid mood destabilization caused by typical stimulant medications used for the treatment of ADHD. When used in combination with [naltrexone] in the marketed product ContraveⓇ for chronic weight management, the two components are thought to have effects on areas of the brain involved in the regulation of food intake. This includes the hypothalamus, which is involved in appetite regulation, and the mesolimbic dopamine circuit, which is involved in reward pathways. Studies have shown that the combined activity of bupropion and [naltrexone] increase the firing rate of hypothalamic pro-opiomelanocortin (POMC) neurons and blockade of opioid receptor-mediated POMC auto-inhibition, which are associated with a reduction in food intake and increased energy expenditure.[L6562,A179038,A179050] The combination of naltrexone and bupropion was shown to result in a statistically significant weight loss, with a mean change in body weight of -6.3% compared to -1.3% for placebo.
Major
2
[ [ [ 939, 25, 593 ] ], [ [ 939, 5, 11585 ], [ 11585, 44, 593 ] ], [ [ 939, 6, 8374 ], [ 8374, 45, 593 ] ], [ [ 939, 21, 28757 ], [ 28757, 60, 593 ] ], [ [ 939, 1, 601 ], [ 601, 24, 593 ] ], [ [ 939, 40, 371 ], [ 371, 63, 593 ] ], [ [ 939, 63, 506 ], [ 506, 24, 593 ] ], [ [ 939, 40, 847 ], [ 847, 24, 593 ] ], [ [ 939, 24, 1383 ], [ 1383, 63, 593 ] ], [ [ 939, 1, 358 ], [ 358, 63, 593 ] ] ]
[ [ [ "Benzphetamine", "{u} may lead to a major life threatening interaction when taken with {v}", "Bupropion" ] ], [ [ "Benzphetamine", "{u} (Compound) treats {v} (Disease)", "obesity" ], [ "obesity", "{u} (Disease) is treated by {v} (Compound)", "Bupropion" ] ], [ [ "Benzphetamine", "{u} (Compound) binds {v} (Gene)", "CYP3A4" ], [ "CYP3A4", "{u} (Gene) is bound by {v} (Compound)", "Bupropion" ] ], [ [ "Benzphetamine", "{u} (Compound) causes {v} (Side Effect)", "Dyspepsia" ], [ "Dyspepsia", "{u} (Side Effect) is caused by {v} (Compound)", "Bupropion" ] ], [ [ "Benzphetamine", "{u} (Compound) resembles {v} (Compound)", "Trimethaphan" ], [ "Trimethaphan", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Bupropion" ] ], [ [ "Benzphetamine", "{u} (Compound) resembles {v} (Compound)", "Propafenone" ], [ "Propafenone", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Bupropion" ] ], [ [ "Benzphetamine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Dextromethorphan" ], [ "Dextromethorphan", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Bupropion" ] ], [ [ "Benzphetamine", "{u} (Compound) resembles {v} (Compound)", "Atomoxetine" ], [ "Atomoxetine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Bupropion" ] ], [ [ "Benzphetamine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Sodium sulfate" ], [ "Sodium sulfate", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Bupropion" ] ], [ [ "Benzphetamine", "{u} (Compound) resembles {v} (Compound)", "Orphenadrine" ], [ "Orphenadrine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Bupropion" ] ] ]
Benzphetamine (Compound) treats obesity (Disease) and obesity (Disease) is treated by Bupropion (Compound) Benzphetamine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Bupropion (Compound) Benzphetamine (Compound) causes Dyspepsia (Side Effect) and Dyspepsia (Side Effect) is caused by Bupropion (Compound) Benzphetamine (Compound) resembles Trimethaphan (Compound) and Trimethaphan may cause a moderate interaction that could exacerbate diseases when taken with Bupropion Benzphetamine (Compound) resembles Propafenone (Compound) and Propafenone may cause a moderate interaction that could exacerbate diseases when taken with Bupropion Benzphetamine may cause a moderate interaction that could exacerbate diseases when taken with Dextromethorphan and Dextromethorphan may cause a moderate interaction that could exacerbate diseases when taken with Bupropion Benzphetamine (Compound) resembles Atomoxetine (Compound) and Atomoxetine may cause a moderate interaction that could exacerbate diseases when taken with Bupropion Benzphetamine may cause a moderate interaction that could exacerbate diseases when taken with Sodium sulfate and Sodium sulfate may cause a moderate interaction that could exacerbate diseases when taken with Bupropion Benzphetamine (Compound) resembles Orphenadrine (Compound) and Orphenadrine may cause a moderate interaction that could exacerbate diseases when taken with Bupropion
DB00620
DB14550
175
821
[ "DDInter1855", "DDInter803" ]
Triamcinolone
Gallium chloride Ga-67
Triamcinolone is a corticosteroid used to treat various inflammatory conditions in the body from allergic rhinitis to acute exacerbations of multiple sclerosis. Triamcinolone can be used as a one time adjunct treatment of osteoarthritic knee pain, or first line as a topical treatment of corticosteroid responsive dermatoses. Triamcinolone is more commonly seen in the forms triamcinolone hexacetonide, triamcinolone acetonide, and triamcinolone diacetate.[L8246,L8249,L8252,L8255,L8258,L8261,L8264] Triamcinolone was granted FDA approval on 3 December 1957. In October 2021, a suspension of triamcinolone acetonide was approved for suprachoroidal injection - the first suprachoroidal injection to receive FDA approval - for the treatment of patients with macular
Gallium chloride Ga-67 is the chloride salt of a gallium radioisotope which is typically complexed with [sodium citrate] to generate [gallium citrate Ga 67], which can be used to image certain cancers and inflammatory lesions.
Moderate
1
[ [ [ 175, 24, 821 ] ], [ [ 175, 63, 663 ], [ 663, 24, 821 ] ], [ [ 175, 40, 1220 ], [ 1220, 24, 821 ] ], [ [ 175, 1, 617 ], [ 617, 24, 821 ] ], [ [ 175, 63, 663 ], [ 663, 24, 1220 ], [ 1220, 24, 821 ] ], [ [ 175, 40, 1220 ], [ 1220, 63, 663 ], [ 663, 24, 821 ] ], [ [ 175, 40, 251 ], [ 251, 24, 663 ], [ 663, 24, 821 ] ], [ [ 175, 1, 617 ], [ 617, 63, 663 ], [ 663, 24, 821 ] ], [ [ 175, 5, 11568 ], [ 11568, 44, 663 ], [ 663, 24, 821 ] ], [ [ 175, 63, 663 ], [ 663, 63, 251 ], [ 251, 24, 821 ] ] ]
[ [ [ "Triamcinolone", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Gallium chloride Ga-67" ] ], [ [ "Triamcinolone", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Methotrexate" ], [ "Methotrexate", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Gallium chloride Ga-67" ] ], [ [ "Triamcinolone", "{u} (Compound) resembles {v} (Compound)", "Dexamethasone" ], [ "Dexamethasone", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Gallium chloride Ga-67" ] ], [ [ "Triamcinolone", "{u} (Compound) resembles {v} (Compound)", "Budesonide" ], [ "Budesonide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Gallium chloride Ga-67" ] ], [ [ "Triamcinolone", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Methotrexate" ], [ "Methotrexate", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Dexamethasone" ], [ "Dexamethasone", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Gallium chloride Ga-67" ] ], [ [ "Triamcinolone", "{u} (Compound) resembles {v} (Compound)", "Dexamethasone" ], [ "Dexamethasone", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Methotrexate" ], [ "Methotrexate", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Gallium chloride Ga-67" ] ], [ [ "Triamcinolone", "{u} (Compound) resembles {v} (Compound)", "Betamethasone" ], [ "Betamethasone", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Methotrexate" ], [ "Methotrexate", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Gallium chloride Ga-67" ] ], [ [ "Triamcinolone", "{u} (Compound) resembles {v} (Compound)", "Budesonide" ], [ "Budesonide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Methotrexate" ], [ "Methotrexate", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Gallium chloride Ga-67" ] ], [ [ "Triamcinolone", "{u} (Compound) treats {v} (Disease)", "psoriatic arthritis" ], [ "psoriatic arthritis", "{u} (Disease) is treated by {v} (Compound)", "Methotrexate" ], [ "Methotrexate", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Gallium chloride Ga-67" ] ], [ [ "Triamcinolone", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Methotrexate" ], [ "Methotrexate", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Betamethasone" ], [ "Betamethasone", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Gallium chloride Ga-67" ] ] ]
Triamcinolone may cause a moderate interaction that could exacerbate diseases when taken with Methotrexate and Methotrexate may cause a moderate interaction that could exacerbate diseases when taken with Gallium chloride Ga-67 Triamcinolone (Compound) resembles Dexamethasone (Compound) and Dexamethasone may cause a moderate interaction that could exacerbate diseases when taken with Gallium chloride Ga-67 Triamcinolone (Compound) resembles Budesonide (Compound) and Budesonide may cause a moderate interaction that could exacerbate diseases when taken with Gallium chloride Ga-67 Triamcinolone may cause a moderate interaction that could exacerbate diseases when taken with Methotrexate and Methotrexate may cause a moderate interaction that could exacerbate diseases when taken with Dexamethasone and Dexamethasone may cause a moderate interaction that could exacerbate diseases when taken with Gallium chloride Ga-67 Triamcinolone (Compound) resembles Dexamethasone (Compound) and Dexamethasone may cause a moderate interaction that could exacerbate diseases when taken with Methotrexate and Methotrexate may cause a moderate interaction that could exacerbate diseases when taken with Gallium chloride Ga-67 Triamcinolone (Compound) resembles Betamethasone (Compound) and Betamethasone may cause a moderate interaction that could exacerbate diseases when taken with Methotrexate and Methotrexate may cause a moderate interaction that could exacerbate diseases when taken with Gallium chloride Ga-67 Triamcinolone (Compound) resembles Budesonide (Compound) and Budesonide may cause a moderate interaction that could exacerbate diseases when taken with Methotrexate and Methotrexate may cause a moderate interaction that could exacerbate diseases when taken with Gallium chloride Ga-67 Triamcinolone (Compound) treats psoriatic arthritis (Disease) and psoriatic arthritis (Disease) is treated by Methotrexate (Compound) and Methotrexate may cause a moderate interaction that could exacerbate diseases when taken with Gallium chloride Ga-67 Triamcinolone may cause a moderate interaction that could exacerbate diseases when taken with Methotrexate and Methotrexate may cause a moderate interaction that could exacerbate diseases when taken with Betamethasone and Betamethasone may cause a moderate interaction that could exacerbate diseases when taken with Gallium chloride Ga-67
DB00486
DB00802
1,614
1,322
[ "DDInter1253", "DDInter43" ]
Nabilone
Alfentanil
Nabilone (marketed as Cesamet) is a synthetic form of delta-9-tetrahydrocannabinol (Δ⁹-THC), the primary psychoactive component of cannabis (marijuana). Although structurally distinct from THC, nabilone mimics THC's structure and pharmacological activity through weak partial agonist activity at Cannabinoid-1 (CB1R) and Cannabinoid-2 (CB2R) receptors, however it is considered to be twice as active as Δ⁹-THC. Nabilone is approved by the FDA for the treatment of nausea and vomiting associated with cancer chemotherapy in patients who have failed to respond adequately to conventional antiemetic treatments [FDA Label]. Tetrahydrocannabinol (THC) and cannabidiol (CBD) are the two most abundant cannabinoids found naturally in the resin of the marijuana plant, both of which are pharmacologically active due to their interaction with cannabinoid receptors that are
A short-acting opioid anesthetic and analgesic derivative of fentanyl. It produces an early peak analgesic effect and fast recovery of consciousness. Alfentanil is effective as an anesthetic during surgery, for supplementation of analgesia during surgical procedures, and as an analgesic for critically ill patients.
Moderate
1
[ [ [ 1614, 24, 1322 ] ], [ [ 1614, 24, 411 ], [ 411, 1, 1322 ] ], [ [ 1614, 21, 29118 ], [ 29118, 60, 1322 ] ], [ [ 1614, 24, 1219 ], [ 1219, 24, 1322 ] ], [ [ 1614, 24, 401 ], [ 401, 63, 1322 ] ], [ [ 1614, 63, 701 ], [ 701, 24, 1322 ] ], [ [ 1614, 40, 530 ], [ 530, 24, 1322 ] ], [ [ 1614, 24, 222 ], [ 222, 64, 1322 ] ], [ [ 1614, 24, 411 ], [ 411, 40, 704 ], [ 704, 1, 1322 ] ], [ [ 1614, 24, 704 ], [ 704, 1, 411 ], [ 411, 1, 1322 ] ] ]
[ [ [ "Nabilone", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Alfentanil" ] ], [ [ "Nabilone", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Remifentanil" ], [ "Remifentanil", "{u} (Compound) resembles {v} (Compound)", "Alfentanil" ] ], [ [ "Nabilone", "{u} (Compound) causes {v} (Side Effect)", "Tachycardia" ], [ "Tachycardia", "{u} (Side Effect) is caused by {v} (Compound)", "Alfentanil" ] ], [ [ "Nabilone", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Azatadine" ], [ "Azatadine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Alfentanil" ] ], [ [ "Nabilone", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Promethazine" ], [ "Promethazine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Alfentanil" ] ], [ [ "Nabilone", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Clemastine" ], [ "Clemastine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Alfentanil" ] ], [ [ "Nabilone", "{u} (Compound) resembles {v} (Compound)", "Dronabinol" ], [ "Dronabinol", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Alfentanil" ] ], [ [ "Nabilone", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Sibutramine" ], [ "Sibutramine", "{u} may lead to a major life threatening interaction when taken with {v}", "Alfentanil" ] ], [ [ "Nabilone", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Remifentanil" ], [ "Remifentanil", "{u} (Compound) resembles {v} (Compound)", "Fentanyl" ], [ "Fentanyl", "{u} (Compound) resembles {v} (Compound)", "Alfentanil" ] ], [ [ "Nabilone", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Fentanyl" ], [ "Fentanyl", "{u} (Compound) resembles {v} (Compound)", "Remifentanil" ], [ "Remifentanil", "{u} (Compound) resembles {v} (Compound)", "Alfentanil" ] ] ]
Nabilone may cause a moderate interaction that could exacerbate diseases when taken with Remifentanil and Remifentanil (Compound) resembles Alfentanil (Compound) Nabilone (Compound) causes Tachycardia (Side Effect) and Tachycardia (Side Effect) is caused by Alfentanil (Compound) Nabilone may cause a moderate interaction that could exacerbate diseases when taken with Azatadine and Azatadine may cause a moderate interaction that could exacerbate diseases when taken with Alfentanil Nabilone may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Alfentanil Nabilone may cause a moderate interaction that could exacerbate diseases when taken with Clemastine and Clemastine may cause a moderate interaction that could exacerbate diseases when taken with Alfentanil Nabilone (Compound) resembles Dronabinol (Compound) and Dronabinol may cause a moderate interaction that could exacerbate diseases when taken with Alfentanil Nabilone may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine and Sibutramine may lead to a major life threatening interaction when taken with Alfentanil Nabilone may cause a moderate interaction that could exacerbate diseases when taken with Remifentanil and Remifentanil (Compound) resembles Fentanyl (Compound) and Fentanyl (Compound) resembles Alfentanil (Compound) Nabilone may cause a moderate interaction that could exacerbate diseases when taken with Fentanyl and Fentanyl (Compound) resembles Remifentanil (Compound) and Remifentanil (Compound) resembles Alfentanil (Compound)
DB00500
DB01067
24
959
[ "DDInter1831", "DDInter826" ]
Tolmetin
Glipizide
A non-steroidal anti-inflammatory agent (anti-inflammatory agents, NON-steroidal) similar in mode of action to indomethacin.
Glipizide is an oral hypoglycemic agent in the second-generation sulfonylurea drug class that is used to control blood sugar levels in patients with type 2 diabetes mellitus. It was first introduced in 1984 and is available in various countries including Canada and the U.S. According to the 2018 Clinical Practice Guidelines by Diabetes Canada, sulfonylurea drugs are considered a second-line glucose-lowering therapy following metformin. Because sulfonylureas require functional pancreatic beta cells for their therapeutic effectiveness, sulfonylureas are more commonly used for early-stage type 2 diabetes when there is no progressed pancreatic failure. Compared to the first-generation sulfonylureas, such as [tolbutamide] and [chlorpropamide], second-generation sulfonylureas contain a more non-polar side chain in their chemical structure, which enhances their hypoglycemic potency. Compared to other members of the sulfonylurea drug group, glipizide displays rapid absorption and onset of action with the shortest half-life and duration of action, reducing the risk for long-lasting hypoglycemia that is often observed with blood glucose-lowering agents. Glipizide was first approved by the FDA in 1994 and is available in extended-release tablets under the brand name Glucotrol®, as well as in combination with metformin under the brand name Metaglip®.
Moderate
1
[ [ [ 24, 24, 959 ] ], [ [ 24, 63, 245 ], [ 245, 40, 959 ] ], [ [ 24, 24, 1411 ], [ 1411, 1, 959 ] ], [ [ 24, 21, 29366 ], [ 29366, 60, 959 ] ], [ [ 24, 24, 1220 ], [ 1220, 63, 959 ] ], [ [ 24, 24, 1479 ], [ 1479, 24, 959 ] ], [ [ 24, 25, 126 ], [ 126, 24, 959 ] ], [ [ 24, 63, 1560 ], [ 1560, 24, 959 ] ], [ [ 24, 25, 1377 ], [ 1377, 63, 959 ] ], [ [ 24, 40, 1263 ], [ 1263, 24, 959 ] ] ]
[ [ [ "Tolmetin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Glipizide" ] ], [ [ "Tolmetin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Glimepiride" ], [ "Glimepiride", "{u} (Compound) resembles {v} (Compound)", "Glipizide" ] ], [ [ "Tolmetin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Tolbutamide" ], [ "Tolbutamide", "{u} (Compound) resembles {v} (Compound)", "Glipizide" ] ], [ [ "Tolmetin", "{u} (Compound) causes {v} (Side Effect)", "Dysuria" ], [ "Dysuria", "{u} (Side Effect) is caused by {v} (Compound)", "Glipizide" ] ], [ [ "Tolmetin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Dexamethasone" ], [ "Dexamethasone", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Glipizide" ] ], [ [ "Tolmetin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Acetylsalicylic acid" ], [ "Acetylsalicylic acid", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Glipizide" ] ], [ [ "Tolmetin", "{u} may lead to a major life threatening interaction when taken with {v}", "Warfarin" ], [ "Warfarin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Glipizide" ] ], [ [ "Tolmetin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Pegaspargase" ], [ "Pegaspargase", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Glipizide" ] ], [ [ "Tolmetin", "{u} may lead to a major life threatening interaction when taken with {v}", "Leflunomide" ], [ "Leflunomide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Glipizide" ] ], [ [ "Tolmetin", "{u} (Compound) resembles {v} (Compound)", "Bromfenac" ], [ "Bromfenac", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Glipizide" ] ] ]
Tolmetin may cause a moderate interaction that could exacerbate diseases when taken with Glimepiride and Glimepiride (Compound) resembles Glipizide (Compound) Tolmetin may cause a moderate interaction that could exacerbate diseases when taken with Tolbutamide and Tolbutamide (Compound) resembles Glipizide (Compound) Tolmetin (Compound) causes Dysuria (Side Effect) and Dysuria (Side Effect) is caused by Glipizide (Compound) Tolmetin may cause a moderate interaction that could exacerbate diseases when taken with Dexamethasone and Dexamethasone may cause a moderate interaction that could exacerbate diseases when taken with Glipizide Tolmetin may cause a moderate interaction that could exacerbate diseases when taken with Acetylsalicylic acid and Acetylsalicylic acid may cause a moderate interaction that could exacerbate diseases when taken with Glipizide Tolmetin may lead to a major life threatening interaction when taken with Warfarin and Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Glipizide Tolmetin may cause a moderate interaction that could exacerbate diseases when taken with Pegaspargase and Pegaspargase may cause a moderate interaction that could exacerbate diseases when taken with Glipizide Tolmetin may lead to a major life threatening interaction when taken with Leflunomide and Leflunomide may cause a moderate interaction that could exacerbate diseases when taken with Glipizide Tolmetin (Compound) resembles Bromfenac (Compound) and Bromfenac may cause a moderate interaction that could exacerbate diseases when taken with Glipizide
DB00322
DB00363
141
695
[ "DDInter742", "DDInter419" ]
Floxuridine
Clozapine
An antineoplastic antimetabolite that is metabolized to fluorouracil when administered by rapid injection. Floxuridine is available as a sterile, nonpyrogenic, lyophilized powder for reconstitution. When administered by slow, continuous, intra-arterial infusion, it is converted to floxuridine monophosphate. It has been used to treat hepatic metastases of gastrointestinal adenocarcinomas and for palliation in malignant neoplasms of the liver and gastrointestinal tract.
Clozapine is a tricyclic dibenzodiazepine, classified as an atypical antipsychotic agent. Clozapine displays affinity to various neuroreceptors with a particularly low affinity to the dopamine receptors, thus breaking the mold of first-generation antipsychotics and deeming it "atypical".. This low affinity to dopamine receptors results in fewer extrapyramidal side effects, especially tardive dyskinesia. However, its promiscuity toward the muscarinic and adrenergic receptors can result in other side effects, notably gastrointestinal hypomotility and orthostatic hypotension. [L905,A215552]. Despite its effectiveness in treating both positive and negative symptoms of schizophrenia, clozapine was briefly removed from the market in various jurisdictions in 1970 due to severe agranulocytosis.[A256713,A256718] However, continued evidence of its effectiveness led to clozapine's eventual reintroduction, although with a reluctance to prescribe it. Clozapine was approved by the FDA in 1989 for treatment-resistant schizophrenia under the brand CLOZARIL. Due to its severe adverse effects profile, clozapine is only available through a restricted program under a Risk Evaluation Mitigation Strategy (REMS) called the Clozapine REMS Program.
Major
2
[ [ [ 141, 25, 695 ] ], [ [ 141, 18, 2976 ], [ 2976, 57, 695 ] ], [ [ 141, 24, 1001 ], [ 1001, 64, 695 ] ], [ [ 141, 1, 1083 ], [ 1083, 64, 695 ] ], [ [ 141, 63, 552 ], [ 552, 25, 695 ] ], [ [ 141, 25, 507 ], [ 507, 64, 695 ] ], [ [ 141, 35, 1238 ], [ 1238, 64, 695 ] ], [ [ 141, 64, 1057 ], [ 1057, 25, 695 ] ], [ [ 141, 24, 482 ], [ 482, 25, 695 ] ], [ [ 141, 18, 2976 ], [ 2976, 57, 1003 ], [ 1003, 1, 695 ] ] ]
[ [ [ "Floxuridine", "{u} may lead to a major life threatening interaction when taken with {v}", "Clozapine" ] ], [ [ "Floxuridine", "{u} (Compound) downregulates {v} (Gene)", "STUB1" ], [ "STUB1", "{u} (Gene) is downregulated by {v} (Compound)", "Clozapine" ] ], [ [ "Floxuridine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Mechlorethamine" ], [ "Mechlorethamine", "{u} may lead to a major life threatening interaction when taken with {v}", "Clozapine" ] ], [ [ "Floxuridine", "{u} (Compound) resembles {v} (Compound)", "Trifluridine" ], [ "Trifluridine", "{u} may lead to a major life threatening interaction when taken with {v}", "Clozapine" ] ], [ [ "Floxuridine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Carmustine" ], [ "Carmustine", "{u} may lead to a major life threatening interaction when taken with {v}", "Clozapine" ] ], [ [ "Floxuridine", "{u} may lead to a major life threatening interaction when taken with {v}", "Samarium (153Sm) lexidronam" ], [ "Samarium (153Sm) lexidronam", "{u} may lead to a major life threatening interaction when taken with {v}", "Clozapine" ] ], [ [ "Floxuridine", "{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Pentostatin" ], [ "Pentostatin", "{u} may lead to a major life threatening interaction when taken with {v}", "Clozapine" ] ], [ [ "Floxuridine", "{u} may lead to a major life threatening interaction when taken with {v}", "Etanercept" ], [ "Etanercept", "{u} may lead to a major life threatening interaction when taken with {v}", "Clozapine" ] ], [ [ "Floxuridine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Tioguanine" ], [ "Tioguanine", "{u} may lead to a major life threatening interaction when taken with {v}", "Clozapine" ] ], [ [ "Floxuridine", "{u} (Compound) downregulates {v} (Gene)", "STUB1" ], [ "STUB1", "{u} (Gene) is downregulated by {v} (Compound)", "Azelastine" ], [ "Azelastine", "{u} (Compound) resembles {v} (Compound)", "Clozapine" ] ] ]
Floxuridine (Compound) downregulates STUB1 (Gene) and STUB1 (Gene) is downregulated by Clozapine (Compound) Floxuridine may cause a moderate interaction that could exacerbate diseases when taken with Mechlorethamine and Mechlorethamine may lead to a major life threatening interaction when taken with Clozapine Floxuridine (Compound) resembles Trifluridine (Compound) and Trifluridine may lead to a major life threatening interaction when taken with Clozapine Floxuridine may cause a moderate interaction that could exacerbate diseases when taken with Carmustine and Carmustine may lead to a major life threatening interaction when taken with Clozapine Floxuridine may lead to a major life threatening interaction when taken with Samarium (153Sm) lexidronam and Samarium (153Sm) lexidronam may lead to a major life threatening interaction when taken with Clozapine Floxuridine (Compound) resembles Pentostatin (Compound) and Floxuridine may cause a moderate interaction that could exacerbate diseases when taken with Pentostatin and Pentostatin may lead to a major life threatening interaction when taken with Clozapine Floxuridine may lead to a major life threatening interaction when taken with Etanercept and Etanercept may lead to a major life threatening interaction when taken with Clozapine Floxuridine may cause a moderate interaction that could exacerbate diseases when taken with Tioguanine and Tioguanine may lead to a major life threatening interaction when taken with Clozapine Floxuridine (Compound) downregulates STUB1 (Gene) and STUB1 (Gene) is downregulated by Azelastine (Compound) and Azelastine (Compound) resembles Clozapine (Compound)
DB00951
DB00969
1,072
2
[ "DDInter986", "DDInter52" ]
Isoniazid
Alosetron
Antibacterial agent used primarily as a tuberculostatic. It remains the treatment of choice for tuberculosis.
Alosetron is a 5-HT3 antagonist used only for the management of severe diarrhoea-predominant irritable bowel syndrome (IBS) in women. Alosetron has an antagonist action on the 5-HT3 receptors and thus may modulate serotonin-sensitive gastrointestinal (GI) processes. Alosetron was voluntarily withdrawn from the US market in November 2000 by the manufacturer due to numerous reports of severe adverse effects including ischemic colitis, severely obstructed or ruptured bowel, and death. In June 2002, the FDA approved a supplemental new drug application allowing the remarketing of the drug under restricted conditions of use.
Moderate
1
[ [ [ 1072, 24, 2 ] ], [ [ 1072, 6, 6017 ], [ 6017, 45, 2 ] ], [ [ 1072, 21, 28826 ], [ 28826, 60, 2 ] ], [ [ 1072, 24, 1362 ], [ 1362, 63, 2 ] ], [ [ 1072, 25, 1510 ], [ 1510, 63, 2 ] ], [ [ 1072, 63, 702 ], [ 702, 24, 2 ] ], [ [ 1072, 6, 6017 ], [ 6017, 45, 44 ], [ 44, 40, 2 ] ], [ [ 1072, 21, 28826 ], [ 28826, 60, 441 ], [ 441, 24, 2 ] ], [ [ 1072, 21, 29093 ], [ 29093, 60, 44 ], [ 44, 40, 2 ] ], [ [ 1072, 21, 28722 ], [ 28722, 60, 1401 ], [ 1401, 62, 2 ] ] ]
[ [ [ "Isoniazid", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Alosetron" ] ], [ [ "Isoniazid", "{u} (Compound) binds {v} (Gene)", "CYP2C9" ], [ "CYP2C9", "{u} (Gene) is bound by {v} (Compound)", "Alosetron" ] ], [ [ "Isoniazid", "{u} (Compound) causes {v} (Side Effect)", "Jaundice" ], [ "Jaundice", "{u} (Side Effect) is caused by {v} (Compound)", "Alosetron" ] ], [ [ "Isoniazid", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Olaparib" ], [ "Olaparib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Alosetron" ] ], [ [ "Isoniazid", "{u} may lead to a major life threatening interaction when taken with {v}", "Teriflunomide" ], [ "Teriflunomide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Alosetron" ] ], [ [ "Isoniazid", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Anagrelide" ], [ "Anagrelide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Alosetron" ] ], [ [ "Isoniazid", "{u} (Compound) binds {v} (Gene)", "CYP2C9" ], [ "CYP2C9", "{u} (Gene) is bound by {v} (Compound)", "Ondansetron" ], [ "Ondansetron", "{u} (Compound) resembles {v} (Compound)", "Alosetron" ] ], [ [ "Isoniazid", "{u} (Compound) causes {v} (Side Effect)", "Jaundice" ], [ "Jaundice", "{u} (Side Effect) is caused by {v} (Compound)", "Delavirdine" ], [ "Delavirdine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Alosetron" ] ], [ [ "Isoniazid", "{u} (Compound) causes {v} (Side Effect)", "Fatigue" ], [ "Fatigue", "{u} (Side Effect) is caused by {v} (Compound)", "Ondansetron" ], [ "Ondansetron", "{u} (Compound) resembles {v} (Compound)", "Alosetron" ] ], [ [ "Isoniazid", "{u} (Compound) causes {v} (Side Effect)", "Nausea" ], [ "Nausea", "{u} (Side Effect) is caused by {v} (Compound)", "Procainamide" ], [ "Procainamide", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Alosetron" ] ] ]
Isoniazid (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Alosetron (Compound) Isoniazid (Compound) causes Jaundice (Side Effect) and Jaundice (Side Effect) is caused by Alosetron (Compound) Isoniazid may cause a moderate interaction that could exacerbate diseases when taken with Olaparib and Olaparib may cause a moderate interaction that could exacerbate diseases when taken with Alosetron Isoniazid may lead to a major life threatening interaction when taken with Teriflunomide and Teriflunomide may cause a moderate interaction that could exacerbate diseases when taken with Alosetron Isoniazid may cause a moderate interaction that could exacerbate diseases when taken with Anagrelide and Anagrelide may cause a moderate interaction that could exacerbate diseases when taken with Alosetron Isoniazid (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Ondansetron (Compound) and Ondansetron (Compound) resembles Alosetron (Compound) Isoniazid (Compound) causes Jaundice (Side Effect) and Jaundice (Side Effect) is caused by Delavirdine (Compound) and Delavirdine may cause a moderate interaction that could exacerbate diseases when taken with Alosetron Isoniazid (Compound) causes Fatigue (Side Effect) and Fatigue (Side Effect) is caused by Ondansetron (Compound) and Ondansetron (Compound) resembles Alosetron (Compound) Isoniazid (Compound) causes Nausea (Side Effect) and Nausea (Side Effect) is caused by Procainamide (Compound) and Procainamide may cause a minor interaction that can limit clinical effects when taken with Alosetron
DB00795
DB01024
50
1,096
[ "DDInter1725", "DDInter1252" ]
Sulfasalazine
Mycophenolic acid
Sulfasalazine is an anti-inflammatory drug structurally related to salicylates and other non-steroidal anti-inflammatory drugs. It is indicated for managing inflammatory diseases such as ulcerative colitis and rheumatoid arthritis (RA).[L39065, A255582] Metabolized by intestinal bacteria, sulfasalazine is broken down into [mesalazine] and [sulfapyridine], 2 compounds that carry out the main pharmacological activity of sulfasalazine. Sulfasalazine was first used in 1940 for rheumatic polyarthritis, and has been firmly established itself as one fo the most useful disease-modifying antirheumatic drug (DMARD). Compared to the first line treatment of RA like methotrexate, sulfasalazine is almost as efficacious as methotrexate although with slightly less tolerability. However, sulfasalazine has less teratogenic side effects and faster onset of action compared to conventional DMARD. Sulf
Mycophenolic acid is a potent immunosuppressant agent that inhibits _de novo_ purine biosynthesis. It was derived from _Penicillium stoloniferum_, and has also shown antibacterial, antifungal and antiviral properties.. Mycophenolic acid is used in immunosuppressive regimens as part of a triple therapy that includes a calcineurin inhibitor (ciclosporin or tacrolimus) and prednisolone. This regimen can be used in place of the older anti-proliferative [azathioprine] due to its stronger immunosuppressive potency. However, mycophenolic acid treatment is more expensive and requires therapeutic drug monitoring to optimize efficacy and minimize toxicity.[A249180,A249185] Mycophenolic acid is available as enteric-coated tablets of delayed-release, in an effort to improve upper gastrointestinal adverse events by delaying mycophenolic acid release until it reaches the small intestine. [Mycophenolate mofetil], a prodrug of mycophenolic acid, is also prescribed to transplant recipients to prevent organ rejection.
Moderate
1
[ [ [ 50, 24, 1096 ] ], [ [ 50, 63, 955 ], [ 955, 1, 1096 ] ], [ [ 50, 18, 5415 ], [ 5415, 46, 1096 ] ], [ [ 50, 63, 157 ], [ 157, 23, 1096 ] ], [ [ 50, 24, 651 ], [ 651, 62, 1096 ] ], [ [ 50, 25, 629 ], [ 629, 24, 1096 ] ], [ [ 50, 24, 361 ], [ 361, 24, 1096 ] ], [ [ 50, 24, 1381 ], [ 1381, 63, 1096 ] ], [ [ 50, 40, 161 ], [ 161, 24, 1096 ] ], [ [ 50, 63, 1441 ], [ 1441, 24, 1096 ] ] ]
[ [ [ "Sulfasalazine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Mycophenolic acid" ] ], [ [ "Sulfasalazine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Mycophenolate mofetil" ], [ "Mycophenolate mofetil", "{u} (Compound) resembles {v} (Compound)", "Mycophenolic acid" ] ], [ [ "Sulfasalazine", "{u} (Compound) downregulates {v} (Gene)", "UBQLN2" ], [ "UBQLN2", "{u} (Gene) is upregulated by {v} (Compound)", "Mycophenolic acid" ] ], [ [ "Sulfasalazine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Ethotoin" ], [ "Ethotoin", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Mycophenolic acid" ] ], [ [ "Sulfasalazine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Fosphenytoin" ], [ "Fosphenytoin", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Mycophenolic acid" ] ], [ [ "Sulfasalazine", "{u} may lead to a major life threatening interaction when taken with {v}", "Sirolimus" ], [ "Sirolimus", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Mycophenolic acid" ] ], [ [ "Sulfasalazine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Neomycin" ], [ "Neomycin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Mycophenolic acid" ] ], [ [ "Sulfasalazine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Plazomicin" ], [ "Plazomicin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Mycophenolic acid" ] ], [ [ "Sulfasalazine", "{u} (Compound) resembles {v} (Compound)", "Sulfadiazine" ], [ "Sulfadiazine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Mycophenolic acid" ] ], [ [ "Sulfasalazine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Bacitracin" ], [ "Bacitracin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Mycophenolic acid" ] ] ]
Sulfasalazine may cause a moderate interaction that could exacerbate diseases when taken with Mycophenolate mofetil and Mycophenolate mofetil (Compound) resembles Mycophenolic acid (Compound) Sulfasalazine (Compound) downregulates UBQLN2 (Gene) and UBQLN2 (Gene) is upregulated by Mycophenolic acid (Compound) Sulfasalazine may cause a moderate interaction that could exacerbate diseases when taken with Ethotoin and Ethotoin may cause a minor interaction that can limit clinical effects when taken with Mycophenolic acid Sulfasalazine may cause a moderate interaction that could exacerbate diseases when taken with Fosphenytoin and Fosphenytoin may cause a minor interaction that can limit clinical effects when taken with Mycophenolic acid Sulfasalazine may lead to a major life threatening interaction when taken with Sirolimus and Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Mycophenolic acid Sulfasalazine may cause a moderate interaction that could exacerbate diseases when taken with Neomycin and Neomycin may cause a moderate interaction that could exacerbate diseases when taken with Mycophenolic acid Sulfasalazine may cause a moderate interaction that could exacerbate diseases when taken with Plazomicin and Plazomicin may cause a moderate interaction that could exacerbate diseases when taken with Mycophenolic acid Sulfasalazine (Compound) resembles Sulfadiazine (Compound) and Sulfadiazine may cause a moderate interaction that could exacerbate diseases when taken with Mycophenolic acid Sulfasalazine may cause a moderate interaction that could exacerbate diseases when taken with Bacitracin and Bacitracin may cause a moderate interaction that could exacerbate diseases when taken with Mycophenolic acid
DB09312
DB14443
967
987
[ "DDInter106", "DDInter1931" ]
Antithymocyte immunoglobulin (rabbit)
Vibrio cholerae CVD 103-HgR strain live antigen
Rabbit anti-thymocyte globulin. Thymoglobulin is a polyclonal antibody that suppresses certain types of immune cells responsible for acute organ rejection in transplant patients. Thymoglobulin is a mixture of antibodies intended to bind to various cell surface antigens. The most common mode of action of Thymoglobulin is via selective depletion of T-cells.
_Vibrio cholerae_ CVD 103-HgR strain live antigen is a component of Vaxchora, an oral vaccine for immunization against _Vibrio cholerae_ serogroup O1. Cholera is an acute bacterial disease of the small intestine caused by _Vibrio cholerae_, which is gram-negative bacteria. Two serogroups of _V. cholerae_, O1 and O139, are causative agents of epidemic cholera. Serogroup O1 is responsible for the majority of cholera outbreaks. Cholera outbreaks remain a major global public health problem that mainly affects countries with limited access to clean water, poor hygiene, and proper sanitation; thus, effective vaccines to protect individuals against cholera disease are critical. The FDA approved the cholera vaccine containing _Vibrio cholerae_ CVD 103-HgR strain live antigen under the brand name Vaxchora in June 2016, making it the first vaccine indicated for cholera prevention to become available in the U.S. Vaxchora was later approved by the European Commission in April 2020. It is indicated for individuals aged two years and older.
Moderate
1
[ [ [ 967, 24, 987 ] ], [ [ 967, 63, 259 ], [ 259, 24, 987 ] ], [ [ 967, 64, 581 ], [ 581, 24, 987 ] ], [ [ 967, 25, 1510 ], [ 1510, 24, 987 ] ], [ [ 967, 24, 1531 ], [ 1531, 24, 987 ] ], [ [ 967, 25, 676 ], [ 676, 63, 987 ] ], [ [ 967, 63, 259 ], [ 259, 24, 1480 ], [ 1480, 24, 987 ] ], [ [ 967, 64, 581 ], [ 581, 25, 1480 ], [ 1480, 24, 987 ] ], [ [ 967, 25, 1510 ], [ 1510, 25, 1480 ], [ 1480, 24, 987 ] ], [ [ 967, 24, 1531 ], [ 1531, 24, 1480 ], [ 1480, 24, 987 ] ] ]
[ [ [ "Antilymphocyte immunoglobulin (horse)", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Vibrio cholerae CVD 103-HgR strain live antigen" ] ], [ [ "Antilymphocyte immunoglobulin (horse)", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Rilonacept" ], [ "Rilonacept", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Vibrio cholerae CVD 103-HgR strain live antigen" ] ], [ [ "Antilymphocyte immunoglobulin (horse)", "{u} may lead to a major life threatening interaction when taken with {v}", "Infliximab" ], [ "Infliximab", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Vibrio cholerae CVD 103-HgR strain live antigen" ] ], [ [ "Antilymphocyte immunoglobulin (horse)", "{u} may lead to a major life threatening interaction when taken with {v}", "Teriflunomide" ], [ "Teriflunomide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Vibrio cholerae CVD 103-HgR strain live antigen" ] ], [ [ "Antilymphocyte immunoglobulin (horse)", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Canakinumab" ], [ "Canakinumab", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Vibrio cholerae CVD 103-HgR strain live antigen" ] ], [ [ "Antilymphocyte immunoglobulin (horse)", "{u} may lead to a major life threatening interaction when taken with {v}", "Upadacitinib" ], [ "Upadacitinib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Vibrio cholerae CVD 103-HgR strain live antigen" ] ], [ [ "Antilymphocyte immunoglobulin (horse)", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Rilonacept" ], [ "Rilonacept", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Ixazomib" ], [ "Ixazomib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Vibrio cholerae CVD 103-HgR strain live antigen" ] ], [ [ "Antilymphocyte immunoglobulin (horse)", "{u} may lead to a major life threatening interaction when taken with {v}", "Infliximab" ], [ "Infliximab", "{u} may lead to a major life threatening interaction when taken with {v}", "Ixazomib" ], [ "Ixazomib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Vibrio cholerae CVD 103-HgR strain live antigen" ] ], [ [ "Antilymphocyte immunoglobulin (horse)", "{u} may lead to a major life threatening interaction when taken with {v}", "Teriflunomide" ], [ "Teriflunomide", "{u} may lead to a major life threatening interaction when taken with {v}", "Ixazomib" ], [ "Ixazomib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Vibrio cholerae CVD 103-HgR strain live antigen" ] ], [ [ "Antilymphocyte immunoglobulin (horse)", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Canakinumab" ], [ "Canakinumab", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Ixazomib" ], [ "Ixazomib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Vibrio cholerae CVD 103-HgR strain live antigen" ] ] ]
Antilymphocyte immunoglobulin (horse) may cause a moderate interaction that could exacerbate diseases when taken with Vibrio cholerae CVD 103-HgR strain live antigen Antilymphocyte immunoglobulin (horse) may cause a moderate interaction that could exacerbate diseases when taken with Rilonacept and Rilonacept may cause a moderate interaction that could exacerbate diseases when taken with Vibrio cholerae CVD 103-HgR strain live antigen Antilymphocyte immunoglobulin (horse) may lead to a major life threatening interaction when taken with Infliximab and Infliximab may cause a moderate interaction that could exacerbate diseases when taken with Vibrio cholerae CVD 103-HgR strain live antigen Antilymphocyte immunoglobulin (horse) may lead to a major life threatening interaction when taken with Teriflunomide and Teriflunomide may cause a moderate interaction that could exacerbate diseases when taken with Vibrio cholerae CVD 103-HgR strain live antigen Antilymphocyte immunoglobulin (horse) may cause a moderate interaction that could exacerbate diseases when taken with Canakinumab and Canakinumab may cause a moderate interaction that could exacerbate diseases when taken with Vibrio cholerae CVD 103-HgR strain live antigen Antilymphocyte immunoglobulin (horse) may lead to a major life threatening interaction when taken with Upadacitinib and Upadacitinib may cause a moderate interaction that could exacerbate diseases when taken with Vibrio cholerae CVD 103-HgR strain live antigen Antilymphocyte immunoglobulin (horse) may cause a moderate interaction that could exacerbate diseases when taken with Rilonacept and Rilonacept may cause a moderate interaction that could exacerbate diseases when taken with Ixazomib and Ixazomib may cause a moderate interaction that could exacerbate diseases when taken with Vibrio cholerae CVD 103-HgR strain live antigen Antilymphocyte immunoglobulin (horse) may lead to a major life threatening interaction when taken with Infliximab and Infliximab may lead to a major life threatening interaction when taken with Ixazomib and Ixazomib may cause a moderate interaction that could exacerbate diseases when taken with Vibrio cholerae CVD 103-HgR strain live antigen Antilymphocyte immunoglobulin (horse) may lead to a major life threatening interaction when taken with Teriflunomide and Teriflunomide may lead to a major life threatening interaction when taken with Ixazomib and Ixazomib may cause a moderate interaction that could exacerbate diseases when taken with Vibrio cholerae CVD 103-HgR strain live antigen Antilymphocyte immunoglobulin (horse) may cause a moderate interaction that could exacerbate diseases when taken with Canakinumab and Canakinumab may cause a moderate interaction that could exacerbate diseases when taken with Ixazomib and Ixazomib may cause a moderate interaction that could exacerbate diseases when taken with Vibrio cholerae CVD 103-HgR strain live antigen
DB01193
DB06691
819
849
[ "DDInter12", "DDInter1155" ]
Acebutolol
Mepyramine
A cardioselective beta-adrenergic antagonist with little effect on the bronchial receptors. The drug has stabilizing and quinidine-like effects on cardiac rhythm as well as weak inherent sympathomimetic action.
Mepyramine, or pyrilamine, targets the H1 receptor. It is a first generation antihistamine. However, it rapidly permeates the brain and so often causes drowsiness as a side effect. It has been found in over-the-counter combination products for colds and menstrual symptoms, but is considered to be an unapproved prescription medication used for cough, cold, or allergic conditions.
Moderate
1
[ [ [ 819, 24, 849 ] ], [ [ 819, 6, 12523 ], [ 12523, 45, 849 ] ], [ [ 819, 63, 770 ], [ 770, 24, 849 ] ], [ [ 819, 40, 88 ], [ 88, 24, 849 ] ], [ [ 819, 24, 407 ], [ 407, 63, 849 ] ], [ [ 819, 24, 1511 ], [ 1511, 24, 849 ] ], [ [ 819, 6, 12523 ], [ 12523, 45, 23 ], [ 23, 40, 849 ] ], [ [ 819, 63, 770 ], [ 770, 63, 1594 ], [ 1594, 24, 849 ] ], [ [ 819, 40, 88 ], [ 88, 6, 12523 ], [ 12523, 45, 849 ] ], [ [ 819, 63, 1648 ], [ 1648, 24, 1594 ], [ 1594, 24, 849 ] ] ]
[ [ [ "Acebutolol", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Mepyramine" ] ], [ [ "Acebutolol", "{u} (Compound) binds {v} (Gene)", "CYP2D6" ], [ "CYP2D6", "{u} (Gene) is bound by {v} (Compound)", "Mepyramine" ] ], [ [ "Acebutolol", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Thalidomide" ], [ "Thalidomide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Mepyramine" ] ], [ [ "Acebutolol", "{u} (Compound) resembles {v} (Compound)", "Metoprolol" ], [ "Metoprolol", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Mepyramine" ] ], [ [ "Acebutolol", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Opium" ], [ "Opium", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Mepyramine" ] ], [ [ "Acebutolol", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Mepenzolate" ], [ "Mepenzolate", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Mepyramine" ] ], [ [ "Acebutolol", "{u} (Compound) binds {v} (Gene)", "CYP2D6" ], [ "CYP2D6", "{u} (Gene) is bound by {v} (Compound)", "Rosiglitazone" ], [ "Rosiglitazone", "{u} (Compound) resembles {v} (Compound)", "Mepyramine" ] ], [ [ "Acebutolol", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Thalidomide" ], [ "Thalidomide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Doxylamine" ], [ "Doxylamine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Mepyramine" ] ], [ [ "Acebutolol", "{u} (Compound) resembles {v} (Compound)", "Metoprolol" ], [ "Metoprolol", "{u} (Compound) binds {v} (Gene)", "CYP2D6" ], [ "CYP2D6", "{u} (Gene) is bound by {v} (Compound)", "Mepyramine" ] ], [ [ "Acebutolol", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Aldesleukin" ], [ "Aldesleukin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Doxylamine" ], [ "Doxylamine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Mepyramine" ] ] ]
Acebutolol (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Mepyramine (Compound) Acebutolol may cause a moderate interaction that could exacerbate diseases when taken with Thalidomide and Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine Acebutolol (Compound) resembles Metoprolol (Compound) and Metoprolol may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine Acebutolol may cause a moderate interaction that could exacerbate diseases when taken with Opium and Opium may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine Acebutolol may cause a moderate interaction that could exacerbate diseases when taken with Mepenzolate and Mepenzolate may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine Acebutolol (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Rosiglitazone (Compound) and Rosiglitazone (Compound) resembles Mepyramine (Compound) Acebutolol may cause a moderate interaction that could exacerbate diseases when taken with Thalidomide and Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Doxylamine and Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine Acebutolol (Compound) resembles Metoprolol (Compound) and Metoprolol (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Mepyramine (Compound) Acebutolol may cause a moderate interaction that could exacerbate diseases when taken with Aldesleukin and Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Doxylamine and Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine
DB00792
DB01219
832
716
[ "DDInter1878", "DDInter473" ]
Tripelennamine
Dantrolene
A histamine H1 antagonist with low sedative action but frequent gastrointestinal irritation. It is used to treat asthma; HAY fever; urticaria; and rhinitis; and also in veterinary applications. Tripelennamine is administered by various routes, including topically.
Chemically, dantrolene is a hydantoin derivative, but does not exhibit antiepileptic activity like other hydantoin derivates such as phenytoin.
Moderate
1
[ [ [ 832, 24, 716 ] ], [ [ 832, 24, 1609 ], [ 1609, 63, 716 ] ], [ [ 832, 24, 100 ], [ 100, 24, 716 ] ], [ [ 832, 63, 13 ], [ 13, 24, 716 ] ], [ [ 832, 40, 649 ], [ 649, 63, 716 ] ], [ [ 832, 35, 272 ], [ 272, 24, 716 ] ], [ [ 832, 74, 662 ], [ 662, 24, 716 ] ], [ [ 832, 63, 475 ], [ 475, 25, 716 ] ], [ [ 832, 24, 1609 ], [ 1609, 63, 100 ], [ 100, 24, 716 ] ], [ [ 832, 24, 100 ], [ 100, 6, 8374 ], [ 8374, 45, 716 ] ] ]
[ [ [ "Tripelennamine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Dantrolene" ] ], [ [ "Tripelennamine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Pentoxyverine" ], [ "Pentoxyverine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Dantrolene" ] ], [ [ "Tripelennamine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Brompheniramine" ], [ "Brompheniramine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Dantrolene" ] ], [ [ "Tripelennamine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Cyproheptadine" ], [ "Cyproheptadine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Dantrolene" ] ], [ [ "Tripelennamine", "{u} (Compound) resembles {v} (Compound)", "Clofedanol" ], [ "Clofedanol", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Dantrolene" ] ], [ [ "Tripelennamine", "{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Chlorpheniramine" ], [ "Chlorpheniramine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Dantrolene" ] ], [ [ "Tripelennamine", "{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Carbinoxamine" ], [ "Carbinoxamine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Dantrolene" ] ], [ [ "Tripelennamine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Morphine" ], [ "Morphine", "{u} may lead to a major life threatening interaction when taken with {v}", "Dantrolene" ] ], [ [ "Tripelennamine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Pentoxyverine" ], [ "Pentoxyverine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Brompheniramine" ], [ "Brompheniramine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Dantrolene" ] ], [ [ "Tripelennamine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Brompheniramine" ], [ "Brompheniramine", "{u} (Compound) binds {v} (Gene)", "CYP3A4" ], [ "CYP3A4", "{u} (Gene) is bound by {v} (Compound)", "Dantrolene" ] ] ]
Tripelennamine may cause a moderate interaction that could exacerbate diseases when taken with Pentoxyverine and Pentoxyverine may cause a moderate interaction that could exacerbate diseases when taken with Dantrolene Tripelennamine may cause a moderate interaction that could exacerbate diseases when taken with Brompheniramine and Brompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Dantrolene Tripelennamine may cause a moderate interaction that could exacerbate diseases when taken with Cyproheptadine and Cyproheptadine may cause a moderate interaction that could exacerbate diseases when taken with Dantrolene Tripelennamine (Compound) resembles Clofedanol (Compound) and Clofedanol may cause a moderate interaction that could exacerbate diseases when taken with Dantrolene Tripelennamine (Compound) resembles Chlorpheniramine (Compound) and Tripelennamine may cause a moderate interaction that could exacerbate diseases when taken with Chlorpheniramine and Chlorpheniramine may cause a moderate interaction that could exacerbate diseases when taken with Dantrolene Tripelennamine (Compound) resembles Carbinoxamine (Compound) and Tripelennamine may cause a moderate interaction that could exacerbate diseases when taken with Carbinoxamine and Carbinoxamine may cause a moderate interaction that could exacerbate diseases when taken with Dantrolene Tripelennamine may cause a moderate interaction that could exacerbate diseases when taken with Morphine and Morphine may lead to a major life threatening interaction when taken with Dantrolene Tripelennamine may cause a moderate interaction that could exacerbate diseases when taken with Pentoxyverine and Pentoxyverine may cause a moderate interaction that could exacerbate diseases when taken with Brompheniramine and Brompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Dantrolene Tripelennamine may cause a moderate interaction that could exacerbate diseases when taken with Brompheniramine and Brompheniramine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Dantrolene (Compound)
DB09322
DB12498
1,114
76
[ "DDInter1966", "DDInter1238" ]
Zinc sulfate
Mogamulizumab
Zinc sulfate is the inorganic compound with the formula ZnSO4 and historically known as "white vitriol". It is on the World Health Organization's List of Essential Medicines, a list of the most important medication needed in a basic health system.
Mogamulizumab is a humanized monoclonal antibody (mAb) directed against CC chemokine receptor 4 (CCR4) for the treatment of Mycosis Fungoides (MF) and Sézary Syndrome (SS), the most common subtypes of cutaneous T-cell lymphoma. Cutaneous T-cell lymphomas occur when certain white blood cells, called T cells, become cancerous; these cancers typically affect the skin, causing various types of skin lesions. On August 8 2018, the U.S. Food and Drug Administration (FDA) approved mogamulizumab injection (also known as _Poteligeo_) for intravenous use for the treatment of adult patients with relapsed or refractory mycosis fungoides (MF) or Sézary syndrome (SS) after at least one prior systemic therapy. It was approved for the same indications in Canada in June 2022. Mogamulizumab is derived from Kyowa Hakko Kirin's POTELLIGENT (®) technology, which produces antibodies with enhanced antibody-dependent cell-mediated cytotoxicity (ADCC) activity. Approval in Japan was granted on April 30 2012 by the Japanese Ministry of Health, Labour and Welfare for patients with relapsed or refractory CCR4-positive adult T-cell leukemia-lymphoma.
Minor
0
[ [ [ 1114, 23, 76 ] ], [ [ 1114, 62, 1531 ], [ 1531, 24, 76 ] ], [ [ 1114, 23, 270 ], [ 270, 24, 76 ] ], [ [ 1114, 23, 676 ], [ 676, 64, 76 ] ], [ [ 1114, 62, 1510 ], [ 1510, 25, 76 ] ], [ [ 1114, 63, 1292 ], [ 1292, 25, 76 ] ], [ [ 1114, 23, 1259 ], [ 1259, 25, 76 ] ], [ [ 1114, 62, 1531 ], [ 1531, 62, 1461 ], [ 1461, 23, 76 ] ], [ [ 1114, 62, 58 ], [ 58, 23, 1461 ], [ 1461, 23, 76 ] ], [ [ 1114, 23, 270 ], [ 270, 62, 1461 ], [ 1461, 23, 76 ] ] ]
[ [ [ "Zinc sulfate", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Mogamulizumab" ] ], [ [ "Zinc sulfate", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Canakinumab" ], [ "Canakinumab", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Mogamulizumab" ] ], [ [ "Zinc sulfate", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Ocrelizumab" ], [ "Ocrelizumab", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Mogamulizumab" ] ], [ [ "Zinc sulfate", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Upadacitinib" ], [ "Upadacitinib", "{u} may lead to a major life threatening interaction when taken with {v}", "Mogamulizumab" ] ], [ [ "Zinc sulfate", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Teriflunomide" ], [ "Teriflunomide", "{u} may lead to a major life threatening interaction when taken with {v}", "Mogamulizumab" ] ], [ [ "Zinc sulfate", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Deferiprone" ], [ "Deferiprone", "{u} may lead to a major life threatening interaction when taken with {v}", "Mogamulizumab" ] ], [ [ "Zinc sulfate", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Baricitinib" ], [ "Baricitinib", "{u} may lead to a major life threatening interaction when taken with {v}", "Mogamulizumab" ] ], [ [ "Zinc sulfate", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Canakinumab" ], [ "Canakinumab", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Vitamin E" ], [ "Vitamin E", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Mogamulizumab" ] ], [ [ "Zinc sulfate", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Alefacept" ], [ "Alefacept", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Vitamin E" ], [ "Vitamin E", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Mogamulizumab" ] ], [ [ "Zinc sulfate", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Ocrelizumab" ], [ "Ocrelizumab", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Vitamin E" ], [ "Vitamin E", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Mogamulizumab" ] ] ]
Zinc sulfate may cause a minor interaction that can limit clinical effects when taken with Canakinumab and Canakinumab may cause a moderate interaction that could exacerbate diseases when taken with Mogamulizumab Zinc sulfate may cause a minor interaction that can limit clinical effects when taken with Ocrelizumab and Ocrelizumab may cause a moderate interaction that could exacerbate diseases when taken with Mogamulizumab Zinc sulfate may cause a minor interaction that can limit clinical effects when taken with Upadacitinib and Upadacitinib may lead to a major life threatening interaction when taken with Mogamulizumab Zinc sulfate may cause a minor interaction that can limit clinical effects when taken with Teriflunomide and Teriflunomide may lead to a major life threatening interaction when taken with Mogamulizumab Zinc sulfate may cause a moderate interaction that could exacerbate diseases when taken with Deferiprone and Deferiprone may lead to a major life threatening interaction when taken with Mogamulizumab Zinc sulfate may cause a minor interaction that can limit clinical effects when taken with Baricitinib and Baricitinib may lead to a major life threatening interaction when taken with Mogamulizumab Zinc sulfate may cause a minor interaction that can limit clinical effects when taken with Canakinumab and Canakinumab may cause a minor interaction that can limit clinical effects when taken with Vitamin E and Vitamin E may cause a minor interaction that can limit clinical effects when taken with Mogamulizumab Zinc sulfate may cause a minor interaction that can limit clinical effects when taken with Alefacept and Alefacept may cause a minor interaction that can limit clinical effects when taken with Vitamin E and Vitamin E may cause a minor interaction that can limit clinical effects when taken with Mogamulizumab Zinc sulfate may cause a minor interaction that can limit clinical effects when taken with Ocrelizumab and Ocrelizumab may cause a minor interaction that can limit clinical effects when taken with Vitamin E and Vitamin E may cause a minor interaction that can limit clinical effects when taken with Mogamulizumab
DB00526
DB05528
1,555
1,070
[ "DDInter1355", "DDInter1228" ]
Oxaliplatin
Mipomersen
Oxaliplatin is a platinum-based chemotherapy drug in the same family as cisplatin and carboplatin. Compared to cisplatin the two amine groups are replaced by diamino cyclohexane (DACH) group to provide a greater antitumor effect. However, this leads to poorer water solubility, which was compensated by the addition of the chloride moieties. Due to this chemical moiety, oxaliplatin readily undergoes non-enzymatic biotransformation, thus complicating oxaliplatin's pharmacokinetics. Like most platinum-based compounds, oxaliplatin's mechanism of action is primarily through DNA damage through DNA crosslinking, particularly intrastrand and interstrand crosslinking. However, due to the structure of oxaliplatin, its adducts make the binding of mismatch repair protein to DNA harder compared to cisplatin or carboplatin's adducts, resulting in greater cytotoxic effects. The
Mipomersen sodium, which was known as the investigational drug, isis-301012, is the salt form of a synthetic phosphorothioate oligonucleotide. Mipomersen sodium prevents the formation of apo B-100, resulting in a decrease in the levels of apolipoprotein B (apo B), low density lipoprotein (LDL), and total cholesterol. Mipomersen is indicated in patients with homozygous familial hypercholesterolemia as an adjunct to diet and other lipid-lowering medications. It is marketed under the brand name Kynamro in the United States, and the FDA label includes a black box warning of hepatoxicity. Specifically, elevations in the liver enzymes, i.e. transaminases, and in liver fat (hepatic steatosis) have been reported. Due to this serious risk of liver toxicity, mipomersen sodium is only available to patients under the restricted program called Kynamro Risk Evaluation and Mitigation Strategy program.
Major
2
[ [ [ 1555, 25, 1070 ] ], [ [ 1555, 24, 1512 ], [ 1512, 25, 1070 ] ], [ [ 1555, 24, 1250 ], [ 1250, 64, 1070 ] ], [ [ 1555, 63, 552 ], [ 552, 25, 1070 ] ], [ [ 1555, 64, 581 ], [ 581, 25, 1070 ] ], [ [ 1555, 25, 868 ], [ 868, 64, 1070 ] ], [ [ 1555, 25, 1377 ], [ 1377, 25, 1070 ] ], [ [ 1555, 24, 1512 ], [ 1512, 25, 292 ], [ 292, 64, 1070 ] ], [ [ 1555, 24, 1250 ], [ 1250, 63, 14 ], [ 14, 25, 1070 ] ], [ [ 1555, 24, 14 ], [ 14, 24, 292 ], [ 292, 64, 1070 ] ] ]
[ [ [ "Oxaliplatin", "{u} may lead to a major life threatening interaction when taken with {v}", "Mipomersen" ] ], [ [ "Oxaliplatin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Diclofenac" ], [ "Diclofenac", "{u} may lead to a major life threatening interaction when taken with {v}", "Mipomersen" ] ], [ [ "Oxaliplatin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Pazopanib" ], [ "Pazopanib", "{u} may lead to a major life threatening interaction when taken with {v}", "Mipomersen" ] ], [ [ "Oxaliplatin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Carmustine" ], [ "Carmustine", "{u} may lead to a major life threatening interaction when taken with {v}", "Mipomersen" ] ], [ [ "Oxaliplatin", "{u} may lead to a major life threatening interaction when taken with {v}", "Infliximab" ], [ "Infliximab", "{u} may lead to a major life threatening interaction when taken with {v}", "Mipomersen" ] ], [ [ "Oxaliplatin", "{u} may lead to a major life threatening interaction when taken with {v}", "Vemurafenib" ], [ "Vemurafenib", "{u} may lead to a major life threatening interaction when taken with {v}", "Mipomersen" ] ], [ [ "Oxaliplatin", "{u} may lead to a major life threatening interaction when taken with {v}", "Leflunomide" ], [ "Leflunomide", "{u} may lead to a major life threatening interaction when taken with {v}", "Mipomersen" ] ], [ [ "Oxaliplatin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Diclofenac" ], [ "Diclofenac", "{u} may lead to a major life threatening interaction when taken with {v}", "Regorafenib" ], [ "Regorafenib", "{u} may lead to a major life threatening interaction when taken with {v}", "Mipomersen" ] ], [ [ "Oxaliplatin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Pazopanib" ], [ "Pazopanib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Rosuvastatin" ], [ "Rosuvastatin", "{u} may lead to a major life threatening interaction when taken with {v}", "Mipomersen" ] ], [ [ "Oxaliplatin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Rosuvastatin" ], [ "Rosuvastatin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Regorafenib" ], [ "Regorafenib", "{u} may lead to a major life threatening interaction when taken with {v}", "Mipomersen" ] ] ]
Oxaliplatin may cause a moderate interaction that could exacerbate diseases when taken with Diclofenac and Diclofenac may lead to a major life threatening interaction when taken with Mipomersen Oxaliplatin may cause a moderate interaction that could exacerbate diseases when taken with Pazopanib and Pazopanib may lead to a major life threatening interaction when taken with Mipomersen Oxaliplatin may cause a moderate interaction that could exacerbate diseases when taken with Carmustine and Carmustine may lead to a major life threatening interaction when taken with Mipomersen Oxaliplatin may lead to a major life threatening interaction when taken with Infliximab and Infliximab may lead to a major life threatening interaction when taken with Mipomersen Oxaliplatin may lead to a major life threatening interaction when taken with Vemurafenib and Vemurafenib may lead to a major life threatening interaction when taken with Mipomersen Oxaliplatin may lead to a major life threatening interaction when taken with Leflunomide and Leflunomide may lead to a major life threatening interaction when taken with Mipomersen Oxaliplatin may cause a moderate interaction that could exacerbate diseases when taken with Diclofenac and Diclofenac may lead to a major life threatening interaction when taken with Regorafenib and Regorafenib may lead to a major life threatening interaction when taken with Mipomersen Oxaliplatin may cause a moderate interaction that could exacerbate diseases when taken with Pazopanib and Pazopanib may cause a moderate interaction that could exacerbate diseases when taken with Rosuvastatin and Rosuvastatin may lead to a major life threatening interaction when taken with Mipomersen Oxaliplatin may cause a moderate interaction that could exacerbate diseases when taken with Rosuvastatin and Rosuvastatin may cause a moderate interaction that could exacerbate diseases when taken with Regorafenib and Regorafenib may lead to a major life threatening interaction when taken with Mipomersen
DB00696
DB06589
826
1,250
[ "DDInter665", "DDInter1400" ]
Ergotamine
Pazopanib
A vasoconstrictor found in ergot of Central Europe. It is an alpha-1 selective adrenergic agonist and is commonly used in the treatment of migraine disorders.
Pazopanib is a small molecule inhibitor of multiple protein tyrosine kinases with potential antineoplastic activity. It is developed by GlaxoSmithKline and was FDA approved on October 19, 2009.
Moderate
1
[ [ [ 826, 24, 1250 ] ], [ [ 826, 6, 7950 ], [ 7950, 45, 1250 ] ], [ [ 826, 21, 28658 ], [ 28658, 60, 1250 ] ], [ [ 826, 40, 628 ], [ 628, 24, 1250 ] ], [ [ 826, 63, 1419 ], [ 1419, 24, 1250 ] ], [ [ 826, 24, 214 ], [ 214, 63, 1250 ] ], [ [ 826, 1, 1131 ], [ 1131, 24, 1250 ] ], [ [ 826, 24, 86 ], [ 86, 24, 1250 ] ], [ [ 826, 24, 868 ], [ 868, 64, 1250 ] ], [ [ 826, 25, 384 ], [ 384, 64, 1250 ] ] ]
[ [ [ "Ergotamine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Pazopanib" ] ], [ [ "Ergotamine", "{u} (Compound) binds {v} (Gene)", "CYP1A2" ], [ "CYP1A2", "{u} (Gene) is bound by {v} (Compound)", "Pazopanib" ] ], [ [ "Ergotamine", "{u} (Compound) causes {v} (Side Effect)", "Vomiting" ], [ "Vomiting", "{u} (Side Effect) is caused by {v} (Compound)", "Pazopanib" ] ], [ [ "Ergotamine", "{u} (Compound) resembles {v} (Compound)", "Ergometrine" ], [ "Ergometrine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Pazopanib" ] ], [ [ "Ergotamine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Imatinib" ], [ "Imatinib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Pazopanib" ] ], [ [ "Ergotamine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Fostamatinib" ], [ "Fostamatinib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Pazopanib" ] ], [ [ "Ergotamine", "{u} (Compound) resembles {v} (Compound)", "Methysergide" ], [ "Methysergide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Pazopanib" ] ], [ [ "Ergotamine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Miconazole" ], [ "Miconazole", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Pazopanib" ] ], [ [ "Ergotamine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Vemurafenib" ], [ "Vemurafenib", "{u} may lead to a major life threatening interaction when taken with {v}", "Pazopanib" ] ], [ [ "Ergotamine", "{u} may lead to a major life threatening interaction when taken with {v}", "Idelalisib" ], [ "Idelalisib", "{u} may lead to a major life threatening interaction when taken with {v}", "Pazopanib" ] ] ]
Ergotamine (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Pazopanib (Compound) Ergotamine (Compound) causes Vomiting (Side Effect) and Vomiting (Side Effect) is caused by Pazopanib (Compound) Ergotamine (Compound) resembles Ergometrine (Compound) and Ergometrine may cause a moderate interaction that could exacerbate diseases when taken with Pazopanib Ergotamine may cause a moderate interaction that could exacerbate diseases when taken with Imatinib and Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Pazopanib Ergotamine may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib and Fostamatinib may cause a moderate interaction that could exacerbate diseases when taken with Pazopanib Ergotamine (Compound) resembles Methysergide (Compound) and Methysergide may cause a moderate interaction that could exacerbate diseases when taken with Pazopanib Ergotamine may cause a moderate interaction that could exacerbate diseases when taken with Miconazole and Miconazole may cause a moderate interaction that could exacerbate diseases when taken with Pazopanib Ergotamine may cause a moderate interaction that could exacerbate diseases when taken with Vemurafenib and Vemurafenib may lead to a major life threatening interaction when taken with Pazopanib Ergotamine may lead to a major life threatening interaction when taken with Idelalisib and Idelalisib may lead to a major life threatening interaction when taken with Pazopanib
DB00607
DB01268
1,249
1,151
[ "DDInter1256", "DDInter1731" ]
Nafcillin
Sunitinib
A semi-synthetic antibiotic related to penicillin, Naficillin is a narrow-spectrum beta-lactam antibiotic drug. It is a beta-lactamase-resistant penicillin that is indicated for the treatment of Staphylococcal infections caused by strains that are resistant to other penicillins, except those caused by MRSA. It may be used as a first-line therapy in Methicillin-Sensitive *Staphylococcus aureus* infections.
Sunitinib is a small-molecule multi-targeted receptor tyrosine kinase (RTK) inhibitor. On January 26, 2006, the agent was formally approved by the US FDA for the indications of treating renal cell carcinoma (RCC) and imatinib-resistant gastrointestinal stromal tumor (GIST). For these purposes, sunitinib is generally available as an orally administered formulation. Sunitinib inhibits cellular signaling by targeting multiple RTKs. These include all platelet-derived growth factor receptors (PDGF-R) and vascular endothelial growth factor receptors (VEGF-R). Sunitinib also inhibits KIT (CD117), the RTK that drives the majority of GISTs. In addition, sunitinib inhibits other RTKs including RET, CSF-1R, and flt3.
Moderate
1
[ [ [ 1249, 24, 1151 ] ], [ [ 1249, 6, 8374 ], [ 8374, 45, 1151 ] ], [ [ 1249, 21, 28868 ], [ 28868, 60, 1151 ] ], [ [ 1249, 24, 1250 ], [ 1250, 63, 1151 ] ], [ [ 1249, 63, 1424 ], [ 1424, 24, 1151 ] ], [ [ 1249, 24, 392 ], [ 392, 24, 1151 ] ], [ [ 1249, 25, 927 ], [ 927, 63, 1151 ] ], [ [ 1249, 64, 663 ], [ 663, 24, 1151 ] ], [ [ 1249, 25, 126 ], [ 126, 24, 1151 ] ], [ [ 1249, 23, 609 ], [ 609, 24, 1151 ] ] ]
[ [ [ "Nafcillin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Sunitinib" ] ], [ [ "Nafcillin", "{u} (Compound) binds {v} (Gene)", "CYP3A4" ], [ "CYP3A4", "{u} (Gene) is bound by {v} (Compound)", "Sunitinib" ] ], [ [ "Nafcillin", "{u} (Compound) causes {v} (Side Effect)", "Stomatitis" ], [ "Stomatitis", "{u} (Side Effect) is caused by {v} (Compound)", "Sunitinib" ] ], [ [ "Nafcillin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Pazopanib" ], [ "Pazopanib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Sunitinib" ] ], [ [ "Nafcillin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Quinine" ], [ "Quinine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Sunitinib" ] ], [ [ "Nafcillin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Lapatinib" ], [ "Lapatinib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Sunitinib" ] ], [ [ "Nafcillin", "{u} may lead to a major life threatening interaction when taken with {v}", "Encorafenib" ], [ "Encorafenib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Sunitinib" ] ], [ [ "Nafcillin", "{u} may lead to a major life threatening interaction when taken with {v}", "Methotrexate" ], [ "Methotrexate", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Sunitinib" ] ], [ [ "Nafcillin", "{u} may lead to a major life threatening interaction when taken with {v}", "Warfarin" ], [ "Warfarin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Sunitinib" ] ], [ [ "Nafcillin", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Clarithromycin" ], [ "Clarithromycin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Sunitinib" ] ] ]
Nafcillin (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Sunitinib (Compound) Nafcillin (Compound) causes Stomatitis (Side Effect) and Stomatitis (Side Effect) is caused by Sunitinib (Compound) Nafcillin may cause a moderate interaction that could exacerbate diseases when taken with Pazopanib and Pazopanib may cause a moderate interaction that could exacerbate diseases when taken with Sunitinib Nafcillin may cause a moderate interaction that could exacerbate diseases when taken with Quinine and Quinine may cause a moderate interaction that could exacerbate diseases when taken with Sunitinib Nafcillin may cause a moderate interaction that could exacerbate diseases when taken with Lapatinib and Lapatinib may cause a moderate interaction that could exacerbate diseases when taken with Sunitinib Nafcillin may lead to a major life threatening interaction when taken with Encorafenib and Encorafenib may cause a moderate interaction that could exacerbate diseases when taken with Sunitinib Nafcillin may lead to a major life threatening interaction when taken with Methotrexate and Methotrexate may cause a moderate interaction that could exacerbate diseases when taken with Sunitinib Nafcillin may lead to a major life threatening interaction when taken with Warfarin and Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Sunitinib Nafcillin may cause a minor interaction that can limit clinical effects when taken with Clarithromycin and Clarithromycin may cause a moderate interaction that could exacerbate diseases when taken with Sunitinib
DB08871
DB12161
36
730
[ "DDInter666", "DDInter512" ]
Eribulin
Deutetrabenazine
Eribulin is a microtubule inhibitor indicated for the treatment of patients with metastatic breast cancer who have previously received at least two chemotherapeutic regimens for the treatment of metastatic disease. Eribulin was isolated from the marine sponge Halichondria okadai. Eribulin is also being investigated for use in the treatment of advanced solid tumors.
Deutetrabenazine is a novel, highly selective vesicular monoamine transporter 2 (VMAT2) inhibitor indicated for the management of chorea associated with Huntington’s disease. It is a hexahydro-dimethoxybenzoquinolizine derivative and a deuterated . The presence of deuterium in deutetrabenazine increases the half-lives of the active metabolite and prolongs their pharmacological activity by attenuating CYP2D6 metabolism of the compound . This allows less frequent dosing and a lower daily dose with improvement in tolerability . Decreased plasma fluctuations of deutetrabenazine due to attenuated metabolism may explain a lower incidence of adverse reactions associated with deutetrabenazine . Deutetrabenazine is a racemic mixture containing RR-Deutetrabenazine and SS-Deutetrabenazine [FDA Label]. Huntington's disease (HD) is a hereditary, progressive neurodegenerative disorder characterized by motor dysfunction, cognitive decline, and neuropsychiatric disturbances that interfere with daily functioning and significantly reduce the quality of life. The most prominent physical symptom of HD that may increase the risk of injury is chorea, which is an involuntary, sudden movement that can affect any muscle and flow randomly across body regions . Psychomotor symptoms of HD, such as chorea, are related to hyperactive dopaminergic neurotransmission . Deutetrabenazine depletes the levels of presynaptic dopamine by blocking VMAT2, which is responsible for the uptake of dopamine into synaptic vesicles in monoaminergic neurons and exocytotic release . As with other agents for the treatment of neurodegenerative diseases, deutetrabenazine is a drug to alleviate the motor symptoms of HD and is not proposed to halt the progression of the disease . In clinical trials of patients with HD, 12 weeks of treatment of deutetrabenazine resulted in overall improvement in mean total maximal chorea scores and motor signs than placebo . It was approved by FDA in April 2017 and is marketed under the trade name Austedo as oral tablets.
Moderate
1
[ [ [ 36, 24, 730 ] ], [ [ 36, 63, 112 ], [ 112, 23, 730 ] ], [ [ 36, 63, 322 ], [ 322, 24, 730 ] ], [ [ 36, 24, 971 ], [ 971, 24, 730 ] ], [ [ 36, 24, 1619 ], [ 1619, 63, 730 ] ], [ [ 36, 64, 11 ], [ 11, 25, 730 ] ], [ [ 36, 25, 877 ], [ 877, 64, 730 ] ], [ [ 36, 25, 985 ], [ 985, 25, 730 ] ], [ [ 36, 24, 351 ], [ 351, 25, 730 ] ], [ [ 36, 63, 401 ], [ 401, 25, 730 ] ] ]
[ [ [ "Eribulin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Deutetrabenazine" ] ], [ [ "Eribulin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Metronidazole" ], [ "Metronidazole", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Deutetrabenazine" ] ], [ [ "Eribulin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Epirubicin" ], [ "Epirubicin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Deutetrabenazine" ] ], [ [ "Eribulin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Gilteritinib" ], [ "Gilteritinib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Deutetrabenazine" ] ], [ [ "Eribulin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Rucaparib" ], [ "Rucaparib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Deutetrabenazine" ] ], [ [ "Eribulin", "{u} may lead to a major life threatening interaction when taken with {v}", "Toremifene" ], [ "Toremifene", "{u} may lead to a major life threatening interaction when taken with {v}", "Deutetrabenazine" ] ], [ [ "Eribulin", "{u} may lead to a major life threatening interaction when taken with {v}", "Macimorelin" ], [ "Macimorelin", "{u} may lead to a major life threatening interaction when taken with {v}", "Deutetrabenazine" ] ], [ [ "Eribulin", "{u} may lead to a major life threatening interaction when taken with {v}", "Osimertinib" ], [ "Osimertinib", "{u} may lead to a major life threatening interaction when taken with {v}", "Deutetrabenazine" ] ], [ [ "Eribulin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Ribociclib" ], [ "Ribociclib", "{u} may lead to a major life threatening interaction when taken with {v}", "Deutetrabenazine" ] ], [ [ "Eribulin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Promethazine" ], [ "Promethazine", "{u} may lead to a major life threatening interaction when taken with {v}", "Deutetrabenazine" ] ] ]
Eribulin may cause a moderate interaction that could exacerbate diseases when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Deutetrabenazine Eribulin may cause a moderate interaction that could exacerbate diseases when taken with Epirubicin and Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Deutetrabenazine Eribulin may cause a moderate interaction that could exacerbate diseases when taken with Gilteritinib and Gilteritinib may cause a moderate interaction that could exacerbate diseases when taken with Deutetrabenazine Eribulin may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib and Rucaparib may cause a moderate interaction that could exacerbate diseases when taken with Deutetrabenazine Eribulin may lead to a major life threatening interaction when taken with Toremifene and Toremifene may lead to a major life threatening interaction when taken with Deutetrabenazine Eribulin may lead to a major life threatening interaction when taken with Macimorelin and Macimorelin may lead to a major life threatening interaction when taken with Deutetrabenazine Eribulin may lead to a major life threatening interaction when taken with Osimertinib and Osimertinib may lead to a major life threatening interaction when taken with Deutetrabenazine Eribulin may cause a moderate interaction that could exacerbate diseases when taken with Ribociclib and Ribociclib may lead to a major life threatening interaction when taken with Deutetrabenazine Eribulin may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may lead to a major life threatening interaction when taken with Deutetrabenazine
DB00570
DB06595
147
1,491
[ "DDInter1936", "DDInter1214" ]
Vinblastine
Midostaurin
Antitumor alkaloid isolated from Vinca rosea. (Merck, 11th ed.)
Midostaurin (as Rydapt) is a multitarget kinase inhibitor for the treatment for adult patients with newly diagnosed acute myeloid leukemia (AML) who have a specific genetic mutation called FLT3. It was initially characterized as a potential broad-spectrum antineoplastic agent, with activity toward diverse solid and hematopoietic tumors . It was approved on April 28, 2017 and has shown to increase the overall survival rate in patients with AML as an adjunct therapy along with chemotherapeutic agents.
Moderate
1
[ [ [ 147, 24, 1491 ] ], [ [ 147, 24, 112 ], [ 112, 23, 1491 ] ], [ [ 147, 63, 289 ], [ 289, 24, 1491 ] ], [ [ 147, 24, 1017 ], [ 1017, 63, 1491 ] ], [ [ 147, 24, 700 ], [ 700, 24, 1491 ] ], [ [ 147, 23, 956 ], [ 956, 24, 1491 ] ], [ [ 147, 25, 1091 ], [ 1091, 24, 1491 ] ], [ [ 147, 25, 1377 ], [ 1377, 25, 1491 ] ], [ [ 147, 63, 839 ], [ 839, 25, 1491 ] ], [ [ 147, 24, 1593 ], [ 1593, 64, 1491 ] ] ]
[ [ [ "Vinblastine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Midostaurin" ] ], [ [ "Vinblastine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Metronidazole" ], [ "Metronidazole", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Midostaurin" ] ], [ [ "Vinblastine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Cerivastatin" ], [ "Cerivastatin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Midostaurin" ] ], [ [ "Vinblastine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Lorlatinib" ], [ "Lorlatinib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Midostaurin" ] ], [ [ "Vinblastine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Atorvastatin" ], [ "Atorvastatin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Midostaurin" ] ], [ [ "Vinblastine", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Norfloxacin" ], [ "Norfloxacin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Midostaurin" ] ], [ [ "Vinblastine", "{u} may lead to a major life threatening interaction when taken with {v}", "Amprenavir" ], [ "Amprenavir", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Midostaurin" ] ], [ [ "Vinblastine", "{u} may lead to a major life threatening interaction when taken with {v}", "Leflunomide" ], [ "Leflunomide", "{u} may lead to a major life threatening interaction when taken with {v}", "Midostaurin" ] ], [ [ "Vinblastine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Grepafloxacin" ], [ "Grepafloxacin", "{u} may lead to a major life threatening interaction when taken with {v}", "Midostaurin" ] ], [ [ "Vinblastine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Crizotinib" ], [ "Crizotinib", "{u} may lead to a major life threatening interaction when taken with {v}", "Midostaurin" ] ] ]
Vinblastine may cause a moderate interaction that could exacerbate diseases when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Midostaurin Vinblastine may cause a moderate interaction that could exacerbate diseases when taken with Cerivastatin and Cerivastatin may cause a moderate interaction that could exacerbate diseases when taken with Midostaurin Vinblastine may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib and Lorlatinib may cause a moderate interaction that could exacerbate diseases when taken with Midostaurin Vinblastine may cause a moderate interaction that could exacerbate diseases when taken with Atorvastatin and Atorvastatin may cause a moderate interaction that could exacerbate diseases when taken with Midostaurin Vinblastine may cause a minor interaction that can limit clinical effects when taken with Norfloxacin and Norfloxacin may cause a moderate interaction that could exacerbate diseases when taken with Midostaurin Vinblastine may lead to a major life threatening interaction when taken with Amprenavir and Amprenavir may cause a moderate interaction that could exacerbate diseases when taken with Midostaurin Vinblastine may lead to a major life threatening interaction when taken with Leflunomide and Leflunomide may lead to a major life threatening interaction when taken with Midostaurin Vinblastine may cause a moderate interaction that could exacerbate diseases when taken with Grepafloxacin and Grepafloxacin may lead to a major life threatening interaction when taken with Midostaurin Vinblastine may cause a moderate interaction that could exacerbate diseases when taken with Crizotinib and Crizotinib may lead to a major life threatening interaction when taken with Midostaurin
DB01229
DB08901
973
1,468
[ "DDInter1377", "DDInter1492" ]
Paclitaxel
Ponatinib
Paclitaxel is a chemotherapeutic agent marketed under the brand name Taxol among others. Used as a treatment for various cancers, paclitaxel is a mitotic inhibitor that was first isolated in 1971 from the bark of the Pacific yew tree which contains endophytic fungi that synthesize paclitaxel. It is available as an intravenous solution for injection and the newer formulation contains albumin-bound paclitaxel marketed under the brand name Abraxane.
Ponatinib is a novel Bcr-Abl tyrosine kinase inhibitor that is especially effective against the T315I mutation for the treatment of chronic myeloid leukemia. FDA approved on December 14, 2012.
Moderate
1
[ [ [ 973, 24, 1468 ] ], [ [ 973, 24, 478 ], [ 478, 24, 1468 ] ], [ [ 973, 6, 10083 ], [ 10083, 45, 1468 ] ], [ [ 973, 7, 1972 ], [ 1972, 46, 1468 ] ], [ [ 973, 18, 3741 ], [ 3741, 57, 1468 ] ], [ [ 973, 7, 6736 ], [ 6736, 57, 1468 ] ], [ [ 973, 21, 29024 ], [ 29024, 60, 1468 ] ], [ [ 973, 63, 752 ], [ 752, 23, 1468 ] ], [ [ 973, 62, 307 ], [ 307, 23, 1468 ] ], [ [ 973, 63, 353 ], [ 353, 24, 1468 ] ] ]
[ [ [ "Paclitaxel", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Ponatinib" ] ], [ [ "Paclitaxel", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Nilotinib" ], [ "Nilotinib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Ponatinib" ] ], [ [ "Paclitaxel", "{u} (Compound) binds {v} (Gene)", "ABCB11" ], [ "ABCB11", "{u} (Gene) is bound by {v} (Compound)", "Ponatinib" ] ], [ [ "Paclitaxel", "{u} (Compound) upregulates {v} (Gene)", "PRKCQ" ], [ "PRKCQ", "{u} (Gene) is upregulated by {v} (Compound)", "Ponatinib" ] ], [ [ "Paclitaxel", "{u} (Compound) downregulates {v} (Gene)", "OXA1L" ], [ "OXA1L", "{u} (Gene) is downregulated by {v} (Compound)", "Ponatinib" ] ], [ [ "Paclitaxel", "{u} (Compound) upregulates {v} (Gene)", "DRAP1" ], [ "DRAP1", "{u} (Gene) is downregulated by {v} (Compound)", "Ponatinib" ] ], [ [ "Paclitaxel", "{u} (Compound) causes {v} (Side Effect)", "Hypertension" ], [ "Hypertension", "{u} (Side Effect) is caused by {v} (Compound)", "Ponatinib" ] ], [ [ "Paclitaxel", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Cimetidine" ], [ "Cimetidine", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Ponatinib" ] ], [ [ "Paclitaxel", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Modafinil" ], [ "Modafinil", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Ponatinib" ] ], [ [ "Paclitaxel", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Griseofulvin" ], [ "Griseofulvin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Ponatinib" ] ] ]
Paclitaxel may cause a moderate interaction that could exacerbate diseases when taken with Nilotinib and Nilotinib may cause a moderate interaction that could exacerbate diseases when taken with Ponatinib Paclitaxel (Compound) binds ABCB11 (Gene) and ABCB11 (Gene) is bound by Ponatinib (Compound) Paclitaxel (Compound) upregulates PRKCQ (Gene) and PRKCQ (Gene) is upregulated by Ponatinib (Compound) Paclitaxel (Compound) downregulates OXA1L (Gene) and OXA1L (Gene) is downregulated by Ponatinib (Compound) Paclitaxel (Compound) upregulates DRAP1 (Gene) and DRAP1 (Gene) is downregulated by Ponatinib (Compound) Paclitaxel (Compound) causes Hypertension (Side Effect) and Hypertension (Side Effect) is caused by Ponatinib (Compound) Paclitaxel may cause a moderate interaction that could exacerbate diseases when taken with Cimetidine and Cimetidine may cause a minor interaction that can limit clinical effects when taken with Ponatinib Paclitaxel may cause a minor interaction that can limit clinical effects when taken with Modafinil and Modafinil may cause a minor interaction that can limit clinical effects when taken with Ponatinib Paclitaxel may cause a moderate interaction that could exacerbate diseases when taken with Griseofulvin and Griseofulvin may cause a moderate interaction that could exacerbate diseases when taken with Ponatinib
DB00820
DB11979
402
1,320
[ "DDInter1736", "DDInter625" ]
Tadalafil
Elagolix
Tadalafil is a selective phosphodiesterase-5 inhibitor that is used in the treatment of erectile dysfunction (ED), pulmonary arterial hypertension (PAH), and benign prostatic hypertrophy.[L39100, L39105] It was first approved in 2003 by the FDA for use in ED and later in 2009 for PAH. In contrast to other PDE5 inhibitors like [sildenafil], tadalafil has greater selectivity for PDE5 and a longer half-life which has made it a more suitable option for chronic once-daily dosing in the treatment of PAH.
Elagolix has been used in trials studying the basic science and treatment of Endometriosis, Folliculogenesis, Uterine Fibroids, Heavy Uterine Bleeding, and Heavy Menstrual Bleeding. As of 24 July 2018, however, the U.S. Food and Drug Administration (FDA) approved AbbVie's elagolix under the brand name Orilissa as the first and only oral gonadotropin-releasing hormone (GnRH) antagonist specifically developed for women with moderate to severe endometriosis pain . It has been determined that endometriosis is one of the most common gynecologic disorders in the United States [A35868, A35869, F801]. In particular, estimates suggest that one in ten women of reproductive age is affected by endometriosis and experience debilitating pain symptoms [A35868, A35869, F801]. Moreover, women who are affected by this condition can suffer for up to six to ten years and visit multiple physicians before receiving a proper diagnosis [A35868, A35869, F801]. Subsequently, as Orilissa (elagolix) was approved by the FDA under priority review , this expedited new approval gives healthcare professionals another valuable option for treating the potentially unmet needs of women who are affected by endometriosis, depending on their specific type and severity of endometriosis pain.
Moderate
1
[ [ [ 402, 24, 1320 ] ], [ [ 402, 24, 129 ], [ 129, 24, 1320 ] ], [ [ 402, 63, 1051 ], [ 1051, 24, 1320 ] ], [ [ 402, 24, 159 ], [ 159, 63, 1320 ] ], [ [ 402, 24, 760 ], [ 760, 25, 1320 ] ], [ [ 402, 24, 129 ], [ 129, 64, 168 ], [ 168, 23, 1320 ] ], [ [ 402, 24, 1213 ], [ 1213, 63, 608 ], [ 608, 23, 1320 ] ], [ [ 402, 24, 868 ], [ 868, 62, 168 ], [ 168, 23, 1320 ] ], [ [ 402, 63, 1051 ], [ 1051, 62, 168 ], [ 168, 23, 1320 ] ], [ [ 402, 63, 723 ], [ 723, 63, 168 ], [ 168, 23, 1320 ] ] ]
[ [ [ "Tadalafil", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Elagolix" ] ], [ [ "Tadalafil", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Enzalutamide" ], [ "Enzalutamide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Elagolix" ] ], [ [ "Tadalafil", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Aminoglutethimide" ], [ "Aminoglutethimide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Elagolix" ] ], [ [ "Tadalafil", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Larotrectinib" ], [ "Larotrectinib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Elagolix" ] ], [ [ "Tadalafil", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Cobicistat" ], [ "Cobicistat", "{u} may lead to a major life threatening interaction when taken with {v}", "Elagolix" ] ], [ [ "Tadalafil", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Enzalutamide" ], [ "Enzalutamide", "{u} may lead to a major life threatening interaction when taken with {v}", "Bortezomib" ], [ "Bortezomib", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Elagolix" ] ], [ [ "Tadalafil", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Dasatinib" ], [ "Dasatinib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Lidocaine" ], [ "Lidocaine", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Elagolix" ] ], [ [ "Tadalafil", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Vemurafenib" ], [ "Vemurafenib", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Bortezomib" ], [ "Bortezomib", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Elagolix" ] ], [ [ "Tadalafil", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Aminoglutethimide" ], [ "Aminoglutethimide", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Bortezomib" ], [ "Bortezomib", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Elagolix" ] ], [ [ "Tadalafil", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Aprepitant" ], [ "Aprepitant", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Bortezomib" ], [ "Bortezomib", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Elagolix" ] ] ]
Tadalafil may cause a moderate interaction that could exacerbate diseases when taken with Enzalutamide and Enzalutamide may cause a moderate interaction that could exacerbate diseases when taken with Elagolix Tadalafil may cause a moderate interaction that could exacerbate diseases when taken with Aminoglutethimide and Aminoglutethimide may cause a moderate interaction that could exacerbate diseases when taken with Elagolix Tadalafil may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib and Larotrectinib may cause a moderate interaction that could exacerbate diseases when taken with Elagolix Tadalafil may cause a moderate interaction that could exacerbate diseases when taken with Cobicistat and Cobicistat may lead to a major life threatening interaction when taken with Elagolix Tadalafil may cause a moderate interaction that could exacerbate diseases when taken with Enzalutamide and Enzalutamide may lead to a major life threatening interaction when taken with Bortezomib and Bortezomib may cause a minor interaction that can limit clinical effects when taken with Elagolix Tadalafil may cause a moderate interaction that could exacerbate diseases when taken with Dasatinib and Dasatinib may cause a moderate interaction that could exacerbate diseases when taken with Lidocaine and Lidocaine may cause a minor interaction that can limit clinical effects when taken with Elagolix Tadalafil may cause a moderate interaction that could exacerbate diseases when taken with Vemurafenib and Vemurafenib may cause a minor interaction that can limit clinical effects when taken with Bortezomib and Bortezomib may cause a minor interaction that can limit clinical effects when taken with Elagolix Tadalafil may cause a moderate interaction that could exacerbate diseases when taken with Aminoglutethimide and Aminoglutethimide may cause a minor interaction that can limit clinical effects when taken with Bortezomib and Bortezomib may cause a minor interaction that can limit clinical effects when taken with Elagolix Tadalafil may cause a moderate interaction that could exacerbate diseases when taken with Aprepitant and Aprepitant may cause a moderate interaction that could exacerbate diseases when taken with Bortezomib and Bortezomib may cause a minor interaction that can limit clinical effects when taken with Elagolix
DB00982
DB05528
1,517
1,070
[ "DDInter991", "DDInter1228" ]
Isotretinoin
Mipomersen
Isotretinoin is a retinoid derivative of vitamin A used in the treatment of severe recalcitrant acne.[Label] It was most widely marketed under the brand name Accutane, which has since been discontinued. Isotretinoin is associated with major risks in pregnancy and is therefore only available under the iPLEDGE program in the United States. The first isotretinoin-containing product was FDA approved on 7 May 1982.
Mipomersen sodium, which was known as the investigational drug, isis-301012, is the salt form of a synthetic phosphorothioate oligonucleotide. Mipomersen sodium prevents the formation of apo B-100, resulting in a decrease in the levels of apolipoprotein B (apo B), low density lipoprotein (LDL), and total cholesterol. Mipomersen is indicated in patients with homozygous familial hypercholesterolemia as an adjunct to diet and other lipid-lowering medications. It is marketed under the brand name Kynamro in the United States, and the FDA label includes a black box warning of hepatoxicity. Specifically, elevations in the liver enzymes, i.e. transaminases, and in liver fat (hepatic steatosis) have been reported. Due to this serious risk of liver toxicity, mipomersen sodium is only available to patients under the restricted program called Kynamro Risk Evaluation and Mitigation Strategy program.
Major
2
[ [ [ 1517, 25, 1070 ] ], [ [ 1517, 24, 384 ], [ 384, 64, 1070 ] ], [ [ 1517, 64, 1101 ], [ 1101, 25, 1070 ] ], [ [ 1517, 25, 1510 ], [ 1510, 64, 1070 ] ], [ [ 1517, 63, 1560 ], [ 1560, 25, 1070 ] ], [ [ 1517, 25, 1377 ], [ 1377, 25, 1070 ] ], [ [ 1517, 24, 384 ], [ 384, 63, 292 ], [ 292, 64, 1070 ] ], [ [ 1517, 64, 1101 ], [ 1101, 24, 1250 ], [ 1250, 64, 1070 ] ], [ [ 1517, 24, 868 ], [ 868, 64, 1250 ], [ 1250, 64, 1070 ] ], [ [ 1517, 24, 1478 ], [ 1478, 63, 1512 ], [ 1512, 25, 1070 ] ] ]
[ [ [ "Isotretinoin", "{u} may lead to a major life threatening interaction when taken with {v}", "Mipomersen" ] ], [ [ "Isotretinoin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Idelalisib" ], [ "Idelalisib", "{u} may lead to a major life threatening interaction when taken with {v}", "Mipomersen" ] ], [ [ "Isotretinoin", "{u} may lead to a major life threatening interaction when taken with {v}", "Bexarotene" ], [ "Bexarotene", "{u} may lead to a major life threatening interaction when taken with {v}", "Mipomersen" ] ], [ [ "Isotretinoin", "{u} may lead to a major life threatening interaction when taken with {v}", "Teriflunomide" ], [ "Teriflunomide", "{u} may lead to a major life threatening interaction when taken with {v}", "Mipomersen" ] ], [ [ "Isotretinoin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Pegaspargase" ], [ "Pegaspargase", "{u} may lead to a major life threatening interaction when taken with {v}", "Mipomersen" ] ], [ [ "Isotretinoin", "{u} may lead to a major life threatening interaction when taken with {v}", "Leflunomide" ], [ "Leflunomide", "{u} may lead to a major life threatening interaction when taken with {v}", "Mipomersen" ] ], [ [ "Isotretinoin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Idelalisib" ], [ "Idelalisib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Regorafenib" ], [ "Regorafenib", "{u} may lead to a major life threatening interaction when taken with {v}", "Mipomersen" ] ], [ [ "Isotretinoin", "{u} may lead to a major life threatening interaction when taken with {v}", "Bexarotene" ], [ "Bexarotene", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Pazopanib" ], [ "Pazopanib", "{u} may lead to a major life threatening interaction when taken with {v}", "Mipomersen" ] ], [ [ "Isotretinoin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Vemurafenib" ], [ "Vemurafenib", "{u} may lead to a major life threatening interaction when taken with {v}", "Pazopanib" ], [ "Pazopanib", "{u} may lead to a major life threatening interaction when taken with {v}", "Mipomersen" ] ], [ [ "Isotretinoin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Ivacaftor" ], [ "Ivacaftor", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Diclofenac" ], [ "Diclofenac", "{u} may lead to a major life threatening interaction when taken with {v}", "Mipomersen" ] ] ]
Isotretinoin may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib and Idelalisib may lead to a major life threatening interaction when taken with Mipomersen Isotretinoin may lead to a major life threatening interaction when taken with Bexarotene and Bexarotene may lead to a major life threatening interaction when taken with Mipomersen Isotretinoin may lead to a major life threatening interaction when taken with Teriflunomide and Teriflunomide may lead to a major life threatening interaction when taken with Mipomersen Isotretinoin may cause a moderate interaction that could exacerbate diseases when taken with Pegaspargase and Pegaspargase may lead to a major life threatening interaction when taken with Mipomersen Isotretinoin may lead to a major life threatening interaction when taken with Leflunomide and Leflunomide may lead to a major life threatening interaction when taken with Mipomersen Isotretinoin may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib and Idelalisib may cause a moderate interaction that could exacerbate diseases when taken with Regorafenib and Regorafenib may lead to a major life threatening interaction when taken with Mipomersen Isotretinoin may lead to a major life threatening interaction when taken with Bexarotene and Bexarotene may cause a moderate interaction that could exacerbate diseases when taken with Pazopanib and Pazopanib may lead to a major life threatening interaction when taken with Mipomersen Isotretinoin may cause a moderate interaction that could exacerbate diseases when taken with Vemurafenib and Vemurafenib may lead to a major life threatening interaction when taken with Pazopanib and Pazopanib may lead to a major life threatening interaction when taken with Mipomersen Isotretinoin may cause a moderate interaction that could exacerbate diseases when taken with Ivacaftor and Ivacaftor may cause a moderate interaction that could exacerbate diseases when taken with Diclofenac and Diclofenac may lead to a major life threatening interaction when taken with Mipomersen
DB01118
DB11837
33
1,297
[ "DDInter76", "DDInter1351" ]
Amiodarone
Osilodrostat
Amiodarone is a benzofuran derivative, anti-arrhythmic drug used commonly in a variety of settings. Most known for its approved indication in life-threatening ventricular arrhythmias, it is also used off-label in the outpatient and inpatient setting for atrial fibrillation. Because of its ability to cause serious toxicity and possibly death, amiodarone use should be reserved for its approved indications, according to prescribing information.[L3561,L11265,L11286]
Osilodrostat is an inhibitor of 11β-hydroxylase (also referred to as CYP11B1), the enzyme that catalyzes the final step in the biosynthesis of endogenous cortisol. It is used to lower circulating cortisol levels in the treatment of Cushing's disease, a disorder in which cortisol levels are chronically and supraphysiologically elevated. Cushing's disease is often the result of ACTH hypersecretion secondary to a pituitary tumor, and surgical resection of the tumour is generally the treatment of choice. As an orally bioavailable drug therapy, osilodrostat provides a novel treatment option for patients in whom removal of the causative tumor is not an option or for whom previous pituitary surgery has not been curative. Osilodrostat is manufactured by Novartis under the brand name Isturisa. It has undergone phase II clinical trials for the treatment of solid tumours, hypertension, and heart failure, but development for these indications was discontinued by Novartis in January 2013. Osilodrostat was approved for use in the EU in January 2020 for the treatment of endogenous Cushing's syndrome (i.e. Cushing's disease), and was granted FDA approval and Orphan Drug designation in the US in March 2020 for the same indication.
Major
2
[ [ [ 33, 25, 1297 ] ], [ [ 33, 23, 1135 ], [ 1135, 23, 1297 ] ], [ [ 33, 63, 112 ], [ 112, 23, 1297 ] ], [ [ 33, 23, 466 ], [ 466, 62, 1297 ] ], [ [ 33, 24, 578 ], [ 578, 24, 1297 ] ], [ [ 33, 64, 401 ], [ 401, 24, 1297 ] ], [ [ 33, 63, 688 ], [ 688, 24, 1297 ] ], [ [ 33, 25, 971 ], [ 971, 63, 1297 ] ], [ [ 33, 25, 1374 ], [ 1374, 24, 1297 ] ], [ [ 33, 24, 159 ], [ 159, 63, 1297 ] ] ]
[ [ [ "Amiodarone", "{u} may lead to a major life threatening interaction when taken with {v}", "Osilodrostat" ] ], [ [ "Amiodarone", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Naloxegol" ], [ "Naloxegol", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Osilodrostat" ] ], [ [ "Amiodarone", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Metronidazole" ], [ "Metronidazole", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Osilodrostat" ] ], [ [ "Amiodarone", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Darolutamide" ], [ "Darolutamide", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Osilodrostat" ] ], [ [ "Amiodarone", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Ticagrelor" ], [ "Ticagrelor", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Osilodrostat" ] ], [ [ "Amiodarone", "{u} may lead to a major life threatening interaction when taken with {v}", "Promethazine" ], [ "Promethazine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Osilodrostat" ] ], [ [ "Amiodarone", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Salbutamol" ], [ "Salbutamol", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Osilodrostat" ] ], [ [ "Amiodarone", "{u} may lead to a major life threatening interaction when taken with {v}", "Gilteritinib" ], [ "Gilteritinib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Osilodrostat" ] ], [ [ "Amiodarone", "{u} may lead to a major life threatening interaction when taken with {v}", "Abiraterone" ], [ "Abiraterone", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Osilodrostat" ] ], [ [ "Amiodarone", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Larotrectinib" ], [ "Larotrectinib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Osilodrostat" ] ] ]
Amiodarone may cause a minor interaction that can limit clinical effects when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Osilodrostat Amiodarone may cause a moderate interaction that could exacerbate diseases when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Osilodrostat Amiodarone may cause a minor interaction that can limit clinical effects when taken with Darolutamide and Darolutamide may cause a minor interaction that can limit clinical effects when taken with Osilodrostat Amiodarone may cause a moderate interaction that could exacerbate diseases when taken with Ticagrelor and Ticagrelor may cause a moderate interaction that could exacerbate diseases when taken with Osilodrostat Amiodarone may lead to a major life threatening interaction when taken with Promethazine and Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Osilodrostat Amiodarone may cause a moderate interaction that could exacerbate diseases when taken with Salbutamol and Salbutamol may cause a moderate interaction that could exacerbate diseases when taken with Osilodrostat Amiodarone may lead to a major life threatening interaction when taken with Gilteritinib and Gilteritinib may cause a moderate interaction that could exacerbate diseases when taken with Osilodrostat Amiodarone may lead to a major life threatening interaction when taken with Abiraterone and Abiraterone may cause a moderate interaction that could exacerbate diseases when taken with Osilodrostat Amiodarone may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib and Larotrectinib may cause a moderate interaction that could exacerbate diseases when taken with Osilodrostat
DB09075
DB11642
498
938
[ "DDInter621", "DDInter1480" ]
Edoxaban
Pitolisant
Edoxaban is a member of the Novel Oral Anti-Coagulants (NOACs) class of drugs, and is a rapidly acting, oral, selective factor Xa inhibitor. By inhibiting factor Xa, a key protein in the coagulation cascade, edoxaban prevents the stepwise amplification of protein factors needed to form blood clots. It is indicated to reduce the risk of stroke and systemic embolism (SE) in patients with nonvalvular atrial fibrillation (NVAF) and for the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) following 5-10 days of initial therapy with a parenteral anticoagulant. Traditionally, warfarin, a vitamin K antagonist, was used for stroke prevention in these individuals but effective use of this drug is limited by it's delayed onset, narrow therapeutic window, need for regular monitoring and INR testing, and numerous drug-drug and
Pitolisant is a selective antagonist or inverse agonist of the histamine H3 receptor used to treat type 1 or 2 narcolepsy. Narcolepsy is a chronic neurological disorder that affects 1 in 2,000 individuals and is characterized by excessive daytime sleepiness, abnormal REM sleep manifestations, sleep paralysis and hypnagogic hallucinations. About 60-70% of patients with narcolepsy experience cataplexy, which is a sudden loss of muscle tone triggered by positive or negative emotions. Histaminergic neuron signalling in the brain plays a role in maintaining wakefulness; by blocking histamine autoreceptors, pitolisant enhances the activity of histaminergic neurons, as well as increasing the signalling of other neurotransmitters in the brain. In a European clinical trial of adult patients with narcolepsy, there was a reduction in the Epworth Sleepiness Scale (ESS) score from pitolisant therapy compared to placebo. The therapeutic effectiveness of pitolisant was comparable to that of [modafinil]. Pitolisant therapy was also effective in treating refractory sleepiness in adolescent patients with narcolepsy, where it decreased ESS score and increased the mean sleep onset latency. Adolescent patients with cataplexy also experienced a slight improvement in the frequency and severity of symptoms ; however, the safety of use in adolescent or paediatric patients have not been established with pitolisant. Commonly marketed under the trade name Wakix, oral pitolisant was approved by the EMA in 2016 for the treatment of narcolepsy with or without cataplexy. FDA approved the use of pitolisant in 2019 for excessive daytime sleepiness (EDS) associated with narcolepsy in adults.
Moderate
1
[ [ [ 498, 24, 938 ] ], [ [ 498, 64, 760 ], [ 760, 24, 938 ] ], [ [ 498, 24, 927 ], [ 927, 63, 938 ] ], [ [ 498, 25, 741 ], [ 741, 24, 938 ] ], [ [ 498, 63, 121 ], [ 121, 24, 938 ] ], [ [ 498, 25, 1421 ], [ 1421, 63, 938 ] ], [ [ 498, 64, 39 ], [ 39, 25, 938 ] ], [ [ 498, 24, 913 ], [ 913, 64, 938 ] ], [ [ 498, 63, 129 ], [ 129, 25, 938 ] ], [ [ 498, 64, 760 ], [ 760, 63, 600 ], [ 600, 24, 938 ] ] ]
[ [ [ "Edoxaban", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Pitolisant" ] ], [ [ "Edoxaban", "{u} may lead to a major life threatening interaction when taken with {v}", "Cobicistat" ], [ "Cobicistat", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Pitolisant" ] ], [ [ "Edoxaban", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Encorafenib" ], [ "Encorafenib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Pitolisant" ] ], [ [ "Edoxaban", "{u} may lead to a major life threatening interaction when taken with {v}", "Rolapitant" ], [ "Rolapitant", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Pitolisant" ] ], [ [ "Edoxaban", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Fenfluramine" ], [ "Fenfluramine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Pitolisant" ] ], [ [ "Edoxaban", "{u} may lead to a major life threatening interaction when taken with {v}", "Betrixaban" ], [ "Betrixaban", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Pitolisant" ] ], [ [ "Edoxaban", "{u} may lead to a major life threatening interaction when taken with {v}", "Panobinostat" ], [ "Panobinostat", "{u} may lead to a major life threatening interaction when taken with {v}", "Pitolisant" ] ], [ [ "Edoxaban", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Apalutamide" ], [ "Apalutamide", "{u} may lead to a major life threatening interaction when taken with {v}", "Pitolisant" ] ], [ [ "Edoxaban", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Enzalutamide" ], [ "Enzalutamide", "{u} may lead to a major life threatening interaction when taken with {v}", "Pitolisant" ] ], [ [ "Edoxaban", "{u} may lead to a major life threatening interaction when taken with {v}", "Cobicistat" ], [ "Cobicistat", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Fluconazole" ], [ "Fluconazole", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Pitolisant" ] ] ]
Edoxaban may lead to a major life threatening interaction when taken with Cobicistat and Cobicistat may cause a moderate interaction that could exacerbate diseases when taken with Pitolisant Edoxaban may cause a moderate interaction that could exacerbate diseases when taken with Encorafenib and Encorafenib may cause a moderate interaction that could exacerbate diseases when taken with Pitolisant Edoxaban may lead to a major life threatening interaction when taken with Rolapitant and Rolapitant may cause a moderate interaction that could exacerbate diseases when taken with Pitolisant Edoxaban may cause a moderate interaction that could exacerbate diseases when taken with Fenfluramine and Fenfluramine may cause a moderate interaction that could exacerbate diseases when taken with Pitolisant Edoxaban may lead to a major life threatening interaction when taken with Betrixaban and Betrixaban may cause a moderate interaction that could exacerbate diseases when taken with Pitolisant Edoxaban may lead to a major life threatening interaction when taken with Panobinostat and Panobinostat may lead to a major life threatening interaction when taken with Pitolisant Edoxaban may cause a moderate interaction that could exacerbate diseases when taken with Apalutamide and Apalutamide may lead to a major life threatening interaction when taken with Pitolisant Edoxaban may cause a moderate interaction that could exacerbate diseases when taken with Enzalutamide and Enzalutamide may lead to a major life threatening interaction when taken with Pitolisant Edoxaban may lead to a major life threatening interaction when taken with Cobicistat and Cobicistat may cause a moderate interaction that could exacerbate diseases when taken with Fluconazole and Fluconazole may cause a moderate interaction that could exacerbate diseases when taken with Pitolisant
DB00860
DB14723
891
159
[ "DDInter1513", "DDInter1026" ]
Prednisolone
Larotrectinib
Prednisolone is a glucocorticoid similar to [cortisol] used for its anti-inflammatory, immunosuppressive, anti-neoplastic, and vasoconstrictive effects. Prednisolone was granted FDA approval on 21 June 1955.
Larotrectinib is an orally administered inhibitor of tropomyosin receptor kinase (Trk), a receptor tyrosine kinase activated by neurotrophins which is mutated in a variety of cancer cell types and plays an important role in tumor cell growth and survival. Upon administration, larotrectinib binds to Trk, thereby preventing neurotrophin-Trk interaction and Trk activation, which results in both the induction of cellular apoptosis and the inhibition of cell growth in tumors that overexpress Trk. Larotrectinib was granted accelerated approval by the FDA in November 2018 for the treatment of Trk-positive solid tumors. It was notable for being the second tissue-agnostic chemotherapy ever approved by the FDA.
Moderate
1
[ [ [ 891, 24, 159 ] ], [ [ 891, 24, 1375 ], [ 1375, 24, 159 ] ], [ [ 891, 62, 307 ], [ 307, 24, 159 ] ], [ [ 891, 24, 1412 ], [ 1412, 63, 159 ] ], [ [ 891, 23, 659 ], [ 659, 24, 159 ] ], [ [ 891, 1, 1486 ], [ 1486, 24, 159 ] ], [ [ 891, 63, 663 ], [ 663, 24, 159 ] ], [ [ 891, 40, 1220 ], [ 1220, 24, 159 ] ], [ [ 891, 64, 839 ], [ 839, 24, 159 ] ], [ [ 891, 25, 676 ], [ 676, 63, 159 ] ] ]
[ [ [ "Prednisolone", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Larotrectinib" ] ], [ [ "Prednisolone", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Lefamulin" ], [ "Lefamulin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Larotrectinib" ] ], [ [ "Prednisolone", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Modafinil" ], [ "Modafinil", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Larotrectinib" ] ], [ [ "Prednisolone", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Calaspargase pegol" ], [ "Calaspargase pegol", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Larotrectinib" ] ], [ [ "Prednisolone", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Vilanterol" ], [ "Vilanterol", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Larotrectinib" ] ], [ [ "Prednisolone", "{u} (Compound) resembles {v} (Compound)", "Methylprednisolone" ], [ "Methylprednisolone", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Larotrectinib" ] ], [ [ "Prednisolone", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Methotrexate" ], [ "Methotrexate", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Larotrectinib" ] ], [ [ "Prednisolone", "{u} (Compound) resembles {v} (Compound)", "Dexamethasone" ], [ "Dexamethasone", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Larotrectinib" ] ], [ [ "Prednisolone", "{u} may lead to a major life threatening interaction when taken with {v}", "Grepafloxacin" ], [ "Grepafloxacin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Larotrectinib" ] ], [ [ "Prednisolone", "{u} may lead to a major life threatening interaction when taken with {v}", "Upadacitinib" ], [ "Upadacitinib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Larotrectinib" ] ] ]
Prednisolone may cause a moderate interaction that could exacerbate diseases when taken with Lefamulin and Lefamulin may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib Prednisolone may cause a minor interaction that can limit clinical effects when taken with Modafinil and Modafinil may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib Prednisolone may cause a moderate interaction that could exacerbate diseases when taken with Calaspargase pegol and Calaspargase pegol may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib Prednisolone may cause a minor interaction that can limit clinical effects when taken with Vilanterol and Vilanterol may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib Prednisolone (Compound) resembles Methylprednisolone (Compound) and Methyl Prednisolone may cause a moderate interaction that could exacerbate diseases when taken with Methotrexate and Methotrexate may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib Prednisolone (Compound) resembles Dexamethasone (Compound) and Dexamethasone may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib Prednisolone may lead to a major life threatening interaction when taken with Grepafloxacin and Grepafloxacin may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib Prednisolone may lead to a major life threatening interaction when taken with Upadacitinib and Upadacitinib may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib
DB00035
DB00586
1,314
1,512
[ "DDInter507", "DDInter537" ]
Desmopressin
Diclofenac
Desmopressin (dDAVP), a synthetic analogue of 8-arginine vasopressin (ADH), is an antidiuretic peptide drug modified by deamination of 1-cysteine and substitution of 8-L-arginine by 8-D-arginine. ADH is an endogenous pituitary hormone that has a crucial role in the control of the water content in the body. Upon release from the stimulation of increased plasma osmolarity or decreased circulating blood volume, ADH mainly acts on the cells of the distal part of the nephron and the collecting tubules in the kidney. The hormone interacts with V1, V2 or V3 receptors with differing signal cascade systems. Desmopressin displays enhanced antidiuretic potency, fewer pressor effects due to V2-selective actions, and a prolonged half-life and duration of action compared to endogenous ADH. It has been employed clinically since 1972
Diclofenac is a phenylacetic acid derivative and non-steroidal anti-inflammatory drug (NSAID).[label] NSAIDs inhibit cyclooxygenase (COX)-1 and-2 which are the enzyme responsible for producing prostaglandins (PGs). PGs contribute to inflammation and pain signalling. Diclofenac, like other NSAIDs, is often used as first line therapy for acute and chronic pain and inflammation from a variety of causes. Diclofenac was the product of rational drug design based on the structures of [phenylbutazone], [mefenamic acid], and [indomethacin]. The addition of two chlorine groups in the ortho position of the phenyl ring locks the ring in maximal torsion which appears to be related to increased potency. It is often used in combination with [misoprostol] to prevent NSAID-induced gastric ulcers. Diclofenac was first approved by the FDA in July 1988 under the trade name Voltaren, marketed by Novartis (previously Ciba-Geigy).
Moderate
1
[ [ [ 1314, 24, 1512 ] ], [ [ 1314, 24, 1263 ], [ 1263, 63, 1512 ] ], [ [ 1314, 6, 7720 ], [ 7720, 45, 1512 ] ], [ [ 1314, 21, 29231 ], [ 29231, 60, 1512 ] ], [ [ 1314, 40, 16 ], [ 16, 62, 1512 ] ], [ [ 1314, 24, 598 ], [ 598, 24, 1512 ] ], [ [ 1314, 23, 1479 ], [ 1479, 63, 1512 ] ], [ [ 1314, 25, 1486 ], [ 1486, 63, 1512 ] ], [ [ 1314, 25, 1028 ], [ 1028, 24, 1512 ] ], [ [ 1314, 24, 886 ], [ 886, 25, 1512 ] ] ]
[ [ [ "Desmopressin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Diclofenac" ] ], [ [ "Desmopressin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Bromfenac" ], [ "Bromfenac", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Diclofenac" ] ], [ [ "Desmopressin", "{u} (Compound) binds {v} (Gene)", "PTGS2" ], [ "PTGS2", "{u} (Gene) is bound by {v} (Compound)", "Diclofenac" ] ], [ [ "Desmopressin", "{u} (Compound) causes {v} (Side Effect)", "Cardiac disorder" ], [ "Cardiac disorder", "{u} (Side Effect) is caused by {v} (Compound)", "Diclofenac" ] ], [ [ "Desmopressin", "{u} (Compound) resembles {v} (Compound)", "Linaclotide" ], [ "Linaclotide", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Diclofenac" ] ], [ [ "Desmopressin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Nabumetone" ], [ "Nabumetone", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Diclofenac" ] ], [ [ "Desmopressin", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Acetylsalicylic acid" ], [ "Acetylsalicylic acid", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Diclofenac" ] ], [ [ "Desmopressin", "{u} may lead to a major life threatening interaction when taken with {v}", "Methylprednisolone" ], [ "Methylprednisolone", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Diclofenac" ] ], [ [ "Desmopressin", "{u} may lead to a major life threatening interaction when taken with {v}", "Torasemide" ], [ "Torasemide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Diclofenac" ] ], [ [ "Desmopressin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Ketorolac" ], [ "Ketorolac", "{u} may lead to a major life threatening interaction when taken with {v}", "Diclofenac" ] ] ]
Desmopressin may cause a moderate interaction that could exacerbate diseases when taken with Bromfenac and Bromfenac may cause a moderate interaction that could exacerbate diseases when taken with Diclofenac Desmopressin (Compound) binds PTGS2 (Gene) and PTGS2 (Gene) is bound by Diclofenac (Compound) Desmopressin (Compound) causes Cardiac disorder (Side Effect) and Cardiac disorder (Side Effect) is caused by Diclofenac (Compound) Desmopressin (Compound) resembles Linaclotide (Compound) and Linaclotide may cause a minor interaction that can limit clinical effects when taken with Diclofenac Desmopressin may cause a moderate interaction that could exacerbate diseases when taken with Nabumetone and Nabumetone may cause a moderate interaction that could exacerbate diseases when taken with Diclofenac Desmopressin may cause a minor interaction that can limit clinical effects when taken with Acetylsalicylic acid and Acetylsalicylic acid may cause a moderate interaction that could exacerbate diseases when taken with Diclofenac Desmopressin may lead to a major life threatening interaction when taken with Methylprednisolone and Methylprednisolone may cause a moderate interaction that could exacerbate diseases when taken with Diclofenac Desmopressin may lead to a major life threatening interaction when taken with Torasemide and Torasemide may cause a moderate interaction that could exacerbate diseases when taken with Diclofenac Desmopressin may cause a moderate interaction that could exacerbate diseases when taken with Ketorolac and Ketorolac may lead to a major life threatening interaction when taken with Diclofenac
DB00342
DB00705
1,181
441
[ "DDInter1770", "DDInter496" ]
Terfenadine
Delavirdine
In the U.S., Terfenadine was superseded by fexofenadine in the 1990s due to the risk of cardiac arrhythmia caused by QT interval prolongation.
A potent, non-nucleoside reverse transcriptase inhibitor with activity specific for HIV-1.
Major
2
[ [ [ 1181, 25, 441 ] ], [ [ 1181, 24, 1374 ], [ 1374, 62, 441 ] ], [ [ 1181, 24, 710 ], [ 710, 63, 441 ] ], [ [ 1181, 23, 1387 ], [ 1387, 63, 441 ] ], [ [ 1181, 25, 868 ], [ 868, 63, 441 ] ], [ [ 1181, 63, 1101 ], [ 1101, 24, 441 ] ], [ [ 1181, 25, 1424 ], [ 1424, 24, 441 ] ], [ [ 1181, 64, 600 ], [ 600, 24, 441 ] ], [ [ 1181, 24, 1419 ], [ 1419, 24, 441 ] ], [ [ 1181, 24, 1491 ], [ 1491, 64, 441 ] ] ]
[ [ [ "Terfenadine", "{u} may lead to a major life threatening interaction when taken with {v}", "Delavirdine" ] ], [ [ "Terfenadine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Abiraterone" ], [ "Abiraterone", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Delavirdine" ] ], [ [ "Terfenadine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Binimetinib" ], [ "Binimetinib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Delavirdine" ] ], [ [ "Terfenadine", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Terbinafine" ], [ "Terbinafine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Delavirdine" ] ], [ [ "Terfenadine", "{u} may lead to a major life threatening interaction when taken with {v}", "Vemurafenib" ], [ "Vemurafenib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Delavirdine" ] ], [ [ "Terfenadine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Bexarotene" ], [ "Bexarotene", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Delavirdine" ] ], [ [ "Terfenadine", "{u} may lead to a major life threatening interaction when taken with {v}", "Quinine" ], [ "Quinine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Delavirdine" ] ], [ [ "Terfenadine", "{u} may lead to a major life threatening interaction when taken with {v}", "Fluconazole" ], [ "Fluconazole", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Delavirdine" ] ], [ [ "Terfenadine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Imatinib" ], [ "Imatinib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Delavirdine" ] ], [ [ "Terfenadine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Midostaurin" ], [ "Midostaurin", "{u} may lead to a major life threatening interaction when taken with {v}", "Delavirdine" ] ] ]
Terfenadine may cause a moderate interaction that could exacerbate diseases when taken with Abiraterone and Abiraterone may cause a minor interaction that can limit clinical effects when taken with Delavirdine Terfenadine may cause a moderate interaction that could exacerbate diseases when taken with Binimetinib and Binimetinib may cause a moderate interaction that could exacerbate diseases when taken with Delavirdine Terfenadine may cause a minor interaction that can limit clinical effects when taken with Terbinafine and Terbinafine may cause a moderate interaction that could exacerbate diseases when taken with Delavirdine Terfenadine may lead to a major life threatening interaction when taken with Vemurafenib and Vemurafenib may cause a moderate interaction that could exacerbate diseases when taken with Delavirdine Terfenadine may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a moderate interaction that could exacerbate diseases when taken with Delavirdine Terfenadine may lead to a major life threatening interaction when taken with Quinine and Quinine may cause a moderate interaction that could exacerbate diseases when taken with Delavirdine Terfenadine may lead to a major life threatening interaction when taken with Fluconazole and Fluconazole may cause a moderate interaction that could exacerbate diseases when taken with Delavirdine Terfenadine may cause a moderate interaction that could exacerbate diseases when taken with Imatinib and Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Delavirdine Terfenadine may cause a moderate interaction that could exacerbate diseases when taken with Midostaurin and Midostaurin may lead to a major life threatening interaction when taken with Delavirdine
DB00069
DB00193
367
534
[ "DDInter946", "DDInter1841" ]
Interferon alfacon-1
Tramadol
Interferon alfacon-1 is a recombinant non-naturally occurring type-I interferon. The 166-amino acid sequence of Interferon alfacon-1 was derived by scanning the sequences of several natural interferon alpha subtypes and assigning the most frequently observed amino acid in each corresponding position. Four additional amino acid changes were made to facilitate the molecular construction, and a corresponding synthetic DNA sequence was constructed using chemical synthesis methodology. Interferon alfacon-1 differs from interferon alfa-2b at 20/166 amino acids (88% homology), and comparison with interferon-beta shows identity at over 30% of the amino acid positions. Interferon alfacon-1 is produced in Escherichia coli (E. coli) cells that have been genetically altered by insertion of a synthetically constructed sequence that codes for Interferon alfacon-1. Prior to final purification, Interferon alfacon-
Tramadol is a centrally acting synthetic opioid analgesic and SNRI (serotonin/norepinephrine reuptake-inhibitor) that is structurally related to [codeine] and [morphine]. Due to its good tolerability profile and multimodal mechanism of action, tramadol is generally considered a lower-risk opioid option for the treatment of moderate to severe pain. It is considered a Step 2 option on the World Health Organization's pain ladder and has about 1/10th of the potency of [morphine]. Tramadol differs from other traditional opioid medications in that it doesn't just act as a μ-opioid agonist, but also affects monoamines by modulating the effects of neurotransmitters involved in the modulation of pain such as serotonin and norepinpehrine which activate descending pain inhibitory pathways. Tramadol's effects on serotonin and norepinephrine mimic the effects of other SNRI antidepressants such as [duloxetine] and [venlafaxine]. Tramadol exists as a racemic mixture consisting of two pharmacologically active enantiomers that both contribute to its analgesic property through different mechanisms and are also themselves metabolized into active metabolites: (+)-tramadol and its primary metabolite (+)-O-desmethyl-tramadol (M1) are agonists of the μ opioid receptor while (+)-tramadol inhibits serotonin reuptake and (-)-tramadol inhibits norepinephrine reuptake. These pathways are complementary and synergistic, improving tramadol's ability to modulate the perception of and response to pain.[A4269,A183842] Tramadol has also been shown to affect a number of other pain modulators within the central nervous system as well as non-neuronal inflammatory markers and immune mediators.[A183728,A183734,A183761,A17159,A182300] Due to the broad spectrum of targets involved in pain and inflammation, it's not surprising that the evidence has shown that tramadol is effective for a number of pain types including neuropathic pain, post-operative pain, lower back pain, as well as pain associated with labour, osteoarthritis, fibromyalgia, and cancer. Due to its SNRI activity, tramadol also has anxiolytic, antidepressant, and anti-shivering effects which are all frequently found as comorbidities with pain. Similar to other opioid medications, tramadol poses a risk for development of tolerance, dependence and abuse. If used in higher doses, or with other opioids, there is a dose-related risk of overdose, respiratory depression, and death.[A183830,F4679] However, unlike other opioid medications, tramadol use also carries a risk of seizure and serotonin syndrome, particularly if used with other serotonergic medications.[A183836,A179926]
Major
2
[ [ [ 367, 25, 534 ] ], [ [ 367, 24, 112 ], [ 112, 62, 534 ] ], [ [ 367, 24, 770 ], [ 770, 63, 534 ] ], [ [ 367, 25, 976 ], [ 976, 63, 534 ] ], [ [ 367, 24, 1487 ], [ 1487, 64, 534 ] ], [ [ 367, 63, 491 ], [ 491, 25, 534 ] ], [ [ 367, 25, 497 ], [ 497, 64, 534 ] ], [ [ 367, 64, 1648 ], [ 1648, 25, 534 ] ], [ [ 367, 24, 112 ], [ 112, 62, 1100 ], [ 1100, 40, 534 ] ], [ [ 367, 24, 770 ], [ 770, 63, 1100 ], [ 1100, 40, 534 ] ] ]
[ [ [ "Interferon alfacon-1", "{u} may lead to a major life threatening interaction when taken with {v}", "Tramadol" ] ], [ [ "Interferon alfacon-1", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Metronidazole" ], [ "Metronidazole", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Tramadol" ] ], [ [ "Interferon alfacon-1", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Thalidomide" ], [ "Thalidomide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Tramadol" ] ], [ [ "Interferon alfacon-1", "{u} may lead to a major life threatening interaction when taken with {v}", "Tofacitinib" ], [ "Tofacitinib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Tramadol" ] ], [ [ "Interferon alfacon-1", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Hydroxychloroquine" ], [ "Hydroxychloroquine", "{u} may lead to a major life threatening interaction when taken with {v}", "Tramadol" ] ], [ [ "Interferon alfacon-1", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Peginterferon alfa-2a" ], [ "Peginterferon alfa-2a", "{u} may lead to a major life threatening interaction when taken with {v}", "Tramadol" ] ], [ [ "Interferon alfacon-1", "{u} may lead to a major life threatening interaction when taken with {v}", "Iohexol" ], [ "Iohexol", "{u} may lead to a major life threatening interaction when taken with {v}", "Tramadol" ] ], [ [ "Interferon alfacon-1", "{u} may lead to a major life threatening interaction when taken with {v}", "Aldesleukin" ], [ "Aldesleukin", "{u} may lead to a major life threatening interaction when taken with {v}", "Tramadol" ] ], [ [ "Interferon alfacon-1", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Metronidazole" ], [ "Metronidazole", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Venlafaxine" ], [ "Venlafaxine", "{u} (Compound) resembles {v} (Compound)", "Tramadol" ] ], [ [ "Interferon alfacon-1", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Thalidomide" ], [ "Thalidomide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Venlafaxine" ], [ "Venlafaxine", "{u} (Compound) resembles {v} (Compound)", "Tramadol" ] ] ]
Interferon alfacon-1 may cause a moderate interaction that could exacerbate diseases when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Tramadol Interferon alfacon-1 may cause a moderate interaction that could exacerbate diseases when taken with Thalidomide and Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Tramadol Interferon alfacon-1 may lead to a major life threatening interaction when taken with Tofacitinib and Tofacitinib may cause a moderate interaction that could exacerbate diseases when taken with Tramadol Interferon alfacon-1 may cause a moderate interaction that could exacerbate diseases when taken with Hydroxychloroquine and Hydroxychloroquine may lead to a major life threatening interaction when taken with Tramadol Interferon alfacon-1 may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon alfa-2a and Peginterferon alfa-2a may lead to a major life threatening interaction when taken with Tramadol Interferon alfacon-1 may lead to a major life threatening interaction when taken with Iohexol and Iohexol may lead to a major life threatening interaction when taken with Tramadol Interferon alfacon-1 may lead to a major life threatening interaction when taken with Aldesleukin and Aldesleukin may lead to a major life threatening interaction when taken with Tramadol Interferon alfacon-1 may cause a moderate interaction that could exacerbate diseases when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Venlafaxine and Venlafaxine (Compound) resembles Tramadol (Compound) Interferon alfacon-1 may cause a moderate interaction that could exacerbate diseases when taken with Thalidomide and Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Venlafaxine and Venlafaxine (Compound) resembles Tramadol (Compound)
DB00283
DB06204
701
768
[ "DDInter395", "DDInter1746" ]
Clemastine
Tapentadol
An ethanolamine-derivative, first generation histamine H1 antagonist used in hay fever, rhinitis, allergic skin conditions, and pruritus. It causes drowsiness.
Tapentadol is a centrally-acting synthetic analgesic with a dual mechanism of action. It is a mu-opioid receptor agonist that also inhibits norepinephrine reuptake.[A260721, A36596] Tapentadol was first approved by the FDA on November 20, 2008. The extended-release formulation of tapentadol was also approved by the FDA on August 26, 2011. Used in the management of pain, tapentadol is typically reserved for patients who have limited alternative treatment options.
Moderate
1
[ [ [ 701, 24, 768 ] ], [ [ 701, 6, 12523 ], [ 12523, 45, 768 ] ], [ [ 701, 21, 28921 ], [ 28921, 60, 768 ] ], [ [ 701, 24, 1123 ], [ 1123, 24, 768 ] ], [ [ 701, 24, 849 ], [ 849, 63, 768 ] ], [ [ 701, 63, 352 ], [ 352, 24, 768 ] ], [ [ 701, 35, 1242 ], [ 1242, 24, 768 ] ], [ [ 701, 24, 1053 ], [ 1053, 25, 768 ] ], [ [ 701, 6, 12523 ], [ 12523, 45, 189 ], [ 189, 40, 768 ] ], [ [ 701, 21, 28921 ], [ 28921, 60, 189 ], [ 189, 40, 768 ] ] ]
[ [ [ "Clemastine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Tapentadol" ] ], [ [ "Clemastine", "{u} (Compound) binds {v} (Gene)", "CYP2D6" ], [ "CYP2D6", "{u} (Gene) is bound by {v} (Compound)", "Tapentadol" ] ], [ [ "Clemastine", "{u} (Compound) causes {v} (Side Effect)", "Dizziness" ], [ "Dizziness", "{u} (Side Effect) is caused by {v} (Compound)", "Tapentadol" ] ], [ [ "Clemastine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Propantheline" ], [ "Propantheline", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Tapentadol" ] ], [ [ "Clemastine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Mepyramine" ], [ "Mepyramine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Tapentadol" ] ], [ [ "Clemastine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Trospium" ], [ "Trospium", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Tapentadol" ] ], [ [ "Clemastine", "{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Cetirizine" ], [ "Cetirizine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Tapentadol" ] ], [ [ "Clemastine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Procarbazine" ], [ "Procarbazine", "{u} may lead to a major life threatening interaction when taken with {v}", "Tapentadol" ] ], [ [ "Clemastine", "{u} (Compound) binds {v} (Gene)", "CYP2D6" ], [ "CYP2D6", "{u} (Gene) is bound by {v} (Compound)", "Rivastigmine" ], [ "Rivastigmine", "{u} (Compound) resembles {v} (Compound)", "Tapentadol" ] ], [ [ "Clemastine", "{u} (Compound) causes {v} (Side Effect)", "Dizziness" ], [ "Dizziness", "{u} (Side Effect) is caused by {v} (Compound)", "Rivastigmine" ], [ "Rivastigmine", "{u} (Compound) resembles {v} (Compound)", "Tapentadol" ] ] ]
Clemastine (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Tapentadol (Compound) Clemastine (Compound) causes Dizziness (Side Effect) and Dizziness (Side Effect) is caused by Tapentadol (Compound) Clemastine may cause a moderate interaction that could exacerbate diseases when taken with Propantheline and Propantheline may cause a moderate interaction that could exacerbate diseases when taken with Tapentadol Clemastine may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine and Mepyramine may cause a moderate interaction that could exacerbate diseases when taken with Tapentadol Clemastine may cause a moderate interaction that could exacerbate diseases when taken with Trospium and Trospium may cause a moderate interaction that could exacerbate diseases when taken with Tapentadol Clemastine (Compound) resembles Cetirizine (Compound) and Clemastine may cause a moderate interaction that could exacerbate diseases when taken with Cetirizine and Cetirizine may cause a moderate interaction that could exacerbate diseases when taken with Tapentadol Clemastine may cause a moderate interaction that could exacerbate diseases when taken with Procarbazine and Procarbazine may lead to a major life threatening interaction when taken with Tapentadol Clemastine (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Rivastigmine (Compound) and Rivastigmine (Compound) resembles Tapentadol (Compound) Clemastine (Compound) causes Dizziness (Side Effect) and Dizziness (Side Effect) is caused by Rivastigmine (Compound) and Rivastigmine (Compound) resembles Tapentadol (Compound)
DB11718
DB11952
927
800
[ "DDInter640", "DDInter612" ]
Encorafenib
Duvelisib
Encorafenib, also known as _BRAFTOVI_, is a kinase inhibitor. Encorafenib inhibits BRAF gene, which encodes for B-raf protein, which is a proto-oncogene involved in various genetic mutations. This protein plays a role in regulating the MAP kinase/ERK signaling pathway, which impacts cell division, differentiation, and secretion. Mutations in this gene, most frequently the V600E mutation, are the most commonly identified cancer-causing mutations in melanoma, and have been isolated in various other cancers as well, including non-Hodgkin lymphoma, colorectal cancer, thyroid carcinoma, non-small cell lung carcinoma, hairy cell leukemia and adenocarcinoma of the lung. On June 27, 2018, the Food and Drug Administration approved encorafenib and [binimetinib] (BRAFTOVI and MEKTOVI, Array BioPharma Inc.) in combination for patients with unre
Duvelisib, also known as IPI-145 and INK-1197, is a small-molecule inhibitor of phosphoinositide-3 kinases that was designed initially to prove that simultaneous inhibition of the isoforms delta and gamma can produce a broad adaptative and innate immune cell inhibitory activity. All the work around duvelisib showed that this agent is a potent inhibitor of both forms. Duvelisib was developed by Verastem, Inc and FDA approved on September 24, 2018.
Major
2
[ [ [ 927, 25, 800 ] ], [ [ 927, 63, 310 ], [ 310, 24, 800 ] ], [ [ 927, 24, 1476 ], [ 1476, 63, 800 ] ], [ [ 927, 64, 11 ], [ 11, 24, 800 ] ], [ [ 927, 25, 1017 ], [ 1017, 63, 800 ] ], [ [ 927, 25, 351 ], [ 351, 24, 800 ] ], [ [ 927, 24, 1297 ], [ 1297, 24, 800 ] ], [ [ 927, 64, 609 ], [ 609, 25, 800 ] ], [ [ 927, 63, 1135 ], [ 1135, 25, 800 ] ], [ [ 927, 24, 484 ], [ 484, 64, 800 ] ] ]
[ [ [ "Encorafenib", "{u} may lead to a major life threatening interaction when taken with {v}", "Duvelisib" ] ], [ [ "Encorafenib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Cabazitaxel" ], [ "Cabazitaxel", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Duvelisib" ] ], [ [ "Encorafenib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Brigatinib" ], [ "Brigatinib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Duvelisib" ] ], [ [ "Encorafenib", "{u} may lead to a major life threatening interaction when taken with {v}", "Toremifene" ], [ "Toremifene", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Duvelisib" ] ], [ [ "Encorafenib", "{u} may lead to a major life threatening interaction when taken with {v}", "Lorlatinib" ], [ "Lorlatinib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Duvelisib" ] ], [ [ "Encorafenib", "{u} may lead to a major life threatening interaction when taken with {v}", "Ribociclib" ], [ "Ribociclib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Duvelisib" ] ], [ [ "Encorafenib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Osilodrostat" ], [ "Osilodrostat", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Duvelisib" ] ], [ [ "Encorafenib", "{u} may lead to a major life threatening interaction when taken with {v}", "Clarithromycin" ], [ "Clarithromycin", "{u} may lead to a major life threatening interaction when taken with {v}", "Duvelisib" ] ], [ [ "Encorafenib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Naloxegol" ], [ "Naloxegol", "{u} may lead to a major life threatening interaction when taken with {v}", "Duvelisib" ] ], [ [ "Encorafenib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Entrectinib" ], [ "Entrectinib", "{u} may lead to a major life threatening interaction when taken with {v}", "Duvelisib" ] ] ]
Encorafenib may cause a moderate interaction that could exacerbate diseases when taken with Cabazitaxel and Cabazitaxel may cause a moderate interaction that could exacerbate diseases when taken with Duvelisib Encorafenib may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib and Brigatinib may cause a moderate interaction that could exacerbate diseases when taken with Duvelisib Encorafenib may lead to a major life threatening interaction when taken with Toremifene and Toremifene may cause a moderate interaction that could exacerbate diseases when taken with Duvelisib Encorafenib may lead to a major life threatening interaction when taken with Lorlatinib and Lorlatinib may cause a moderate interaction that could exacerbate diseases when taken with Duvelisib Encorafenib may lead to a major life threatening interaction when taken with Ribociclib and Ribociclib may cause a moderate interaction that could exacerbate diseases when taken with Duvelisib Encorafenib may cause a moderate interaction that could exacerbate diseases when taken with Osilodrostat and Osilodrostat may cause a moderate interaction that could exacerbate diseases when taken with Duvelisib Encorafenib may lead to a major life threatening interaction when taken with Clarithromycin and Clarithromycin may lead to a major life threatening interaction when taken with Duvelisib Encorafenib may cause a moderate interaction that could exacerbate diseases when taken with Naloxegol and Naloxegol may lead to a major life threatening interaction when taken with Duvelisib Encorafenib may cause a moderate interaction that could exacerbate diseases when taken with Entrectinib and Entrectinib may lead to a major life threatening interaction when taken with Duvelisib
DB01067
DB12130
959
1,017
[ "DDInter826", "DDInter1094" ]
Glipizide
Lorlatinib
Glipizide is an oral hypoglycemic agent in the second-generation sulfonylurea drug class that is used to control blood sugar levels in patients with type 2 diabetes mellitus. It was first introduced in 1984 and is available in various countries including Canada and the U.S. According to the 2018 Clinical Practice Guidelines by Diabetes Canada, sulfonylurea drugs are considered a second-line glucose-lowering therapy following metformin. Because sulfonylureas require functional pancreatic beta cells for their therapeutic effectiveness, sulfonylureas are more commonly used for early-stage type 2 diabetes when there is no progressed pancreatic failure. Compared to the first-generation sulfonylureas, such as [tolbutamide] and [chlorpropamide], second-generation sulfonylureas contain a more non-polar side chain in their chemical structure, which enhances their hypoglycemic potency. Compared to other members of the sulfonyl
Lorlatinib is a third-generation ALK tyrosine kinase inhibitor (TKI) for patients with ALK-positive metastatic non-small cell lung cancer which was first approved by the US FDA in November of 2018. It was subsequently approved by the EMA in 2019 for the treatment of select patients with previously treated advanced ALK-positive non-small cell lung cancer, followed by an expanded approval in 2022 to include lorlatinib as a first-line treatment option in advanced ALK-positive NSCLC.
Moderate
1
[ [ [ 959, 24, 1017 ] ], [ [ 959, 63, 1101 ], [ 1101, 23, 1017 ] ], [ [ 959, 63, 175 ], [ 175, 24, 1017 ] ], [ [ 959, 24, 1491 ], [ 1491, 24, 1017 ] ], [ [ 959, 40, 1411 ], [ 1411, 24, 1017 ] ], [ [ 959, 24, 1654 ], [ 1654, 63, 1017 ] ], [ [ 959, 25, 86 ], [ 86, 24, 1017 ] ], [ [ 959, 64, 839 ], [ 839, 24, 1017 ] ], [ [ 959, 1, 245 ], [ 245, 24, 1017 ] ], [ [ 959, 24, 1220 ], [ 1220, 25, 1017 ] ] ]
[ [ [ "Glipizide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Lorlatinib" ] ], [ [ "Glipizide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Bexarotene" ], [ "Bexarotene", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Lorlatinib" ] ], [ [ "Glipizide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Triamcinolone" ], [ "Triamcinolone", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Lorlatinib" ] ], [ [ "Glipizide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Midostaurin" ], [ "Midostaurin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Lorlatinib" ] ], [ [ "Glipizide", "{u} (Compound) resembles {v} (Compound)", "Tolbutamide" ], [ "Tolbutamide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Lorlatinib" ] ], [ [ "Glipizide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Somapacitan" ], [ "Somapacitan", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Lorlatinib" ] ], [ [ "Glipizide", "{u} may lead to a major life threatening interaction when taken with {v}", "Miconazole" ], [ "Miconazole", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Lorlatinib" ] ], [ [ "Glipizide", "{u} may lead to a major life threatening interaction when taken with {v}", "Grepafloxacin" ], [ "Grepafloxacin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Lorlatinib" ] ], [ [ "Glipizide", "{u} (Compound) resembles {v} (Compound)", "Glimepiride" ], [ "Glimepiride", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Lorlatinib" ] ], [ [ "Glipizide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Dexamethasone" ], [ "Dexamethasone", "{u} may lead to a major life threatening interaction when taken with {v}", "Lorlatinib" ] ] ]
Glipizide may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Lorlatinib Glipizide may cause a moderate interaction that could exacerbate diseases when taken with Triamcinolone and Triamcinolone may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib Glipizide may cause a moderate interaction that could exacerbate diseases when taken with Midostaurin and Midostaurin may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib Glipizide (Compound) resembles Tolbutamide (Compound) and Tolbutamide may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib Glipizide may cause a moderate interaction that could exacerbate diseases when taken with Somapacitan and Somapacitan may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib Glipizide may lead to a major life threatening interaction when taken with Miconazole and Miconazole may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib Glipizide may lead to a major life threatening interaction when taken with Grepafloxacin and Grepafloxacin may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib Glipizide (Compound) resembles Glimepiride (Compound) and Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib Glipizide may cause a moderate interaction that could exacerbate diseases when taken with Dexamethasone and Dexamethasone may lead to a major life threatening interaction when taken with Lorlatinib
DB05773
DB12240
1,047
110
[ "DDInter1848", "DDInter1485" ]
Trastuzumab emtansine
Polatuzumab vedotin
Trastuzumab emtansine, formerly called Trastuzumab-DM1 (T-DM1) is a first-in-class HER2 antibody drug conjugate (ADC) comprised of Genentech's trastuzumab antibody linked to ImmunoGen's cell-killing agent, DM1. T-DM1 combines two strategies-- anti-HER2 activity and targeted intracellular delivery of the potent anti-microtubule agent, DM1 (a maytansine derivative)--to produce cell cycle arrest and apoptosis. Trastuzumab emtansine is marketed under the brand name Kadcyla and is indicated for use in HER2-positive, metastatic breast cancer patients who have already used taxane and/or trastuzumab for metastatic disease or had their cancer recur within 6 months of adjuvant treatment. The FDA label has two precautions. First that trastuzumab emtansine and trast
Polatuzumab vedotin is a CD79b-directed antibody-drug conjugate that delivers monomethyl auristatin E (MMAE), an anti-mitotic agent, to cancer cells. The drug consists of three components - a humanized immunoglobulin G1 (IgG1) monoclonal antibody specific for human CD79b (polatuzumab), MMAE, and protease-cleavable linker called maleimidocaproyl-valine-citrulline-p-aminobenzyloxycarbonyl (mc-vc-PAB) that covalently attaches MMAE to polatuzumab. Polatuzumab vedotin was granted accelerated FDA approval on June 10, 2019 and was approved by Health Canada on July 9, 2020.
Moderate
1
[ [ [ 1047, 24, 110 ] ], [ [ 1047, 63, 467 ], [ 467, 24, 110 ] ], [ [ 1047, 25, 578 ], [ 578, 24, 110 ] ], [ [ 1047, 24, 980 ], [ 980, 24, 110 ] ], [ [ 1047, 64, 1213 ], [ 1213, 24, 110 ] ], [ [ 1047, 24, 148 ], [ 148, 63, 110 ] ], [ [ 1047, 63, 609 ], [ 609, 25, 110 ] ], [ [ 1047, 24, 760 ], [ 760, 25, 110 ] ], [ [ 1047, 25, 1510 ], [ 1510, 25, 110 ] ], [ [ 1047, 64, 1377 ], [ 1377, 25, 110 ] ] ]
[ [ [ "Trastuzumab emtansine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Polatuzumab vedotin" ] ], [ [ "Trastuzumab emtansine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Simvastatin" ], [ "Simvastatin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Polatuzumab vedotin" ] ], [ [ "Trastuzumab emtansine", "{u} may lead to a major life threatening interaction when taken with {v}", "Ticagrelor" ], [ "Ticagrelor", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Polatuzumab vedotin" ] ], [ [ "Trastuzumab emtansine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Tocilizumab" ], [ "Tocilizumab", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Polatuzumab vedotin" ] ], [ [ "Trastuzumab emtansine", "{u} may lead to a major life threatening interaction when taken with {v}", "Dasatinib" ], [ "Dasatinib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Polatuzumab vedotin" ] ], [ [ "Trastuzumab emtansine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Secnidazole" ], [ "Secnidazole", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Polatuzumab vedotin" ] ], [ [ "Trastuzumab emtansine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Clarithromycin" ], [ "Clarithromycin", "{u} may lead to a major life threatening interaction when taken with {v}", "Polatuzumab vedotin" ] ], [ [ "Trastuzumab emtansine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Cobicistat" ], [ "Cobicistat", "{u} may lead to a major life threatening interaction when taken with {v}", "Polatuzumab vedotin" ] ], [ [ "Trastuzumab emtansine", "{u} may lead to a major life threatening interaction when taken with {v}", "Teriflunomide" ], [ "Teriflunomide", "{u} may lead to a major life threatening interaction when taken with {v}", "Polatuzumab vedotin" ] ], [ [ "Trastuzumab emtansine", "{u} may lead to a major life threatening interaction when taken with {v}", "Leflunomide" ], [ "Leflunomide", "{u} may lead to a major life threatening interaction when taken with {v}", "Polatuzumab vedotin" ] ] ]
Trastuzumab emtansine may cause a moderate interaction that could exacerbate diseases when taken with Simvastatin and Simvastatin may cause a moderate interaction that could exacerbate diseases when taken with Polatuzumab vedotin Trastuzumab emtansine may lead to a major life threatening interaction when taken with Ticagrelor and Ticagrelor may cause a moderate interaction that could exacerbate diseases when taken with Polatuzumab vedotin Trastuzumab emtansine may cause a moderate interaction that could exacerbate diseases when taken with Tocilizumab and Tocilizumab may cause a moderate interaction that could exacerbate diseases when taken with Polatuzumab vedotin Trastuzumab emtansine may lead to a major life threatening interaction when taken with Dasatinib and Dasatinib may cause a moderate interaction that could exacerbate diseases when taken with Polatuzumab vedotin Trastuzumab emtansine may cause a moderate interaction that could exacerbate diseases when taken with Secnidazole and Secnidazole may cause a moderate interaction that could exacerbate diseases when taken with Polatuzumab vedotin Trastuzumab emtansine may cause a moderate interaction that could exacerbate diseases when taken with Clarithromycin and Clarithromycin may lead to a major life threatening interaction when taken with Polatuzumab vedotin Trastuzumab emtansine may cause a moderate interaction that could exacerbate diseases when taken with Cobicistat and Cobicistat may lead to a major life threatening interaction when taken with Polatuzumab vedotin Trastuzumab emtansine may lead to a major life threatening interaction when taken with Teriflunomide and Teriflunomide may lead to a major life threatening interaction when taken with Polatuzumab vedotin Trastuzumab emtansine may lead to a major life threatening interaction when taken with Leflunomide and Leflunomide may lead to a major life threatening interaction when taken with Polatuzumab vedotin
DB00405
DB09293
128
116
[ "DDInter517", "DDInter954" ]
Dexbrompheniramine
Iodide I-131
Dexbrompheniramine maleate is an antihistamine agent that is used for the treatment of allergic conditions, such as hay fever or urticaria.
Iodide I-131 (as Sodium iodide I-131) is a radioisotopic drug used for the treatment and palliation of thyroid malignancy. Iodine-131 is notable for causing mutation and death in cells that it penetrates, which is due to its mode of beta decay. As a result of beta decay, approximately 10% of its energy and radiation dose is via gamma radiation, while the other 90% (beta radiation) causes tissue damage without contributing to any ability to see or image the isotope. Low levels of beta radiation are also known for causing cancer as this dose is highly mutagenic. For this reason, less toxic iodine isotopes such as I-123 are more frequently used in nuclear imaging, while I-131 is reserved for its tissue destroying effects. Because the thyroid gland naturally takes up iodine from the body, therapeutic methods using radioisotopes can take advantage of this mechanism for localization of drug to the site of malignancy. Therapeutic solutions of Sodium Iodide-131 are indicated for the treatment of hyperthyroidism and thyroid carcinomas that take up iodine. Palliative effects may be observed in patients with advanced thyroid malignancy if the metastatic lesions take up iodine. It is also indicated for use in performance of the radioactive iodide (RAI) uptake test to evaluate thyroid function.
Moderate
1
[ [ [ 128, 24, 116 ] ], [ [ 128, 63, 701 ], [ 701, 24, 116 ] ], [ [ 128, 24, 252 ], [ 252, 24, 116 ] ], [ [ 128, 24, 337 ], [ 337, 63, 116 ] ], [ [ 128, 63, 701 ], [ 701, 35, 252 ], [ 252, 24, 116 ] ], [ [ 128, 24, 252 ], [ 252, 74, 701 ], [ 701, 24, 116 ] ], [ [ 128, 24, 682 ], [ 682, 63, 701 ], [ 701, 24, 116 ] ], [ [ 128, 63, 1242 ], [ 1242, 74, 701 ], [ 701, 24, 116 ] ], [ [ 128, 63, 523 ], [ 523, 23, 1486 ], [ 1486, 24, 116 ] ], [ [ 128, 63, 1174 ], [ 1174, 24, 701 ], [ 701, 24, 116 ] ] ]
[ [ [ "Dexbrompheniramine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Iodide I-131" ] ], [ [ "Dexbrompheniramine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Clemastine" ], [ "Clemastine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Iodide I-131" ] ], [ [ "Dexbrompheniramine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Hydroxyzine" ], [ "Hydroxyzine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Iodide I-131" ] ], [ [ "Dexbrompheniramine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Phenyltoloxamine" ], [ "Phenyltoloxamine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Iodide I-131" ] ], [ [ "Dexbrompheniramine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Clemastine" ], [ "Clemastine", "{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Hydroxyzine" ], [ "Hydroxyzine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Iodide I-131" ] ], [ [ "Dexbrompheniramine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Hydroxyzine" ], [ "Hydroxyzine", "{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Clemastine" ], [ "Clemastine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Iodide I-131" ] ], [ [ "Dexbrompheniramine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Thiopental" ], [ "Thiopental", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Clemastine" ], [ "Clemastine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Iodide I-131" ] ], [ [ "Dexbrompheniramine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Cetirizine" ], [ "Cetirizine", "{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Clemastine" ], [ "Clemastine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Iodide I-131" ] ], [ [ "Dexbrompheniramine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Alprazolam" ], [ "Alprazolam", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Methylprednisolone" ], [ "Methylprednisolone", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Iodide I-131" ] ], [ [ "Dexbrompheniramine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Temazepam" ], [ "Temazepam", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Clemastine" ], [ "Clemastine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Iodide I-131" ] ] ]
Dexbrompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Clemastine and Clemastine may cause a moderate interaction that could exacerbate diseases when taken with Iodide I-131 Dexbrompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Hydroxyzine and Hydroxyzine may cause a moderate interaction that could exacerbate diseases when taken with Iodide I-131 Dexbrompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Phenyltoloxamine and Phenyltoloxamine may cause a moderate interaction that could exacerbate diseases when taken with Iodide I-131 Dexbrompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Clemastine and Clemastine (Compound) resembles Hydroxyzine (Compound) and Clemastine may cause a moderate interaction that could exacerbate diseases when taken with Hydroxyzine and Hydroxyzine may cause a moderate interaction that could exacerbate diseases when taken with Iodide I-131 Dexbrompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Hydroxyzine and Hydroxyzine (Compound) resembles Clemastine (Compound) and Hydroxyzine may cause a moderate interaction that could exacerbate diseases when taken with Clemastine and Clemastine may cause a moderate interaction that could exacerbate diseases when taken with Iodide I-131 Dexbrompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Thiopental and Thiopental may cause a moderate interaction that could exacerbate diseases when taken with Clemastine and Clemastine may cause a moderate interaction that could exacerbate diseases when taken with Iodide I-131 Dexbrompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Cetirizine and Cetirizine (Compound) resembles Clemastine (Compound) and Cetirizine may cause a moderate interaction that could exacerbate diseases when taken with Clemastine and Clemastine may cause a moderate interaction that could exacerbate diseases when taken with Iodide I-131 Dexbrompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Alprazolam and Alprazolam may cause a minor interaction that can limit clinical effects when taken with Methylprednisolone and Methylprednisolone may cause a moderate interaction that could exacerbate diseases when taken with Iodide I-131 Dexbrompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Temazepam and Temazepam may cause a moderate interaction that could exacerbate diseases when taken with Clemastine and Clemastine may cause a moderate interaction that could exacerbate diseases when taken with Iodide I-131
DB00241
DB00741
288
167
[ "DDInter257", "DDInter885" ]
Butalbital
Hydrocortisone
Butalbital, or 5-allyl-5-isobutylbarbituric acid, is a derivative of barbituric acid which the hydrogens at position 5 are substituted by an allyl group and an isobutyl group. It is a short-to-intermediate acting member of barbiturates that exhibit muscle-relaxing and anti-anxiety properties that produce central nervous system (CNS) depression that ranges from mild sedation to general anesthesia. Butalbital has a low degree of selectivity and a narrow therapeutic index. Typically indicated to manage tension (or muscle contraction) headaches, butalbital is often combined with one or more therapeutic agents, such as acetylsalicylic acid, acetaminophen, aspirin, and caffeine. There have not been clinical trials that evaluate the clinical efficacy of butalbital in migraines thus it is not indicated for such condition. As with other barbiturates
Hydrocortisone, or cortisol, is a glucocorticoid secreted by the adrenal cortex. Hydrocortisone is used to treat immune, inflammatory, and neoplastic conditions.[L10529,L10532,L10535,L10538,L7772,L7321] It was discovered in the 1930s by Edward Kendall and named Compound F, or 17-hydroxycorticosterone. Hydrocortisone was granted FDA approval on 5 August 1952.
Moderate
1
[ [ [ 288, 24, 167 ] ], [ [ 288, 24, 1220 ], [ 1220, 40, 167 ] ], [ [ 288, 24, 870 ], [ 870, 1, 167 ] ], [ [ 288, 24, 392 ], [ 392, 63, 167 ] ], [ [ 288, 23, 1101 ], [ 1101, 24, 167 ] ], [ [ 288, 25, 126 ], [ 126, 24, 167 ] ], [ [ 288, 40, 1023 ], [ 1023, 24, 167 ] ], [ [ 288, 63, 1648 ], [ 1648, 24, 167 ] ], [ [ 288, 24, 1031 ], [ 1031, 24, 167 ] ], [ [ 288, 1, 536 ], [ 536, 24, 167 ] ] ]
[ [ [ "Butalbital", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Hydrocortisone" ] ], [ [ "Butalbital", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Dexamethasone" ], [ "Dexamethasone", "{u} (Compound) resembles {v} (Compound)", "Hydrocortisone" ] ], [ [ "Butalbital", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Fludrocortisone" ], [ "Fludrocortisone", "{u} (Compound) resembles {v} (Compound)", "Hydrocortisone" ] ], [ [ "Butalbital", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Lapatinib" ], [ "Lapatinib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Hydrocortisone" ] ], [ [ "Butalbital", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Bexarotene" ], [ "Bexarotene", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Hydrocortisone" ] ], [ [ "Butalbital", "{u} may lead to a major life threatening interaction when taken with {v}", "Warfarin" ], [ "Warfarin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Hydrocortisone" ] ], [ [ "Butalbital", "{u} (Compound) resembles {v} (Compound)", "Pentobarbital" ], [ "Pentobarbital", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Hydrocortisone" ] ], [ [ "Butalbital", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Aldesleukin" ], [ "Aldesleukin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Hydrocortisone" ] ], [ [ "Butalbital", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Theophylline" ], [ "Theophylline", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Hydrocortisone" ] ], [ [ "Butalbital", "{u} (Compound) resembles {v} (Compound)", "Secobarbital" ], [ "Secobarbital", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Hydrocortisone" ] ] ]
Butalbital may cause a moderate interaction that could exacerbate diseases when taken with Dexamethasone and Dexamethasone (Compound) resembles Hydrocortisone (Compound) Butalbital may cause a moderate interaction that could exacerbate diseases when taken with Fludrocortisone and Fludrocortisone (Compound) resembles Hydrocortisone (Compound) Butalbital may cause a moderate interaction that could exacerbate diseases when taken with Lapatinib and Lapatinib may cause a moderate interaction that could exacerbate diseases when taken with Hydrocortisone Butalbital may cause a minor interaction that can limit clinical effects when taken with Bexarotene and Bexarotene may cause a moderate interaction that could exacerbate diseases when taken with Hydrocortisone Butalbital may lead to a major life threatening interaction when taken with Warfarin and Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Hydrocortisone Butalbital (Compound) resembles Pentobarbital (Compound) and Pentobarbital may cause a moderate interaction that could exacerbate diseases when taken with Hydrocortisone Butalbital may cause a moderate interaction that could exacerbate diseases when taken with Aldesleukin and Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Hydrocortisone Butalbital may cause a moderate interaction that could exacerbate diseases when taken with Theophylline and Theophylline may cause a moderate interaction that could exacerbate diseases when taken with Hydrocortisone Butalbital (Compound) resembles Secobarbital (Compound) and Secobarbital may cause a moderate interaction that could exacerbate diseases when taken with Hydrocortisone
DB00988
DB08907
817
1,344
[ "DDInter584", "DDInter280" ]
Dopamine
Canagliflozin
One of the catecholamine neurotransmitters in the brain. It is derived from tyrosine and is the precursor to norepinephrine and epinephrine. Dopamine is a major transmitter in the extrapyramidal system of the brain, and important in regulating movement. A family of receptors (receptors, dopamine) mediate its action.
Canagliflozin, also known as _Invokana_, is a sodium-glucose cotransporter 2 (SGLT2) inhibitor used in the management of type 2 diabetes mellitus along with lifestyle changes including diet and exercise [FDA label]. It was initially approved by the FDA in 2013 for the management of diabetes and later approved in 2018 for a second indication of reducing the risk of cardiovascular events in patients diagnosed with type 2 diabetes mellitus , [FDA label]. Canagliflozin is the first oral antidiabetic drug approved for the prevention of cardiovascular events in patients with type 2 diabetes . Cardiovascular disease is the most common cause of death in these patients .
Moderate
1
[ [ [ 817, 24, 1344 ] ], [ [ 817, 24, 549 ], [ 549, 1, 1344 ] ], [ [ 817, 21, 28722 ], [ 28722, 60, 1344 ] ], [ [ 817, 24, 1148 ], [ 1148, 24, 1344 ] ], [ [ 817, 63, 176 ], [ 176, 24, 1344 ] ], [ [ 817, 40, 1551 ], [ 1551, 24, 1344 ] ], [ [ 817, 24, 1296 ], [ 1296, 63, 1344 ] ], [ [ 817, 1, 874 ], [ 874, 24, 1344 ] ], [ [ 817, 24, 549 ], [ 549, 6, 16207 ], [ 16207, 45, 1344 ] ], [ [ 817, 21, 28722 ], [ 28722, 60, 549 ], [ 549, 1, 1344 ] ] ]
[ [ [ "Dopamine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Canagliflozin" ] ], [ [ "Dopamine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Dapagliflozin" ], [ "Dapagliflozin", "{u} (Compound) resembles {v} (Compound)", "Canagliflozin" ] ], [ [ "Dopamine", "{u} (Compound) causes {v} (Side Effect)", "Nausea" ], [ "Nausea", "{u} (Side Effect) is caused by {v} (Compound)", "Canagliflozin" ] ], [ [ "Dopamine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Isoprenaline" ], [ "Isoprenaline", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Canagliflozin" ] ], [ [ "Dopamine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Insulin glargine" ], [ "Insulin glargine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Canagliflozin" ] ], [ [ "Dopamine", "{u} (Compound) resembles {v} (Compound)", "Methyldopa" ], [ "Methyldopa", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Canagliflozin" ] ], [ [ "Dopamine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Insulin degludec" ], [ "Insulin degludec", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Canagliflozin" ] ], [ [ "Dopamine", "{u} (Compound) resembles {v} (Compound)", "Epinephrine" ], [ "Epinephrine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Canagliflozin" ] ], [ [ "Dopamine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Dapagliflozin" ], [ "Dapagliflozin", "{u} (Compound) binds {v} (Gene)", "SLC5A1" ], [ "SLC5A1", "{u} (Gene) is bound by {v} (Compound)", "Canagliflozin" ] ], [ [ "Dopamine", "{u} (Compound) causes {v} (Side Effect)", "Nausea" ], [ "Nausea", "{u} (Side Effect) is caused by {v} (Compound)", "Dapagliflozin" ], [ "Dapagliflozin", "{u} (Compound) resembles {v} (Compound)", "Canagliflozin" ] ] ]
Dopamine may cause a moderate interaction that could exacerbate diseases when taken with Dapagliflozin and Dapagliflozin (Compound) resembles Canagliflozin (Compound) Dopamine (Compound) causes Nausea (Side Effect) and Nausea (Side Effect) is caused by Canagliflozin (Compound) Dopamine may cause a moderate interaction that could exacerbate diseases when taken with Isoprenaline and Isoprenaline may cause a moderate interaction that could exacerbate diseases when taken with Canagliflozin Dopamine may cause a moderate interaction that could exacerbate diseases when taken with Insulin glargine and Insulin glargine may cause a moderate interaction that could exacerbate diseases when taken with Canagliflozin Dopamine (Compound) resembles Methyldopa (Compound) and Methyldopa may cause a moderate interaction that could exacerbate diseases when taken with Canagliflozin Dopamine may cause a moderate interaction that could exacerbate diseases when taken with Insulin degludec and Insulin degludec may cause a moderate interaction that could exacerbate diseases when taken with Canagliflozin Dopamine (Compound) resembles Epinephrine (Compound) and Epinephrine may cause a moderate interaction that could exacerbate diseases when taken with Canagliflozin Dopamine may cause a moderate interaction that could exacerbate diseases when taken with Dapagliflozin and Dapagliflozin (Compound) binds SLC5A1 (Gene) and SLC5A1 (Gene) is bound by Canagliflozin (Compound) Dopamine (Compound) causes Nausea (Side Effect) and Nausea (Side Effect) is caused by Dapagliflozin (Compound) and Dapagliflozin (Compound) resembles Canagliflozin (Compound)
DB00478
DB09268
1,369
1,662
[ "DDInter1597", "DDInter1464" ]
Rimantadine
Picosulfuric acid
An RNA synthesis inhibitor that is used as an antiviral agent in the prophylaxis and treatment of influenza.
Picosulfuric acid is found in laxative products. Sodium picosulfate is a used to treat constipation or induce colon cleansing to prepare the large bowels before colonoscopy or surgery. The combination product containing sodium picosulfate and magnesium citrate was introduced to the Canadian market in 2005 and has been used in European countries for many years.
Moderate
1
[ [ [ 1369, 24, 1662 ] ], [ [ 1369, 40, 1170 ], [ 1170, 24, 1662 ] ], [ [ 1369, 63, 1503 ], [ 1503, 24, 1662 ] ], [ [ 1369, 25, 593 ], [ 593, 24, 1662 ] ], [ [ 1369, 40, 1170 ], [ 1170, 24, 820 ], [ 820, 24, 1662 ] ], [ [ 1369, 63, 1503 ], [ 1503, 24, 1164 ], [ 1164, 24, 1662 ] ], [ [ 1369, 54, 19350 ], [ 19350, 15, 1170 ], [ 1170, 24, 1662 ] ], [ [ 1369, 25, 593 ], [ 593, 63, 1252 ], [ 1252, 23, 1662 ] ], [ [ 1369, 21, 28854 ], [ 28854, 60, 514 ], [ 514, 24, 1662 ] ], [ [ 1369, 25, 593 ], [ 593, 64, 1164 ], [ 1164, 24, 1662 ] ] ]
[ [ [ "Rimantadine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Picosulfuric acid" ] ], [ [ "Rimantadine", "{u} (Compound) resembles {v} (Compound)", "Amantadine" ], [ "Amantadine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Picosulfuric acid" ] ], [ [ "Rimantadine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Lindane" ], [ "Lindane", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Picosulfuric acid" ] ], [ [ "Rimantadine", "{u} may lead to a major life threatening interaction when taken with {v}", "Bupropion" ], [ "Bupropion", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Picosulfuric acid" ] ], [ [ "Rimantadine", "{u} (Compound) resembles {v} (Compound)", "Amantadine" ], [ "Amantadine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Alimemazine" ], [ "Alimemazine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Picosulfuric acid" ] ], [ [ "Rimantadine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Lindane" ], [ "Lindane", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Trimipramine" ], [ "Trimipramine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Picosulfuric acid" ] ], [ [ "Rimantadine", "{u} (Compound) is included by {v} (Pharmacologic Class)", "M2 Protein Inhibitors" ], [ "M2 Protein Inhibitors", "{u} (Pharmacologic Class) includes {v} (Compound)", "Amantadine" ], [ "Amantadine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Picosulfuric acid" ] ], [ [ "Rimantadine", "{u} may lead to a major life threatening interaction when taken with {v}", "Bupropion" ], [ "Bupropion", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Digoxin" ], [ "Digoxin", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Picosulfuric acid" ] ], [ [ "Rimantadine", "{u} (Compound) causes {v} (Side Effect)", "Pallor" ], [ "Pallor", "{u} (Side Effect) is caused by {v} (Compound)", "Benzylpenicillin" ], [ "Benzylpenicillin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Picosulfuric acid" ] ], [ [ "Rimantadine", "{u} may lead to a major life threatening interaction when taken with {v}", "Bupropion" ], [ "Bupropion", "{u} may lead to a major life threatening interaction when taken with {v}", "Trimipramine" ], [ "Trimipramine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Picosulfuric acid" ] ] ]
Rimantadine (Compound) resembles Amantadine (Compound) and Amantadine may cause a moderate interaction that could exacerbate diseases when taken with Picosulfuric acid Rimantadine may cause a moderate interaction that could exacerbate diseases when taken with Lindane and Lindane may cause a moderate interaction that could exacerbate diseases when taken with Picosulfuric acid Rimantadine may lead to a major life threatening interaction when taken with Bupropion and Bupropion may cause a moderate interaction that could exacerbate diseases when taken with Picosulfuric acid Rimantadine (Compound) resembles Amantadine (Compound) and Amantadine may cause a moderate interaction that could exacerbate diseases when taken with Alimemazine and Alimemazine may cause a moderate interaction that could exacerbate diseases when taken with Picosulfuric acid Rimantadine may cause a moderate interaction that could exacerbate diseases when taken with Lindane and Lindane may cause a moderate interaction that could exacerbate diseases when taken with Trimipramine and Trimipramine may cause a moderate interaction that could exacerbate diseases when taken with Picosulfuric acid Rimantadine (Compound) is included by M2 Protein Inhibitors (Pharmacologic Class) and M2 Protein Inhibitors (Pharmacologic Class) includes Amantadine (Compound) and Amantadine may cause a moderate interaction that could exacerbate diseases when taken with Picosulfuric acid Rimantadine may lead to a major life threatening interaction when taken with Bupropion and Bupropion may cause a moderate interaction that could exacerbate diseases when taken with Digoxin and Digoxin may cause a minor interaction that can limit clinical effects when taken with Picosulfuric acid Rimantadine (Compound) causes Pallor (Side Effect) and Pallor (Side Effect) is caused by Benzylpenicillin (Compound) and Benzylpenicillin may cause a moderate interaction that could exacerbate diseases when taken with Picosulfuric acid Rimantadine may lead to a major life threatening interaction when taken with Bupropion and Bupropion may lead to a major life threatening interaction when taken with Trimipramine and Trimipramine may cause a moderate interaction that could exacerbate diseases when taken with Picosulfuric acid
DB00741
DB01072
167
915
[ "DDInter885", "DDInter129" ]
Hydrocortisone
Atazanavir
Hydrocortisone, or cortisol, is a glucocorticoid secreted by the adrenal cortex. Hydrocortisone is used to treat immune, inflammatory, and neoplastic conditions.[L10529,L10532,L10535,L10538,L7772,L7321] It was discovered in the 1930s by Edward Kendall and named Compound F, or 17-hydroxycorticosterone. Hydrocortisone was granted FDA approval on 5 August 1952.
Atazanavir (formerly known as BMS-232632) is an antiretroviral drug of the protease inhibitor (PI) class. Like other antiretrovirals, it is used to treat infection of human immunodeficiency virus (HIV). Atazanavir is distinguished from other PIs in that it can be given once daily (rather than requiring multiple doses per day) and has lesser effects on the patient's lipid profile (the amounts of cholesterol and other fatty substances in the blood). Like other protease inhibitors, it is used only in combination with other HIV medications. The U.S. Food and Drug Administration (FDA) approved atazanavir on June 20, 2003.
Moderate
1
[ [ [ 167, 24, 915 ] ], [ [ 167, 24, 1327 ], [ 1327, 1, 915 ] ], [ [ 167, 6, 4973 ], [ 4973, 45, 915 ] ], [ [ 167, 21, 29051 ], [ 29051, 60, 915 ] ], [ [ 167, 63, 1031 ], [ 1031, 23, 915 ] ], [ [ 167, 24, 5 ], [ 5, 63, 915 ] ], [ [ 167, 1, 423 ], [ 423, 63, 915 ] ], [ [ 167, 63, 1101 ], [ 1101, 24, 915 ] ], [ [ 167, 1, 1351 ], [ 1351, 24, 915 ] ], [ [ 167, 25, 1011 ], [ 1011, 63, 915 ] ] ]
[ [ [ "Hydrocortisone", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Atazanavir" ] ], [ [ "Hydrocortisone", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Saquinavir" ], [ "Saquinavir", "{u} (Compound) resembles {v} (Compound)", "Atazanavir" ] ], [ [ "Hydrocortisone", "{u} (Compound) binds {v} (Gene)", "ABCB1" ], [ "ABCB1", "{u} (Gene) is bound by {v} (Compound)", "Atazanavir" ] ], [ [ "Hydrocortisone", "{u} (Compound) causes {v} (Side Effect)", "Fluid retention" ], [ "Fluid retention", "{u} (Side Effect) is caused by {v} (Compound)", "Atazanavir" ] ], [ [ "Hydrocortisone", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Theophylline" ], [ "Theophylline", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Atazanavir" ] ], [ [ "Hydrocortisone", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Liraglutide" ], [ "Liraglutide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Atazanavir" ] ], [ [ "Hydrocortisone", "{u} (Compound) resembles {v} (Compound)", "Ciclesonide" ], [ "Ciclesonide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Atazanavir" ] ], [ [ "Hydrocortisone", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Bexarotene" ], [ "Bexarotene", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Atazanavir" ] ], [ [ "Hydrocortisone", "{u} (Compound) resembles {v} (Compound)", "Flunisolide" ], [ "Flunisolide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Atazanavir" ] ], [ [ "Hydrocortisone", "{u} may lead to a major life threatening interaction when taken with {v}", "Fingolimod" ], [ "Fingolimod", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Atazanavir" ] ] ]
Hydrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Saquinavir and Saquinavir (Compound) resembles Atazanavir (Compound) Hydrocortisone (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Atazanavir (Compound) Hydrocortisone (Compound) causes Fluid retention (Side Effect) and Fluid retention (Side Effect) is caused by Atazanavir (Compound) Hydrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Theophylline and Theophylline may cause a minor interaction that can limit clinical effects when taken with Atazanavir Hydrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Liraglutide and Liraglutide may cause a moderate interaction that could exacerbate diseases when taken with Atazanavir Hydrocortisone (Compound) resembles Ciclesonide (Compound) and Ciclesonide may cause a moderate interaction that could exacerbate diseases when taken with Atazanavir Hydrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a moderate interaction that could exacerbate diseases when taken with Atazanavir Hydrocortisone (Compound) resembles Flunisolide (Compound) and Flunisolide may cause a moderate interaction that could exacerbate diseases when taken with Atazanavir Hydrocortisone may lead to a major life threatening interaction when taken with Fingolimod and Fingolimod may cause a moderate interaction that could exacerbate diseases when taken with Atazanavir
DB01037
DB06704
1,161
247
[ "DDInter1653", "DDInter952" ]
Selegiline
Iobenguane (I-131)
A selective, irreversible inhibitor of Type B monoamine oxidase. It is used in newly diagnosed patients with Parkinson's disease. It may slow progression of the clinical disease and delay the requirement for levodopa therapy. It also may be given with levodopa upon onset of disability. (From AMA Drug Evaluations Annual, 1994, p385) The compound without isomeric designation is Deprenyl.
2-[(3-iodophenyl)methyl]guanidine is an organoiodine compound.
Major
2
[ [ [ 1161, 25, 247 ] ], [ [ 1161, 21, 28787 ], [ 28787, 60, 247 ] ], [ [ 1161, 24, 820 ], [ 820, 24, 247 ] ], [ [ 1161, 63, 999 ], [ 999, 24, 247 ] ], [ [ 1161, 37, 1090 ], [ 1090, 64, 247 ] ], [ [ 1161, 25, 1629 ], [ 1629, 64, 247 ] ], [ [ 1161, 24, 31 ], [ 31, 25, 247 ] ], [ [ 1161, 40, 551 ], [ 551, 25, 247 ] ], [ [ 1161, 40, 93 ], [ 93, 37, 247 ] ], [ [ 1161, 64, 1048 ], [ 1048, 37, 247 ] ] ]
[ [ [ "Selegiline", "{u} may lead to a major life threatening interaction when taken with {v}", "Iobenguane" ] ], [ [ "Selegiline", "{u} (Compound) causes {v} (Side Effect)", "Dermatitis" ], [ "Dermatitis", "{u} (Side Effect) is caused by {v} (Compound)", "Iobenguane" ] ], [ [ "Selegiline", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Alimemazine" ], [ "Alimemazine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Iobenguane" ] ], [ [ "Selegiline", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Thiethylperazine" ], [ "Thiethylperazine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Iobenguane" ] ], [ [ "Selegiline", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v} and {u} may lead to a major life threatening interaction when taken with {v}", "Tetryzoline" ], [ "Tetryzoline", "{u} may lead to a major life threatening interaction when taken with {v}", "Iobenguane" ] ], [ [ "Selegiline", "{u} may lead to a major life threatening interaction when taken with {v}", "Methylene blue" ], [ "Methylene blue", "{u} may lead to a major life threatening interaction when taken with {v}", "Iobenguane" ] ], [ [ "Selegiline", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Xylometazoline" ], [ "Xylometazoline", "{u} may lead to a major life threatening interaction when taken with {v}", "Iobenguane" ] ], [ [ "Selegiline", "{u} (Compound) resembles {v} (Compound)", "Phenelzine" ], [ "Phenelzine", "{u} may lead to a major life threatening interaction when taken with {v}", "Iobenguane" ] ], [ [ "Selegiline", "{u} (Compound) resembles {v} (Compound)", "Dextroamphetamine" ], [ "Dextroamphetamine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v} and {u} may lead to a major life threatening interaction when taken with {v}", "Iobenguane" ] ], [ [ "Selegiline", "{u} may lead to a major life threatening interaction when taken with {v}", "Doxapram" ], [ "Doxapram", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v} and {u} may lead to a major life threatening interaction when taken with {v}", "Iobenguane" ] ] ]
Selegiline may lead to a major life threatening interaction when taken with Iobenguane Selegiline (Compound) causes Dermatitis (Side Effect) and Dermatitis (Side Effect) is caused by Iobenguane (Compound) Selegiline may cause a moderate interaction that could exacerbate diseases when taken with Alimemazine and Alimemazine may cause a moderate interaction that could exacerbate diseases when taken with Iobenguane Selegiline may cause a moderate interaction that could exacerbate diseases when taken with Thiethylperazine and Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken with Iobenguane Selegiline may cause a moderate interaction that could exacerbate diseases when taken with Tetryzoline and Selegiline may lead to a major life threatening interaction when taken with Tetryzoline and Tetryzoline may lead to a major life threatening interaction when taken with Iobenguane Selegiline may lead to a major life threatening interaction when taken with Methylene blue and Methylene blue may lead to a major life threatening interaction when taken with Iobenguane Selegiline may cause a moderate interaction that could exacerbate diseases when taken with Xylometazoline and Xylometazoline may lead to a major life threatening interaction when taken with Iobenguane Selegiline (Compound) resembles Phenelzine (Compound) and Phenelzine may lead to a major life threatening interaction when taken with Iobenguane Selegiline (Compound) resembles Dextroamphetamine (Compound) and Dextroamphetamine may cause a moderate interaction that could exacerbate diseases when taken with Iobenguane and Dextroamphetamine may lead to a major life threatening interaction when taken with Iobenguane Selegiline may lead to a major life threatening interaction when taken with Doxapram and Doxapram may cause a moderate interaction that could exacerbate diseases when taken with Iobenguane and Doxapram may lead to a major life threatening interaction when taken with Iobenguane
DB00193
DB00196
534
600
[ "DDInter1841", "DDInter743" ]
Tramadol
Fluconazole
Tramadol is a centrally acting synthetic opioid analgesic and SNRI (serotonin/norepinephrine reuptake-inhibitor) that is structurally related to [codeine] and [morphine]. Due to its good tolerability profile and multimodal mechanism of action, tramadol is generally considered a lower-risk opioid option for the treatment of moderate to severe pain. It is considered a Step 2 option on the World Health Organization's pain ladder and has about 1/10th of the potency of [morphine]. Tramadol differs from other traditional opioid medications in that it doesn't just act as a μ-opioid agonist, but also affects monoamines by modulating the effects of neurotransmitters involved in the modulation of pain such as serotonin and norepinpehrine which activate descending pain inhibitory pathways. Tramadol's effects on serotonin and norepinephrine mimic the effects of other SNRI antidepressants such as [dul
Fluconazole, commonly known as _Diflucan_, is an antifungal drug used for the treatment of both systemic and superficial fungal infections in a variety of tissues. It was initially approved by the FDA in 1990. This drug is an _azole_ antifungal, in the same drug family as [ketoconazole] and [itraconazole]. Fluconazole has many advantages over the other antifungal drugs including the option of oral administration. The side effect profile of this drug is minimal. It has been demonstrated as an efficacious treatment for vaginal yeast infections in one single dose.
Moderate
1
[ [ [ 534, 24, 600 ] ], [ [ 534, 6, 8374 ], [ 8374, 45, 600 ] ], [ [ 534, 21, 29698 ], [ 29698, 60, 600 ] ], [ [ 534, 25, 222 ], [ 222, 62, 600 ] ], [ [ 534, 24, 609 ], [ 609, 62, 600 ] ], [ [ 534, 23, 112 ], [ 112, 62, 600 ] ], [ [ 534, 25, 913 ], [ 913, 63, 600 ] ], [ [ 534, 24, 1148 ], [ 1148, 63, 600 ] ], [ [ 534, 63, 618 ], [ 618, 24, 600 ] ], [ [ 534, 64, 912 ], [ 912, 24, 600 ] ] ]
[ [ [ "Tramadol", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Fluconazole" ] ], [ [ "Tramadol", "{u} (Compound) binds {v} (Gene)", "CYP3A4" ], [ "CYP3A4", "{u} (Gene) is bound by {v} (Compound)", "Fluconazole" ] ], [ [ "Tramadol", "{u} (Compound) causes {v} (Side Effect)", "Rigors" ], [ "Rigors", "{u} (Side Effect) is caused by {v} (Compound)", "Fluconazole" ] ], [ [ "Tramadol", "{u} may lead to a major life threatening interaction when taken with {v}", "Sibutramine" ], [ "Sibutramine", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Fluconazole" ] ], [ [ "Tramadol", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Clarithromycin" ], [ "Clarithromycin", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Fluconazole" ] ], [ [ "Tramadol", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Metronidazole" ], [ "Metronidazole", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Fluconazole" ] ], [ [ "Tramadol", "{u} may lead to a major life threatening interaction when taken with {v}", "Apalutamide" ], [ "Apalutamide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Fluconazole" ] ], [ [ "Tramadol", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Isoprenaline" ], [ "Isoprenaline", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Fluconazole" ] ], [ [ "Tramadol", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Abarelix" ], [ "Abarelix", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Fluconazole" ] ], [ [ "Tramadol", "{u} may lead to a major life threatening interaction when taken with {v}", "Interferon beta-1a" ], [ "Interferon beta-1a", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Fluconazole" ] ] ]
Tramadol (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Fluconazole (Compound) Tramadol (Compound) causes Rigors (Side Effect) and Rigors (Side Effect) is caused by Fluconazole (Compound) Tramadol may lead to a major life threatening interaction when taken with Sibutramine and Sibutramine may cause a minor interaction that can limit clinical effects when taken with Fluconazole Tramadol may cause a moderate interaction that could exacerbate diseases when taken with Clarithromycin and Clarithromycin may cause a minor interaction that can limit clinical effects when taken with Fluconazole Tramadol may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Fluconazole Tramadol may lead to a major life threatening interaction when taken with Apalutamide and Apalutamide may cause a moderate interaction that could exacerbate diseases when taken with Fluconazole Tramadol may cause a moderate interaction that could exacerbate diseases when taken with Isoprenaline and Isoprenaline may cause a moderate interaction that could exacerbate diseases when taken with Fluconazole Tramadol may cause a moderate interaction that could exacerbate diseases when taken with Abarelix and Abarelix may cause a moderate interaction that could exacerbate diseases when taken with Fluconazole Tramadol may lead to a major life threatening interaction when taken with Interferon beta-1a and Interferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Fluconazole
DB00539
DB00850
11
1,630
[ "DDInter1837", "DDInter1432" ]
Toremifene
Perphenazine
Toremifene is a selective estrogen receptor modulator (SERM) and a nonsteroidal antiestrogen used to treat estrogen receptor positive breast cancer. Like [tamoxifen], toremifene is part of the first-generation triphenylethylene derivative chemical class of SERMs. Toremifene possesses tissue-specific actions: it has estrogenic (agonist) activity on the cardiovascular system and on bone tissue and it has weak estrogenic effects on uterine tissue, however, it also has antiestrogenic (estrogen-antagonist) activity on breast tissue.
An antipsychotic phenothiazine derivative with actions and uses similar to those of chlorpromazine.
Major
2
[ [ [ 11, 25, 1630 ] ], [ [ 11, 25, 252 ], [ 252, 40, 1630 ] ], [ [ 11, 64, 508 ], [ 508, 40, 1630 ] ], [ [ 11, 24, 673 ], [ 673, 40, 1630 ] ], [ [ 11, 6, 7950 ], [ 7950, 45, 1630 ] ], [ [ 11, 7, 16703 ], [ 16703, 46, 1630 ] ], [ [ 11, 18, 2183 ], [ 2183, 57, 1630 ] ], [ [ 11, 7, 20113 ], [ 20113, 57, 1630 ] ], [ [ 11, 21, 28695 ], [ 28695, 60, 1630 ] ], [ [ 11, 23, 112 ], [ 112, 62, 1630 ] ] ]
[ [ [ "Toremifene", "{u} may lead to a major life threatening interaction when taken with {v}", "Perphenazine" ] ], [ [ "Toremifene", "{u} may lead to a major life threatening interaction when taken with {v}", "Hydroxyzine" ], [ "Hydroxyzine", "{u} (Compound) resembles {v} (Compound)", "Perphenazine" ] ], [ [ "Toremifene", "{u} may lead to a major life threatening interaction when taken with {v}", "Promazine" ], [ "Promazine", "{u} (Compound) resembles {v} (Compound)", "Perphenazine" ] ], [ [ "Toremifene", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Aripiprazole" ], [ "Aripiprazole", "{u} (Compound) resembles {v} (Compound)", "Perphenazine" ] ], [ [ "Toremifene", "{u} (Compound) binds {v} (Gene)", "CYP1A2" ], [ "CYP1A2", "{u} (Gene) is bound by {v} (Compound)", "Perphenazine" ] ], [ [ "Toremifene", "{u} (Compound) upregulates {v} (Gene)", "ST3GAL5" ], [ "ST3GAL5", "{u} (Gene) is upregulated by {v} (Compound)", "Perphenazine" ] ], [ [ "Toremifene", "{u} (Compound) downregulates {v} (Gene)", "CDC20" ], [ "CDC20", "{u} (Gene) is downregulated by {v} (Compound)", "Perphenazine" ] ], [ [ "Toremifene", "{u} (Compound) upregulates {v} (Gene)", "IER3" ], [ "IER3", "{u} (Gene) is downregulated by {v} (Compound)", "Perphenazine" ] ], [ [ "Toremifene", "{u} (Compound) causes {v} (Side Effect)", "Dyspnoea" ], [ "Dyspnoea", "{u} (Side Effect) is caused by {v} (Compound)", "Perphenazine" ] ], [ [ "Toremifene", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Metronidazole" ], [ "Metronidazole", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Perphenazine" ] ] ]
Toremifene may lead to a major life threatening interaction when taken with Hydroxyzine and Hydroxyzine (Compound) resembles Perphenazine (Compound) Toremifene may lead to a major life threatening interaction when taken with Promazine and Promazine (Compound) resembles Perphenazine (Compound) Toremifene may cause a moderate interaction that could exacerbate diseases when taken with Aripiprazole and Aripiprazole (Compound) resembles Perphenazine (Compound) Toremifene (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Perphenazine (Compound) Toremifene (Compound) upregulates ST3GAL5 (Gene) and ST3GAL5 (Gene) is upregulated by Perphenazine (Compound) Toremifene (Compound) downregulates CDC20 (Gene) and CDC20 (Gene) is downregulated by Perphenazine (Compound) Toremifene (Compound) upregulates IER3 (Gene) and IER3 (Gene) is downregulated by Perphenazine (Compound) Toremifene (Compound) causes Dyspnoea (Side Effect) and Dyspnoea (Side Effect) is caused by Perphenazine (Compound) Toremifene may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Perphenazine
DB00224
DB01190
215
568
[ "DDInter917", "DDInter398" ]
Indinavir
Clindamycin
A potent and specific HIV protease inhibitor that appears to have good oral bioavailability. [PubChem]
Clindamycin is a semi-synthetic lincosamide antibiotic used in the treatment of a variety of serious infections due to susceptible microorganisms[L11599,L11596] as well as topically for acne vulgaris. It has a relatively narrow spectrum of activity that includes anaerobic bacteria as well as gram-positive cocci and bacilli and gram-negative bacilli. Interestingly, clindamycin appears to carry some activity against protozoans, and has been used off-label in the treatment of toxoplasmosis, malaria, and babesiosis. Clindamycin is derived from, and has largely replaced, [lincomycin], a naturally occurring lincosamide and the eponymous member of this antibiotic class, due to its improved properties over the parent compound. The name lincomycin is derived from Lincoln, Nebraska, where it was first isolated from _Streptomyces lincolnensis_ found in a soil sample.
Moderate
1
[ [ [ 215, 24, 568 ] ], [ [ 215, 6, 8374 ], [ 8374, 45, 568 ] ], [ [ 215, 21, 29278 ], [ 29278, 60, 568 ] ], [ [ 215, 23, 609 ], [ 609, 63, 568 ] ], [ [ 215, 24, 384 ], [ 384, 63, 568 ] ], [ [ 215, 40, 798 ], [ 798, 24, 568 ] ], [ [ 215, 40, 1327 ], [ 1327, 63, 568 ] ], [ [ 215, 6, 8374 ], [ 8374, 45, 609 ], [ 609, 63, 568 ] ], [ [ 215, 21, 29278 ], [ 29278, 60, 859 ], [ 859, 63, 568 ] ], [ [ 215, 21, 28680 ], [ 28680, 60, 1208 ], [ 1208, 1, 568 ] ] ]
[ [ [ "Indinavir", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Clindamycin" ] ], [ [ "Indinavir", "{u} (Compound) binds {v} (Gene)", "CYP3A4" ], [ "CYP3A4", "{u} (Gene) is bound by {v} (Compound)", "Clindamycin" ] ], [ [ "Indinavir", "{u} (Compound) causes {v} (Side Effect)", "Inflammation" ], [ "Inflammation", "{u} (Side Effect) is caused by {v} (Compound)", "Clindamycin" ] ], [ [ "Indinavir", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Clarithromycin" ], [ "Clarithromycin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Clindamycin" ] ], [ [ "Indinavir", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Idelalisib" ], [ "Idelalisib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Clindamycin" ] ], [ [ "Indinavir", "{u} (Compound) resembles {v} (Compound)", "Nelfinavir" ], [ "Nelfinavir", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Clindamycin" ] ], [ [ "Indinavir", "{u} (Compound) resembles {v} (Compound)", "Saquinavir" ], [ "Saquinavir", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Clindamycin" ] ], [ [ "Indinavir", "{u} (Compound) binds {v} (Gene)", "CYP3A4" ], [ "CYP3A4", "{u} (Gene) is bound by {v} (Compound)", "Clarithromycin" ], [ "Clarithromycin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Clindamycin" ] ], [ [ "Indinavir", "{u} (Compound) causes {v} (Side Effect)", "Inflammation" ], [ "Inflammation", "{u} (Side Effect) is caused by {v} (Compound)", "Posaconazole" ], [ "Posaconazole", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Clindamycin" ] ], [ [ "Indinavir", "{u} (Compound) causes {v} (Side Effect)", "Rash" ], [ "Rash", "{u} (Side Effect) is caused by {v} (Compound)", "Lincomycin" ], [ "Lincomycin", "{u} (Compound) resembles {v} (Compound)", "Clindamycin" ] ] ]
Indinavir (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Clindamycin (Compound) Indinavir (Compound) causes Inflammation (Side Effect) and Inflammation (Side Effect) is caused by Clindamycin (Compound) Indinavir may cause a minor interaction that can limit clinical effects when taken with Clarithromycin and Clarithromycin may cause a moderate interaction that could exacerbate diseases when taken with Clindamycin Indinavir may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib and Idelalisib may cause a moderate interaction that could exacerbate diseases when taken with Clindamycin Indinavir (Compound) resembles Nelfinavir (Compound) and Nelfinavir may cause a moderate interaction that could exacerbate diseases when taken with Clindamycin Indinavir (Compound) resembles Saquinavir (Compound) and Saquinavir may cause a moderate interaction that could exacerbate diseases when taken with Clindamycin Indinavir (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Clarithromycin (Compound) and Clarithromycin may cause a moderate interaction that could exacerbate diseases when taken with Clindamycin Indinavir (Compound) causes Inflammation (Side Effect) and Inflammation (Side Effect) is caused by Posaconazole (Compound) and Posaconazole may cause a moderate interaction that could exacerbate diseases when taken with Clindamycin Indinavir (Compound) causes Rash (Side Effect) and Rash (Side Effect) is caused by Lincomycin (Compound) and Lincomycin (Compound) resembles Clindamycin (Compound)
DB00880
DB01129
359
379
[ "DDInter360", "DDInter1559" ]
Chlorothiazide
Rabeprazole
A thiazide diuretic with actions and uses similar to those of hydrochlorothiazide. (From Martindale, The Extra Pharmacopoeia, 30th ed, p812)
Rabeprazole is an antiulcer drug in the class of proton pump inhibitors. It is a prodrug - in the acid environment of the parietal cells it turns into active sulphenamide form. Rabeprazole inhibits the H+, K+ATPase of the coating gastric cells and dose-dependent oppresses basal and stimulated gastric acid secretion.
Moderate
1
[ [ [ 359, 24, 379 ] ], [ [ 359, 63, 1215 ], [ 1215, 40, 379 ] ], [ [ 359, 63, 660 ], [ 660, 1, 379 ] ], [ [ 359, 21, 29232 ], [ 29232, 60, 379 ] ], [ [ 359, 62, 126 ], [ 126, 24, 379 ] ], [ [ 359, 40, 178 ], [ 178, 63, 379 ] ], [ [ 359, 40, 1577 ], [ 1577, 24, 379 ] ], [ [ 359, 63, 663 ], [ 663, 25, 379 ] ], [ [ 359, 63, 1215 ], [ 1215, 40, 660 ], [ 660, 1, 379 ] ], [ [ 359, 63, 660 ], [ 660, 1, 1215 ], [ 1215, 40, 379 ] ] ]
[ [ [ "Chlorothiazide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Rabeprazole" ] ], [ [ "Chlorothiazide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Lansoprazole" ], [ "Lansoprazole", "{u} (Compound) resembles {v} (Compound)", "Rabeprazole" ] ], [ [ "Chlorothiazide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Esomeprazole" ], [ "Esomeprazole", "{u} (Compound) resembles {v} (Compound)", "Rabeprazole" ] ], [ [ "Chlorothiazide", "{u} (Compound) causes {v} (Side Effect)", "Urticaria" ], [ "Urticaria", "{u} (Side Effect) is caused by {v} (Compound)", "Rabeprazole" ] ], [ [ "Chlorothiazide", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Warfarin" ], [ "Warfarin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Rabeprazole" ] ], [ [ "Chlorothiazide", "{u} (Compound) resembles {v} (Compound)", "Polythiazide" ], [ "Polythiazide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Rabeprazole" ] ], [ [ "Chlorothiazide", "{u} (Compound) resembles {v} (Compound)", "Hydroflumethiazide" ], [ "Hydroflumethiazide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Rabeprazole" ] ], [ [ "Chlorothiazide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Methotrexate" ], [ "Methotrexate", "{u} may lead to a major life threatening interaction when taken with {v}", "Rabeprazole" ] ], [ [ "Chlorothiazide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Lansoprazole" ], [ "Lansoprazole", "{u} (Compound) resembles {v} (Compound)", "Esomeprazole" ], [ "Esomeprazole", "{u} (Compound) resembles {v} (Compound)", "Rabeprazole" ] ], [ [ "Chlorothiazide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Esomeprazole" ], [ "Esomeprazole", "{u} (Compound) resembles {v} (Compound)", "Lansoprazole" ], [ "Lansoprazole", "{u} (Compound) resembles {v} (Compound)", "Rabeprazole" ] ] ]
Chlorothiazide may cause a moderate interaction that could exacerbate diseases when taken with Lansoprazole and Lansoprazole (Compound) resembles Rabeprazole (Compound) Chlorothiazide may cause a moderate interaction that could exacerbate diseases when taken with Esomeprazole and Esomeprazole (Compound) resembles Rabeprazole (Compound) Chlorothiazide (Compound) causes Urticaria (Side Effect) and Urticaria (Side Effect) is caused by Rabeprazole (Compound) Chlorothiazide may cause a minor interaction that can limit clinical effects when taken with Warfarin and Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Rabeprazole Chlorothiazide (Compound) resembles Polythiazide (Compound) and Polythiazide may cause a moderate interaction that could exacerbate diseases when taken with Rabeprazole Chlorothiazide (Compound) resembles Hydroflumethiazide (Compound) and Hydroflumethiazide may cause a moderate interaction that could exacerbate diseases when taken with Rabeprazole Chlorothiazide may cause a moderate interaction that could exacerbate diseases when taken with Methotrexate and Methotrexate may lead to a major life threatening interaction when taken with Rabeprazole Chlorothiazide may cause a moderate interaction that could exacerbate diseases when taken with Lansoprazole and Lansoprazole (Compound) resembles Esomeprazole (Compound) and Esomeprazole (Compound) resembles Rabeprazole (Compound) Chlorothiazide may cause a moderate interaction that could exacerbate diseases when taken with Esomeprazole and Esomeprazole (Compound) resembles Lansoprazole (Compound) and Lansoprazole (Compound) resembles Rabeprazole (Compound)
DB00647
DB00902
675
104
[ "DDInter528", "DDInter1168" ]
Dextropropoxyphene
Methdilazine
Dextropropoxyphene is an opioid analgesic manufactured by Eli Lilly and Company. It is used in the symptomatic treatment of mild pain. It displays antitussive and local anaesthetic actions. Due to the risk of cardiac arrhythmias and overdose, possibly leading to death, dextropropoxyphene has been withdrawn from the market in Europe and the United States. The drug is often referred to as the general form, "propoxyphene", however only the dextro-isomer (dextropropoxyphene) has any analgesic effect. The levo-isomer appears to exhibit a very limited antitussive effect.
Methdilazine is a phenothiazine compound with antihistaminic activity. It is used in the treatment of various dermatoses to relieve pruritus.
Major
2
[ [ [ 675, 25, 104 ] ], [ [ 675, 64, 13 ], [ 13, 24, 104 ] ], [ [ 675, 40, 11233 ], [ 11233, 1, 104 ] ], [ [ 675, 25, 820 ], [ 820, 1, 104 ] ], [ [ 675, 25, 537 ], [ 537, 40, 104 ] ], [ [ 675, 25, 401 ], [ 401, 63, 104 ] ], [ [ 675, 24, 286 ], [ 286, 62, 104 ] ], [ [ 675, 63, 1503 ], [ 1503, 24, 104 ] ], [ [ 675, 24, 274 ], [ 274, 24, 104 ] ], [ [ 675, 24, 1192 ], [ 1192, 63, 104 ] ] ]
[ [ [ "Dextropropoxyphene", "{u} may lead to a major life threatening interaction when taken with {v}", "Methdilazine" ] ], [ [ "Dextropropoxyphene", "{u} may lead to a major life threatening interaction when taken with {v}", "Cyproheptadine" ], [ "Cyproheptadine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Methdilazine" ] ], [ [ "Dextropropoxyphene", "{u} (Compound) resembles {v} (Compound)", "Dimetacrine" ], [ "Dimetacrine", "{u} (Compound) resembles {v} (Compound)", "Methdilazine" ] ], [ [ "Dextropropoxyphene", "{u} may lead to a major life threatening interaction when taken with {v}", "Alimemazine" ], [ "Alimemazine", "{u} (Compound) resembles {v} (Compound)", "Methdilazine" ] ], [ [ "Dextropropoxyphene", "{u} may lead to a major life threatening interaction when taken with {v}", "Cyclizine" ], [ "Cyclizine", "{u} (Compound) resembles {v} (Compound)", "Methdilazine" ] ], [ [ "Dextropropoxyphene", "{u} may lead to a major life threatening interaction when taken with {v}", "Promethazine" ], [ "Promethazine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Methdilazine" ] ], [ [ "Dextropropoxyphene", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Magnesium hydroxide" ], [ "Magnesium hydroxide", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Methdilazine" ] ], [ [ "Dextropropoxyphene", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Lindane" ], [ "Lindane", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Methdilazine" ] ], [ [ "Dextropropoxyphene", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Phentolamine" ], [ "Phentolamine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Methdilazine" ] ], [ [ "Dextropropoxyphene", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Glycopyrronium" ], [ "Glycopyrronium", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Methdilazine" ] ] ]
Dextropropoxyphene may lead to a major life threatening interaction when taken with Cyproheptadine and Cyproheptadine may cause a moderate interaction that could exacerbate diseases when taken with Methdilazine Dextropropoxyphene (Compound) resembles Dimetacrine (Compound) and Dimetacrine (Compound) resembles Methdilazine (Compound) Dextropropoxyphene may lead to a major life threatening interaction when taken with Alimemazine and Alimemazine (Compound) resembles Methdilazine (Compound) Dextropropoxyphene may lead to a major life threatening interaction when taken with Cyclizine and Cyclizine (Compound) resembles Methdilazine (Compound) Dextropropoxyphene may lead to a major life threatening interaction when taken with Promethazine and Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Methdilazine Dextropropoxyphene may cause a moderate interaction that could exacerbate diseases when taken with Magnesium hydroxide and Magnesium hydroxide may cause a minor interaction that can limit clinical effects when taken with Methdilazine Dextropropoxyphene may cause a moderate interaction that could exacerbate diseases when taken with Lindane and Lindane may cause a moderate interaction that could exacerbate diseases when taken with Methdilazine Dextropropoxyphene may cause a moderate interaction that could exacerbate diseases when taken with Phentolamine and Phentolamine may cause a moderate interaction that could exacerbate diseases when taken with Methdilazine Dextropropoxyphene may cause a moderate interaction that could exacerbate diseases when taken with Glycopyrronium and Glycopyrronium may cause a moderate interaction that could exacerbate diseases when taken with Methdilazine